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Abstract 
 2 
Diabetes is a chronic disorder of glucose metabolism and a major cause of premature 
mortality. The potential use of replacement beta cells as therapy for diabetes requires 
an ability to culture such cells while maintaining their functional status. Glucose 
stimulated insulin secretion (GSIS) is lost in long-term cultured MIN6 heterogeneous 
cells. MIN6 B1, a clonal sub-line derived from MIN6, has been described as highly 
glucose-responsive. This study aimed to investigate the GSIS function, changes in 
gene expression and, subsequently, to develop possible experimental approaches to 
overcome this loss. Understanding the molecular basis for loss of GSIS may 
contribute to better culture conditions for islets in transplantation programmes; it may 
also add to our understanding of beta cell insensitivity to high blood glucose in Type 
2 diabetes. 
Whole genome microarray analysis on biological triplicate samples of glucose-
responsive low passage (p19) (MIN6 B1(GSIS)) and non glucose-responsive high 
passage (p23) (MIN6 B1(Non-GSIS)) was performed. 111 differentially-regulated 
genes were identified and 16 gene transcripts were selected based on p-value <0.05; 
fold change ≥1.2; difference ≥100 and validated using qRT-PCR including Txnip, 
Gcg and Pcsk9.  
Txnip was up-regulated whereas Gcg and Pcsk9 were down-regulated in MIN6 
B1(Non-GSIS) compared to MIN6 B1(GSIS). siRNA and shRNA silencing of Txnip 
in MIN6(H) (non-responsive) significantly increased the GSIS. Over-expression of 
Txnip cDNA in MIN6(L) (glucose-responsive) caused significant loss of GSIS. 
siRNA silencing of Gcg and Pcsk9 caused a significant loss of GSIS in MIN6(L) 
compared to scrambled-transfected cells. Over-expression of Gcg cDNA in MIN6(H) 
increased GSIS.  
In parallel, in an attempt to identify more reliable biomarkers for diabetes, we also 
investigated if extracellular mRNAs are reproducibly detectable in conditioned 
medium (CM) from a range of insulin-producing cell types and in serum specimens 
from Type 2 diabetes and controls. Pdx1, Npy, Egr1, Pld1, Chgb, Ins1, Ins2, and beta-
actin from MIN6(L), MIN6(H), and MIN6 B1 cells and their CM suggests that beta 
cells transcribe and release these mRNAs into their culture environment.This study 
was subsequently translated to analysis of serum from people with Type 2 diabetes 
and controls to help establish the clinical relevance of these findings. The result from 
this clinical phase of the study indicated Txnip to be up-regulated and Egr1 to be 
down-regulated in Type 2 diabetes compared to controls.  
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1.1 Diabetes  
Diabetes is a chronic disease that occurs when the pancreas does not produce 
enough insulin or, alternatively, when the body cannot effectively use the insulin 
it produces. Diabetes currently affects 246 million people worldwide and is 
expected to affect 380 million by 2025. In 2007, the five countries with the 
largest numbers of people with diabetes were India (40.9 million), China (39.8 
million), the United States (19.2 million), Russia (9.6 million) and Germany (7.4 
million). Each year a further 7 million people develop diabetes and 3.8 million 
deaths are attributable to diabetes. An even greater number die from 
cardiovascular disease made worse by diabetes-related lipid disorders and 
hypertension (International Diabetes Federation http://www.idf.org/). 
The World Health Organization recognizes three main forms of diabetes (World 
Health Organisation Department of Non communicable Disease Surveillance 
http://www.who.int/mediacentre/factsheets/fs312/en/):  
• Type 1 diabetes also known as insulin-dependent diabetes mellitus (IDDM),  
• Type 2 diabetes non-insulin-dependent diabetes (NIDDM), and  
• Gestational diabetes, occurring during pregnancy. 
1.1.1 Type 1 diabetes  
Patients with Type 1 diabetes have a low to zero levels of insulin and C-peptide 
in blood as the pancreas does not make any insulin (Webb et al., 1981; Palmer et 
al., 2004). Type 1 diabetes is characterized by autoimmune destruction of 
insulin-producing beta cells in the pancreas by CD4+ and CD8+ T cells and 
macrophages infiltrating the islets (Foulis et al., 1991). Genetic factors, 
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autoantigens and, as yet undefined, environmental triggers act together to initiate 
the disease (Gillespie, 2006). Susceptibility genes include those within the major 
histocompatibility complex (MHC)—especially HLA-DR3,DQB1*0201 and 
HLA-DR4,DQB1*0302, which are present in > 90% of patients with Type 1 DM 
(Redondo et al., 2001; Young et al., 2004). Autoantigens include glutamic acid 
decarboxylase, insulin, insulinoma-associated protein and other proteins in beta 
cells. These proteins are thought to be exposed or released during normal beta 
cell injury (Blancou et al., 2007). Several viral infections have been associated 
with subsequent development of human Type 1 diabetes including enterovirus 
(Lönnrot et al., 2000; Salminen et al., 2003), rubella (Ginsberg-Fellner et al., 
1984), mumps (Hyöty et al., 1988), rotavirus (Honeyman, 2005) and 
cytomegalovirus (CMV) (Pak et al., 1988; van der Werf et al., 2007), but it is 
unclear which if any of these is the major triggering factor. 
Type 1 diabetes accounts for about 5-10% of all diagnosed cases of diabetes 
(National Diabetes Fact Sheet, 2007). The warning signs for Type 1 diabetes 
include frequent urination, unusual thirst, extreme hunger, unusual weight loss, 
extreme fatigue and irritability (Kuzuya, 2000).  
Pathogenesis 
The pathogenesis of the autoimmune beta cell destruction is not fully understood. 
An examination of islet tissue obtained from pancreatic biopsy from patients 
with recent onset type 1 diabetes confirmed insulitis. The examination also 
confirmed presence of CD4 and CD8 T lymphocytes, B lymphocytes and 
macrophages, suggesting that these cells have a role in destruction of the beta 
cells (Imagawa et al., 1999). The process starts years before overt diabetes 
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develops and is evident when the beta cell volume is reduced by approximately 
80% (Klöppel et al., 1985). 
1.1.2 Type 2 diabetes 
Type 2 diabetes is a metabolic disorder that is characterized by insulin resistance 
(particularly in fat, muscle and liver cells) leading to high levels of glucose in the 
bloodstream and eventually failure of beta cells. A person with Type 2 diabetes 
has a normal or high level of C-peptide (Webb et al., 1981). The warning signs 
for Type 2 diabetes are - any of the Type 1 diabetes symptoms, frequent 
infections, blurred vision, cuts/bruises that are slow to heal; tingling/numbness in 
the hands/feet; recurring skin, gum, or bladder infections. Sometimes people with 
Type 2 diabetes have no overt symptoms.  
Type 2 diabetes accounts for approximately 90-95% of all diagnosed cases of 
diabetes (National Diabetes Fact Sheet, 2007; 
http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf). Type 2 diabetes is 
becoming increasingly common in children. About 40 to 50% of new-onset 
diabetes mellitus in children is now Type 2 as childhood obesity has become 
epidemic (Brunton, 2008). 
Pathogenesis 
Insulin resistance: Insulin resistance is regarded as a reduced rate of insulin-
mediated glucose uptake in insulin-sensitive tissues of the body including fat, 
muscle and liver cells (DeFronzo et al., 1991; Moller et al., 1991). 
 7 
Beta cell dysfunction: Type 2 diabetes shows marked reduction in first-phase 
insulin secretion and established diabetes shows attenuated second phase insulin 
secretion (See Section: 1.3.3.2) (Holt, 2004). 
Hyperglycemia develops when insulin secretion can no longer compensate for 
insulin resistance. Hyperglycemia itself may cause impaired insulin secretion, as 
high glucose levels desensitize beta cells resulting in beta cell dysfunction or 
glucose toxicity (Leahy, 1996). Obesity and weight gain are important causative 
factors for insulin resistance in Type 2 diabetes. Adipose tissue increases plasma 
levels of free fatty acids leading to impaired insulin-stimulated glucose transport 
and muscle glycogen synthase activity (Camastra et al., 1999). 
1.1.6 Gestational diabetes 
Gestational diabetes is a form of glucose intolerance diagnosed in some women 
during pregnancy. Gestational diabetes may require treatment to normalize 
maternal blood glucose levels to avoid complications in the infant. After 
pregnancy, 5-10% of women with gestational diabetes are found to have Type 2 
diabetes. Women who have had gestational diabetes have a 20-50% chance of 
developing Type 2 diabetes in the next 5-10 years. 70% of women who have had 
gestational diabetes will develop Type 2 diabetes at some point during their 
lifetime (National Diabetes Fact Sheet, 2007; 
http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf). 
Pathogenesis  
In the case of gestational diabetes, insulin resistance usually begins in the second 
trimester and progresses throughout the remainder of the pregnancy. Insulin 
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resistance and inadequate insulin secretion (to compensate for it) play a central 
role in the pathophysiology of gestational diabetes. Insulin resistance appears to 
result from a combination of increased maternal adiposity and the insulin-
desensitizing effects of hormonal products of the placenta such as progesterone, 
cortisol, placental lactogen, prolactin, and growth hormone (Setji et al., 2005; 
Buchanan et al., 2005). 
1.1.7 Health complications 
Diabetes can cause many complications. Acute complications (hypoglycaemia, 
ketoacidosis or nonketotic hyperosmolar coma) may occur if the disease is not 
adequately controlled. Serious long-term complications include cardiovascular 
disease (doubled risk), chronic renal failure (diabetic nephropathy is the main 
cause of dialysis in developed world adults), retinal damage (which can lead to 
blindness and is the most significant cause of adult blindness in the non-elderly 
in the developed world), nerve damage (of several kinds), and microvascular 
damage (Nathan et al., 2005). 
The complications of diabetes are not an inevitable outcome, and the risk can be 
reduced substantially by appropriate therapy. Diabetes therapy is no longer 
mainly about glucose lowering per se, but about overall reduction in the risk 
factors for diabetic complications (Table: 1.1.4). 
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Table: 1.1.4 Chronic Complications of Diabetes 
 
Chronic Complications of Type 1 and Type 2 Diabetes 
 
    * OCULAR COMPLICATIONS 
         1. Diabetic cataracts 
         2. Diabetic retinopathy 
         3. Glaucoma 
 
    * DIABETIC NEPHROPATHY 
         1. Microalbuminuria 
         2. Progressive diabetic nephropathy 
 
    * DIABETIC NEUROPATHY 
         1. Peripheral neuropathy 
              - Distal symmetric polyneuropathy 
              - Isolated peripheral neuropathy 
              - Painful diabetic neuropathy 
         2. Autonomic neuropathy 
              - Management of autonomic neuropathy 
              - Management of erectile dysfunction 
 
    * CARDIOVASCULAR COMPLICATIONS 
         1. Heart disease 
         2. Peripheral vascular disease 
 
    * SKIN AND MUCOUS MEMBRANE COMPLICATIONS 
1. Chronic pyogenic infections of the skin 
2. Necrobiosis lipoidica diabeticorum 
3. Eruptive xanthomas 
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1.1.5 Therapy for diabetes 
The common therapy for diabetes is daily injections of insulin, but this therapy 
does not solve serious long-term complication which, as a consequence, results 
in a shortened life expectancy of diabetic patients (Nathan et al., 1993). Using 
this form of therapy, it is difficult to provide exact amounts of insulin needed at 
any given time, resulting in episodes of hyperglycaemia or hypoglycaemia. 
Hyperglycaemia causes accumulated cell damage in many tissues, leading to the 
development of long–term complications in IDDM patients. The Diabetes 
Control and Complications Trial (Centers for Disease Control and Prevention 
http://www.cdc.gov/) has shown that tight regulation of blood glucose levels can 
effectively prevent these complications.  
Long-term studies strongly suggest that tight control of blood glucose can 
prevent the development, and retard the progression, of chronic complications of 
Type 1 diabetes. In contrast to conventional insulin treatment, replacement of a 
patient's islets of Langerhans either by pancreas organ transplantation or by 
isolated islet transplantation is the only treatment to achieve a constant 
normoglycemic state and avoiding hypoglycaemic episodes, a typical adverse 
event of multiple daily insulin injections (Bretzel et al., 2004). 
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1.2 The Pancreas 
The pancreas is an organ in the digestive and endocrine system of vertebrates. It 
is both exocrine (secreting pancreatic juice containing digestive enzymes) and 
endocrine (producing several important hormones as detailed below). The 
endocrine (i.e. hormone-producing) cells of the pancreas are grouped in the islets 
of Langerhans. Discovered in 1869 by the German pathological anatomist Paul 
Langerhans, the islets of Langerhans constitute approximately 1 to 2% of the 
mass of the pancreas (Kobayashi et al., 2004) (Fig: 1.2).  
 
 
 
 
 
 
 
 
Fig: 1.2 Structure of pancreas showing different types of cells present 
(http://health.howstuffworks.com/diabetes1.htm). 
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Hormones produced in the Islets of Langerhans are secreted directly into the 
blood flow by at least four different types of cells (Brissova et al., 2005; 
Kobayashi et al., 2004; Suckale et al., 2008) (Fig: 1.2). 
• Beta cells producing insulin and amylin (65-80% of the islet cells)  
• Alpha cells releasing glucagon (15-20%)  
• Delta cells producing somatostatin (3-10%)  
• PP cells containing polypeptide (1%)  
The beta cells present in pancreatic islet of Langerhans play an important role in 
glucose haemostasis. Insulin and glucagon directly influence glucose 
homeostasis, while somatostatin and pancreatic polypeptide have modulatory 
function. After a carbohydrate-rich meal, beta cells secrete insulin that facilitate 
glucose uptake by liver, adipose tissue and muscle, thereby reducing glucose 
concentration in blood. When glucose concentration is decreased, alpha cells 
secrete glucagon, which increases glucose concentration in blood by activating 
glycogenolysis and gluconeogenesis. This way both insulin and glucagon 
maintain blood glucose concentration (Nussey et al., 2001). 
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1.3 Insulin 
1.3.1 Structure of Insulin 
Insulin is a small protein of approx. 5.8kDa. Insulin is synthesized by humans 
and other mammals in the beta cells of pancreas. Insulin, a polypeptide hormone, 
consists of two polypeptide chains, one 21 amino acids long, called the “A” 
chain, and a second, the “B” chain, which is 30 amino acids long. The two chains 
are bound together in their quaternary structure by two disulfide bridges.  
The secondary structure of both chains is mostly alpha helical (Fig: 1.3.1). 
Insulin is created as a single peptide chain, which is looped around, bonded to 
itself by covalent disulfide bonds between cysteine residues (Brange et al., 
1993). In addition, a third disulfide bridge between two amino acids in the “A” 
chain helps stabilize its tertiary structure (Brange et al., 1993). 
Most animals have a single copy of the insulin gene, with the exception of Arctic 
salmon, African clawed frog and the murine species including rat and mouse 
(Bell et al., 1980). Apparently insulin gene duplication in mouse resulted from 
reverse transcription and reintegration of an incompletely processed RNA 
transcript of the original insulin gene (insulin gene II) (Soares et al., 1985). 
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Fig: 1.3.1 Structure (amino acid sequence) of human insulin. Following post-
translational modification of their precursor chains, these are assembled in 
endoplasmic reticulum. The disulfide bridges, which create the quaternary 
assembly of this molecule, are shown as black bonds connecting the cysteine 
(Cys) residues.  
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1.3.2 Biosynthesis of insulin  
The biosynthesis of insulin starts in the nucleus of the beta cells of the pancreas. 
It is thought that translation of the mRNA into preproinsulin starts while the 
ribosome is free in the cytosol. The signal sequence of the preproinsulin anchors 
the ribosome to the membrane of the rough Endoplasmic Reticulum (RER), after 
which the protein is translocated into the lumen of Endoplasmic Reticulum (ER). 
Translocation of preproinsulin is mediated by a signal-peptide across the RER 
(Rhodes et al., 2000). In the RER of beta cells, insulin is synthesized as a single 
polypeptide chain; preproinsulin precursor molecules are held together by the C-
peptide (connecting peptide) and contain a hydrophobic signal peptide, 
consisting of 23 amino acids at the N- terminal. After preproinsulin is 
synthesized in the ER, it is converted into proinsulin (Ren et al., 2007). The 
influx of Ca+ from the calcium storehouse ER causes the fusion of secretory 
vesicles to the plasma membrane (Varadi et al., 2002). Then with the help of 
secretory vesicle the proinsulin is transported through the Golgi apparatus and 
packaged into immature clathrin-coated granules. Here the proinsulin is broken 
down into the center portion of the molecule C-peptide, liberated from the C- and 
N- terminal ends of the proinsulin. The signal peptide is removed by the action of 
proteolytic enzymes known as prohormone convertases (PC1 and PC2), as well 
as the exoprotease carboxypeptidase E to produce proinsulin (Nie et al., 2000). 
The remaining polypeptides (51 amino acids), i.e. the B- and A- chains, are held 
together by disulfide bonds forming mature insulin. At exocytosis, equimolar 
amounts of insulin and C-peptide are released into the circulation, together with 
up to 5% proinsulin (Goodman, 2003). 
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1.3.3 Insulin secretion and regulation 
Insulin plays a central role in the control of the body's metabolism. It accelerates 
the glucose uptake into a number of tissues while simultaneously suppressing 
glucose production and lipolysis. The beta cell glucose transporter, GLUT2, 
senses the glucose concentration and transports it into the cell. Glucose is 
phosphorylated into glucose 6-phosphate (G-6-P) by glucokinase, which is a part 
of the glucose-sensing mechanism (Nilsson et al., 1996). Glucose 
phosphorylation increases ATP production in the beta cell, increasing the 
intracellular ratio of ATP/ADP (Ghosh et al., 1991). ATP binds to KATP channels 
on the beta cell membrane, probably concomitant with phosphorylation of KATP 
channel, closes the channels, resulting in depolarization of the beta cell 
membrane (Tarasov et al., 2004). When the beta cell membrane potential reaches 
–30 to –40 mV, the voltage-sensitive calcium channels (Ca2+-channels) open 
leading to an influx of calcium ions. The increase of intracellular calcium ions 
triggers the exocytosis of insulin granules (Ohara-Imaizumi et al., 2006). In 
addition, increased (Ca2+)
 i then activates (opens) voltage-sensitive potassium 
channels, thereby restoring the resting potential to –70 to -60 mV and increasing 
the concentration of cytoplasmic free calcium (Ohara-Imaizumi et al., 2006). The 
final result is insulin exocytosis (Fig: 1.3.3).  
After glucose stimulation, insulin secretion from the beta cell is biphasic. The 
first phase of insulin secretion occurs within 10–15 minutes of stimulation and 
involves the release of preformed insulin. The second phase, which lasts up to 2 
hours, is the release of newly synthesized insulin (Henquin et al., 2000). 
 17 
 
 
 
 
 
 
 
 
 
 
Fig: 1.3.3 Rising blood glucose levels triggers insulin secretion from beta 
cells. Starting with the uptake of glucose by the GLUT2 transporter, the 
glycolytic phosphorylation of glucose causes a rise in the ATP: ADP ratio. 
This rise inactivates the potassium channels that depolarize the membrane, 
causing the calcium channel to open up allowing calcium ions to flow 
inward. The ensuing rise in levels of intracellular calcium leads to the 
exocytotic release of insulin from their storage granules. 
 
 
 
Insulin release 
Storage granule 
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Gastrointestinal hormones and some amino acids, such as leucine, arginine, and 
lysine, also stimulate insulin secretion. Gastrointestinal hormones, such as 
glucose-dependent insulinotropic peptide (GIP), cholecystokinin, glucagon-like 
peptide-1 (GLP-1) and vasoactive intestinal peptide (VIP), are secreted following 
ingestion of foods and potentiate insulin secretion (Drucker et al., 2006).  
1.3.3.1 Role of Endoplasmic Reticulum (ER) in insulin secretion 
One of the salient attribute of beta cells is a highly developed Endoplasmic 
Reticulum (ER) which helps in its function of glucose response and insulin 
secretion. ER is entrusted with post-translational modification, folding and 
assembly of newly synthesized secretory proteins. Proper functioning of ER is 
essential for cell survival (Webb et al., 2000; Araki et al., 2003). The pancreatic 
beta cells respond to glucose by the biosynthesis of preproinsulin and the release 
of insulin. The ER is also responsible for proper three-dimensional folding of 
precursor insulin (proinsulin) into mature insulin (Fonseca et al., 2005). The 
correct folding of the proinsulin is essential for the efficient production of insulin 
(Halban et al., 1994).  
Preproinsulin is the original single polypeptide used to form mature insulin. It 
consists of four regions, from N-terminal to C-terminal i.e. a hydrophobic signal 
sequence (SS), B-chain polypeptide, connecting peptide (C-peptide) and A-chain 
polypeptide. The transcribed mRNA for preproinsulin moves to a ribosome and 
sequentially binds to the signal recognition particle (SRP) initiating protein 
translation. The translated SS peptide (also called nascent chain) tags onto the 
SRP and migrates to a high-affinity receptor for SRP named the SRP docking 
protein (SRPdp) that is located at the external surface of the RER (Gilmore et al., 
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1982). Subsequently, the ribosome dissociates from the SRP and SRPdp and is 
restrained by the ribosome receptor (RR) on the ER membrane. The natural 
hydrophobic property of SS (22 of 24 amino acids in SS are hydrophobic) 
facilitates and enhances the binding affinity between ribosome-mRNA complex 
and the phospholipids bilayer of the ER membrane (Do et al., 1996). In addition 
to SRPdp, other membrane proteins such as translocating-chain associated 
membrane (TRAM) and Sec61 proteins are essential for directing the ribosome-
mRNA complex to the ER membrane (High et al., 1993; Voigt et al., 1996; 
Knight et al., 1998). Through the joint interaction of membrane proteins, the 
complex is placed at the site on the ER membrane termed translocon 
(McCormick et al., 2003) where the SS peptide guides the extension of the 
preproinsulin polypeptide chain into the ER lumen. The SS peptide is excised by 
signal peptidase positioned on the inner ER membrane and proinsulin is formed. 
The proinsulin is then folded by a molecular chaperone (e.g. protein disulfide 
isomerase, PDI) by the formation of the disulfide bonds (Winter et al., 2002). 
The vesicles filled with proinsulin then bud out from the RER towards the Golgi 
apparatus where the zinc/calcium environment around the Golgi favours the 
formation of the zinc-containing proinsulin hexamer (Dodson et al., 1998). 
Proinsulin passes through cis, medial and trans Golgi cisternae and is converted 
to insulin at the stage of vesicle formation. This transformation is driven by 
membrane-associated prohormone convertase enzymes (PCs). The catalytic sites 
targeted by PCs are called the dibasic sites (Goodge et al., 2000). 
Subsequently the granules are packed with mature insulin coupled with the 
precipitation of removed C-peptide and are maintained in the cytoplasm as an 
“insulin secreting vesicles pool” or “readily releasable pool (RRP)”. Once the 
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beta cells sense certain physiological variations of glucose level (high glucose) 
the insulin is secreted through the release of these primary granules in order to 
maintain normoglycaemia. 
 As described above, the release of insulin by beta cells is dependent upon 
glucose-induced alteration of Ca2+. Glucose dependent sequestration of cytosolic 
Ca2+ into ER via activation of the ER Ca2+ -ATPase, and its subsequent release, 
has been demonstrated to play an important role in glucose-activated beta cell 
Ca2+ signalling (Roe et al., 1994).  
1.3.3.2 Mechanism of glucose-stimulated insulin secretion (GSIS)  
The secretion of insulin from pancreatic beta cell is a complex process involving 
the integration and interaction of multiple external and internal stimuli. The 
primary stimulus for insulin secretion in the beta cell is to response to changes in 
ambient glucose (Rajan et al., 2002).  
As described in section 1.3.3, insulin secretion in response to glucose in beta 
cells exhibits two phases. Glucose enters beta cells via the GLUT2 transporter. 
Glucokinase is the first enzyme of the glycolytic pathway and serves as a glucose 
sensor. The metabolism of glucose by means of glycolysis and the citric acid 
cycle generates nicotinamide adenine dinucleotide (NADH) and the reduced 
form of flavin adenine dinucleotide (FADH2), which donate electrons to the 
mitochondrial electron-transport chain (ETC). Protons are then pumped out by 
respiratory chain complexes I, III, and IV, creating a proton electrochemical 
gradient. When protons re-enter the mitochondrial matrix, through adenosine 
triphosphate (ATP) synthase, ATP is generated from adenosine diphosphate 
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(ADP) and inorganic phosphate (Pi) leading to increased cytosolic ATP: ADP 
ratio (Langin, 2001). Mitochondrial ATP production is essential for GSIS 
(Wiederkehr et al., 2006) (Fig: 1.3.3.2.1 and Fig: 1.3.3.2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 1.3.3.2.1 Role of mitochondria in metabolism and secretion coupling of 
the beta cell. Respiratory chain complexes I–IV (orange), complex V/ATP 
synthase (green), calcium transport systems (yellow), transporters/shuttles 
of the inner mitochondrial membrane (pale blue), and open and closed 
forms of the KATP channel (dark blue) are indicated. ACC, Acetyl-CoA 
carboxylase; GDH, glutamate dehydrogenase; GK, glucokinase; ME, malic 
enzyme; TCA, TCA cycle (Wiederkehr et al., 2006).  
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The pancreatic beta cell KATP channel is comprised of Sulfonylurea receptor -1 
(SUR1) and potassium channel Kir6.2. The SUR1 channel maintains a potassium 
current, generating cell-membrane polarization (Donley et al., 2005). This 
increased cytosolic ATP: ADP ratio in turn results in closure of the SUR1 
receptor channel, depolarizing the membrane and initiation of electrical activity 
(Ren et al., 2007). This glucose-induced closure of the KATP channel activates the 
KATP channel-dependent signalling pathway, depolarizing the beta cell to cause 
increased Ca2+ entry via voltage-dependent Ca2+ channels and increased [Ca2+] 
ion. In response to the rise in intracellular Ca2+, some docked and primed insulin 
storage granules fuse and release insulin, while storage granules traffic to join the 
RRP at the cell surface. Insulin secretion from the beta cells is biphasic, with the 
first phase resulting from the release of insulin granules from an immediate 
releasable pool pre-primed at the plasma membrane. The second phase only 
occurs with nutrient stimulation and is thought to represent secretion from those 
granules which are mobilized to re-fill the readily and immediate releasable 
pools of granules. This increased [Ca2+] ion triggers the exocytosis of a small 
pool of granules that is responsible for the first phase of insulin release (Straub et 
al., 2002).  
Second phase of insulin secretion includes mobilization and trafficking of 
intracellular storage pools of insulin secretory granules to the plasma membrane 
(Spurlin et al., 2006). The fusion of insulin secretory granules is known to be 
regulated by soluble N-ethylmaleimide sensitive factor attachment protein 
receptor (SNARE) protein complexes at the plasma membrane (Spurlin et al., 
2006). 
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Fig: 1.3.3.2.2. The various components discussed in the text are illustrated in 
the cartoon of a beta cell and a mitochondrion within it. Glucose and fatty 
acid metabolism leads to an increase in NADH and Ca2+ and to a decrease in 
ADP. In turn, decreased ADP leads to increased mitochondrial membrane 
potential ( ). Increased glycolytic flux, decreased ADP concentration, and 
increased intracellular Ca2+ concentration may all contribute to increased 
GSIS in the electron transport chain (ETC). Solid lines indicate flux of 
substrates, and dashed lines indicate regulating effects, where (+) represents 
activation and (–) represents repression (Fridlyand et al., 2004). 
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Upon stimulation with glucose, the target membrane t-SNARE proteins Syntaxin 
1 (Syn1) and SNAP-25 (soluble NSF (N-ethylmaleimide sensitive factor) 
attachment protein) receptor leads the insulin granules to the plasma membrane 
through interaction with their cognate vesicle v-SNARE protein, vesicle-
associated membrane protein VAMP2.  Heterotrimeric SNARE core complex is 
composed of the vesicle-associated membrane protein (VAMP 2; synaptobrevin) 
and two predominantly plasma membrane proteins, syntaxin 1 and 
synaptosomal-associated protein of 25kDa (SNAP-25) (Quetglas et al., 2000). 
SNARE core complex facilitates the fusion of the insulin secretory granule with 
the plasma membrane and release of insulin from the cell (Spurlin et al., 2006). 
1.3.4 Insulin function 
The biological effects of insulin on the integration of fuel metabolism are 
primarily to promote the storage of glucose as glycogen, amino acids as proteins 
and fats as triglycerides. Insulin promotes fuel storage via a number of 
mechanisms.  
1.3.4.1 Glucose metabolism 
Once in the blood, insulin controls glucose homeostasis by stimulating the uptake 
of glucose into skeletal muscle and, to a lesser extent, into liver and adipose 
tissue. In skeletal muscle, heart muscle, and fat this uptake is mediated by the so-
called insulin-sensitive glucose transporter GLUT-4 (Shi et al., 2008). Once 
glucose enters the cells it is phosphorylated by hexokinase to glucose-6-
phosphate. Glucose-6-phosphate then undergoes glycolysis for energy production 
or it is stored as glycogen.  
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1.3.4.2 Lipid metabolism 
Lipids are basically insoluble in blood and are transported as lipoproteins. 
Triglycerides are hydrolysed to fatty acids and glycerol by the action of an 
enzyme lipoprotein lipase. Insulin stimulates the synthesis of the enzyme 
lipoprotein lipase (Gibson et al., 2002). 
1.3.4.3 Protein synthesis 
Insulin can stimulate protein synthesis in many types of cells in vivo and tissues, 
including human and rat muscles, and many types of cells in culture. This 
involves two major kinds of effects: the rapid activation of existing components 
of the translational apparatus and the longer term increase in the capacity of the 
cell or tissue for protein synthesis, which includes an increase in ribosome 
number (Proud, 2006). 
1.3.5 C-peptide 
C-peptide was discovered in 1967 and is a by-product of insulin production 
(Steiner, 2004). Insulin is synthesized in the pancreatic beta cell as a component 
of a polypeptide called proinsulin. Proinsulin is subsequently cleaved 
enzymatically, releasing insulin into the circulation along with a residual 3,000 
molecular weight fragment called C-peptide or connecting peptide. It is named 
connecting peptide as it connects the A chain and B chain of insulin within the 
proinsulin molecule (Rendell, 1983). Chen et al. (2002) reported that the highly 
conserved acidic N-terminal part of C-peptide plays an important role in insulin 
precursor folding. C-peptide also has some intramolecular chaperone-like 
function in the folding of insulin precursor (Chen et al., 2002). 
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 As insulin and C-peptide are secreted nearly in equal amounts, measurements of 
immunoreactive C-peptide release has proven to be useful as a measure of insulin 
secretory rate in vivo in humans (Rubenstein et al., 1969). The half-life of insulin 
is shorter than that of C-peptide approximately 3.0 minutes or less under normal 
conditions (Rendell, 1983). Beta cell function can be evaluated by calculating 
insulin secretion rate by deconvolution of peripheral C-peptide concentrations as 
proposed by Eaton et al. (1980) and again by Polonsky et al. (1986). 
Serum/plasma C-peptide assays have enabled evaluation of beta cell reserve in 
both diabetic and normal subjects (Polonsky et al., 1986). 
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1.4 Glucagon 
Glucagon was given its name by Kimball and Murlin (Murlin et al., 1923). In 
1955 Staub et al. purified and crystallized glucagon and 2 years later the amino 
acid sequence of glucagon was reported by Bromer et al. (1957).  
1.4.1 Structure of Glucagon 
Glucagon is a polypeptide that consists of a peptide chain of 29 amino acids (Fig: 
1.4.1). After cleavage of the signal peptide, proglucagon is cleaved into active 
glucagon, glucagon-related polypeptide (GRPP) and the major proglucagon 
fragment (Nussey et al., 2001; Pineda, 2003). 
 
 
 
Fig: 1.4.1 Amino acid sequence of Glucagon 
1.4.2 Biosynthesis of Glucagon  
Preproglucagon is produced in the alpha cells in pancreatic islets and L cells in 
the jejunum and ileum. A number of peptides can be produced from 
preproglucagon depending on posttranslational processing at dibasic amino acid 
sites. PC2 and PC1/3 is prohormone convertase enzyme and are found in high 
concentration in islet cells. PC2 converts preproglucagon to glucagon by 
cleaving the N-terminal part in alpha cells (Porte et al., 2003). Whereas PC1/3 
    NH2 
 
His-Ser-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser                                 
 
                  Thr-Asp-Met-Leu-Try-Glu-Val-Phe-Asp-Glu-Ala-Arg-Arg 
 
    NH2           NH2  NH2 
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cleaves the C-terminal part of preproglucagon, leading to the formation of GLP-1 
(Damholt et al., 1999) (Fig: 1.4.2).  
 
 
 
 
 
 
 
 
 
 
Fig: 1.4.2 Processing of the proglucagon to peptides in the alpha cells and 
intestinal L cells. GLP=glucagon-like peptide, GRPP= glicentin-related 
pancreatic peptide, IP= intervening peptide. The peptides shown are GRPP 
(proglucagon 1-30), glucagon (proglucagon 33-61), IP-1 (proglucagon 64-69), 
and MPGF (proglucagon 72-158) (Furuta et al., 2001). 
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Glucagon is derived from proglucagon which is also known as glicentin. 
Proglucagon is a 158 amino acid precursor containing glucagon and two related 
peptide sequences, glucagon-like peptides 1 and 2 (GLP-1 and -2). It is cleaved 
at a series of dibasic sites and at a single basic site to release a number of 
peptides, including glucagon, 2 glucagon containing peptides (GLP) and 2 other 
peptides known as intervening peptides (IP) (Fricker, 1991).  
These peptides are separated by three intervening peptides called glucagon-
related polypeptide (GRPP), intervening peptide I (IVP-I) and intervening 
peptide II (IVP-II) (Okamoto, 1990). 
In the islet cells of the pancreas the glucagon precursor is cleaved at Lys-Arg 
sequence thereby giving rise to glucagon and three possible inactive fragments: 
GRPP, IVP-I and MPGF (major proglucagon fragment). Glucagon and GRPP are 
released together from the pancreas (Moody et al., 1981). 
1.4.3 Glucagon secretion 
Glucose enters the alpha cell through either of glucose-transporter SLC2A1 or 
GLUT1. At low-glucose concentrations, the activity of KATP channels is low 
rendering a membrane potential of about –60 mV (Gromada et al., 2004). ATP-
dependent K+ (KATP) channels play a fundamental role in alpha cells, as they do 
in beta cells. However, lower ATP concentrations are required to obtain the 
maximum inhibition of KATP conductance in alpha cells compared to beta cells 
(Leung et al., 2005). The voltage-gated Ca2+-channels are divided into three 
subfamilies: 1) L-type Ca2+-channel; 2) N-type Ca2+-channels and 3) T-type 
Ca2+-channel (Gromada et al., 2007) (Fig: 1.4.3).  
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Fig: 1.4.3 Schematic model for glucose-dependent regulation of glucagon 
secretion in alpha cell. Glucose enters the alpha cell through glucose-
transporter SLC2A1. Glucose uptake and metabolism lead to an increase in 
the ATP/ADP ratio and closure of ATP-sensitive K+-channels (KATP-
channels) leading to membrane depolarization. This membrane 
depolarization leads to activation of voltage-gated Ca2+ -channels (T-, L- and 
N-type) and Ca2+ influx. This increase in the [Ca2+]i stimulates exocytosis of 
the glucagon-containing granules. 
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At the potential between –40 and –30 mV, voltage-dependent T-type Ca2+-
channel opens, depolarizing the plasma membrane. This depolarization leads to 
activation of N-type Ca2+ channels and voltage-dependent Na+ channels 
(MacDonald et al., 2007). Their activation triggers Ca2+ influx and exocytosis of 
glucagon granules (Gromada et al., 2007). 
The opening of A-type K+ channels is necessary for action potential 
repolarization (Quesada et al., 2006). However, high-glucose concentrations 
elevate the intracellular ATP/ADP ratio completely blocking the KATP channels 
leading to greater membrane depolarization (MacDonald et al., 2007). The 
voltage-gated Ca2+ and Na+ channels therefore become inactivated and electrical 
activity ceases. This result in reduced Ca2+ influx and suppressed glucagon 
secretion (Gromada et al., 2004; Quesada et al., 2008).  
1.4.4 Actions of glucagon 
The function of glucagon is antagonistic to that of insulin. The release of 
glucagon is stimulated by hypoglycemia and inhibited by hyperglycemia, insulin 
and somatostatin (Muñoz et al., 2005). The control of glucagon secretion is 
regulated by low glucose and by intra-islet insulin. The physiological role of 
glucagon is to stimulate production and secretion of glucose. Glucagon acts 
primarily on the liver, stimulating glycogenolysis and gluconeogenesis 
increasing the blood glucose levels (Chiasson et al., 1975; Magnusson et al., 
1995). Glucagon stimulates lipolysis that increases the circulating concentration 
of free fatty acids. Hormone-sensitive lipase mediates the lipolysis of 
triacylglycerol into the non-esterified fatty acids and glycerol, which are released 
from adipocytes. It has been reported that glucagon increases the release of 
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glycerol from adipocytes (Slavin et al., 1994). It stimulates the hepatic uptake of 
amino acids for gluconeogenesis in the liver (Goodman, 2003).  Glucagon may 
also be involved in diabetic ketoacidosis, a medical complication in diabetes 
derived from the overproduction of ketone bodies (Eledrisi et al., 2006). 
1.4.5 Glucagon in diabetes 
Diabetes is the result of an insulin deficiency or resistance along with an absolute 
or relative excess of glucagon, resulting in a higher rate of hepatic glucose 
production than glucose utilization, favouring hyperglycaemia. The rate of 
hepatic glucose output has been correlated with the hyperglycaemia found in 
animal models of diabetes as well as in human diabetes, and the maintenance of 
this abnormality has also been associated with hyperglucagonaemia (Dunning et 
al., 2007; Li et al., 2008). Lack of suppression of glucagon release is observed in 
hyperglycaemic conditions, which further contributes to postprandial 
hyperglycaemia in both Type 1 and Type 2 diabetes (Shah et al., 2000.  
Impaired insulin secretion is found to mediate both the impaired postprandial 
suppression of glucagon release (Meier et al., 2006) and the impaired glucagon 
response to hypoglycemia (Gosmanov et al., 2005; Raju et al., 2005). The 
glucagon response to hypoglycaemia is known to disappear within a few months 
after the onset of Type 1 diabetes, whereas the response to other stimuli remains 
intact (Jauch-Chara et al., 2007). Lorenzi et al. (1984) also reported that in 
patients with Type 1 diabetes for more than ten years the glucagon responses to 
insulin hypoglycemia was severely blunted or absent and also the abrupt 
restoration of plasma glucose levels was impaired. The loss of the glucagon 
response to falling plasma glucose concentrations has been observed, which is a 
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key feature of the pathogenesis of induced hypoglycemia, in insulin-deficient 
(Type 1 and advanced Type 2) diabetes (Raju et al., 2005). Whether all 
abnormalities of alpha cell function in Type 2 diabetes are secondary to beta cell 
dysfunction is still controversial (Dunning et al., 2007). 
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1.5 Somatostatin  
Somatostatin was first discovered in hypothalamic extracts and identified as 
acting on pituitary to inhibit growth hormones. Subsequently it was also found to 
be secreted by other extra hypothalamic regions of the central nervous system, 
present in the cells of peripheral nervous system and in non-neural tissues 
including thyroid, gut and endocrine pancreas (Srikant, 2004). 
1.5.1 Structure of Somatostatin  
Somatostatin is present in two forms- somatostatin 14 (SST-14) and somatostatin 
28 (SST-28), reflecting its amino acid chain length. SST is synthesized from a 
116 amino acid peptide, preprosomatostatin by proteolytic cleavages (Funckes et 
al., 1983). In mammals, preprosomatostatin is encoded by a single mRNA 
sequence (Montminy et al., 1984). Proteolytic cleavage of 24 amino acids at the 
N-terminus of preprosomatostatin leads to the formation of prosomatostatin (Noe 
et al., 1989). Prosomatostatin is processed in two different ways to generate SST-
14 and SST-28 (Montminy et al., 1984) in a tissue specific manner. SST-14 is 
synthesized in brain, pancreas and gastric tissue, while SST-28 is mainly 
synthesized in the intestinal epithelium (McPhee et al., 2006).  
1.5.2 Actions of somatostatin 
Somatostatin has an inhibitory effect on the insulin-releasing action of beta cells. 
It is also found to suppress the activity of glucagon release from adjacent alpha 
cells (Berts et al., 1996). Hypothalamic somatostatin has been established as an 
inhibitor of growth hormone release from the pituitary cells (Thermos, 2008). 
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1.6 Pancreatic Polypeptide 
Pancreatic polypeptide (PP) is a 36 amino acid polypeptide and belongs to the 
family of regulatory peptides consisting of neuropeptide Y (Npy) and peptide 
YY (PYY) (Glover et al., 1984; Mor et al., 1994). PP is produced by PP cells, 
which are localized in the periphery of pancreatic islets of Langerhans and 
scattered between the acinar cells of the pancreatic head and uncinate lobe 
(Larsson et al., 1976). More than 95% of PP is of pancreatic origin and the rest is 
released from the gastrointestinal tract (Liu et al., 1999; Stanley et al., 2004). 
1.6.1 Role of Pancreatic polypeptide 
Physiologically, pancreatic polypeptide (PP) is released in response to food 
ingestion (Dembiński et al., 2004). PP reduces the secretion from the exocrine 
pancreas. It also decreases gall bladder contraction and inhibits gastric and small 
intestine motility. It also helps to pace the entry of nutrients into the circulation 
by slowing down the digestive process (Liu et al., 1999). 
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1.7 Insulin producing cell lines 
In contrast to conventional insulin treatment, either replacement of a patient's 
islets of Langerhans by whole pancreas transplantation or by isolated islet 
transplantation is a likely cure for diabetes (Bretzel et al., 2007). Isolated islet 
transplantation has shown success (Shapiro et al., 2000). Islet transplantation was 
performed on sixty-five patients in Edmonton in 2004. Five-year follow-up study 
carried on these transplanted patients revealed that approximately 80% had C-
peptide present post–islet transplantation, but only a minority (~10%) maintained 
insulin independence (Ryan et al., 2005). The 2008 CITR report describes 325 
islet transplant recipients. Of these recipients, most (86%) received islet-alone 
infusions, while the others (14%) had previously received a kidney transplant and 
followed by islet transplant (Collaborative Islet Transplant Registry 2008).  
Low numbers of donated pancreas necessitates the search for other beta cell/islet 
sources. It has been proposed that replacement beta cells may be generated from 
stem/progenitor cells, from the pancreas and expanded in vitro, making it a 
possibility that enough islets could be produced from a pancreas obtained from a 
single donor for one or more successful transplants (Ren et al., 2007). However, 
so far, an adequate supply of such cells has not been identified. Another 
alternative source includes the use of cultured beta cell lines isolated from rodent 
islets or human islets (Suzuki et al., 2003; Limbert et al., 2008). 
Cultured beta cell lines are important for research purposes, as they provide a 
“pure cell” population to work with and great for studying islet cell biology and 
transcriptional cascade of endocrine differentiation (Limbert et al., 2008). 
However, beta cell lines generated to date lack the characteristics of mature beta 
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cells and generally demonstrate reduced insulin secretion and some show loss of 
proliferation (Kayo et al., 1996; O’Driscoll et al., 2006; Limbert et al., 2008). 
The most widely used insulin-secreting cell lines are RIN, HIT, βTC, MIN6 and 
INS-1 cells. These cells secrete mainly insulin but are also known to secrete 
glucagon and somatostatin (Poitout et al., 1996; Hohmeier et al., 2004). There 
has been evidence of loss of GSIS along with down-regulation of glucagon 
mRNA expression with increased passage in MIN6 cells (O'Driscoll et al., 
2004). 
1.7.1 MIN6 cell line  
MIN6 cell lines have been established from insulinomas obtained by targeted 
expression of the simian virus 40 T antigen genes in transgenic mice. MIN6 cell 
line produces insulin and T antigen and have morphological characteristics of 
pancreatic beta cells. MIN6 cells exhibit GSIS comparable with cultured normal 
mouse islet cells (Miyazaki et al., 1990) and have been considered as an 
appropriate model for investigating the mechanism of GSIS. The results indicate 
that glucose metabolism and the glucose concentration-dependence of insulin 
secretion from MIN6 cells closely resemble those in normal beta cells, and that 
this cell line is thus a useful tool for studying GSIS in normal pancreatic beta 
cells (Ishihara et al., 1993). Previous MIN6 studies showed loss in functional 
GSIS correlated with changes in morphology, increased proliferation and 
increased alkaline phosphatase activity, suggesting that the loss of GSIS may be 
due to de-differentiation of the high passage MIN6 cells (O'Driscoll et al., 2004 
and 2006). 
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1.7.2 MIN6 B1 cell line 
MIN6 B1 cell line was derived from the mouse pancreatic beta cell line MIN6. 
MIN6 B1 responded to glucose in a concentration- and cell confluence-
dependent manner. MIN6 B1 insulin secretion, when stimulated by glucose in a 
concentration-dependent fashion, repeatedly reached 12-fold after 1 hour of 
stimulation with 16.7 vs. 2.8 mmol/L glucose (Lilla et al., 2003).  
1.7.3 Vero–PPI cell line 
Vero cells were derived from epithelial cells of kidney from African green 
monkey (Cercopithecus aethiops) (Yasumura et al., 1963). In our laboratory this 
non-beta cell line was engineered by Dr. Lorraine O’Driscoll to produce and 
process human proinsulin by transfection of the human PPI cDNA. These Vero-
PPI cells secreted mature human insulin but failed to show GSIS (O’Driscoll et 
al., 2002). 
1.7.4 RIN cell lines 
Two cell lines were derived from a transplantable islet-cell tumour. One named 
RIN-r and maintained in NEDH rats. The other cell line named RIN-m and had 
been maintained in nude mice (Gazdar et al., 1980). Further research on these 
early cell lines lead to various subclones originating either from the RIN-m line 
(Bhathena et al., 1980) or the RIN-r line (Philippe et al., 1986). Low passage of 
the RINm5F subclone, derived from the RIN-m line, exhibited modest GSIS, 
with a 50% increase in insulin release between 0 and 1.4mmol/L glucose (Praz et 
al., 1983). RINm5F is a cell line that is less differentiated than the MIN6 cell line 
(Kayo et al., 1996) and show a defective physiological insulin secretory response 
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to glucose stimulation (Tiedge et al., 1996). RINm5F tumour cells can thus be 
used as a model for studying the glucose-recognition apparatus on glucose-
induced insulin biosynthesis and secretion (Tiedge et al., 1993). 
1.7.5 HIT cell lines 
Hamster insulinoma (HIT) cells were isolated from Syrian hamster pancreatic 
islet cells and transformed by infection with simian virus 40. The HIT-T15 line 
was subcloned from the original cell lines and selected for high insulin content. 
HIT-T15 cells were reported to be responsive to a glucose stimulus and many 
other secretagogues (Hohmeier et al., 2004). The dose–response curve for 
glucose showed a threshold of responsiveness below 1 mmol/L (i.e. sub-
physiological), with peak stimulation between 7.5 and 10mmol/L, and a half-
maximal response at approximately 5mmol/L. The magnitude of responsiveness 
to glucose was two-fold. However, responses to glucose, as well as other 
secretagogues, such as arginine and forskolin, were found to decrease with 
increasing time in culture (Zhang et al., 1989).  
1.7.6 βTC cell lines 
The βTC class of insulinoma cell lines was established by targeted expression of 
the SV40 large T-antigen in beta cells of transgenic mice (Hanahan, 1985). The 
first cell lines established from these mice (βTC1, βTC2 and βTC3) produced 
and secreted insulin in response to a glucose stimulus (Efrat et al., 1988). 
However, insulin secretion occurred with a left shift of the dose–response curve, 
with maximal insulin secretion at 1.25mmol/L glucose. A more detailed analysis 
of the βTC3 line showed that insulin secretion increased progressively between 
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glucose concentrations of 0.1 and 16.7mmol/L (D’Ambra et al., 1990) but with a 
lower threshold for maximal stimulation than that for normal beta cells (Efrat et 
al., 1988). βTC cell lines maintain their features of differentiated beta cells for 
about 50 passages in culture (Efrat et al., 1988).  
βTC3 was reported to secrete insulin with increasing glucose concentration and 
produce significantly higher levels of insulin compared to RIN (rat islet 
insulinoma) or HIT (hamster islet cell line) cells. βTC3 cells have shown to 
possess the ATP-dependent K+ (KATP) channel electrical activity and also used 
for studies of cytoplasmic Ca2+ release (Gromada et al., 1996; Kozak et al., 
1998). 
1.7.7 INS-1 line 
A widely used cell line for insulin secretion studies is the INS-1 cell line which 
was derived from the original radiation induced tumour (Chick et al., 1977). The 
INS-1 cell line was established by growing the tumour material in the presence 
of 2-mercaptoethanol (2-ME) (Asfari et al., 1992).  
INS-1 cells express GLUT2 and glucokinase maintaining glucose responsiveness 
in the physiological range. The maximum glucose stimulated insulin secretion is 
generally only 2–4-fold (when treated with 3 or 20mmol/L glucose), well below 
the 15-fold responses observed in freshly isolated rodent islets (Asfari et al., 
1992; Antinozzi et al., 1998).  
1.7.8 Human beta cell line for transplantation therapy 
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There is limited donor tissue supply compared to the large number of diabetes 
patients detected each year. Therefore, great efforts have been undertaken to 
develop alternative strategies including ex vivo expansion of beta cells, in vitro 
differentiation of embryonic/adult stem cells into insulin producing beta cell 
phenotypes and gene therapy (Giannoukakis et al., 2002; Bretzel et al., 2004; 
Onaca et al., 2007; Limbert et al., 2008). 
Alternative sources of islets have been sought in stem cells (Assady et al., 2001; 
Moritoh et al., 2005), porcine islets (Korsgren et al., 2003) and beta cell 
expansion with growth factors (Hayek et al., 1995; Beattie et al., 2002). 
Embryonic stem (ES) cells are derived from embryos at the blastocyst-stage and 
have the ability to differentiate into all cell types. Xu et al. (2006) and D’Amour 
et al. in 2006 demonstrated that human ES cells could be differentiated into 
hormone-expressing endocrine cells. The insulin-positive cells thus generated 
had insulin content similar to that found in adult islet cells, along with ATP-
sensitive potassium channel and voltage-dependent calcium channels. But these 
cells lacked GSIS and insulin-positive cells made up only about 7% of the 
differentiated population (Claiborn et al., 2008).  
Expansion of primary beta cells by growth factors is also hampered by the 
senescence of the cells (Halvorsen et al., 2000). Immortalization of purified beta 
cells by the addition of genes such as TERT could allow the cells to grow 
indefinitely; however, immortalized beta cell lines established in this way lose 
their differentiated function (de la Tour et al., 2001). 
Kroon et al. (2008) reported that glucose-responsive endocrine cells could be 
generated from human ES cells after implantation into mice. These insulin-
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expressing cells that were generated after engraftment showed many properties 
of functional beta cells, including expression of beta cell transcription factors, 
processing of proinsulin along with the presence of mature endocrine secretory 
granules. Upon histopathological analysis Kroon et al. (2008) reported that the 
proportion of endocrine cells within the pancreatic-type tissue was >50%. 
Glucose stimulation of the implanted mice resulted in secreted human insulin and 
C-peptide at levels similar to those of mice transplanted with approx 3,000 
human islets. Human ES cell–derived endocrine cells as reported in this study 
were functionally very similar to adult human islets, providing evidence that 
human ES cells may provide a renewable source of islets for cell replacement 
therapies (Kroon et al., 2008; Stanley et al., 2008). 
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1.8 Thioredoxin-interacting protein (Txnip)  
Thioredoxin-interacting protein (Txnip), also known as Vitamin D (3)-up-
regulated protein-1, Vdup1; TRX-binding protein-2, TBP-2, is a ubiquitous 
protein that binds with high affinity to thioredoxin, and inhibits its ability to 
reduce sulfhydryl groups via NADPH oxidation (Hui et al., 2004). Thioredoxin 
is an oxidoreductase that reduces oxidized proteins and scavenges free radicals 
(Muoio et al., 2007) (Fig: 1.8.1). Txnip is also found to be stress responsive and 
inhibits thioredoxin activity (Yamawaki et al., 2005). It is believed that 
thioredoxin facilitates the processing and maturation of insulin and, thus, may 
prevent unfolded protein response-induced apoptosis of pancreatic beta cells 
(Hui et al., 2004). 
Using FISH Ludwig et al. (2001) mapped mouse Txnip gene to chromosome 3, a 
region showing homology of genetic loci to human chromosome 1q21.1. 
Chromosome 1q21.1 is a region that has shown to be the most consistent linkage 
to Type 2 diabetes mellitus (T2DM) (Elbein et al., 1999; Vionnet et al., 2000). 
The 1q21-1q23 chromosomal area has been implicated in T2DM and localization 
of Txnip on the same chromosome could lead to the hypothesis that variation in 
Txnip gene may affect susceptibility to T2DM (Greevenbroek et al., 2007).  
Txnip is a pro-apoptotic factor and is involved in beta cell glucose toxicity and 
oxidative stress (Chen et al., 2006; Chen et al., 2008). Txnip is over-expressed in 
diabetes in the cardiovascular system and has deleterious effects on pancreatic 
beta cells (Schulze et al., 2002). Txnip has been identified as the most 
dramatically glucose-induced gene in human islet microarray study (Minn et al., 
2005). 
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Fig: 1.8.1 Models of Txnip showing the role of Txnip in the thioredoxin 
system. Thioredoxin (TXN) reduces oxidized cysteine residues (protein-S2) 
on cellular proteins. Reduced TXN (TXN-(SH)2) is regenerated via the 
action of thioredoxin reductase (TXR) at the expenditure of NADPH. When 
TXN reduces the oxidized form of thioredoxin peroxidase (TXP), the 
reduced enzyme (TXP-(SH)2) is available to scavenge reactive oxygen 
species (ROS) such as hydrogen peroxide (H2O2) and the superoxide anion 
(O2•−). Txnip binds and inhibits the reduced form of TXN, thereby 
functioning as a rheostat that modulates both redox status and ROS-
mediated signalling to regulate metabolism and other cellular processes. 
(Dashed arrows indicate unknown mechanisms) (Muoio et al., 2007). 
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Parikh et al., (2007) proposed that Txnip functions as a homeostatic regulator that 
incorporate glucose sensing and insulin signaling to control cellular energy 
status. They suggested that insulin-mediated suppression of Txnip might act as a 
signal that enhances glucose uptake in the periphery to facilitate post-meal 
energy uptake. Whereas, surplus intracellular glucose activates Txnip, bringing 
glucose uptake to a halt (Parikh et al., 2007) (Fig: 1.8.2).  
 
 
 
 
 
 
Fig: 1.8.2 Role of Txnip in Type 2 diabetes. Insulin-mediated suppression of 
muscle Txnip serves as a signal to enhance glucose uptake and facilitates 
post-meal energy uptake. A surplus of glucose activates Txnip, which exerts 
negative feedback (−) to discourage glucose uptake. The energy burden of 
over nutrition and inactivity (blue lines) leads to high levels of Txnip in 
muscle and is aggravated further by insulin resistance. This leads to a 
chronic glucose load on the pancreas, triggering Txnip -mediated beta cell 
failure and leading to diabetes (adapted from Muoio et al., 2007). 
 
Muscle 
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Hui et al. (2004) reported that Txnip regulates glycolysis. Over-expression of 
Txnip might signal to reduce uptake of glucose and reduced insulin secretion 
from the pancreatic beta cells (Fig: 1.8.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 1.8.3 Schematic representation of effect of Txnip on insulin secretion. 
Increased Txnip reduces the uptake of glucose and thereby may reduce the 
production of insulin in the pancreatic beta cell. 
It has been proved that, in addition to regulating the cellular redox status, Txnip 
modulates overall gene transcription and thereby may further enhance beta cell 
death and impair insulin secretion, suggesting that it may be involved in glucose 
toxicity, beta cell loss and diabetes complications (Minn et al., 2005). Txnip is 
elevated in the vasculature and pancreas of diabetic animals, suggesting a broad 
role in diabetes complications (World et al., 2006). Over-expression of Txnip 
Glucose
Glucose 6-phosphate
ATP : ADP
K+
K+ AT P
channel
Glucokinase
Glucose
GL UT 2
Voltage-g ated
Ca2+ channel
Ca2+
In su lin
Metabolism
+
_
Nucleus
Insu lin
Secretory
Granules
I
+
RER
Golgi
Txnip
Reduced or 
no glucose 
uptake
Reduced or 
no insulin 
secretion
 
 47 
sensitizes various cell types including endothelial cells, pancreatic beta cells and 
cardiomyocytes to oxidative stress with concomitant induction of apoptosis 
(World et al., 2006; Muoio et al., 2007). 
Reduced Txnip expression is associated with increased tumour cell growth and 
metastatic potential (Goldberg et al., 2003), and this phenomenon has been 
observed in human breast cancer and colon cancer (Butler et al., 2002; Ohta et 
al., 2005). The anti-cancer agent suberoylanilide hydroxamic acid (SAHA) acts 
in part by increasing Txnip expression (Butler et al., 2002). Txnip leads to cell 
cycle arrest at the G0/G1 phase (Han et al., 2003) and it has been shown to 
inhibit proliferation in a variety of cells (Junn et al., 2000; Schulze et al., 2002). 
Over-expression of Txnip renders cells more susceptible to oxidative stress and 
induces apoptosis (Junn et al., 2000; Wang et al., 2002; Minn et al., 2005).  
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1.9 Proprotein convertase subtilisin/kexin type 9 (Pcsk9) 
Proprotein convertase subtilisin/kexin type 9 (Pcsk9) is also known as convertase 
subtilisin; neural apoptosis regulated convertase 1, Narc1; and is located on the 
chromosome 4. It is a 692-residue extracellular protein expressed primarily in the 
kidneys, liver and intestines representing the 9th member of the secretory 
subtilase family. Pcsk9 gene is a novel putative proprotein convertase belonging 
to the subtilase subfamily (Seidah et al., 2003). It is synthesized as a soluble 
zymogen that undergoes autocatalytic intramolecular processing in the 
endoplasmic reticulum (ER) as a precursor that undergoes autocatalytic 
processing, intracellular trafficking and finally, release into the extracellular 
medium (Lambert et al., 2006). 
The Pcsk9 protein domains comprises of 30 amino acid signal peptide (SP), the 
propeptide or inhibitory prodomain consists of 31–152 amino acids, the 
subtilisin-like catalytic domain (amino acids 153–452), and a cysteine-rich, 
unique, C-terminal domain (CRD) consists of 453–692 amino acids (Fig: 1.9). 
The central part of the catalytic domain consists of seven-stranded parallel β-
strand sandwiches between sets of alpha-helices. Three disulfide bonds are found 
within this region (Lopez et al., 2008). 
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Fig: 1.9 The protein domains that comprise Pcsk9 are a 30 amino acid signal 
peptide (SP), the propeptide, the subtilisin-like catalytic domain, and a 
cysteine-rich, unique, C-terminal domain. Important residues such as the 
triad of active site residues: aspartate 186 (D186), histidine 226 (H226) and 
serine 386 (S386), the highly conserved asparagine 317 (N317), and an N-
glycosylation site (Asn533) have been indicated. The autocleavage site has 
been mapped to SVFAQ↓152 (Lopez et al., 2008). 
Pcsk9 mRNA is expressed in a limited number of tissues including the liver, 
kidney, cerebellum, and small intestine. It is also found to be transiently 
expressed in kidney epithelial and brain telencephalon cells (Seidah et al., 2003). 
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1.10 Important gene transcripts associated with beta cell  
1.10.1 Insulin I (Ins1) and Insulin II (Ins2) 
In contrast to humans, rodents express two proinsulin isoforms. One isoform, 
proinsulin 1, is expressed exclusively in islet beta cells. The second, proinsulin 2, 
is expressed in islets and in other tissues, especially the thymus. Both insulin are 
the product of nonallelic preproinsulin gene and are very similar (Soares et al., 
1985). Insulin II (Ins2) is the murine homologue of the human insulin gene and is 
located on mouse chromosome 7. Insulin I (Ins1) is thought to have evolved by a 
gene duplication event, lacks the second intron of the Ins2 gene, and is located on 
mouse chromosome 19 (Paronen et al., 2003). 
The Ins1 gene possesses an intron homologous to the 119 base pair (bp) intron of 
Ins2. The Ins2 gene contains two introns: a 499 bp intron interrupting the region 
encoding the connecting peptide and a 119 bp intron interrupting the segment 
encoding the 5 noncoding region of the mRNA. The introns are transcribed and 
present in a preproinsulin mRNA precursor (Lomedico et al., 1979).  
1.10.2 Phospholipase D1 (Pld1) 
Pld1 gene is also known as choline phosphatase 1 and is located on chromosome 
3. Three Pld isoenzymes have been identified: two Pld1 alternative spliced forms 
(Pld1a, Pld1b) and Pld2. Pld1 plays an important role in signal transduction, cell 
growth, intracellular protein trafficking, secretion and glucose transport (Hughes 
et al., 2004; Viparelli et al., 2008). It has been established that Pld1 activity is 
required for both phases of glucose-stimulated insulin release, suggesting its role 
in exocytosis. The results suggest that phosphatidic acid formation on the granule 
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membrane by Pld1 is essential for the regulated secretion of insulin from 
pancreatic beta cells (Hughes et al., 2004). Pld1 hydrolyzes membrane 
phospholipid phosphatidylcholine to generate phosphatidic acid (PA) and choline 
with subsequent activation of protein kinase C and stimulation of insulin release 
(Du et al., 2003; Cho et al., 2008). 
Hughes et al. (2004) suggested Pld1 to be the predominant isoform in MIN6 
cells, and to be located at least partially on insulin granules. Over-expression of 
wild-type or a dominant negative catalytically inactive mutant of Pld1 
augmented or inhibited, secretagogue-stimulated secretion, respectively (Hughes 
et al., 2004). 
1.10.3 Early growth response 1 (Egr1) 
Egr1 is also known as nerve growth factor-induced clone A (NGFI-A) and is 
located on chromosome 18. It is an immediate-early response gene implicated in 
the regulation of cell growth, differentiation and apoptosis. In beta cells, Egr1 
induction is specifically associated with insulin secretion. Glucose rapidly and 
transiently induces Egr1 mRNA in MIN6 (Josefsen et al., 1999). Changes in 
Egr1 expression levels, in response to extracellular signals including glucose, 
regulate Pdx1 expression and insulin production in pancreatic beta cells. Egr1 
regulates expression of Pdx1 in pancreatic beta cells by both direct and indirect 
activation of the Pdx1 promoter. Egr1 expression levels may act as a sensor in 
pancreatic beta cells to translate extracellular signals into changes in Pdx1 
expression levels and pancreatic beta cell function (Eto et al., 2007). 
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1.10.4 Homeodomain transcription factor pancreas duodenum homeobox-1 
(Pdx1) 
The homeodomain transcription factor pancreas duodenum homeobox-1 is also 
known as homeodomain transcription factor, IPF1; somatostatin transcription 
factor 1, STF1; pancreas duodenum homeobox-1, Pdx1 and Idx1. Pdx1 gene is 
located on chromosome 5. Pdx1 belongs to the antp-family of homeobox proteins 
(Hui et al., 2002). 
Pdx1 is a key regulator of pancreatic beta cell development, function, and 
survival and is known to serve as “a master control switch” for expression of 
both the exocrine and endocrine pancreatic cells. During embryogenesis, Pdx1 is 
initially expressed by exocrine and endocrine cells of the pancreas and it is 
important for pancreas development and function of the mature islet cells 
(Gannon et al., 2008).  
Pdx1 expression is restricted to beta and delta cells of the islets (Sharma et al., 
1997) and it is required for activating transcription of genes including insulin, 
somatostatin, islet amyloid polypeptide, glucose transporter type 2, and 
glucokinase (Guz et al., 1995). In addition, glucose induces Pdx1 activity by 
phosphorylation and nuclear translocation via the PI3-kinase-dependent pathway. 
On the other hand, chronic hyperglycemia and elevated fatty acid levels down-
regulate the expression of Pdx1 (Harmon et al., 1999). Deficits in Pdx1 
expression result in insulin deficiency and hyperglycemia (Eto et al., 2007). 
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1.10.5 Chromogranin B (Chgb)  
Chromogranin B (Chgb) is also known as secretogranin I (scg1) and is located 
on chromosome 2 (Jenkins et al., 1991). Chgb functions as a neuroendocrine 
secretory granule protein and it may be the precursor for other biologically active 
peptides. Chgb are major Ca2+ storage proteins of the secretory granules of 
neuroendocrine cells (Yoo et al., 2002).  Giordano et al. (2008) suggested the co-
existence of insulin and chgb in various insulin-secreting beta cells of various 
types of secretory granules. They also reported that changes in chgb release may 
result in alterations of insulin secretion and may therefore contribute to various 
types of metabolic diseases (Giordano et al., 2008). 
 1.10.6 Prohormone convertase 2 (PC2)  
Prohormone convertase 2 is now officially known as proprotein convertase 
subtilisin/kexin type 2 (Pcsk2). It is located on the chromosome 2. 
Proinsulin is converted to insulin by the concerted action of two sequence-
specific subtilisin-like proteases termed prohormone convertase 1 (PC1) (PC1 is 
also known as PC3) and prohormone convertase 2 (PC2) (Neerman-Arbez et al., 
1994). PC2 is a type II proinsulin-processing enzyme, and it cleaves the 
proinsulin molecule on the COOH-terminal side of dibasic peptide, Lys [64]-
Arg[65], which joins the C-peptide and the A-chain domains (Yoshida et al., 
1995). 
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1.10.7 Glutamate decarboxylase (GAD) 
GAD is an enzyme found on the surface of beta cells that helps metabolize 
glutamic acid. There are two forms of GAD i.e. GAD65 (also known as Glutamic 
acid decarboxylase 2 (Gad2)) and GAD67 (also known as Glutamic acid 
decarboxylase 1 (Gad1)). The presences of GAD autoantibodies serve as a 
marker for the early diagnosis (up to 7 years before the clinical onset) of Type 1 
diabetes (Park et al., 2006). Ludvigsson et al. (2008) assessed the ability of 
alum-formulated GAD (GAD-alum) to reverse recent-onset Type 1 diabetes 
patients. They reported that following GAD-alum treatment (subcutaneous 
injections of GAD-alum) there was slow loss of residual beta cell function up to 
30 month compared to placebo (alum alone) patients (Ludvigsson et al., 2008). 
GAD65 has been assigned to chromosome 10, whereas GAD67 is located on 
chromosome 2 (Kelly et al., 1992).  
1.10.8 Neuropeptide Y (Npy) 
Neuropeptide Y (Npy) is neuroendocrine regulatory peptide consisting of 36 
amino acids. It is present in central nervous system, peripheral nerve fibres, and 
neuroendocrine tissues, including the pituitary gland and adrenal glands 
(Terenghi et al., 1987).  Synthesis of Npy is also demonstrated within rat islets 
(Jamal et al., 1991; Wang et al., 1994) and in RIN-m5F and INS 1 (Waeber et 
al., 1993) clonal rat insulinoma cells, suggesting a possible role for Npy as a 
paracrine regulator in the islet. Npy has been co-localized, by means of double 
label immunohistochemistry, with insulin and glucagon in embryonic mouse 
islets, and it has been identified with glucagon in both adult human and adult 
mouse alpha cells (Waeber et al., 1995). Hirai et al. (2008) reported Npy
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new potential autoantigen associated with secretory vesicles in Type 1 diabetes. 
Npy was also found to be significantly higher in sera from patients with Type 1 
diabetes compared to controls (Hirai et al., 2008). 
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1.11 siRNA and shRNA 
Small interfering RNA (siRNA) is also known as short interfering RNA or 
silencing RNA. It is a class of 20-25 nucleotide-long double-stranded RNA 
molecules. In the late nineties RNA silencing was discovered in plants during the 
course of transgenic experiments that eventually led to the silencing of the 
introduced transgene and, in some cases, of homologous endogenous genes or 
resident transgenes (Matzke et al., 1989; Linn et al., 1990; Napoli et al., 1990; 
Smith et al., 1990; van der Krol et al., 1990). However, this approach could not 
be used in mammalian cells as the long double-stranded RNAs (dsRNAs) 
triggered a cytotoxic reaction leading to cell death (Hunter et al., 1975). 
Cytotoxic reaction, mediated by the interferon system, protected the organism 
from RNA viruses by sacrificing the infected cell and thus preventing the spread 
of the virus (Stark et al., 1998). It was later reported that the dsRNAs shorter 
than 30 nucleotides do not trigger the interferon response; therefore artificially 
produced siRNAs and their delivery into mammalian cells were able to 
efficiently induce RNA silencing (Elbashir et al., 2001).  
siRNA-induced silencing is short-lived and cannot be used to study long-term 
effects therefore constructs were developed to directly express siRNA-like 
molecules in cells (Brummelkamp et al., 2002). These constructs uses RNA-
polymerase III to express a short hairpin RNA (shRNA). This polymerase is 
specialised to transcribe short templates with a precisely defined termination 
signal. The resulting transcript is about twice as long as the mature siRNA and 
folds back upon itself to form a double-stranded precursor with one end 
exhibiting the 2-nucleotide overhang that is typical for siRNAs, while the other 
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end forms a bulge. Dicer recognises the open end of this structure and excises the 
mature siRNA, thus producing a single siRNA from each transcript (Kim et al., 
2005; Siolas et al., 2005) (Fig: 1.11.1). 
1.11.1 Mechanism of action  
Long double-stranded RNA (dsRNA) (typically >200 nt) upon introduction, 
enters a cellular pathway that is commonly referred to as the RNA interference 
(RNAi) pathway. During the initiation stage, long dsRNA is cleaved into siRNA 
(Hamilton et al., 2002), mediated by type III RNase Dicer enzyme. RNase III 
family members are among the few nucleases that show specificity for dsRNAs 
(Nicholson, 1999) and are evolutionarily conserved in worms, flies, fungi, plants, 
and mammals (Agrawal et al., 2003). Complete digestion by RNase III enzyme 
results in dsRNA fragments of 23- to 28-mer diced siRNA products (Blaszczyk et 
al., 2001).  
During the effector stage, the siRNAs assemble into endoribonuclease-containing 
complexes known as RNA-induced silencing complexes (RISCs). siRNAs 
undergo unwinding before being incorporated into a high-molecular-weight 
protein complex called RISC (Hammond et al., 2000). Dicers are part of the 
RISC complex, which includes several different proteins such as the Argonaute 
gene family members and an ATP-dependant RNA helicase activity that unwinds 
the two strands of RNA. Functional RISCs contain only single stranded siRNA 
(Martinez et al., 2002). The siRNA strands subsequently guide the RISC to 
complementary RNA molecules, where base pairing takes place between the 
antisense strand of the siRNA and the sense strand of the target mRNA. This 
leads to endonuclease cleavage of the target RNA (Novina and Sharp, 2004). 
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Gene silencing by RISC is accomplished via homology-dependent mRNA 
degradation (Tuschl et al., 1999; Hamilton & Baulcombe, 1999), translational 
repression (Grishok et al., 2001) or transcriptional gene silencing (Pal-Bhadra et 
al., 2002) (Figure 1.11.1). 
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Fig: 1.11.1 siRNA mechanism of action. dsRNAs are processed by a host 
Dicer enzyme to form siRNAs. Dicer-processed siRNAs and synthetic 
siRNAs undergo ATP dependent unwinding before being incorporated into 
a protein complex called RISC (RNA-induced silencing complex) that 
contains single stranded siRNAs. The RISC is reconfigured to active RISC 
which contains the proteins required for cleaving the target mRNA at the 
point where the antisense siRNA binds. After the cleavage the active RISC is 
released to cleave additional mRNA molecules whereas the cleaved mRNA is 
degraded by cellular ribonucleases. 
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1.12 Biomarkers for diabetes 
There are no reported circulating biomarkers for detecting beta cell mass and 
function. As Type 1 diabetes is usually detected after a loss of about 90-95% of 
the beta cells (Atkinson et al., 2005), association of gene expression with beta 
cell loss, if detectable in serum, may aid in early detection of the disease. 
Autoimmune processes are involved in pancreatic beta cell destruction in Type 1 
diabetes. Autoantibodies including islet cell antibodies (ICA), glutamic acid 
decarboxylase antibodies (GADA) and antibodies directed against protein 
tyrosine phosphatase/IA2 (IA2-Ab) have been detected in the circulation years 
before clinical onset of the disease and are awaiting clinical trial (Gale, 1996).  
1.12.1 Circulating extracellular nucleic acid 
Mandel and Métais reported the finding of extracellular nucleic acids in plasma 
in 1948 (Mandel et al., 1948). It was some 30 years later Leon et al., 
demonstrated elevated circulating cell-free nucleic acid levels in cancer patients 
when compared with healthy controls. Leon et al. (1977) predicted poor survival 
of cancer patients with higher circulating nucleic acid level after therapies, 
introducing a profound implication of this area of work in diagnostic medicine.  
DNA and mRNA from foetal origin have been discovered in the plasma of 
pregnant women (Bianchi et al., 1997; Poon et al., 2000; Nancy et al., 2006). 
Quantitative alterations of cell-free placental-derived mRNA in the maternal 
circulation are associated with many pregnancy-related disorders, such as 
preeclampsia and preterm labour (Zhong et al., 2008) (Fig: 1.12.1). Plasma levels 
of endothelial-specific mRNA and DNA was found to be acutely elevated 
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following burns, and related to the severity in terms of the percentage of total 
body surface area burn (Fox et al., 2008). Significantly higher levels of 
rhodopsin mRNA have been reported in peripheral blood from diabetic 
individuals compared to healthy controls (Hamaoui et al., 2004). Circulating 
TGF-beta1 mRNA has been proposed as sensitive biomarkers for the diagnosis 
and prognosis of hepatocellular carcinoma (Dong et al., 2008). Skvortsova et al. 
(2006) based on their study of circulating DNA proposed that total circulating 
DNA combined with the quantitative analysis of circulating DNA distribution 
between cell-bound and cell-free fractions in blood it could be possible to 
accurately detect and discriminate malignant from benign breast tumours. With 
recent advances in sensitive and specific analytical techniques, DNA/RNA has 
potential to be used as a tool for early detection of disease, clinical diagnosis, 
monitoring treatment and in prognosis of diabetes and oncology (Gahan, 2008).  
Many of the developed cancer markers are serum proteins, such as alpha-
fetoprotein (AFP) in liver cancer; carcinoembryonic antigen (CEA) in colorectal 
cancer and prostate-specific antigen (PSA) in prostate cancer (Labrie et al., 2004; 
Fernandes et al., 2005; Ren et al., 2006). The sensitivity and specificity of these 
markers are often not satisfactory as some of these markers are also expressed in 
benign conditions. Moreover, these markers provide little information on the 
complex molecular progression of the tumour throughout the course of the 
disease, so the development of a ‘molecular marker’ is long awaited in diagnostic 
medicine (Tsang et al., 2007) (Fig: 1.12.1).  
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Fig: 1.12.1 Diagram showing the flow of studies on circulating nucleic acid 
(Tsang et al., 2007). 
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1.12.1.1 Extracellular DNA  
The presence of cell-free circulating DNA was reported in 1966, when higher 
levels of circulating DNA were found in patients with systemic lupus 
erythematosus, compared to healthy individuals (Tan et al., 1966). Similarly, 
associations between elevated circulating DNA levels and other 
clinicopathological conditions, including pancreatitis, hepatitis, inflammatory 
bowel disease, glomerular nephritis, rheumatoid arthritis and cancer (Koffler et 
al., 1973; Leon et al., 1977) have been reported. Higher levels of circulating 
DNA were associated with metastatic cancer compared to localised disease and 
reduced levels of DNA were found following radiotherapy in lymphoma, lung, 
ovary, uterus and cervical tumours (Anker et al., 2001). Elevation of plasma 
foetal DNA has been observed in a variety of pregnancy complications (Tsang et 
al., 2007). These findings have also opened up the possibility of predicting the 
diseases by close monitoring of foetal DNA level and the area is now under 
investigation (Farina et al., 2004). Neutrophil-derived circulating free DNA has 
been reported to be of prognostic value in severely injured patients (Margraf et 
al., 2008).  
1.12.1.2 Extracellular RNA  
Extracellular RNA has been detected in plasma and serum of patients presenting 
with various forms of cancer (Wieczorek et al., 1987; Kopreski et al., 1999; 
Hasselmann et al., 2001). Extracellular RNAs have been detected in a range of 
biological matrices, including serum/plasma, saliva (Li et al., 2004; Li et al., 
2004), urine (Bryzgunova et al., 2006), milk (Semenov et al., 2004), bronchial 
lavage (Schmidt et al., 2005), as well as cell culture supernatants (Stroun et al., 
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1978; Morozkin et al., 2004; O’Driscoll et al., 2005; O’Driscoll et al., 2008). 
How they are released from cells – whether that is by active secretion, as a result 
of apoptosis/necrosis, or some combination of these mechanisms - is not yet 
defined (Rykova et al., 2006). The protection of extracellular RNA from 
degradation by RNases may be due to it being packaged into apoptotic bodies 
(Hasselmann et al., 2001), integrated within nucleoprotein complexes (Sisco et 
al., 2001), with phospholipids (Wieczorek et al., 1985; Rosi et al., 1988) and 
proteins (Masella et al., 1989). Rykova et al. (2008) proposed that specific RNA 
quantification in blood plasma could prove to be valuable for discrimination 
between cancer and benign tumours by analysing extracellular circulating 
RASSF1A, Cyclin D2 and RARbeta2 gene transcripts (Rykova et al., 2008). 
1.12.2 Circulating Nucleic acids and diabetic complications 
Diabetes is known to cause deleterious effects on almost every organ of the body. 
Major diabetic complications are retinopathy, coronary heart disease, 
nephropathy, neuropathy and peripheral vascular disease. Measurement of tissue-
specific nucleic acids in the circulation may have some potential for prognostic 
and diagnostic purposes. It has been shown previously that plasma nucleic acids 
(DNA and RNA) appear to reflect the amount of cell death occurring in the 
organism (Stroun et al., 2001).  
Malik et al. (2005) reported an increased plasma protein level of CD105 in 
diabetic patient with proliferative retinopathy. They also reported higher VEGF 
mRNA levels in the vitreous fluid in patients with advanced retinopathy (Malik 
et al., 2005). As described in section 1.12.1, higher circulating mRNA for 
rhodopsin was reported in diabetic retinopathy (DR) patients and could be used 
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as an early predictor of DR (Hamaoui et al., 2004). Rhodopsin mRNA could also 
be a useful marker in assessment of DR and may also be useful in detection and 
evaluation of other retinal lesions including maculopathy, glaucoma and pigment 
lesions.  Nephron-specific mRNA (nephrin) detected in peripheral blood of 
diabetic patient suggests a marker for glomerular function in diabetes 
nephropathy patients (Butt et al., 2006).  Circulating heat shock protein 27 levels 
in serum were found to be significantly higher in cases with distal symmetrical 
polyneuropathy than in controls (Gruden et al., 2008). 
Several acute-phase proteins e.g. fibrinogen and PAI-1 are elevated in NIDDM 
(Ganda et al., 1992). Serum levels of interleukin-6 and interleukin-6/interleukin-
6 receptor complex were also found to be elevated in diabetic patients (Kado et 
al., 1999). Berney et al. (2006) reported that circulating insulin mRNA was 
detected using qRT-PCR assay immediately after islet transplantation. They also 
suggested that detection of insulin mRNA in the peripheral blood may be a 
promising method for predicting islet graft damage (Berney et al., 2006). Serum 
concentration of polyclonal free light chains, a bi-product of normal 
immunoglobulin synthesis, was found to be significantly raised in Type 2 
diabetes patients before overt renal impairment developed (Hutchison et al., 
2008) compared to controls. 
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1.13 Aims of Thesis 
The aim of this project was:- 
• To determine if GSIS was lost in MIN6 B1 cells 
• To identify the passage number at which glucose-responsiveness was lost  
• To investigate the gene expression changes associated with the loss of GSIS 
phenotype, using whole genome microarray and bioinformatics tools. 
•  To validate the panel of differentially-regulated genes from the microarray study 
using quantitative real-time RT-PCR (qRT-PCR). 
• To transfect siRNA for gene targets from qRT-PCR validated microarray study to 
investigate their association with GSIS. 
• To over-express gene targets from qRT-PCR validated microarray study by cDNA 
transfection to investigate their association with GSIS. 
• To detect amplifiable mRNA in media conditioned by insulin producing cells. 
• To establish if gene transcripts extracellular to beta cells reflect the numbers of 
insulin-producing cell conditioning the medium. 
•  To identify gene transcripts extracellular to beta cells showing the functional 
status of the beta cells (i.e. GSIS vs. non-GSIS). 
• To establish if gene transcripts are detectable in serum from people with diabetes 
and those without this condition, as control.  
• To determine if gene transcripts, which may be potential biomarkers, are 
differentially-regulated in Type 2 diabetes and control serum.  
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Previously in our laboratory we found that MIN6, a heterogeneous cell line, lost its 
GSIS phenotype in long term culture (O'Driscoll et al., 2006). In the present study we 
aimed to investigate MIN6 B1 cell line, a homogenous cell population, for any 
changes in the long term culture. Furthermore, we aimed to identify gene transcripts 
associated with loss of GSIS and to investigate if manipulating such gene transcripts 
would restore GSIS function. This study would provide an insight into the molecular 
basis for beta cell dysfunction in Type 2 diabetes. 
Earlier in our laboratory, extracellular nucleic acids were amplified in medium 
conditioned by cancerous cell line (O'Driscoll et al., 2005). Here in this project we 
tried to detect amplifiable mRNA in medium conditioned by insulin producing cell 
lines. As Type 1 diabetes is usually diagnosed after a loss of 70% – 80% of the 
insulin-secreting beta cells in the pancreas (Sia, 2004), detecting an association of 
gene expression in the circulating serum with beta cell loss could aid in early disease 
detection. Furthermore detection of extracellular mRNAs indicating impaired beta cell 
function that might be important for determining beta cell abnormalities in Type 2 
diabetes. 
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Section 2.0 Materials and Methods 
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2.1 Cell Culture Methods 
2.1.1     Water 
Ultra high pure water (UHP) was used in the preparation of all media and solutions.  
Pre-treatment of water, involving activated carbon, pre-filtration and anti-scaling was 
first carried out. This water was then purified by a reverse osmosis system (Millipore 
Milli-RO 10 Plus, Elgastat UHP), which is low in organic salts, organic matter, 
colloids and bacteria with a standard of 12 - 18 MΩ/cm resistance. 
2.1.2 Treatment of Glassware 
All solutions for use in cell culture and maintenance were prepared and stored in 
sterile glass bottles. Bottles, lids and all other glassware used for any cell-related work 
were prepared as follows: - all glassware and lids were soaked in a 2% (v/v) solution 
of RBS-25 (AGB Scientific) for at least 1hrs. This is a deproteinising agent, which 
removes proteineous material from the bottles. Glassware was scrubbed and rinsed 
several times in tap water; the bottles were then washed by machine using Neodisher 
detergent, an organic, phosphate-based acid detergent. The bottles were then rinsed 
twice with distilled water, once with UHP water and sterilised by autoclaving. 
2.1.3    Sterilisation 
Water, glassware and all thermostable solutions were sterilised by autoclaving at 
121°C for 20 min under 15 p.s.i. pressures. Thermolabile solutions were filtered 
through a 0.22 µm sterile filter (Millipore, millex-gv, SLGV-025BS). Low protein-
binding filters were used for all protein-containing solutions. Acrodisc (Pall Gelman 
Laboratory, C4187) 0.8/0.2 µm filters were used for non-serum/protein solutions. 
 70 
2.1.4 Media Preparation 
Medium was routinely prepared and sterility checked by Mr. Joe Carey (technician) 
as in SOP NCTCC 003-02. 10X media were added to sterile UHP water buffered with 
HEPES (N- [2-Hydroxyethyl]-N’- [2-ethanesulphonic acid]) (Sigma, H-9136) and 
NaHCO3 (BDH, 30151) and adjusted to a pH of 7.45 - 7.55 using sterile 1.5M NaOH 
and 1.5M HCl. The media were then filtered through sterile 0.22 µm bell filters 
(Gelman, 121-58) and stored in 500 ml sterile bottles at 4°C. The basal media used 
during routine cell culture were prepared according to the formulations shown in 
Table 2.1.4. Sterility checks were carried out on each 500 ml bottle of medium as 
described in Section 2.2.6. 
The basal media were stored at 4oC up to their expiry dates as specified on each 
individual 10X medium container. Working stocks of culture media were prepared as 
100 ml aliquots and supplemented as required.  These were stored for up to 3 weeks at 
4oC, after this time, fresh culture medium was prepared. 
Table: 2.1.4 Preparation of basal media 
 
DMEM (Dulbecco's Modified 
Eagle Medium) (mls) 
(Sigma, D-5648) 
MEM 
(Gibco, 21430-020) 
10X Medium 500 ml 500 ml 
Ultra pure H20 4300 ml 4300 ml 
1M HEPES* 
(Sigma, H-9136) 100 ml 100 ml 
7.5% NaHCO3 
(BDH, 30151) 45 ml 45 ml 
* The weight equivalent of 1M N- (2-Hydroxyethyl) piperazine-N'- (2-ethanesulfonic 
acid) (HEPES) was dissolved in an 80% volume of ultra pure water and autoclaved. 
The pH was adjusted to 7.5 with 5M NaOH. 
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2.2 Maintenance of cell lines  
2.2.1 Safety Precautions  
All cell culture work was carried out in a class II down-flow re-circulating laminar 
flow cabinet (Nuaire Biological Cabinet) and any work, which involved toxic 
compounds, was carried out in a cytoguard (Gelman). Strict aseptic techniques were 
adhered to at all times. The laminar flow cabinet was swabbed with 70% industrial 
methylated spirits (IMS) before and after use, as were all the items used in the 
cabinet.  Each cell line (including low and high passage cells) was assigned specific 
media and waste bottles and only one cell line was used at a time in the cabinet, 
which, was allowed to clear for 15 min between different cell lines. The cabinet and 
incubators were cleaned each week with industrial detergents (Virkon, Antec. 
International; TEGO, TH. Goldschmidt Ltd.). A separate Laboratory coat was kept for 
aseptic work and gloves were worn at all times during cell work.  
2.2.2 Culture of Adherent Cell Lines 
The cell lines used during the course of this study, their sources and their basal media 
requirements are listed in Table 2.2.2.2. Cell lines were generally maintained in vented 
25 cm2 (Costar, 3056) and 75 cm2 flasks (Costar, 3376) and fed every one to three day. 
2.2.2.1 Subculture of Adherent Cell Lines 
Prior to subculture cells were always monitored for any contamination and were only 
subcultured when the cells were 70-80% confluent. During routine subculturing or 
harvesting of adherent cell lines, cells were removed from their flasks by enzymatic 
detachment.  
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2.2.2.2 Subculture of Vero-PPI cell line 
Culture media from the flasks were removed and discarded in waste bottle. To the 
T25 cm2 flask 1-2 mls of pre-warmed 1X calcium and magnesium- free (Ca2+/Mg2+- 
free) phosphate-buffered saline (Gibco, 14200-067) was added and washed back and 
forth to remove all the traces of serum and dead cells. 
The wash solution was removed and discarded in waste bottle. The purpose of this 
was to eliminate any naturally occurring TV (Trypsin Versene - TV) inhibitor, which 
would be present in residual serum. Pre-warmed (37°C) trypsin/EDTA (TV) solution 
(2.5% trypsin (Gibco, 15090), 0.01% ethylene diamine tetra acetic acid (Sigma, 
E5134) solution in phosphate buffered saline (PBS) (Oxoid, BR14a)) was then placed 
on the cells (2 ml/25cm2 flask or 3 ml/75cm2 flask) and the flasks were incubated at 
37°C until the cells were seen to have detached (2 min). The TV was deactivated by 
addition of an equal volume of growth medium (containing serum). The entire 
solution was transferred to a 30 ml sterile universal tube (Sterilin, 128a) and 
centrifuged at 900 rpm (revolutions per minute) for 5 min.  The resulting cell pellet 
was re-suspended in pre-warmed (37°C) fresh growth medium, counted (See Section: 
2.2.3) and used to re-seed a flask at the required cell density or to set up an assay.  
Cells were never re-seeded back into the same flask. 
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Table: 2.2.2.2 Cell lines used in this study 
Cell 
Line 
Source of 
Cell Line 
Basal medium and 
additives 
Cell Type CO2 
Requirement 
MIN6 Dr. Per 
Bendix 
Jeppesen 
DMEM with 20% heat-
inactivated at 56oC for 
1hrs. fetal calf serum 
(FCS) 
Murine beta 
Cell Line 
5% CO2 
MIN6 
B1 
Dr. 
Valeria 
Lilla 
DMEM with 15% heat 
inactivated FCS at 56oC for 
1hrs. (BioWhittaker, 
DE14-801F), 1% L-Glut, 
and ß-mercaptoethanol 
(Sigma, M-3148) 
clonal 
population 
of Murine 
beta Cell 
Line 
(MIN6) 
5% CO2 
Vero-
PPI 
cells 
Vero – 
ATCC, 
Vero-PPI 
Dr 
Lorraine 
O’Driscoll 
MEM with 5.6mmol/L 
glucose, 1% nonessential 
amino acids 
Vero cells 
engineered 
to produce 
human 
insulin 
5% CO2 
    
2.2.2.3 Subculture of MIN6 and MIN6 B1 Cell Line  
MIN6 and MIN6 B1 flasks were emptied of conditioned medium and the cells were 
rinsed in pre-warmed 1X Ca2+/Mg2+- free PBS (Gibco, 14200-067). TV (3 ml) was 
then added and incubated at 37oC for 2 min exactly. The flask was tapped sharply to 
dislodge the cells and then 3 ml of culture medium was added to inhibit the TV. The 
cell suspension was aspirated gently and with care to avoid separating the cells in to a 
single cell suspension. Following this the cells were centrifuged at 900 rpm for 5 min. 
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The resulting pellet was re-suspended in pre-warmed culture medium, counted (See 
Section: 2.2.3) and re-seeded to flasks or assay plates. MIN6 and MIN6 B1 cells were 
never re-seeded back in to the same flask. 
2.2.3 Cell Counting 
Cell counting and viability determinations were carried out using a trypan-blue 
(Gibco, 15250-012) dye exclusion technique. 
An aliquot of trypan-blue was added to a sample from a single cell suspension at a 
ratio of 1:4. After 3 min incubation at room temperature, a sample of this mixture was 
applied to the chamber of a haemocytometer over which a glass cover slip had been 
placed. Trypan-blue only stains dead cells, whereas viable cells appear bright with a 
halo and remain unstained. Cells in the 16 squares of the four outer corner grids of the 
chamber were counted microscopically. An average per corner grid was calculated 
with the dilution factor being taken into account. Final cell numbers were multiplied 
by 104 to determine the number of cells per ml (volume occupied by sample in 
chamber is 0.1cm x 0.1cm x 0.01cm i.e. 0.0001cm3 therefore cell number x 104 is 
equivalent to cells per ml). Non-viable cells were those, which stained blue while 
viable cells excluded the trypan-blue dye and remained unstained. 
2.2.4  Freezing MIN6 and MIN6 B1 cells 
Cryoprotective medium or freezing medium was prepared in complete culture 
medium containing 20% dimethylsulfoxide (DMSO; Sigma, D-5879) and filter 
sterilised using 0.22 µm filter and syringe. The freezing medium was then placed on 
ice until used. Appropriate number of cryogenic vials (Greiner, 122 278) were 
labelled with the cell line, passage no, date and placed on ice at this point. MIN6 and 
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MIN6 B1 cells were trypsinised as outlined previously (See Section: 2.2.2.3). The 
supernatant from the centrifuged cells were removed and re-suspend the cell pellet in 
1 ml of fresh media. This solution (20% DMSO) was slowly added drop wise to the 
cell suspension to give a final concentration to 10% of DMSO, and a final cell 
concentration of 5 x 106 – 1 x 107 cells/ml. This step was very important, as DMSO is 
toxic to cells. When added slowly, the cells had a period of time to adapt to the 
presence of the DMSO, otherwise cells may have lysed.  Then 1.5 to 1.8 mls of the 
DMSO containing cell suspension was added to each of the vials. The cryovials were 
cooled on ice for 10 min, and then transferred to a –20oC freezer in a Boehringer 
Mannheim enzyme box for 30 min. Following this, the cells were placed at –80oC 
until required. 
2.2.5  Thawing MIN6 and MIN6 B1 Cells  
Prior to thawing 8 mls of culture media was added into the flasks and the flasks was 
allowed to equilibrate in a 37°C, 5% CO2 humidified incubator for at least 30 min or 
overnight. A sterile universal tube containing 5 ml growth medium was pre-warmed 
and prepared for thawing back the cells. This allowed for the rapid transfer and 
dilution of thawed cells to reduce their exposure time to the DMSO freezing solution 
(DMSO is toxic at room temperature). The cryovial taken from the –80oC storage was 
partially thawed and its contents were transferred to the universal. The suspension 
was centrifuged at 900 rpm for 5 min, the DMSO-containing supernatant was 
removed and the pellet was then resuspended in fresh growth medium. Viability 
counts were carried out (See Section: 2.2.3) to determine the efficacy of the freezing/ 
thawing procedures. A sample was also taken for sterility analysis (See Section: 
2.2.6). Thawed cells were placed into tissue culture flasks with the appropriate 
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volume of medium (3-4 ml/25cm2 flask and 8-10 ml/75cm2 flask) and allowed to 
attach overnight. 24hrs. after thawing, the cells were re-fed with fresh warmed 
medium to remove any residual traces of DMSO. 
2.2.6 Sterility Checks 
Sterility checks were routinely carried out on all media, supplements and TV used for 
cell culture. Samples of basal media were inoculated into Columbia (Oxoid, CM331) 
blood agar plates, Sabauraud (Oxoid, CM217) dextrose and Thioglycollate (Oxoid, 
CM173) broth’s which should between them detect most contaminants including 
bacteria, fungus and yeast. Growth media (i.e. supplemented with serum) were 
sterility checked at least 3 days prior to use by incubating samples at 37°C. These 
were subsequently examined for turbidity and other indications of contamination. 
Freshly thawed cells were also subjected to sterility checks. 
2.2.7 Mycoplasma Analysis 
Mycoplasma examinations were carried out routinely (at least every 3 months) on all 
cell lines used in this study.  This analysis was preformed by Michael Henry and 
Shane Kelly at the National Institute for Cellular Biotechnology (NICB). 
2.2.7.1 Indirect Staining Procedure 
In this procedure, Mycoplasma-negative NRK cells (a normal rat kidney fibroblast 
line) were used as indicator cells and incubated with supernatant from test cell lines to 
test for Mycoplasma contamination.  NRK cells were used for this procedure because 
cell integrity is well maintained during fixation. A fluorescent Hoechst stain was 
utilised which binds specifically to DNA and so will stain the nucleus of the cells in 
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addition to any Mycoplasma DNA present. A Mycoplasma infection would thus be 
seen as small fluorescent bodies in the cytoplasm of the NRK cells and occasionally 
outside the cells.  
NRK cells were seeded onto sterile cover slips in sterile Petri dishes (Greiner, 633 
185) at a cell density of 2x103 cells per ml and were allowed to attach overnight at 
37°C in a 5% CO2, humidified incubator.  1 ml of cell-free (cleared by centrifugation 
at 1,000 rpm for 5 min) supernatant from each test cell line was then inoculated onto a 
NRK cover slip and incubated as before until the cells reached 20 - 50% confluency 
(4-5 days). After this time, the waste medium was removed from the Petri dish; the 
cover slips (Chance Propper, 22 x 22 mm) were washed twice with sterile PBS, once 
with a cold PBS/Carnoys (50/50) solution and fixed with 2 ml of Carnoys solution 
(acetic acid: methanol - 1:3) for 10 min. The fixative was then removed and after air-
drying, the cover slips were washed twice in deionised water and stained with 2 ml of 
Hoechst 33258 dye (BDH) (50 ng/ml) for 10 min. 
From this point on, work proceeded in the dark to limit quenching of the fluorescent 
stain. The cover slips were rinsed three times in PBS.  They were then mounted in 
50% (v/v) glycerol in 0.05 M citric acid and 0.1 M disodium phosphate and examined 
using a fluorescence microscope with a UV (ultraviolet) filter.  
Prior to removing a sample for Mycoplasma analysis, cells were to be passaged a 
minimum of 3 times after thawing to facilitate the detection of low-level infection. 
Optimum conditions for harvesting supernatant for analysis occur when the culture is in 
log-phase near confluency and the medium has not been renewed in 2-3 days. 
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2.3 Specialised techniques in cell culture 
2.3.1 Proliferation assays experimental protocol  
The proliferation rates (doubling times) of the MIN6 low passage (L) cells, high 
passage (H) cells, MIN6 B1 low passage (MIN6 B1(GSIS)) cells and high passage 
MIN6 B1(Non-GSIS) cells were determined by monitoring their growth over 
consecutive 24hrs. time periods. For this, the cells were seeded at 5x104 cells/well in 
24-well plates (Costar, 3524). Cells were incubated over-night at 37oC / 5% CO2 and 
3 wells were trypsinised and counted on each of the 7 days following seeding. Cell 
doubling times were calculated from a graph of cell numbers against time. 
2.3.2 Stimulated Insulin Secretion Analysis of Cultured Cells 
 MIN6 and MIN6 B1 were seeded at a cell density of 2 x 105 cells/well in a 24-well 
plate (taking care not to generate a single-cell suspension (See Section: 2.2.2.3)). The 
GSIS (Glucose-stimulated insulin secretion) profiles of MIN6 B1 cells were analysed 
at glucose concentrations of 3.3 and 16.7mmol/L. These cells were allowed to grow 
for 72hrs. prior to the GSIS assay (Fig: 2.3.2.2). Following this, 1xKRB (Krebs-
Ringer Buffer) was prepared from an aliquot of frozen 10xKRB stock (Table: 
2.3.2.1), BSA (an insulin carrier) was added to a final concentration of 0.1%, and the 
KRB–BSA was pH-adjusted to 7.36 with 1 mol/L NaOH. This solution was pre-
incubated for 30 min at 37oC and 5% CO2 and glucose concentrations of 3.3 and 
16.7mmol/L were prepared with KRB solution and were subsequently placed at 37oC 
and 5% CO2 for 30 min. MIN6 B1 cells to be analysed were rinsed (twice) in 1xKRB 
and were equilibrated at 3.3mmol/L glucose for 30 min at 37oC. After equilibration, 
the glucose-containing stimulation medium was added (1 ml/well) and incubated at 
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37oC in 5% CO2 for 60 min. The GSIS assay was then terminated by placing the plate 
on ice. Supernatant (300 µl) was removed from each well, placed in an ice-cold 
eppendorf tube, centrifuged at 2000 rpm for 2 min. 200 µl of supernatant was then 
transferred to a fresh eppendorf tube  for analysis by (pro)insulin ELISA (Mercodia, 
10-1124-10) (See Section: 2.3.2.4). 
Table : 2.3.2.1 10 X Krebs Ringer Buffer (KRB)   
    Amount    Reagent 
36.525g    NaCl 
 2.2g     KCl 
     0.941g    CaCl2.2H2O 
     1.22g     MgCl2.6H2O 
     29.8g     HEPES  
500 ml    UHP H2O 
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Fig: 2.3.2.2 GSIS flow chart 
 
Cells equilibrated with 3.3 
mmol/L glucose for 30 min at 
37oC 
Cells seeded at 2x105 
cells/well in 24-well plate 
To stop reaction place on ice and remove 
300 µl to pre-chilled eppendrofs, spin at 
2,000 rpm for 2 min and transfer 200 µl to 
fresh tubes and store at –20oC 
Remove media and rinse twice with 
0.5 ml KRB buffer containing 0.1% 
BSA, pH 7.36 
Remove and incubate in 1 ml of 
3.3 and 16.7mmol/L glucose –
KRB buffer 
Discard remainder of 
media & add 200 µl of 
0.1M NaOH x15 min (for 
protein quantification) and 
store at –20oC 
Insulin secretion is 
measured by ELISA 
assay 
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2.3.3 Insulin content analysis 
MIN6 B1(GSIS) and MIN6 B1(Non-GSIS) cells were re-suspended in 200 µl of 1mM 
NaOH and left to incubate at room temperature for 5 min. The cells were left to lyse 
on ice for another 10 min and stored in -20oC until used. 
2.3.4 Protein Quantification 
Lysed samples were removed from the freezer and placed on ice.  A BSA standard of 
1 mg/ml was prepared in UHP.  Diluted BSA Standards was prepared and 5 µl of 
standard and 5 µl of sample were placed in triplicate wells on a 96-well plate (Costar, 
3596). The Biorad Dc Protein Assay was used for protein quantification. 25 µl of 
Reagent A (containing 20 µl Reagent S (Biorad, 500-0115) per ml of Reagent A (500-
0113)) followed by 200 µl of Reagent B (Biorad, 500-0114) were added to each test 
well.  The plate was kept at room temperature for 15 min prior to reading on the 
Spectra Max Plus using a softmax Lowry protein assay (750nm) program. 
2.3.5 ELISA Analysis for Insulin and Proinsulin 
Insulin secretion studies have already been described (See Section: 2.3.21). Analyses 
on conditioned media were carried out using a proinsulin ELISA kit (Mercodia, 10-
1124-10). The kits were supplied with reagents, standards etc. Standard protocol was 
followed as per manufacturer’s instructions. In brief, standards and samples (25 µl) 
were added directly to the coated plate (mouse monoclonal anti-insulin) in triplicate. 
50 µl conjugate solution (enzyme conjugate 11X in enzyme conjugate buffer by 
dilution of 1 + 10) was then added to the samples and standards. The plate was 
wrapped in foil (to prevent debris falling into the wells) and incubated at room 
temperature for 2hrs. on a belly dancer set to maximum speed. Following this, the 
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conjugate/sample mixes were tapped off into the sink and the wells were washed 6 
times with washing solution (wash buffer 21X diluted 1 + 20 in UHP prior to use). 
Washing was carried out using a wash bottle with a wide bore nozzle and care was 
taken not to overflow wells during washing (to prevent cross contamination between 
samples). After washing, the plate was tapped firmly on tissue to remove the excess 
wash solution. At this point 200 µl peroxidase substrate was added to each well. As it 
is light sensitive this reaction was allowed to develop in the dark (the plate was 
wrapped in tinfoil) for 15 - 30 min and stopped by adding 50 µl stop solution per well. 
The plates were mixed gently and any bubbles were burst manually. The plates were 
read at 450nm on a plate reader (Labsystems Multiskan Ex) and the data was 
processed using Excel sheet. 
2.3.6 Proliferation using Acid Phosphatase assay  
Proliferation using Acid Phosphatase assay was performed following siRNA 
transfection. Cells were incubated for a period of 72hrs. after siRNA transfection. 
Media was removed from the plates and each well on the plate was washed with 100 
µl of PBS. After washing 100 µl of freshly prepared phosphatase substrate (10mM p-
nitrophenol phosphate (Sigma, 104-0) in 0.1 M sodium acetate (Sigma, S8625), 0.1% 
triton X-100 (BDH, 30632), pH 5.5) was added to each well. The plates were wrapped 
in tinfoil and incubated in the dark at 37°C for 2hrs. After incubation the enzymatic 
reaction was stopped by the addition of 50 µl of 1 M NaOH to each well. The plate 
was read in a dual beam plate reader at 405nm with a reference wavelength of 620nm. 
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2.4 Sampling different insulin producing cells and their CM 
2.4.1 Identifying a suitable time point for CM collection (Protocol-1) 
The experimental design to identify a suitable time point for CM collection and 
analysis is shown in Fig: 2.4.1. MIN6 B1 cells were set up in T75cm2 flasks at a 
density of 5 x 106 cells with 8 mls of media added to it. After each 24hrs, 500 µl of 
conditioned media (CM) was taken off the cells and replaced by same amount of fresh 
culture media. CM was filtered with a 0.45 µm filter. Immediately 250 µl aliquots of 
filtered CM was added in to 750 µl aliquots of TriReagent and stored at -80°C until 
RNA extraction (See Section: 2.5.1.2.1) was carried out. After 96hrs. the cells were 
trypsinised, counted and washed twice with PBS. The pellet was stored in 1 ml 
aliquots of TriReagent at -80°C until RNA extraction. 
 
 
 
 
 
 
 
 
 84 
 
 
 
 
  
 
 
 
 
 
Fig: 2.4.1 Experimental design of study to identify a suitable time point post cell 
seeding for CM collection and analysis 
2.4.2 Identifying a suitable time point for CM collection (Protocol-2) 
The experimental design to identify a suitable time point for CM collection and 
analysis is shown in Fig: 2.4.2, MIN6 B1 cells were set up in T75cm2 flasks at a 
density of 5 x 106 cells and 8 mls of media was added. After each consecutive 24hrs. 
CM and cells were taken from each of the flask and the same procedure was followed 
as above (See Section: 2.4.1).  
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Fig: 2.4.2 Experimental design of study to identify a suitable time point post cell 
seeding for CM collection and analysis 
2.4.3 Conditioned media (CM) filtration  
2.4.3.1 Conditioned media filtration from insulin-producing cells 
Insulin-producing MIN6 B1 and Vero-PPI cells were seeded at different densities i.e. 
1x 106 cells, 5x106 cells and 1x107 cells per T25cm2 flask along with a total of 4 mls 
of culture media. Cells were allowed to grow for 48hrs. Conditioned media was taken 
off and sterile filtered using 0.45 µm to make sure that there are no cells included.  
Cultured cells in the flask was trypsinised, counted and centrifuged at 900 rpm for 5 
min to form a pellet. These pellets were washed twice with cold PBS prior to re-
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suspending in 1 ml of TriReagent, incubating as above and storing in -80oC for further 
RNA isolation (See Section: 2.5.1.2.1). 
2.4.3.2 Conditioned media filtration from MIN6 (L) and (H) 
MIN6 (L) and (H) cells were allowed to grow to 80% confluency in 75cm2 flasks and 
cultured further for 48hrs. in 8mls of media (reaching approximately 90% 
confluency). CM was removed and passed through 0.45 µm filters to ensure that there 
were no cells present.  
2.4.4 Collecting Serum from blood 
Two blood specimens of approximately 10 ml were taken with consent from each 
patient recruited for the Type 2 diabetes and control serum study. From the collected 
blood samples, the red blood cells were allowed to clot naturally. These specimens 
were processed within 3-4hrs. of blood draw. Serum specimens from control 
volunteers (i.e. no history or symptoms of diabetes) were also collected and processed 
in the similar way. 
All serum specimens were processed by removing the serum from the clotted blood 
and placing into a 10 ml centrifuge tube. A balance tube was made by adding an equal 
amount of water to another 10 ml centrifuge tube. The tubes were then centrifuged at 
room temperature for 15 min at 400 rcf (relative centrifugal force). After 
centrifugation the cleared serum was carefully removed and passed through a 0.45 µm 
filter to further ensure no particles/ platelets were retained. The serum was then 
aliquoted into 1 ml/1.5 ml aliquots and stored at -80°C until required. RNA extraction 
from the serum was carried out using a slightly modified version of the optimised 
TriReagent protocol developed here (See Section: 2.5.1.2.1). In order to minimise the 
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amount of time the serum was defrosting without protection from RNases, when 
required, 500 µl of TriReagent was added to the frozen serum specimens and the 
samples were gently pipetted to ensure thorough mixing. This serum-TriReagent mix 
was then added in 500 µl aliquots to clean eppendorf tubes containing 250 µl of 
TriReagent, so that the final ratio of TriReagent to serum was 3:1 (i.e.750 µl : 250 µl).  
 
 
 
 88 
2.5 Analytical Techniques and Assays 
2.5.1  RNA Analysis 
2.5.1.1 Preparation for RNA Analysis 
RNA is easily degraded by RNase (ribonuclease) enzymes, which are ubiquitous, thus 
the following precautions were taken prior to RNA work. 
All solutions for RNA related work were prepared from sterile UHP H2O that had 
been treated with 0.1% diethyl pyrocarbonate (DEPC) (Sigma, D5758) before 
autoclaving (autoclaving inactivates DEPC).  All Eppendorfs, PCR (polymerase chain 
reaction) tubes etc. were RNase-free and pre-autoclaved prior to use as were Gilson 
pipette tips. Disposable nitrile gloves were worn at all times during RNA work (to 
protect the operator and to prevent RNA degradation) and changed frequently.  
2.5.1.2 RNA Extraction 
RNA was extracted from cultured cells and their conditioned media stored in 
TriReagent at -80oC until required (Fig: 2.5.1.2.1). 
2.5.1.2.1 RNA Isolation from CM and Serum samples 
The frozen TriReagent samples were allowed to thaw at room temperature and upon 
thawing, were allowed to sit for at least 5 min to ensure complete dissociation of 
nucleoprotein complexes. To this was added 0.2 ml of chloroform per ml of 
TriReagent. Samples were shaken vigorously for 15 sec and allowed to stand for 15 
min at room temperature. 
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Fig: 2.5.1.2.1 RNA isolation using TriReagent from cells and CM 
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The resulting mixtures were then centrifuged at 13000 rpm in a microfuge for 15 min 
at 4oC. The colourless upper aqueous phase (containing RNA) was removed into a 
fresh RNase-free 1.5 ml eppendrof tube. Glycogen (Sigma, G1767) 1.25 µl (final 
concentration 120 µg/ml) and 0.5 ml of ice-cold isopropanol (Sigma, I9516) was 
added. The samples were mixed and incubated at room temperature for 5-10 min and 
stored at -20oC over-night, to ensure maximum RNA precipitation. The Eppendrof 
tubes were then centrifuge at 12,000 rpm for 30 min at 4oC to pellet the precipitated 
RNA. 
Taking care not to disturb RNA pellet, the supernatant was removed and the pellet 
was subsequently washed by the addition of 750 µl of 75% of ethanol and vortexed. 
Centrifugation was followed at 7,500 rpm for 5 min at 4oC. The supernatant was 
removed and the wash step was repeated. The RNA pellet was then allowed to air-dry 
for 5-10 min and subsequently was re-suspended in 15 µl of DEPC-treated water. To 
facilitate dissolution repeated pipetting was done (Fig: 2.5.1.2.1).  
2.5.1.2.2 RNA Isolation from Cells 
Approximately 1x107 cells were trypsinised, washed once with PBS, pelleted and 
lysed using 1 ml of TriReagent (Sigma, T-9424). The samples were allowed to stand 
for 5 min at room temperature to allow complete dissociation of nucleoprotein 
complexes and then stored at –80oC. When required, sample was allowed to stand at 
room temperature for 5-10 min. To this was added 0.2 ml of chloroform per ml of 
TriReagent was added. Samples were shaken vigorously for 15 sec and allowed to 
stand for 15 min at room temperature. The resulting mixtures were then centrifuged at 
13000 rpm in a microfuge for 15 min at 4oC. The colourless upper aqueous phase 
(containing RNA) was removed into a fresh RNase-free 1.5 ml eppendrof tube. To 
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this 0.5 ml of ice-cold isopropanol (Sigma, I9516) was added. The samples were 
mixed and incubated at room temperature for 5-10 min. The eppendrof tubes were 
then centrifuge at 12,000 rpm for 30 min at 4oC to pellet the precipitated RNA. 
Taking care not to disturb RNA pellet, the supernatant was removed and the pellet 
was subsequently washed by the addition of 750 µl of 75% of ethanol and vortexed. 
Centrifugation was followed at 7,500 rpm for 5 min at 4oC. The supernatant was 
removed and the wash step was repeated. The RNA pellet was then allowed to air-dry 
for 5-10 min and subsequently was re-suspended in 15 µl of DEPC-treated water. To 
facilitate dissolution repeated pipetting was done.   
2.5.1.2.3 Preparation of total RNA from cells using RNeasy Mini Prep Kit® 
(QIAGEN, 74104) 
Alternatively, high quality RNA used for microarray studies was isolated from cells 
using the RNeasy mini-kit (Qiagen, 74104). Cell pellets for RNA extraction (stored at 
–80oC) were re-suspended in 1.2 ml of buffer RLT (supplemented with 10 µl/ml of β-
mercaptoethanol) and vortexed to loosen the pellets. The lysed pellets were aspirated 
a number of times and vortexed until the samples were completely homogenised. 1 
volume (1.2 ml) of 70% ethanol was added to the homogenised samples and mixed 
well by pipetting. This mixture was then loaded in 700 µl aliquots on to an RNeasy 
mini column, which was placed in a collection tube and centrifuged at 8,000 x g for 
15 sec (this was continued until the entire mixture had been passed through the 
column). Once all the homogenised cells had been passed through the column, the 
washes were carried out. Initially 700 µl RW1 was loaded on to the column and 
centrifuged at 8,000 x g for 15 sec. This was closely followed by 2 washes in buffer 
RPE (also followed by centrifuging at 8,000 rpm for 15 sec). To completely dry the 
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spin column, it was placed in a fresh collection tube and centrifuged at full speed for 1 
min. The RNA was eluted by passing two lots of 25 µl RNase free water (supplied) 
through the column by centrifuging it at 8,000 rpm for 1 min. The eluted RNA was 
then quantified (See Section: 2.5.1.4). 
2.5.1.3 Treatment of RNA 
RNA was treated with DNase and RNase enzyme to establish that RT-PCR signals in 
this study are from RNA, and not from contaminating DNA. Fig 2.5.1.3 shows 
experimental design for untreated, DNase and RNase treatments. 
 
Fig: 2.5.1.3 Experimental design of RNase- and DNase-treated RNA samples. 
2.5.1.3.1 DNase-treated RNA 
In order to remove any contaminating genomic DNA that may be present in the RNA 
isolates, samples from cells and their corresponding CM was treated with 1U of 
RNase-free DNase (Promega, M6101) per 1 µg RNA in a reaction mixture of 10 µl 
including reaction buffer (Promega, M198A) (Table: 2.5.1.3.1). RNA was incubated 
RNA extract was divided into three separate treatments: 
 
Untreated DNase-treated RNase-treated 
RNA/DNA (if present) 
mixture 
Pure genomic 
DNA 
contaminant  
Pure RNA  
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at 37oC for 30 min in the reaction mixture containing RNase-free DNase (Promega, 
M6101) as recommended by the manufacturer as follow: - 
 Table: 2.5.1.3.1 preparation of master mix for DNA digestion reaction 
  Reagent      Volume 
    RNA in water       1–8 µl 
RQ1 RNase-Free DNase 10X Reaction Buffer  1 µl 
RQ1 RNase-Free DNase      1 U/µg RNA 
Nuclease-free water to a final volume of   10 µl 
To this mixture was added 1 µl of RQ1 DNase Stop Solution (Promega, M199A) to 
terminate the reaction and incubated further at 65°C for 10 min to inactivate the 
DNase. 
2.5.1.3.2 RNase-treated RNA 
To establish that RT-PCR signals in this study are from RNA, and not from 
contaminating DNA, isolated samples were treated with 1U RNase ONE 
ribonucleases (Promega, M4261) per 0.1 µg RNA in a 10 µl reaction mixture 
containing buffer (Promega, M2174) (Table: 2.5.1.3.2). Incubate the RNA at 37oC for 
30 min in the reaction mixture containing RNase-ONE Ribonuclease (Promega, 
M4261) as recommended by the manufacturer as follow: - 
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Table: 2.5.1.3.2 preparation of master mix for RNA digestion reaction 
Reagent      Volume  
    RNA in water      1–8 µl 
10X Reaction Buffer     1 µl 
RNase-ONE Ribonuclease   1 U/0.1µg RNA 
Nuclease-free water to a final volume of  10 µl 
2.5.1.4 RNA Quantification using NanoDrop 
The NanoDrop® ND-1000 is a full-spectrum (220-750nm) spectrophotometer that 
measures 1 µl samples with high accuracy and reproducibility. It uses a sample 
retention technology that relies on surface tension alone to hold the sample in place 
eliminating the need for cuvettes and other sample containment devices. In addition, 
the NanoDrop has the capability to measure highly concentrated samples without 
dilution (50X higher concentration than the samples measured by a standard cuvette 
spectrophotometer).  
To quantify an RNA sample, 1 µl of the sample is pipetted onto the end of a fibre 
optic cable (the receiving fibre, Fig: 2.5.1.4.1 (A)). A second fibre optic cable (the 
source fibre, Fig: 2.5.1.4.1 (B)) is then brought into contact with the liquid sample 
causing the liquid to bridge the gap between the fibre optic ends. The gap is controlled 
to a 1mm path (Fig: 2.5.1.4.1 (C)). A pulsed xenon flash lamp provides the light 
source and a spectrometer utilising a linear CCD array is used to analyse the light 
after passing through the sample. The instrument is controlled by special software run 
from a computer, and the data is logged in an archive file on the computer.  
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A B C
When measurement of the sample is complete, the sample can be simply wiped away 
using a soft laboratory wipe. This is sufficient to prevent sample carryover because 
each measurement pedestal is a highly polished end of a fibre optic cable, with no 
cracks or crevices for residual sample to reside in. 
Fig: 2.5.1.4.1 Samples are quantified by loading 1 µl onto the receiving fibre (A), 
the source fibre, connected to the sampling arm (B) is brought down into contact 
with the sample allowing a 1mm gap between the upper and lower pedestal (C), 
through which the light is passed. (Pictures adapted from ND-1000 
Spectrophotometer users manual V 3.1.0).  
RNA (like DNA) was quantified using an ND-1000 spectrophotometer. The ND-1000 
software automatically calculated the quantity of RNA in the samples using the 
OD260. 
i.e. OD260 x 40 x Dilution Factor/1000 = RNA content (µg/µl) 
The software simultaneously measured the OD280 of the samples allowing the purity 
of the sample to be estimated. 
Purity = OD260/OD280 
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This was typically in the range of 1.8-2.0. A ratio of <1.6 indicated that the RNA may 
not be fully in solution. The RNA was diluted to 1 µg/µl stocks for the reverse 
transcription (RT).   
2.5.1.5 RNA Quality Analysis by Electrophoresis 
For RNA quality analysis agarose (Sigma, A-9539) gel electrophoresis was used. 1% 
agarose gel was prepared in 1X TBE buffer (prepared in autoclaved dH2O), and gel 
was casted within an RNase-free gel box (soak gel box in 5 mM NaOH overnight and 
rinse twice with DEPC treated water before use). 5 µl of the sample and 2 µl of dye 
were loaded. The gel was run at 100 V until the dye reached the end of the gel (~30 
min). The RNA gel was observed using a UV gel box. 
2.5.1.6 Total RNA Analysis using the Bioanalyzer 
The Agilent 2100 Bioanalyzer is a microfluidics-based platform for the analysis of 
proteins, DNA and RNA. The miniature chips are made from glass and contain a 
network of interconnected channels and reservoirs. The RNA 6000 Nano LabChip kit 
enables analysis of samples containing as little as 5 ng of total RNA. 
a) Reagent Preparation: 
The channels are firstly filled with a gel matrix and the sample wells with buffer or 
sample, there are 12 sample wells per chip. 1 µl of each sample is loaded into a 
sample well along with a fluorescent dye (marker). An RNA ladder is loaded into 
another sample well for size comparison. RNA Gel Matrix was prepared fresh just 
before use.  
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RNA Gel Matrix was vortexed and aliquoted 550 µl (room temperature), into top 
receptacle of spin filter and centrifuged at 1500 x g (4000 rpm) for 10 min discarding 
the spin filter. 
Gel-Dye Mix was prepared by using 65 µl filtered Gel Matrix in a microcentrifuge 
tube. To this is added 1 µl RNA Dye Concentrate after vortexing for 10 sec. It was 
mixed properly by vortexing and centrifuged for 10 min at 13,000 x g (14,000 rpm).  
b) Sample Preparation 
RNA samples were thawed on ice and 1 µl of RNA was dispensed into each PCR 
tube. Samples and ladder were heat denatured at 70°C for at least 2 min and then 
placed on ice for 2 min and centrifuged briefly to collect sample at the bottom of the 
tube. 
c) Loading the Gel-Dye Mix 
New chip was taken out of its sealed bag and placed on the Chip Priming Station. 
Then 9.0 µl of the gel-dye mix was pipetted in each of the wells marked (light 
letter). Then Chip Priming Station was closed by pressing the plunger until it was held 
by the clip and was released after 30 sec. Then 9.0 µl of the gel-dye mix was pipetted 
in each of the wells marked  and discarding the remaining gel-dye mix. 
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Fig: 2.5.1.6.1 Picture showing (A) the Chip Priming Station and (B) plunger held 
by the clip.  
d) Loading a Primed Chip 
RNA 6000 Nano Marker was pipetted (5 µl) into each well, including the well marked 
with a ladder. Then 1 µl denatured RNA sample was added into each well, one sample 
per well and 1 µl denatured ladder into the well marked with a ladder. Care was taken 
to fill all the unused wells as well. Then the chip was vortexed using chip vortexer. 
The chip was vortexed at the Set Point indicated on the right side of the dial for one 
minute. 
e) Running the Agilent 2100 Bioanalyzer 
The channels were firstly filled with a gel matrix and the sample wells with buffer or 
sample, there are 12 sample wells per chip. 1 µl of each sample was loaded into a 
sample well along with a fluorescent dye (marker). An RNA ladder was loaded into 
another sample well for size comparison. When all the samples were loaded, the chip 
was briefly vortexed and loaded onto the Bioanalyzer machine (Fig: 2.5.1.6.2 for 
picture of chip).  
 
 
 
A B
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Fig: 2.5.1.6.2 The RNA 6000 Nano chip, a picture of the front of the RNA Nano 
chip (A) and a diagram of the microchannels in the chip (B), the sample moves 
through microchannels (1) and is injected into separation chamber (2) were 
components are electrophoretically separated (3) and detected by their 
fluorescence and translated into gel-like images and electropherograms. Both 
pictures available from http://www.agilent.com/chem/labonachip  
The machine is fully automated and electrophoretically separates the samples by 
injecting the individual samples contained in the sample wells into a separation 
chamber. The resulting data was presented as an electropherogram (Fig: 2.5.1.6.3).  
The fluorescence was measured on the Y-axis and the time in seconds is measured on 
the X-axis. The smaller fragments are detected first and are shown on the left-hand 
side of the electropherogram. Fig. 2.5.1.6.3 is an example of good quality cell RNA, 
the 18S and 28S ribosomal RNA peaks are quite sharp and the 28S is higher than the 
18S peak. As RNA degrades, the 28S RNA peak decreases and smaller fragments are 
visible.  
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Fig: 2.5.1.6.3 Examples of electropherogram generated using the Agilent 
Bioanalyzer. Electropherogram showing first small peak as marker, second peak 
as 5s RNA, followed by sharp 18S and 28S ribosomal bands. MIN6 B1 cell RNA 
as evident by the sharp 18S and 28S ribosomal bands. 
2.5.2 Reverse-Transcription Polymerase Chain Reaction Analysis 
2.5.2.1 Reverse Transcription of RNA from cells (cDNA Synthesis)  
mRNA was copied to cDNA by reverse transcriptase using an oligo dT primer. First-
strand cDNA was synthesised by reverse transcription (RT) by mixing the following 
components in a 0.5 ml eppendorf tube (Eppendorf, 0030 121 023) and heated at 70oC 
for 10 min followed by cooling on ice. Table 2.5.2.1.1 shows the protocol for 
preparation cDNA from cell RNA whereas; table 2.5.2.1.2 shows the protocol for 
preparation of cDNA from CM RNA.  
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Table: 2.5.2.1.1 First strand cDNA from cell RNA 
  Volume  Reagents 
1 µl   Oligo dT (0.5 µg/µl) (MWG) 
1 µl   RNA (1 µg/µl) 
3 µl   DEPC-treated H2O 
Table: 2.5.2.1.2 First strand cDNA from CM RNA 
  Volume  Reagents 
1 µl   Oligo dT (0.5 µg/µl) (MWG) 
4 µl   RNA  
This step gets rid of RNA secondary structures and allows the oligo dT to bind the 
poly (A)+ tail of the RNA. While this mixture was incubated, the following reaction 
mix was generated (all volumes listed in master mix assume 1 µg total RNA) (Table: 
2.5.2.13). 
Table: 2.5.2.1.3 Reverse Transcription Reaction Mixture 
  Volume  Reagents 
  2 µl   10X buffer (Sigma, B8559) 
1 µl   RNasin  (40U/µl) (Sigma, R2520) 
                            1 µl   dNTP (deoxynucleotide triphosphate)  
     (10mM of each   dNTP) (Sigma, DNTP100) 
  10 µl   DEPC -treated water 
1 µl   MMLV-RT (200 U/µl) (Sigma, M1302) 
  15 µl   Total  
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Once the RNA mixture had cooled (~2 min) 15 µl of the master mix (Table: 2.5.2.1.3) 
was added and mixed by flicking. The mixture was centrifuged to collect the material 
in the bottom of the tube and then incubated at 37oC for 1hr. The resultant cDNA was 
stable overnight at 4oC but for prolonged storage it was maintained at –20oC.   
2.5.2.2 Polymerase Chain Reaction 
The cDNA was analysed for the expression of genes of interest by PCR. The 
standardised PCR mix is listed below and did not change significantly with any of the 
PCRs carried out in this thesis. 2.5 µl cDNA was added to the following reaction 
mixture (Table: 2.5.2.2). The samples were mixed and centrifuged before being 
placed on the thermocycler (Biometra). 
Table: 2.5.2.2 PCR Reaction Mixture 
 Volume  Reagents  
12.25 µl   H2O 
2.5 µl    10X PCR buffer (Sigma, P2317) 
1.5 µl    25 mM MgCl2 (Sigma, M8787) 
4 µl    1.25 mM dNTP  
0.5 µl    each of the forward and reverse primers  
(250 ng/µl) for the target gene (MWG) 
0.25 µl   Taq Polymerase (5 U/µl) (Sigma, D4545). 
  20 µl   Total 
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A typical PCR protocol is outlined below. However annealing temperatures can vary 
from primer set to primer set therefore a full list of the primers used in this thesis and 
the annealing temperatures are listed in Table 2.5.2.5.2. 
95oC for 3 min    (Denaturation step) 
Followed by   
25-30 cycles of: 
 95oC for 30 sec  (Denaturation) 
52-60oC for 30 sec  (Annealing) 
72oC for 30 sec  (Extension) 
And 
   72oC for 7 min  (Extension) 
PCR products were stored at 4oC until they were analysed by gel electrophoresis. 
* 30 cycles were sufficient when amplifying gene transcripts from cell RNA however; 
it was necessary to increase this to 45 cycles when using RNA extracted from CM.  
2.5.2.3 Gel Electrophoresis of PCR Products 
Typically, 2% agarose (Sigma, A9539) gels were used for PCR gel electrophoresis, 
which were prepared and run in 1X TBE (10.8 g Tris base, 5.5 g Boric Acid, 4 ml 0.5 
M EDTA (pH 8.0) and made up to 1 L with UHP) and melted in a laboratory 
microwave. Upon cooling, the gel was supplemented with 5 µl ethidium bromide (10 
mg/ml) to allow visualisation of the DNA. Ethidium bromide is a dye that binds to 
double stranded DNA by interpolation (intercalation) between the base pairs. Here it 
fluoresces when irradiated in the UV part of the spectrum. The gel was then poured in 
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to the electrophoresis unit (Biorad) and allowed to set. Sample wells were formed by 
placing a comb into the top of the gel prior to hardening. 
To run the samples, 2 µl of 6X loading buffer (50% Glycerol, 1 mg/ml bromophenol 
blue, 1 mM EDTA) was added to 10 µl PCR product and the mixture was loaded to 
the gel with an appropriate size marker (Sigma, D0672). The gels were 
electrophoresed at 120-150 V for 1 - 2hrs. (depending on size of the target gene, i.e. to 
get adequate separation). Once the internal control and target bands have migrated to 
the required extent, the gel was taken to the gel analyzer (an EpiChemi II Darkroom, 
UVP Laboratory Products), photographed and densitometrically analysed using 
Labworks software (UVP). 
2.5.2.4    Densitometry Analysis 
Densitometric analysis of the PCR products was carried out using the MS Windows 
3.1 compatible Molecular Analyst software/PC image analysis software available for 
use on the 670 Imaging Densitometer (Bio-Rad. CA) Version 1.3. Developed 
negatives of gels were scanned using transmission light and the image transferred to 
the computer. The amount of light blocked by the DNA band is in direct proportion to 
the intensity of the DNA present. A standard area was set and scanned and a value 
was taken for the Optical Density (O.D.) of each individual pixel on the screen. The 
average value of this O.D. (within a set area, usually cm2) is normalised for 
background of an identical set area. The normalised reading is taken as the 
densitometric value used in analysis. As a result, these O.D. readings were unitless. 
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2.5.2.5 Primer sequences used for RT-PCR studies 
To investigate if any secreted mRNAs detected were likely to be full-length 
transcripts or fragmented products, PCR primers were designed in such a way as to 
amplify regions close to the 3’ end (e.g. Pdx1, Pld1, Ppi), the 5’ region (e.g. Egr 1, 
Chgb, Pax4) or stretching along most of the length of the transcript (e.g. Ins I, Ins II, 
Nyp) (Fig: 2.5.2.5.1). Primers amplifying 4 different regions along the length of the 
beta-actin transcript were evaluated. All primers used in this study are listed in the 
Table 2.5.2.5.2.  
 
 
 
 
 
 
 
Fig: 2.5.2.5.1 Location of regions selected for amplification. 5’, central or 3’ 
location of the regions selected for the amplification (………) along the coding 
regions (______) of transcript analysed.  
Ins I
Ins II
egr 1
chgb
pdx 1
pax 4
pld 1
npy
ppi
β-actin
5’
5’
3’5’
5’ 3’
5’ 3’
5’ 3’
3’
5’ 3’
3’
5’ 3’
5’ 3’
5’ 3’
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Gene Sequence (5' to 3') 
Annealing 
Temp.(°C) 
RNA 
Fragment 
Size (bp) 
DNA 
Fragment 
Size (bp) 
Ref  Seq. Gene ID 
Pdx1 
ggtggagctggcagtgatgtt 
accgcccccactcggggtcccgc 
60 127 127 NM_008814 18609 
Gck 
gatgctggatgacagagccaggatg 
agatgcactcagagatgtagtcga 
54 392 30,892 NM_010292 103988 
Pax 4 
tggcttcctgtccttctgtgagg 
tccaagacacctgtgcggtagtag 
52 242 883 NM_011038 18506 
Npy 
tgaccctcgctctatctctg 
aagggtcttcaagccttgtt 
58 249 5,689 NM_023456 109648 
Egr1 
atggacaactaccccaaact 
attcagagcgatgtcagaaa 
56 240 918 NM_007913 13653 
Pld1 
tcttatcccttcctgctacc 
ccaccttgttgaacacaact 
56 250 11,039 NM_008875 18805 
Chgb 
atccaagtccagtgttccaa 
tctcattgcctaccttcgtc 
58 227 6,011 NM_007694 12653 
Gad1 
aaggatgcaaccagatgtgt 
ttggcgtagaggtaatcagc 
58 205 22,694 NM_008077 14415 
PC2 
cacagatgactggttcaaca 
tcacagttgcagtcatcgta 
56 359 
Do not 
amplify 
NM_008792 18549 
Ppi 
agcgtggcttcttctacacacc 
ggtgcagcactgatccaccatg 
54 158 945 
NM_008386/ 
NM_008387 
16333/ 
16334 
Ins I 
tagtgaccagctataatcagag 
acgccaaggtctgaaggtcc 
62 288 407 NM_008386 16333 
Ins II 
ccctgctggccctgctctt 
aggtctgaaggtcacctgct 
62 212 701 NM_008387 16334 
beta-
actin 
acggccaggtcatcactattg 
caagaaggaaggctggaaaaga 
60 70 603 NM_007393 11461 
Table: 2.5.2.5.2 Oligonucleotide primers used in RT-PCR analyses showing Gene 
symbol, nucleotide sequence, annealing temperature, RNA fragment size, Ref 
Seq. ID and gene ID .  
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2.5.3 Quantitative real time RT-PCR (qRT-PCR) 
TaqMan probes are oligonucleotides that have fluorescent reporter dyes attached to 
the 5' end and a quencher moiety coupled to the 3' end. These probes are designed to 
hybridize to an internal region of a PCR product. In the unhybridized state, the 
proximity of the fluor and the quench molecules prevents the detection of fluorescent 
signal from the probe. During PCR, when the polymerase replicates a template on 
which a TaqMan probe is bound, the 5'- nuclease activity of the polymerase cleaves 
the probe. This decouples the fluorescent dye thus, increasing the fluorescence in each 
cycle, proportional to the amount of probe cleavage. 
2.5.3.1 TaqMan® Real time PCR 
RNA was isolated (See Section: 2.5.1.2.3) and cDNA synthesised as per Section 
2.5.2.1.  In order to exclude any amplification product derived from genomic DNA or 
any other contaminent that could contaminate the RNA preparation, total RNA 
without reverse transcription was used as a negative control.  Water on its own was 
amplified as a negative control to rule out presence of any contaminating RNA or 
DNA in it. 
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Table: 2.5.3.1.1 qRT-PCR Reaction Mixture 
Volume  Reagents  
6.8 µl            Nuclease-Free water (Ambion, 9930) 
10 µl          TaqMan® Fast Universal PCR master mix (2 X) (Applied 
BioSystems, 4352042) 
0.2 µl        AmpErase® Uracil N-glycosylase (UNG) (Applied 
BioSystems, N8080096) 
1 µl                 Assay-on-demand 
18 µl    Total 
The TaqMan® Real time PCR analysis was preformed using the Applied BioSystems 
Assays on Demand PCR Kits, using primer probe pairs as outlined in Table 2.5.3.1.2 
and Table 2.5.3.1.3. 
2 µl of the cDNA was added to the MicoAmp fast optical 96-well reaction plate 
(Applied BioSystems, 4346906) followed by 18 µl of reaction master mix (Table: 
2.5.3.1.1). 
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Table: 2.5.3.1.2 qRT-PCR primer and their assay ID used for microarray 
validation study. 
Primer Pair Supplier  Assay ID 
Thioredoxin interacting protein Applied BioSystems Mm00452393_m1 
Annexin A2 Applied BioSystems Mm00500307_m1 
Early growth response 1 Applied BioSystems Mm00656724_m1 
Kruppel-like factor 4 (gut) Applied BioSystems Mm00516104_m1 
Thioredoxin domain containing 5 Applied BioSystems Mm00520294_m1 
FBJ osteosarcoma oncogene Applied BioSystems Mm00487425_m1 
Growth arrest and DNA-damage-
inducible 45 gamma 
Applied BioSystems Mm00442225_m1 
FBJ osteosarcoma oncogene B Applied BioSystems Mm00500401_m1 
Proprotein convertase 
subtilisin/kexin type 9 
Applied BioSystems Mm00463738_m1 
Solute carrier family 38, member 4 Applied BioSystems Mm00459056_m1 
Dual specificity phosphatase 1 Applied BioSystems Mm00457274_g1 
Glucagons Applied BioSystems Mm00801712_m1 
Jun oncogen Applied BioSystems Mm00495062_s1 
Immediate early response 5 Applied BioSystems Mm00494887_s1 
SRY-box containing gene 4 Applied BioSystems Mm00486317_s1 
Mitogen activated protein kinase 3 Applied BioSystems Mm00662375_g1 
GAPDH Applied BioSystems 4352932E 
Beta-actin Applied BioSystems 4352933E 
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Table: 2.5.3.1.3 qRT-PCR primer and their assay ID used for serum study 
Primer Pair Supplier  Assay ID 
Thioredoxin interacting protein Applied BioSystems Hs00197750_m1 
Early growth response 1 Applied BioSystems Hs00152928_m1 
Chromogranin B Applied BioSystems Hs00174956_m1 
Pancreatic and duodenal 
homeobox 1 
Applied BioSystems Hs00426216_m1 
Phospholipase D1 Applied BioSystems Hs00160118_m1 
Neuropeptide Y Applied BioSystems Hs00173470_m1 
Insulin Applied BioSystems Hs00355773_m1 
Pax4 Applied BioSystems Mm01159036_m1 
Beta-actin Applied BioSystems 4352933E 
Note for table 2.5.3.1.2 and 2.5.3.1.3: - Assay suffix “_m1” means that the probe 
spans an exon-exon junction and will not detect genomic DNA. 
Assay suffix “_s1” means that the primers and probes are designed within a single 
exon, such assays will, by definition detect genomic DNA 
Assay suffix “_g1” means that although the assay probe spans an exon-exon junction, 
the assay may detect genomic DNA if present in the sample. 
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Table: 2.5.3.1.4 Thermal cycling conditions used in this study 
AmpErase UNG 
Activation 
Denature PCR 
CYCLE (40 cycles) 
Step 
HOLD HOLD 
Denature Anneal/Ext 
Time 2 min 20 sec 3  sec 30 sec 
Temp 50oC 95oC 95oC 60oC 
 
2.5.4 Large scale plasmid preparation 
Luria-Bertani (LB Broth) was prepared as per table 2.5.4 and was autoclaved. An 
aliquot of 10 mls LB Broth was taken in a 20 ml universal. Carbenicillin   was added 
to this broth at a concentration of 100 µg/ml and inoculated with 10-20 µl of glycerol 
stock for one unique clone. This was grown for 6-7hrs. in the upright shaker at 37oC 
at ~300rpm. This was further inoculated into a 1000 ml flask with 400 mls of LB 
Broth containing carbenicillin antibiotic (100 µg/ml). The culture was incubated at 
37oC with vigorous shaking (~300rpm) for ~8hrs. The bacterial cells were then 
harvested by centrifugation at 6000x g for 15 min at 4oC. Plasmid DNA was then 
extracted using the QIAGEN ® Endofree Plasmid Purification Kit (Qiagen, 12362). 
DNA concentration was determined by measuring using NanoDrop at OD260nm (See 
Section: 2.5.1.4). 
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Table: 2.5.4 2X-LB broth (low-salt) media preparation  
   Reagents  Volume 
Peptone   20g/L  
Yeast Extract   10g/L  
NaCl    5g/L 
2.5.4.1 Optimising Antibiotic Selection Conditions 
To identify the lowest level of puromycin that kills non-transfected cells within 
approximately 5 days puromycin concentrations were tested from 1-10 µg/ml keeping 
all other culture conditions same. Cells were plated 2x105 cells per well in a 24-well 
plate containing 1 ml of culture medium. After 24hrs., 1ml culture medium containing 
1-10 µg/ml puromycin were added to the cells. Cells were cultured for 10–14 days, 
replacing the puromycin-containing medium every 2- 3 days. Plates were examined 
for viable cells every 2 days. The lowest puromycin concentration that begins to give 
massive cell death in approximately 3–5 days were identified and used this puromycin 
concentration to select cells after transfection. 
2.5.4.2 Optimisation of plasmid transfection protocol 
To determine the optimal conditions for plasmid transfection in 24-well plates, an 
optimisation with GFP plasmid was carried out for MIN6 cell line.  Cell suspensions 
were prepared at 2x105 cells per 500 µl of plating media.  Solutions of GFP plasmid at 
a concentration of 1-5 µg were prepared in optiMEM (Gibco, 31985). Lipofectamine 
2000 (3 µl) solutions were prepared in optiMEM and incubated at room temperature 
for 5 min.  After incubation, lipofectamine solution was added to each GFP plasmid 
concentrations. These solutions were mixed well and incubated for a further 20 min at 
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room temperature. 100 µl of the plasmid/lipofectamine solutions were added to a 24-
well plate. The cell suspensions were added to each plate at a final cell concentration 
of 2x105 cells per well. The plates were mixed gently and incubated at 37°C for 24hrs.  
After 24hrs., the transfection mixture was removed from the cells and the plates were 
fed with fresh medium. After 72hrs. cells were observed under the fluorescent 
microscope. Those conditions were used that showed more fluorescent cells and few 
dead floating cells. 
2.5.4.3 Single cell cloning 
For single cell cloning a cell solution of about 1000 cells / ml was prepared. 100 µl of 
the cell suspension was added to the first row of wells. 100 µl of the culture media 
was added to the rest of the 96-well plate. Then using the single channel pipettor 40 µl 
of the cell suspension was transfered from the first row of wells to the second row of 
wells and mixed by gently pipetting avoiding bubbles. Using the same tip this was 
repeated down the entire column.  
Clones were then chosen by microscopy after 4 to 5 days. Each wells were checked 
and marked that contained just a single colony. These colonies were then subcultured 
from the 96-well plates into 24-well plate. Each clone was transferred into a single 
well in a 24-well plate. 
2.5.5 RNA interference (RNAi) 
RNAi using small interfering RNAs (siRNAs) was carried out to silence specific 
genes. The siRNAs used were purchased from Ambion Inc.  These siRNAs were 21-
23 bp in length and were introduced to the cells via reverse transfection with the 
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transfection agent NeoFX (Ambion Inc., 4511) and lipofectamine 2000 (Invitrogen, 
11668-027).  
2.5.5.1 Transfection optimisation 
2.5.5.1.1  24-well plate optimisation using NeoFX Transfection Reagent 
To determine the optimal conditions for siRNA transfection in 24-well plates, an 
optimisation with a siRNA for Gapdh (Ambion Inc., 4605) was carried out for MIN6 
cell line.  Cell suspensions were prepared at 2x105 cells per 500 µl of plating media.  
Solutions of negative control i.e. scrambled siRNA and Gapdh siRNAs at a final 
concentration of 50nM were prepared in optiMEM (Gibco, 31985). NeoFX solutions 
at a range of concentrations were prepared in optiMEM and incubated at room 
temperature for 10 min (Table: 2.5.5.1.1).  After incubation, both negative control and 
Gapdh siRNA solution was added to each NeoFX concentration. These solutions were 
mixed well and incubated for a further 10 min at room temperature. 100 µl of the 
siRNA/NeoFX solutions were added to a 24-well plate. The cell suspensions were 
added to each plate at a final cell concentration of 2x105 cells per well. The plates 
were mixed gently and incubated at 37°C for 24hrs.  After 24hrs., the transfection 
mixture was removed from the cells and the plates were fed with fresh medium. After 
72hrs. cells were removed for protein extraction and western blot analysis was carried 
out. Optimal conditions for transfection were determined as the combination of 
conditions that gave the greatest reduction of Gapdh protein as determined by western 
blotting after Gapdh siRNA transfection and the least cell kill in the presence of 
transfection reagent (Table: 2.5.5.1.4).  
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Table: 2.5.5.1.1 Different conditions used for siRNA optimization in 24-well plate 
Cell No 
SiRNA 
Concentration 
Transfecting 
reagent 
Transfection 
type 
2x 105 50nm Gapdh 
NeoFX 
1 and 2 µl 
Reverse 
transfection 
2x 105 100nm Gapdh 
NeoFX 
1 and 2 µl 
Reverse 
transfection 
2x 105 50nm Gapdh 
NeoFX 
1 and 2 µl 
Direct  
transfection 
2x 105 50nm Gapdh Lipofectamine 2000 1, 2 and 4 µl 
Reverse 
transfection 
2x 105 50nm Gapdh Lipofectamine 2000 1, 2 and 4 µl 
Direct 
transfection 
 
2.5.5.1.2 24-well plate optimisation using Lipofectamine 2000 Transfection 
Reagent 
To determine the optimal conditions for siRNA transfection in 24-well plates, an 
optimisation with a siRNA for Gapdh (Ambion Inc., 4605) was carried out for each 
cell line.  Cell suspensions were prepared at 2x105 cells per 500 µl of plating media.  
Solutions of negative control (scrambled siRNA) and Gapdh siRNAs at a final 
concentration of 50nM were prepared in optiMEM (Gibco, 31985) lipofectamine 
(Invitrogen, 11668-027) solutions range of concentrations were prepared in optiMEM 
and incubated at room temperature for 5 min.  After incubation lipofectamine solution 
was added to each negative control and Gapdh siRNA solution. These solutions were 
mixed well and incubated for a further 20 min at room temperature. 100 µl of the 
siRNA/lipofectamine solutions were added to a 24-well plate. The cell suspensions 
were added to each plate at a final cell concentration of 2x105 cells per well. The 
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plates were mixed gently and incubated at 37oC for 24hrs.  After 24hrs. the 
transfection mixture was removed from the cells and the plates were fed with fresh 
medium. After 72hrs. cells were removed for protein extraction and western blot 
analysis carried out. Optimal conditions for transfection were determined as the 
combination of conditions that gave the greatest reduction of Gapdh protein as 
determined by western blotting after Gapdh siRNA transfection and the least cell kill 
in the presence of transfection reagent (Table: 2.5.4.1.4).  
2.5.5.1.3 96-well plate optimisation using NeoFX Transfection Reagent 
In order to determine the optimal conditions for siRNA transfection in 96-well plates, 
an optimisation with a siRNA for kinesin (Ambion Inc., 16704) was carried out for 
each cell line. Cell suspensions were prepared at 5x103, 1x104 and 5x104 cells per ml.  
Solutions of negative control and kinesin siRNA at a final concentration of 50nM 
were prepared in optiMEM (Gibco, 31985).  
NeoFX solutions at a range of concentrations were prepared in optiMEM in duplicate 
and incubated at room temperature for 10 min.  After incubation, either negative 
control or kinesin siRNA solution was added to each NeoFX concentration. These 
solutions were mixed well and incubated for a further 10 min at room temperature 
(Table: 2.5.5.1.3). 50 µl of the siRNA/NeoFX solutions were added to a 96-well plate. 
The cell suspensions were added to each plate at a final cell concentration of 5x103, 
1x104 and 5x104 cells per well. The plates were mixed gently and incubated at 37°C 
for 24hrs.  After 24hrs, the transfection mixture was removed from the cells and the 
plates were fed with fresh medium. The plates were assayed for changes in 
proliferation at 72hrs. using the acid phosphatase assay (See Section: 2.3.3). Optimal 
conditions for transfection were determined as the combination of conditions that 
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gave the greatest reduction in cell number after kinesin siRNA transfection and the 
least cell kill in the presence of transfection reagent (Table: 2.5.4.1.4).  
Table: 2.5.5.1.3 Different conditions used for siRNA optimization in 96-well plate 
Cell No 
SiRNA 
Concentration 
Transfecting 
reagent 
Transfection 
type 
5x103 50nm Kinesin 
NeoFX 
0.5, 0.75 and 1µl 
Reverse 
transfection 
1x 104 50nm Kinesin 
NeoFX 
0.5, 0.75 and 1µl 
Reverse 
transfection 
5x 104 50nm Kinesin 
NeoFX 
0.5, 0.75 and 1µl 
Reverse 
transfection 
5x103 50nm Kinesin 
Lipofectamine 2000 
0.5, 0.75 and 1µl 
Reverse 
transfection 
1x 104 50nm Kinesin 
Lipofectamine 2000 
0.5, 0.75 and 1µl 
Reverse 
transfection 
5x 104 50nm Kinesin 
Lipofectamine 2000 
0.5, 0.75 and 1µl 
Reverse 
transfection 
 
2.5.5.1.4 96-well plate optimisation using Lipofectamine 2000 Transfection 
Reagent 
In order to determine the optimal conditions for siRNA transfection in 96-well plates, 
an optimisation with siRNA for kinesin (Ambion Inc., 16704) was carried out for each 
cell line. Cell suspensions were prepared at 5x103, 1x104 and 5x104 cells per ml.  
Solutions of negative control and kinesin siRNA at a final concentration of 50nM 
were prepared in optiMEM (Gibco, 31985). Lipofectamine 2000 solutions at a range 
of concentrations were prepared in optiMEM in duplicate and incubated at room 
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temperature for 5 min.  After incubation, either negative control or kinesin siRNA 
solution was added to each Lipofectamine 2000 concentration. These solutions were 
mixed well and incubated for a further 20 min at room temperature (Table: 2.5.5.1.3). 
50 µl of the siRNA/ Lipofectamine 2000 solutions were added to a 96-well plate. The 
cell suspensions were added to each plate at a final cell concentration of 5x103, 1x104 
and 5x104 cells per well. The plates were mixed gently and incubated at 37°C for 
24hrs.  After 24hrs, the transfection mixture was removed from the cells and the 
plates were fed with fresh medium. The plates were assayed for changes in 
proliferation at 72hrs. using the acid phosphatase assay (See Section: 2.3.3). Optimal 
conditions for transfection were determined as the combination of conditions that 
gave the greatest reduction in cell number after kinesin siRNA transfection and the 
least cell kill in the presence of transfection reagent (Table: 2.5.5.1.4).  
Table: 2.5.5.1.4 Optimised conditions for siRNA transfection 
Seeding density 
per well 
Volume 
Lipofectamine2000  
per well (µl) 
Plate type 
5x 104   0.5 µl 96-well plate 
2x 105 1 µl 24-well plate 
2.5.6 Western Blot analysis 
2.5.6.1 Lysis of cell pellet 
Stock of lysis buffer was prepared using the reagents as shown in the Table 2.5.6.1.1. 
Working lysis buffer was prepared fresh every time before use as shown in the table 
2.5.6.1.2.  
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Table: 2.5.6.1.1 NP40 Lysis Buffer Stock 
  Reagents     Volume 
   1M Tris pH 7.4   2 ml 
3M NaCl    1.66 ml 
1M NaF    5 ml 
10% NP40    1 ml 
   H2O     90.34 ml 
   Total      100 ml 
Table: 2.5.6.1.2 Working Lysis Buffer 
  Reagents     Volume 
100 mM Sodium Orthovanidate 10 µl 
100 mM PMSF   10 µl 
Protease Inhib Cocktail  40 µl 
   NP40 Lysis Buffer   940 µl 
   Total      1000 µl 
After 72hrs. of transfection cells were lysed in the 24-well plate. Prior to lysis, plate 
was washed twice with cold PBS and drained off of all supernatant. Cold lysis buffer 
was added to the cells, dropping it evenly over the whole well/plate (20 µl). The cells 
were scraped from the well and all the lysed/scraped cells gathered in one corner of 
the well. The solution was pipetted up and down without frothing and placed in a pre-
chilled eppendorf tube. The tube was vortexed for 30-60 sec until the solution was 
homogenised. The tube was placed on ice for 20 min and the tube was centrifuged at 
maximum in a microfuge for 15 min. The supernatant was transferred to a fresh 
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chilled eppendorf tube and immediately quantified for the protein (See Section: 
2.3.2.3). The samples were prepared with 2-5X loading buffer (Sigma, S-3401) and 
water was added to make all the samples at the same concentration. Parafilm was 
wrapped around the lids of the eppendorfs (to avoid evaporation) and the samples 
were boiled for 3-5 min. If not used immediately the samples were stored at –20oC 
until needed. 
2.5.6.2   Gel electrophoresis 
Proteins for Western blot analysis were separated by SDS-polyacylamide gel 
electrophoresis (SDS-PAGE). Resolving and stacking gels were prepared as outlined 
in Table 2.5.6.3.1 and poured into clean 10 cm x 8 cm gel cassettes, separated by 0.75 
cm plastic spacers. The plates were cleaned by tap water, followed by UHP. After 
drying, the plates were wiped down in one direction using tissue paper soaked in 70% 
Industrial Methylated Spirits (IMS). The spacers and comb used were also cleaned in 
this way. After these had dried, the resolving gel was poured first and allowed to set 
for 20 min at room temperature. The stacking gel was then poured and a comb was 
placed into the stacking gel in order to create wells for sample loading. Once set, the 
gels could be used immediately or wrapped in wet tissue paper and stored at 4oC for 
24hrs. 
1X running buffer (Table: 2.5.6.2) was added to the running apparatus before samples 
were loaded. The samples were loaded onto the stacking gels, in equal amounts 
relative to the protein concentration of the sample. The empty wells were loaded with 
loading buffer. 
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Table: 2.5.6.2 Running Buffer 
  Reagents    Volume 
Glycine   14.4 g 
Tris    3.03 g 
SDS    1g 
H2O    1L 
The samples were loaded including 7 µl of molecular weight colour protein markers 
(New England Biolabs, P7708S). The gels were run at 200 V, 45 mA for 
approximately 1.5hrs. When the bromophenol blue dye front was seen to have 
reached the end of the gels, electrophoresis was stopped. 
2.5.6.3 Western blotting  
Following electrophoresis, the acrylamide gels were equilibrated in transfer buffer (25 
mM Tris, 192 mM glycine (Sigma, G-7126) pH 8.3-8.5 without adjusting) for 10 min. 
Protein in gels were transferred onto nitrocellulose membranes (Boehringer 
Mannheim, 1722026) by semi-dry electroblotting. Eight sheets of Whatman 3 mm 
filter paper (Whatman, 1001824) were soaked in transfer buffer and placed on the 
cathode plate of a semi-dry blotting apparatus (Biorad).  Excess air was removed from 
between the filters by rolling a universal tube over the filter paper.  A piece of 
nitrocellulose membrane, cut to the same size of the gel, was prepared for transfer 
(soaked in transfer buffer) and placed over the filter paper, making sure there were no 
air bubbles.   
The acrylamide gel was placed over the nitrocellulose membrane and eight more 
sheets of pre-soaked filter paper were placed on top of the gel. Excess air was again 
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removed by rolling the universal over the filter paper. The proteins were transferred 
from the gel to the nitrocellulose at a current of 34 mA at 15V for 24-25 min.   
All incubation steps from now on, including the blocking step, were carried out on a 
revolving apparatus (Stovall, Bellydancer) to ensure even exposure of the blot to all 
reagents. The nitrocellulose membranes were blocked for 2hrs. at room temperature 
with fresh 5% non-fat dried milk (Cadburys, Marvel skimmed milk) in Tris-buffered 
saline (TBS) with 0.5% Tween (Sigma, P-1379). After blocking, the membranes was 
washed 3 x 5 min using 1X TBS/PBS. The membrane was then incubated with 5 to 10 
mls primary antibody (concentration of primary antibody was used as in Table 
2.5.6.3.2) for 1hr. The membrane was again washed 3 x 5 min using 1X TBS/PBS. It 
was then incubated in secondary antibody and the specific conditions for each 
antibody are outlined in Table 2.5.6.3.3 below. Finally the membrane was washed 3 x 
5 min using 1X TBS/PBS. Bound antibody was detected using enhanced 
chemiluminescence (ECL) (Amersham, RPN2109). 
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 Table: 2.5.6.3.1 Preparation of electrophoresis gels 
Components             Resolving gel                Resolving gel                Stacking gel 
   (7.5%)      (12%)        
Acrylamide stock*   3.8 mls  5.25 mls  0.8 mls 
(Sigma, A3574) 
Ultra pure water  8.0 mls  6.45 mls  3.6 mls 
1.5M-Tris/HCl, pH 8.8  
(BioRad, 161-0798)  3.0 mls  3.0 mls  - 
1.25M-Tris/HCl, pH 6.8 
(BioRad, 161-0799)      -        -   0.5 mls 
10% SDS  
(Sigma, L-4509)  150 mls  150 mls  50 mls 
10% Ammonium persulphate  
(Sigma, A-1433)  60 mls   60 mls   17 mls 
TEMED (Sigma, T-8133) 10 mls   10 mls   6 mls 
Note: *Acrylamide stock solution consists of 29.1g acrylamide (Sigma, A8887) and 
0.9g NN’-methylene bis-acrylamide (Sigma, 7256) dissolved in 60ml UHP water and 
made up to 100ml final volume. The solution was stored in the dark at 4oC for up to 1 
month. All components were purchased from Sigma, SDS (L-4509), NH4-persulphate 
(A-1433) and TEMED, N,N,N,N’-tetramethylethylenediamine (T-8133).  
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Table 2.5.6.3.2 List of primary antibodies used for western blot analysis 
Antibody  Dilution/ Concentration         supplier Cat. No.   
Anti-VDUP-1/Txnip  10 µg/ml  MBL  K0204-3 
(Mouse monoclonal IgG2b) 
Glucagon   1/1000   abcam  ab23468 
(Mouse monoclonal IgG2a) 
Pcsk9    1 µg/ml  abcam  ab31762 
(Rabbit polyclonal IgG) 
GAPDH    1/10000  abcam  ab9482 
(Mouse monoclonal IgG2b) 
α tubulin   1/5000   abcam  ab7291 
(Mouse monoclonal IgG1) 
Table 2.5.6.3.3 List of secondary antibodies used for western blot analysis 
Antibody      Dilution/ Concentration supplier Cat. No. 
Mouse    1/1000   Dako Cytomation P 0260 
Rabbit    1/1000   Dako Cytomation P0448 
2.5.6.4   Enhanced chemiluminescence detection 
Protein bands were developed using the Enhanced Chemiluminescence Kit (ECL) 
(Amersham, RPN2109) according to the manufacturer’s instructions. The blot was 
removed to a darkroom for all subsequent manipulations. A sheet of parafilm was 
flattened over a smooth surface, e.g. a glass plate, making sure all air bubbles were 
removed. The membrane was placed on the parafilm, and excess fluid removed.  1.5 
mls of ECL detection reagent 1 and 1.5 mls of reagent 2 were mixed and covered over 
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the membrane. Charges on the parafilm ensured the fluid stayed on the membrane.  
The reagent was removed after one minute and the membrane covered in cling film.  
The membrane was exposed to autoradiographic film (Boehringer Mannheim, 
1666916) in an autoradiographic cassette for various times, depending on the signal 
(30 – 15 min).  The autoradiographic film was then developed.  
The exposed film was developed for 5 min in developer (Kodak, LX24, and diluted 
1:6.5 in water).   The film was briefly immersed in water and fixed (Kodak, FX-40, 
diluted 1:5 in water), for 5 min.  The film was transferred to water for 5 min and then 
air-dried. 
2.5.7 Immunoprecipitation  
The cells were washed three times with PBS and suspend in a cold Lysis buffer 
(Table: 2.5.6.2.2). This was incubated on ice for 30 min and centrifuged at 12,000 x g 
for 10 min at 4oC. The supernatant was then transferred to a fresh eppendorf tube. 
Primary antibody was added (2 µg / 200 µl of cell extract) to the cell extract. After 
mixing it by pipetting up and down it was incubated on a revolving apparatus for 30-
120 min at 4oC.  20 µl of 50% protein A agarose beads resuspended in the cold Lysis 
buffer was added to the cell extract mix. After mixing, it was incubated with gentle 
agitation on revolving apparatus for 60 min at 4oC. This mixture was then centrifuged 
at 5000 rpm for 5 min. The beads were washed 3-5 times with the cold Lysis buffer 
and centrifuged 5000 rpm for 5 min. the beads were resuspended in 20 µl of 
Laemmli’s sample buffer and boiled for 3-5 min, and centrifuged for 5 min. 10 µl of 
the samples were loaded per lane in a SDS-polyacrylamide gel for electrophoresis 
(See Section: 2.5.6.3). The protein was then blotted to a nitrocellulose paper (See 
Section: 2.5.6.4). The membrane was then blocked for 10% skimmed milk (in PBS) 
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for 1hr at room temperature. The membrane was then washed three times and 
incubated with primary antibody diluted with PBS, containing 1% skimmed milk as 
suggested in the table 2.5.6.3.2 for 1hr at room temperature or over night at 4oC. The 
membrane was then washed using PBS for 5 min x 3 times and incubated in 
secondary antibody diluted with 1% skimmed milk (in PBS) (Table: 2.5.6.3.3) for 1hr 
at room temperature. The membrane was again washed with PBS (5 min x 3 times) 
and were developed using the Enhanced Chemiluminescence Kit (See Section: 
2.5.6.5). 
2.5.8 Immunofluorescence 
Cells are allowed to adhere to glass slides overnight. The slides where then washed 
twice for 5 min in PBS and fixed using methnol for 10 min or 4% paraformaldehyde 
(Sigma, P6148) (45 min at 4oC). Samples were blocked in relevant serum overnight 
and the following morning the serum was removed. The slide was then washed using 
PBS/PHEM-0.2% Tween at 5 min per wash and the primary antibody was applied 
(antibodies and dilutions are listed in Table 2.5.8.1). This was incubated overnight at 
4oC in a moist environment. The following day, the primary antibody was removed 
and the slides were washed three times in PBS/PHEM-0.2% Tween at 5 min per 
wash. The fluorescent secondary antibodies (light sensitive) were prepared in the dark 
room under dim conditions and were coated in foil. The cells were incubated with 
secondary antibodies (Table: 2.5.8.2) for 60 min in the dark. All work from this point 
onwards was carried out in the dark to prevent ‘quenching’ fluorescent signal. After 
60 min incubation the antibodies were removed and the slides were washed three 
times in PBS/PHEM-0.2% Tween. The cells were then counterstained for nuclei with 
DAPI and mounted using vectashield (4', 6-diamidino-2-phenylindole) (Vector, 
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H1000) and covered with cover slips (Chance Propper). Slides were examined by 
Leica TCS AOBS.   
Table 2.5.8.1 List of primary antibodies used for immunofluorescence analysis 
Antibody   Dilution         supplier   Cat. No.   
Insulin + proinsulin  1/1250   abcam   ab8304 
Glucagon   1/200   cell signalling  #2760 
 
Table: 2.5.8.2 List of primary antibodies used for immunofluorescence analysis 
Antibody   Dilution         supplier   Cat. No.   
Alexa Fluor® 488  1/1000   Molecular Probes A21121 
goat anti-mouse IgG 
Alexa Fluor® 488   1/1000   Molecular Probes  A31566 
goat anti-rabbit IgG 
 
2.5.9 Determination of reactive oxygen species (ROS) by fluorescence 
For this assay, 1.875 x 105 cells were seeded per well in a 24-well plate and incubated 
for 48hrs. at 37°C. 2′,7′-dichlorodihydrofluorescein diacetate (DCFHDA) was then 
added to three of the six wells at a final concentration of 30 mM and incubated for 40 
min. The plate was then washed three times with PBS. Fluorescence was then read at 
485 nm excitation and 535 nm emissions in a fluorescence plate reader (Synergy HT, 
Bio-Tek, USA). The wells containing no DCFHDA acted as blanks for each sample. 
ROS production was expressed as % increase in fluorescence relative to empty 
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shRNA transfected cells. 
DCFHDA is a non-fluorescent compound that easily enters the cell by free diffusion 
through the plasmatic membrane; once inside the cytoplasm, this compound loses the 
diacetyl radical by reaction with cellular esterases and remains inside the cell. The 
resulting product, 2’,7’-dichlorodihydrofluorescein (DCFH) is not fluorescent /per se/, 
but upon reaction with reactive oxygen species (ROS), particularly hydroxyl radical 
and superoxide, it is converted to the fluorescent compound dichlorofluorescein. 
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2.6       Affymetrix GeneChips® 
The microarray gene expression experiments of this study were performed using the 
GeneChip® Mouse Genome 430 2.0 Array. The GeneChip® Mouse Genome 430A 
2.0 Array is a single array representing approximately 34,000 well-characterized 
mouse genes.  
The GeneChip® Mouse Genome 430 2.0 Array is a single array that contains over 
45,000 probe sets analyze the expression level of over 39,000 transcripts and variants 
from over 34,000 well-characterized mouse genes that can be used to explore 
mechanisms behind biological and disease processes. All probe sets on the GeneChip 
Mouse Expression Array 430A are represented on the GeneChip Mouse Genome 430 
2.0 Array. It provides coverage of well-substantiated genes in the transcribed mouse 
genome on a single array. This chip leverages the Power of the Probe Set to obtain 
multiple independent measurements for each transcript, delivering the greatest 
accuracy and reproducibility of any microarray platform  
Sequences used in the design of the array were selected from GenBank®, dbEST, and 
RefSeq. The sequence clusters were created from the UniGene database (Build 107, 
June 2002) and then refined by analysis and comparison with the publicly available 
draft assembly of the mouse genome from the Whitehead Institute Center for Genome 
Research (MSCG, April 2002). Oligonucleotide probes complementary to each 
corresponding sequence are synthesized in situ on the array. Eleven pairs of 
oligonucleotide probes are used to measure the level of transcription of each sequence 
represented on the GeneChip Mouse Genome 430 2.0 Array. 
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Table: 2.6 Equipment and Chemicals required for Microarray experiment 
Item     Catalogue No. Supplier 
20X SSPE     US51214  CAMBREX 
Anti-Strep Biotinylated Ab (Goat) BA-0500  LABKEM 
Wheaton 1L Sterile Bottles  219980  SHAW SCIENTIFIC 
(Paul Hennessy) 
Herring Sperm DNA   D1816   MSC 
10% Tween 20   28320   MSC 
BSA     15561-020  BIOSCIENCES 
R-Phycoerythro Streptavidin  S-866   BIOSCIENCES 
GeneChip®   
Mouse Genome 430 2.0 Array 900496    AFFYMETRIX 
Test3 Array    900341  AFFYMETRIX 
One-Cycle Target Labelling Kit 900493  AFFYMETRIX 
Two-Cycle Target Labelling Kit 900494  AFFYMETRIX 
0.5M EDTA    E7889   SIGMA 
MES Free Acid Monohydrate M5287   SIGMA 
MES Sodium Salt   M3058   SIGMA 
DMSO     D5879   SIGMA 
Goat IgG    I5256   SIGMA 
Sodium Hypochlorite   42,504-4  SIGMA 
20X SSPE     85637   SIGMA 
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Item     Catalogue No. Supplier 
5M NaCl    9759   AMBION 
1.5 ml Eppys    12400   AMBION 
0.5 ml Eppys    12300   AMBION 
RNase Zap    9780   AMBION 
RNA ladder    7152   AMBION 
0.5M EDTA    9260G   AMBION 
RNase-free UHP   9932   AMBION 
5X Megascript T7 kit   1334 (or B1334-5) AMBION 
RNeasy Mini Kit   74106   QIAGEN 
QIA Shredder    79656   QIAGEN 
Eppendorf Eppy    0030-120-191  UNITECH 
RNA 6000 Nano chip Kit  5065-4476  AGILENT 
2.6.1 First-Strand cDNA synthesis for hybridisation to Affymetrix array chips 
cDNA synthesis was carried out using One-cycle cDNA synthesis kit. Total RNA (1-
8 µg) was placed in an RNase-free 0.5 ml microfuge tubes. To each tube following 
reagents was added (Table: 2.6.1.1) 
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Table: 2.6.1.1 First-Strand cDNA Synthesis 
Reagents    Amount 
      Poly-A RNA Control      2 µl 
        T7-Oligo (dT) Primer (50 µM)    2 µl 
           RNA + RNase-free water    8 µl 
The tube were gently flicked a few times to mix, and then centrifuged briefly to 
collect the reaction mixture at the bottom of the tube. The reaction mixture was 
incubated for 10 min at 70°C and then cooled at 4°C for at least 2 min. 
The tube was centrifuged briefly to collect the sample at the bottom of the tube. In a 
separate tube, the First-Strand Master Mix was assembled for all of the RNA samples. 
The master mix for single reaction was prepared as in Table: 2.6.1.2.  
Table: 2.6.1.2 1st strand master mix 
Reagents    Amount 
    5X 1st strand buffer  4 µl 
   DTT (0.1M)   2 µl 
   dNTP (10 mM)  1 µl 
   Total    7 µl 
A total volume of 7 µl of master mix was added to each RNA/T7-Oligo (dT) Primer 
mix for a final volume of 19 µl. The tubes were mixed thoroughly by flicking a few 
times, centrifuged briefly, and immediately placing the tubes at 42°C incubating it for 
2 min. To each RNA sample, SuperScript II was added for a final volume of 20 µl. 
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The samples were mixed thoroughly by flicking and centrifuged briefly. The tubes 
were incubate for 1hr at 42°C and then cooled for at least 2 min at 4°C.  
2.6.2 Second-Strand cDNA Synthesis 
In a separate tube second-strand master mix was assembled (Table: 2.6.2). To the 
master mix following reagents were added. 
Table: 2.6.2 Second-strand master mix 
Reagents     Amount 
               RNase-free Water    91 µl 
        5X 2nd Strand Reaction Mix        30 µl 
         dNTP (10 mM)             3 µl 
        E. coli DNA ligase     1 µl 
              E. coli DNA Polymerase    4 µl 
        RNase H      1 µl 
Total Volume     130 µl 
The tubes were mixed well by gently flicking and centrifuged briefly. To each first-
strand synthesis sample, 130 µl of second-strand master mix was added (Table: 2.6.2). 
The tubes were mixed well by gently flicking, centrifuged briefly and incubated for 
2hrs. at 160C. After incubation, 2 µl of T4 DNA Polymerase was added to each 
sample and incubated for 5 min at 16°C.  After incubation with T4 DNA Polymerase, 
10 µl of EDTA (0.5M) was added to the sample tube. 
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2.6.3 Cleanup of Double-Stranded cDNA 
For cleaning up of synthesized double-stranded cDNA the sample cleanup module 
was used. cDNA binding buffer (600 µl) was added to the double-stranded cDNA 
synthesis preparation and mixed by vortexing for 3 sec. The cDNA Cleanup Spin 
Column sitting in a 2 ml collection tube was taken and to it was added 500 µl of the 
sample, centrifuged for 1 min at ≥ 8,000 x g (≥ 10,000 rpm) and the flow-through was 
discarded. The spin column was reloaded with the remaining sample and centrifuged 
as above discarding the flow-through and Collection Tube. The spin column was 
transferred into a new 2 ml collection tube. To the column, 750 µl of the cDNA wash 
buffer was added, centrifuged for 1 min at ≥ 8,000 x g (≥ 10,000 rpm) and flow-
through was discarded. The tubes were centrifuged for 5 min at maximum speed with 
caps opened. The flow-through and collection tube were discarded. Spin column was 
transferred into a 1.5 ml collection tube. Care was taken to ensure that the cDNA 
elution buffer was dispensed directly onto the spin column membrane. The tubes were 
incubated for 1 min at room temperature and centrifuged for 1 min at maximum speed 
(≤ 25,000 x g) to elute. 
2.6.4 Synthesis of Biotin-Labeled cRNA 
GeneChip IVT Labeling Kit was used for the IVT labeling step for generating biotin-
labeled cRNA. About 12 µl of template cDNA was transferred to 0.5 ml RNase-free 
microfuge tubes. To carry out the IVT reaction all the reagents were added to the 
cDNA as in the Table 2.6.4.   
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Table: 2.6.4 Master Mix of IVT reaction 
   Reagents     Amount 
RNase-free water   14 µl 
10X IVT labeling buffer     4 µl 
IVT labeling NTP mix   12 µl  
IVT labeling enzyme mix     4 µl 
The reagents were carefully mixed and collected at the bottom of the tube by brief 
microcentrifugation. The reaction tubes are then incubated at 37°C for 16hrs. to 
maximize the labeled cRNA yield with high-quality array results. 
2.6.5 Cleanup and Quantification of Biotin-Labelled cRNA 
Sample Cleanup Module was used for cleaning up the biotin-labelled cRNA, to 
remove unincorporated NTPs. this protocol was performed at room temperature. To 
the labelled cRNA, 60 µl of RNase-free water was added and mixed by vortexing for 
3 sec. To the sample was added 350 µl of IVT cRNA binding buffer and mixed by 
vortexing for 3 sec. A volume of 250 µl ethanol (96-100%) was added to the lysate, 
and mixed well by pipetting. This sample was then applied (700 µl) to the IVT cRNA 
cleanup spin column sitting in a 2 ml collection tube. It was then centrifuged for 15 
sec at ≥ 8,000 x g (≥ 10,000 rpm) discarding the flow-through and collection tube. 
The spin column was transferred into a new 2 ml collection tube. Onto the spin 
column, 500 µl of IVT cRNA wash buffer was added. This column was centrifuged 
for 15 sec at ≥ 8,000x g (≥ 10,000 rpm) to wash discarding the flow-through. To the 
spin column, 500 µl of 80% (v/v) ethanol was added and centrifuged for 15 sec at ≥ 
8,000x g (≥ 10,000 rpm) discarding the flow-through. The spin column was again 
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centrifuged for 5 min at maximum speed with open caps to allow the membrane to 
dry, discarding the flow-through and collection tube. Spin column was transferred 
into a new 1.5 ml collection tube, and 11 µl of RNase-free water was added directly 
onto the spin column membrane ensuring that the water was dispensed directly onto 
the membrane. Tube was centrifuged for 1 min at maximum speed (≤ 25,000 x g) to 
elute. Further 10 µl of RNase-free water was added directly onto the spin column 
membrane ensuring that the water was dispensed directly onto the membrane. Tube 
was again centrifuged for 1 min at maximum speed (≤ 25,000 x g) to elute. The eluted 
cRNA was diluted 1:100 fold for quantification using Nanodrop. A 1:2 dilution of the 
cRNA was also analysed on the Bioanalyzer. 
2.6.6 Fragmentation of the cRNA 
Fragmentation of cRNA target was carried out before hybridisation onto GeneChip 
probe arrays using the sample clean up module. cRNA samples at a final 
concentration of 0.5 µg/µl was used for fragmentation and incubated at 94°C for 35 
min in 5X fragmentation buffer.  
2.6.7 Hybridisation of cRNA to GeneChips 
To each tube of fragmented cRNA (15 µg), 270 µl of hybridization cocktail for single 
probe array was added. Hybridization cocktail contained following reagents per 
reaction as shown in Table 2.6.7  
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Table: 2.6.7 Hybridization cocktail 
   Reagents      Amount 
Control Oligonucleotide B2 3 nM           5 µl 
20X Eukaryotic Hybridization controls   15 µl 
  Herring Sperm DNA (10 mg/mL)      3 µl 
BSA (50 mg/ml)        3 µl 
2X Hybridization Buffer    150 µl   
DMSO       30 µl  
H2O        34 µl  
   Total      270 µl 
The probe array was equilibrated to room temperature immediately before use by 
leaving it for 30 min for the rubber septa to equilibrate to room temperature 
preventing cracking and leading to leaks. The arrays were wetted by filling with 200 
µl of 1X hybridization buffer and incubating it at 45°C for 10 min at a rotation speed 
of 60 rpm. The hybridization cocktail was heated to 99°C for 5 min in a heat block 
and then cooled to 45°C heat block for 5 min. Hybridization cocktail was spinned at 
maximum speed in a microcentrifuge for 5 min to remove any insoluble material. The 
buffer solution from the probe array cartridge was removed and filled with 300 µl of 
the clarified hybridization cocktail, avoiding any insoluble matter at the bottom of the 
tube. Then probe arrays were loaded in a balanced configuration around the axis set to 
45°C, rotated at 60 rpm and hybridized for 16hrs. 
2.6.8 Probe Array Washing and Staining 
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After hybridization, the hybridization cocktail was removed from the probe array and 
the probe array was completely filled with the appropriate volume of Non-Stringent 
Wash Buffer (Wash Buffer A). The SAPE (Streptavidin Phycoerythrin) stain solution 
was prepared fresh (Table: 2.6.8.1). This was mixed well and divided into two 
aliquots of 600 µl per array.  
Table: 2.6.8.1 SAPE (Streptavidin Phycoerythrin) stain solution  
 Reagents        Amount 
2X Stain Buffer 
(100 mM MES, 1M [Na+], 0.05% Tween-20)   600 µl 
BSA (50 mg/ml)        48 µl 
Streptavidin Phycoerythrin (SAPE; 1 mg/ml)      12.0 µl 
Deionised (DI) H20         540 µl 
Total volume       1200 µl 
      Antibody solution mix was prepared as follows (Table: 2.6.8.2):  
Table: 2.6.8.2 Antibody solution 
            Reagents      Amount 
   2X Stain Buffer     300µl 
BSA      24 µl  
Goat IgG Stock (10 mg/ml)   6 µl 
Biotinylated antibody (0.5 mg/ml)  3.6 µl 
DI H20      266.4 µl 
Total volume     600 µl 
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The Affymetrix GeneChip® Operating Software (GCOS) manages the fluidics 
protocol. The Fluidics Station was prepared by running a priming protocol, which 
ensures that the lines of the fluidics station are filled with the appropriate buffers and 
the fluidics station is ready for running. From the Protocol drop-down list, Prime_450 
was chosen and buffer reservoir A was changed to Non-Stringent Wash Buffer, and 
intake buffer reservoir B to Stringent Wash Buffer and then the protocol was run. 
When primed, each module was set up with one GeneChip, two vials of SAPE 
solution and one vial of antibody solution. The antibody amplification for Eukaryotic 
targets protocol was initiated. The details of the protocol EukGE-WS2v4 has been 
listed in the following Table 2.6.8.3. This process takes about 75 min to complete. 
Table: 2.6.8.3 
Fluidics Protocols    EukGE-WS2v4 
Post Hyb Wash #1 10 cycles of 2 mixes/cycle with Wash Buffer A at 25°C 
Post Hyb Wash #2  4 cycles of 15 mixes/cycle with Wash Buffer B at 50°C 
Stain    Stain the probe array for 10 min in SAPE solution at 25°C 
Post Stain Wash  10 cycles of 4 mixes/cycle with Wash Buffer A at 25°C 
2nd Stain  Stain the probe array for 10 min in antibody solution at                              
25°C 
3rd Stain   Stain the probe array for 10 min in SAPE solution at 25°C 
Final Wash   15 cycles of 4 mixes/cycle with Wash Buffer A at 30°C. The 
Hold    Holding temperature is 25°C 
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2.6.9 Probe Array Scan 
After staining and washing, the chips were scanned using an Affymetrix® 
GeneChip® Scanner 3000. The sample door on the scanner was opened and the probe 
array was inserted into the holder. The Data was organized by GCOS. It saves images 
of the scanned probe array in a data file (*.dat). The software derives the *.cel (Cell 
Intensity File) file from a *.dat file and automatically creates it upon opening a *.dat 
file. It contains a single intensity value for each probe cell delineated by the grid 
(calculated by the Cell Analysis algorithm). The Chip File (*.chp) generated from the 
analysis of a probe array contains qualitative and quantitative analysis for every probe 
set. Report File (*.rpt) generated by GCOS summarizes the data quality information 
for a single experiment. The report is generated from the analysis output file (*.chp). 
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2.7  Quality assessment of Affymetrix microarray chips 
The quality of the data generated with Affymetrix microarray chips was assessed 
based on different criteria including the scaling factor, background and noise levels, 
GAPDH 3’/ 5’ ratios and the %Present call. 
Scaling factor: The scaling factor was the multiplication factor applied to each signal 
value on an array. A scaling factor of 1.0 indicates that the average array intensity was 
equal to the target intensity. Scaling factors vary across different samples and so there 
were no set guidelines for any particular sample type. However, Affymetrix advise 
that for replicates and comparisons involving a relatively small number of changes, 
the scaling/normalization factors (calculated by the global method) should be 
comparable among arrays. Larger discrepancies among scaling/normalization factors 
(e.g., three-fold or greater) may indicate significant assay variability or sample 
degradation leading to noisier data.  
Background and noise levels: Although there are no official guidelines regarding 
background, Affymetrix has found that typical Average Background values range 
from 20 to 100 for arrays scanned with the GeneChip® Scanner 3000. Arrays being 
compared should ideally have comparable background values. A high background 
implies that impurities, such as cell debris and salts, are binding to the probe array in a 
non-specific manner, and that these substances are fluorescing at 570nm (the 
detection wavelength). These non-specific binding causes a low signal-to-noise ratio 
(SNR), meaning that transcripts present at very low levels in the sample may be 
incorrectly called as “Absent”. High background creates an overall loss of sensitivity 
in the experiment. The noise is a measure of the pixel-to-pixel variation of probes 
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cells on a GeneChip array. 
GAPDH 3’/ 5’ ratios: β-actin and GAPDH are used to assess RNA sample and assay 
quality for the majority of GeneChip® expression arrays. Specifically, the Signal 
values of the 3’ probe sets for β-actin and GAPDH are compared to the Signal values 
of the corresponding 5’ probe sets. The ratio of the 3’ probe set to the 5’ probe set is 
generally no more than 3 for the 1-cycle assay. A high 3’ to 5’ ratio may indicate 
degraded RNA or inefficient transcription of ds cDNA or biotinylated cRNA. 3’ to 5’ 
ratios for internal controls are displayed in the Expression Report (.rpt) file. 
%Present call: The number of probe sets called “Present” relative to the total number 
of probe sets on the array is displayed as a percentage in the Expression Report (.rpt) 
file. Percent present (%P) values depend on multiple factors including cell/tissue type, 
biological or environmental stimuli, probe array type, and overall quality of RNA. 
Replicate samples should have similar %P values. Extremely low %P values are a 
possible indication of poor sample quality. 
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2.8  Microarray Data Normalisation 
The purpose of data normalisation is to minimise the effects of experimental and 
technical variation between microarray experiments so that meaningful biological 
comparisons can be drawn from the data sets and that real biological changes can be 
identified in microarray experiments. Several approaches have been demonstrated to 
be effective and beneficial.  
 
 
 
 
 
 
 
 
 
 
Fig: 2.8 Flow chart showing expression analysis and interpretation of microarray 
data 
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2.8.1 Normalization and Quantification using dChip 
DNA-Chip Analyzer (dChip) is a software package implementing model-based 
expression analysis of oligonucleotide arrays (Li and Wong, 2001) and several high-
level analysis procedures. This model-based approach allowed probe-level analysis on 
multiple arrays. In this normalisation procedure an array with median overall intensity 
is chosen as the baseline array against which other arrays are normalised at probe 
level intensity. Subsequently a subset of PM probes, with small within-subset rank 
difference in the two arrays, serves as the basis for fitting a normalisation curve.  
2.8.1.1 Quality inspection 
The following Quality Control were taken to estimate the quality of chip 
• Median Intensity: Median intensity is the median intensity of the un-normalized 
probe values.  
• P call %: Calls indicate if the transcript is expressed or not. It can be ‘P’ for 
present, ‘M’ for marginally present and ‘A’ for absent. Total P calls in an array can 
vary widely based on the different nature of samples. 
• % Signal outlier: The signal value greater than 80th percentile multiplied by 3 is 
taken as signal outlier and is represented as % signal outlier.  
• % Array outlier: The array-outliers are the arrays whose probe pattern for selected 
probe set is different from the consensus probe pattern seen in most arrays.  
• Warning: If the array outlier increases over 5%, the chip is marked as outlier chip 
and is marked by ‘*’, indicating potential image contamination or sample 
hybridization problem of that arrays  
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Manual inspection: Apart from the above parameters manual inspection was also done 
to estimate the quality of individual chips. A sample of good and bad quality chip is 
shown below (Fig 2.8.1.1a and Fig 2.8.1.1b). 
 
Fig: 2.8.1.1a An example of a good chip (image simulated by dChip) 
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Fig: 2.8.1.1b A chip with very high background (image simulated by dChip) 
2.8.1.2 Hierarchical Clustering 
Hierarchical clustering is a mathematical technique whereby the samples/genes are 
connected iteratively based on their similarity. The sample/genes with similar 
expression patterns are grouped together and are connected by a series of branches, 
which is called dendrogram (or clustering tree). Hierarchical clustering was used to 
see how well the replicates samples cluster, identify any sub-groups in the samples 
and identify correlated genes.   
2.8.1.3 Finding significant genes 
For most of the places a combination of filtration criteria was used to pick up the 
differentially-regulated genes. These criteria are discussed below.  
Fold change 
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Fold change is the ratio of mean of experimental group to that of baseline. It’s a 
metric to define the gene's mRNA-expression level between two distinct experimental 
conditions. Fold change of 1.2 and 2 was used for different types of analysis. 
Difference 
The difference of Affymetrix expression units was also taken for finding 
differentially-regulated genes. Difference of 100 was taken for most of the 
comparisons. 
t-test: The t-test assesses whether the means of two groups are statistically different 
from each other. The output of the t-test is the p-value. The p-value of less than 0.05 
was taken as significantly different. 
Combination of Fold change ≥1.2, difference≥100 and p-value <0.05 was taken for 
up-regulated genes. Similarly the combination of Fold change ≤1.2, Difference ≤100 
and p-value < 0.05 was taken for down-regulated genes.   
2.8.2 Microsoft access 
This is a database-building package that was used in analysis to compare different 
gene lists. Access allowed comparison of like genes across multiple lists. It allowed 
comparison of genes and also relevant information such as probe sets, difference of 
mean and p-value. Apart from this it was widely used for merging two tables and 
adding annotation to the genelists. 
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2.8.3 GenMAPP 
GenMAPP is a free computer application designed to visualize gene expression and 
other genomic data on maps representing biological pathways and groupings of genes.  
A MAPP is a GenMAPP-produced file format that showed biological relationships 
between genes or gene products. MAPPs could be used to group genes and view data 
by any organizing principle. Examples of the types of MAPPs represented in 
GenMAPP are metabolic pathways, signal transduction cascades, subcellular 
locations, or gene families. GenMAPP automatically linked each gene on a MAPP to 
data from gene expression experiments which had been imported. A sample result is 
shown below. 
Integrated with GenMAPP were programs to perform a global analysis of gene 
expression or genomic data in the context of hundreds of pathway MAPPs and 
thousands of Gene Ontology Terms.  MAPPFinder created a global gene-expression 
profile across all areas of biology by integrating the annotations of the Gene Ontology 
(GO) Project with GenMAPP. The results were displayed in a searchable browser, 
allowing rapid identification of GO terms with over-represented numbers of gene-
expression changes. Clicking on GO terms generated GenMAPP graphical files where 
gene relationships could be explored and annotated. GenMAPP was downloaded from 
http://www.genmapp.org  
MappFinder: 
MAPPFinder is an accessory program that works with GenMAPP and the annotations 
from the Gene Ontology (GO) Consortium to identify global biological trends in gene 
expression data. MAPPFinder relates microarray data meeting a user-defined criterion 
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for a "significant" change to each term in the Gene Ontology hierarchy, calculating 
the percentage of genes changed for each GO biological process, cellular component, 
and molecular function term. MAPPFinder then calculates a cumulative total of genes 
changed for a parent GO term and all of its children and a statistical score, giving a 
complete picture of the gene expression changes associated with a particular GO term. 
Furthermore, this MAPPFinder analysis can be performed on a set of MAPPs local to 
a user's computer, calculating the percentage of genes meeting the criterion for each 
MAPP. 
The calculations made by MAPPFinder are intended to give you an idea of the 
relative amount of genes meeting your criterion that are present in each GO term or 
Local MAPP. The figure below shows a sample line from the MAPPFinder Browser 
with the different numbers that are calculated. Each number displayed in the 
MAPPFinder results and the Calculation Summary is defined below. 
 
 
 
 
Genes meeting the criterion: The number of distinct genes that met the user-defined 
criterion in the Expression Dataset. This may also be referred to as "genes changed." 
Genes measured: The number of distinct genes in your Expression Dataset that were 
found to link to this GO term or MAPP. 
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Genes associated with this GO term or MAPP: The number of genes assigned to 
this GO term or on this MAPP. Also referred to as the number of "Genes in GO" for a 
specific term. 
% genes meeting the criterion: Genes meeting the criterion/genes measured * 100 
% genes measured: genes measured/genes associated * 100 
Nested numbers: The same 5 calculations are repeated, but as nested numbers. The 
GO is arranged in a hierarchy, with child terms having a "is a" or "part of" 
relationship with the parent. As a result, in order to get the full number of genes 
associated with a particular node, it calculates the number of genes in the parent node 
along with its children, grandchildren, etc. MAPPFinder traverses the tree for each 
node to calculate the cumulative, or "nested", number of genes at that node. As genes 
are typically assigned to the most specific category possible, the nested numbers give 
a more accurate representation of the number of genes involved in any biological 
process, cellular component, or molecular function. 
Z score: A positive Z score indicates that there are more genes meeting the criterion 
in a GO term/MAPP than would be expected by random chance. A negative Z score 
indicates that the there are fewer genes meeting the criterion than would be expected 
by random chance. A Z score or 1.96 or -1.96 would correlate with a p-value of 0.05. 
Permute P and Adjusted P: Based on the Z-score permute P and adjusted P values 
are calculated. 
The results of MAPPFinder analysis are both exported as a text file and displayed in a 
searchable MAPPFinder Browser, allowing the user to quickly identify those areas of 
biology that show correlated gene expression changes. Clicking on a GO term in the 
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MAPPFinder Browser window opens a MAPP in GenMAPP that lists all the genes 
associated with that GO term so that the user can view the individual genes. 
MAPPFinder creates a gene expression profile across all areas of biology represented 
in the GO, allowing the user to view at a glance where the largest correlated gene 
expression changes are occurring in the data. A sample result file is shown below. 
2.8.4 Onto-Express 
Intelligent Systems and Bioinformatics Laboratory, Computer Science Department, 
Wayne State University developed Onto-Express (OE) as a novel tool able to 
automatically translate lists of gene transcripts from microarray experiments of 
differentially-regulated gene transcripts into functional profiles characterising the 
impact of the condition studied. The software is freely available to academic users 
from http://vortex.cs.wayne.edu:8080/ontoexpress/servlet/UserInfo. OE constructs 
functional profiles (using Gene Ontology terms) for the categories: biochemical 
function, biological process, cellular role, cellular component, molecular function and 
chromosome location. Statistical significance values are calculated for each category 
(Draghici et al., 2003; Khatri et al., 2005). 
2.8.4.1 Pathway-Express 
Pathway-Express (PE) is a new tool in the Onto-Tools ensemble 
(http://vortex.cs.wayne.edu/ontoexpress/servlet/UserInfo). The Pathway-Express 
works on a list of genes and the system performs a search and builds a list of all 
associated pathways. After generating a list of pathways for the input list of genes 
from the Onto-Tools database, PE first calculates a perturbation factor PF (g) for each 
input gene. This perturbation factor takes into account the (i) normalized fold change 
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of the gene and (ii) the number and amount of perturbation of genes downstream from 
it. This gene perturbation factor reflects the relative importance of each differentially-
regulated gene. The impact factor of the entire pathway includes a probabilistic term 
that takes into consideration the proportion of differentially regulated genes on the 
pathway and gene perturbation factors of all genes in the pathway. The impact factors 
of all pathways are used to rank the pathways before presenting them to the user 
(Khatri et al., 2005). 
2.8.5 DAVID 
Gene and protein identifiers are not mutually mapped to each other and could be 
obtained from three independent resources, NCBI, PIR and UniProt. DAVID is the 
freely available software and has a maximally integrated DAVID Knowledgebase that 
is useful for converting gene/protein identifiers from one type to another (Huang et 
al., 2007). The probe set ID from microarray study and the protein ID was converted 
into entrez ID using DAVID to compare the differentially-regulated genes. 
(http://david.abcc.ncifcrf.gov/). 
2.8.6 MedScan 
Pathway Studio text-mining functions are powered by MedScan text-to-knowledge 
technology. MedScan helps in mining current literature and helps in building 
pathways related to the topic of interest, such as disease, phenotype, or physiological 
process. With the Update Pathway tool, the software downloads all PubMed abstracts 
since the last update, extract relations from them, and add them to the selected 
pathway. 
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2.8.7 Statistical analyses 
 Student’s t test, mean and standard deviation was performed using excel.  
The correlation between two variables reflects the degree to which the variables are 
related. The most common measure of correlation is the Pearson Product Moment 
Correlation (or called Pearson's correlation). A correlation is a number between -1 and 
+1 that measures the degree of association between two variables. 
Homeostasis Model Assessment (HOMA) estimates steady state beta cell function 
(%B) and insulin sensitivity (%S), as percentages of a normal reference population. 
HOMA %B and HOMA %S was calculated using HOMA Calculator v2.2.2 that can 
be downloaded from this site http://www.dtu.ox.ac.uk/index.php?maindoc=/ukpds/  
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3.1 Phenotypic changes occurring in cultured cells 
3.1.1 Phenotypic changes occurring in cultured MIN6 B1 cells 
Continuous culture of MIN6 B1 cells results in many phenotypic changes. The most 
notable change of MIN6 B1 is in its morphology and growth patterns. Morphological 
analysis, using phase contrast light microscopy, indicated that MIN6 B1 cells grow as 
tight, rounded, localised clumps at low passages (MIN6 B1(GSIS), passage 19).  
MIN6 B1(GSIS) does not tend to form a monolayer over the tissue culture surface as 
seen in Fig: 3.1.1 (A). As the cells grow towards high passages (MIN6 B1(Non-
GSIS), passage 23), the cells no longer tend to be associated in clumps and are found 
to form a monolayer of “flat”, stretched, cells (Fig: 3.1.1 (B)).  
MIN6 B1 p 19 (low passage) MIN6 B1 p 23 (high passage) 
 
 
 
 
Fig: 3.1.1 MIN6 B1 cells seen as grown in T75cm2 vented flask, cultured from 
low passage (p 19) to high passage (p 23) and were photographed through a 
microscope, using phase-contrast. (Magnification = 20X; scale bar = 200 µM) 
 
 
A B 
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3.1.2 Phenotypic changes occurring in cultured MIN6 (heterogeneous) cells 
Continuous culture of MIN6 cells results in many phenotypic changes, including in its 
morphology and growth patterns. Morphological analysis, using phase contrast light 
microscopy, has shown a notable deviation between MIN6 cells grown at low (MIN6 
(L)) versus high passage (MIN6 (H)). MIN6 (L) cells grow as tight, rounded, 
localised clumps and do not form a monolayer over the tissue culture surface (Fig: 
3.1.2 (A)). Whereas, MIN6 (H) cells no longer tend to be associated in clumps and are 
found to form a monolayer of “flat”, stretched, cells (Fig: 3.1.2 (B)).  
MIN6 p 16     MIN6 p 40 
      
 
 
 
Fig: 3.1.2 MIN6 cells seen as grown in T75cm2 vented flask, cultured from low 
passage (p 16) to high passage (p 40) and were photographed through a 
microscope, using phase-contrast. (Magnification = 20X; scale bar = 200 µM) 
 
 
 
 
A B 
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3.2 Results from Measurement of Cellular Proliferation 
3.2.1 Proliferation Assay on MIN6 B1 cell line 
Continuous sub-culturing of homogenous clonal population of the murine pancreatic 
beta cell line MIN6 B1 resulted in an increase in proliferation rate. Growth curves 
were plotted over 7 days following seeding at a density of 5 X 104 cells/well (24-well 
plate). An increased proliferation rate was observed as MIN6 B1 cells, as they were 
passaged from low (p 19) to high (p 23) passage. MIN6 B1(Non-GSIS) showed 
significantly increased (p-value=0.02 at 168hrs. time point) proliferation compared to 
that of MIN6 B1(GSIS) cells (approximately 2-fold) (Fig: 3.2.1).  
 
 
 
 
 
 
 
Fig: 3.2.1 Graph showing comparison of proliferation assay done on MIN6 B1 
low and high passage cells. MIN6 B1 high passage cells (p 23) are shown as 
( ) and low passage cells (p 19) are shown as ( ).Mean = ± S.D and 
n=3. 
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3.2.2 Proliferation Assay on MIN6 cells 
Continuous culture of MIN6 cells results in phenotypic changes, most notably 
deviation from characteristic MIN6 morphology and growth patterns. Continuous sub-
culturing resulted in an increase in proliferation rate. Growth curves, plotted over 7 
days, following seeding at a density of 5 x104 cells/well (24-well plate), indicated that 
the rate of proliferation in the high passage cells was approximately 2.4-fold greater 
than that observed in the low passage cells (Fig: 3.2.2). Proliferation of MIN6 cells 
was carried out at passage 18 for low passage and at passage 40 for high passage 
cells.  
 
 
 
 
 
 
Fig: 3.2.2 Graph showing comparison of proliferation assay done on MIN6 low 
(L) and high (H) passage cells. MIN6 (H) (p 40) are shown as ( ) and MIN6 
(L) (p 18) are shown as ( ). Mean = ± S.D and n=3. 
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3.3 Glucose-Stimulated Insulin Secretion (GSIS) 
3.3.1 Glucose-Stimulated Insulin Secretion in MIN6 B1  
The MIN6 B1 cell line is described in the literature as a good model for insulin-
producing pancreatic beta cells (Lilla et al., 2003). MIN6 B1 cell lines have been 
shown to secrete insulin in response to elevated extracellular glucose concentrations 
and retain their differentiated phenotypes in short-term culture. However, when 
passaged repeatedly, we observed that they start losing their function of glucose 
responsiveness. So in order to determine the passage at which the glucose-stimulated 
insulin secretion (GSIS) was lost, GSIS assays were performed at alternate passage as 
the cells were grown from lower (passage 17) to higher passage (passage 27). GSIS 
assays, commencing at passage 17, were done at alternate passage to subsequently 
identify gene transcripts associated with the mechanism of loss of glucose response. 
Cells were seeded in a 24-well plate (cell density of 2 × 105 cells/well), and grown for 
72hrs. Glucose concentration of 3.3mmol/L and 16.7mmol/L were prepared in 1 X 
KRB. GSIS assay was performed as described in section 2.3.2.1. Conditioned medium 
was analysed using ELISA at every alternate passages. At passage 17, MIN6 B1 cells 
showed a 2.9-fold insulin secretion when 3.3mmol/L was compared with 16.7mmol/L 
glucose (Fig: 3.3.1). However, at passage 21 MIN6 B1 cells started losing their 
function of GSIS showing 1.2-fold insulin secretion only (Fig: 3.3.1). These cells 
produced an approximate 2.15-fold GSIS at passage 19; this was reduced to 1.35-fold 
within 4 passages (passage 23). A significant loss of GSIS (p-value=0.01) was 
observed in MIN6 B1(Non-GSIS) compared to MIN6 B1(GSIS) just 4 passages apart.   
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Fig: 3.3.1 Graph showing GSIS in MIN6 B1 cells using glucose as stimulating 
agent. GSIS assays were performed at alternate passage numbers between p 17 
and p 27 inclusively. Results represent mean of n=3 biological repeats ±SD. 
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3.4 Analytical Techniques and Assays 
3.4.1 RNA Quality Analysis by Electrophoresis 
As indicated in section 3.3, MIN6 B1 cells were grown from low passage (p 17) 
to high passage (p 27) and GSIS was performed at every alternate passage. The 
graph (Fig: 3.3.1) showed a gradual loss of GSIS as the cells were grown from 
low passage to high passage. To investigate the gene transcript associated with 
the loss of GSIS, triplicates of p 19 low passage (subsequently termed as MIN6 
B1(GSIS)) and p 23 high passage (subsequently termed as MIN6 B1(Non-GSIS)) 
were selected for microarray experiment. RNA was isolated, using RNeasy kit 
(See Section: 2.5.1.2.3) from biological triplicate of MIN6 B1(GSIS) (A19, B19 
and C19) and MIN6 B1(Non-GSIS) (A23, B23 and C23) cells for microarray 
hybridization. 
The RNA quality was analysed by electrophoresis gel prior to gene expression 
analysis by microarray experiment (See Section: 2.5.1.5). Total RNA run on a 
1% electrophoresis gel showed sharp 28S and 18S rRNA (ribosomal RNA) 
bands (Fig: 3.4.1.). 
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Fig: 3.4.1 Image typical of total RNA analyzed using 1% agarose gel 
electrophoresis. M = molecular weight marker: ФX174 DNA Hae III digest. 
19A, 19B and 19C are biological repeats of MIN6 B1(GSIS); 23A, 23B and 
23C are biological repeats of MIN6 B1(Non-GSIS). 
3.4.2 RNA Quality Analysis by Bioanalyzer 
3.4.2.1 Cell RNA quality analysis 
RNA quality were also analysed using Bioanalyzer. As described in section 
2.5.1.6 the Agilent 2100 Bioanalyzer measures the quantity, integrity and purity 
of RNAs. 
RNA aliquots of each biological triplicate of MIN6 B1(GSIS) (A19, B19 and 
C19) and MIN6 B1(Non-GSIS) (A23, B23 and C23) were run on an Agilent 
Bioanalyzer RNA Nano chip to check the RNA integrity. The electropherogram 
from all triplicate samples of MIN6 B1(GSIS) and MIN6 B1(Non-GSIS) (Fig. 
3.4.2.1) shows a typical Bioanalyzer tracing indicating good quality cellular 
RNA. Integrity of this RNA is measured by 18S and 28S ribosomal bands that  
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A 19      A 23 
 
 
 
  B 19      B23 
 
 
 
C 19      C23 
Fig: 3.4.2.1 Electrophorogram showing first small peak as marker, second 
peak as 5s RNA, followed by sharp 18S and 28S ribosomal bands. Quality of 
MIN6 B1 cell RNA was evident by the sharp 18S and 28S ribosomal bands. 
A19, B19 and C19 are biological triplicate of MIN6 B1(GSIS) whereas A23, 
B23 and C23 are from MIN6 B1(Non-GSIS) cell RNA. 
MIN6 B1(GSIS) MIN6 B1(Non-GSIS) 
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appear at 40 and 47 seconds (time is plotted on the X-axis) correlating to 2000 
and 4000 nucleotides in length, respectively. 
3.4.2.2 Fragmented RNA quality analysis 
Before hybridization to a microarray chip, the cRNA was fragmented to sizes 
ranging from 50–200 bases long to improve target specificity (See Section: 
2.6.6). A quality check of the fragmented cRNA was performed using Agilent 
2100 Bioanalyzer to check that the samples have fragmented as required. 
Fragmented cRNA aliquots from each biological triplicate of MIN6 B1(GSIS) 
(A19, B19 and C19) and MIN6 B1(Non-GSIS) (A23, B23 and C23) were run on 
an Agilent Bioanalyzer RNA Nano chip to check the cRNA integrity. The 
electropherogram from all triplicate samples of MIN6 B1(GSIS) and MIN6 
B1(Non-GSIS) (Fig. 3.4.2.2) shows the size of cRNA. The fragmentation 
procedure usually produces a distribution of RNA fragment sizes from approx. 
35-200 bases. 
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  A 19     A 23 
 
 
 
  B 19     B 23 
 
 
 
  C 19     C 23 
Fig: 3.4.2.2 Bioanalyzer electropherogram for fragmented labelled cRNA 
from MIN6 B1 low and high passage cells total RNA. A19, B19 and C19 are 
biological triplicate of MIN6 B1(GSIS), whereas A23, B23 and C23 are from 
MIN6 B1(Non-GSIS) fragmented cRNA. 
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3.4.3 Microarray studies 
3.4.3.1 Microarray Q.A results by dChip 
The following Quality Control was performed to estimate the quality of data 
from microarray chip. 
• Median Intensity (unnormalised) 
• P call % 
• % Array outlier 
• % Single outlier 
• Warning 
The sample quality output file is shown in Table: 3.4.3.1. 
Array Median Intensity (unnormalised) P call % 
% Array 
outlier 
% Single 
outlier 
19-A 84 57.7 0.08 0.263 
23-A 70 55.1 0.142 0.229 
19-B 82 57.2 0.129 0.421 
23-B 77 58.9 0.078 0.166 
19-C 73 58.3 0.106 0.19 
23-C 68 57.9 0.146 0.209 
Table: 3.4.3.1 Quality parameters from dChip. 19-A, 19-B and 19-C are 
biological triplicate of MIN6 B1(GSIS), whereas 23-A, 23-B and 23-C are 
from MIN6 B1(Non-GSIS). 
Median intensity: The median intensity is computed using un-normalized probe 
values by selecting a probe for every 5 by 5 region on the array. This may give 
slightly different result from using all probes for computing the median. 
P call: Calls indicate if the transcript is expressed or not. It can be ‘P’ for 
present, ‘M’ for marginally present and ‘A’ for absent. Total P calls in an array 
can vary widely based on the different nature of samples.  
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Single outlier: Single outliers are identified using absolute residuals. The 80th 
percentile of the absolute residuals of the data points in one array (probe) 
multiplied by 3 is called the array-wise (probe-wise) residual threshold. If a data 
point has its absolute residual exceeding both the corresponding array-wise 
residual threshold and the probe-wise residual threshold, it is called as a single 
outlier.  
Array outlier: When fitting the model to a probe set, dChip uses the outlier 
detection algorithm to detect array-outliers for this probe set. The array-outliers 
are the arrays whose probe response pattern for this probe set is different from 
the consensus probe response pattern seen in most arrays. After the model is 
fitted for all probe sets by “Analysis/Model-based expression”, the percentage of 
probe sets called as array-outlier in one array is reported as “array outlier 
percentage”. If this percentage exceeds 5% in an array, the array is called as an 
“outlier array”. For such “outlier arrays”, A “*” is shown in the “Warning” 
column of “array summary file”, and the corresponding array icon in the left 
pane become dark blue, indicating potential image contamination or sample 
hybridization problem of these arrays. 
3.4.3.2 Microarray Q.A results by GCOS 
Affymetrix GeneChip Operating Software (GCOS) automates the control of 
GeneChip® Fluidics Stations and Scanners. GCOS acquires data, manages 
sample and experimental information. It also performs gene expression data 
analysis. Table 3.4.3.2 shows the quality parameters as determined by the GCOS 
software. 
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Table: 3.4.3.2 Quality parameters from Affymetrix GeneChip Operating 
Software (GCOS). A19, B19 and C19 are biological triplicate of MIN6 
B1(GSIS), whereas A23, B23 and C23 are from MIN6 B1(Non-GSIS). 
3.4.4 Hierarchical clustering 
Only those gene transcript which had a Standard deviation/Mean of less than 0.5 
and P calls (P call means transcript present or expressed) in at least 20% of the 
samples  and expression values of minimum 20 in 50% of the samples were 
selected for Hierarchical clustering. The total number of gene transcripts that 
passed the above criteria was 214 and was used for hierarchical clustering (Fig: 
3.4.4). This stringent criterion was taken as there were very few differentially-
regulated genes in this microarray study. The Hierarchical clustering was 
Average linkage clustering and the distance Metric was Correlation distance.  
Sample 
name 
Scaling 
factor 
Noise Background 
% 
Present 
3’/5’ Ratio 
GAPDH 
A19 1.00 1.25 46.5 47.1 0.93 
B19 1.00 1.27 44.37 46.2 0.94 
C19 1.00 1.20 44.58 48.2 0.85 
A23 1.00 1.16 42.44 44.7 0.87 
B23 1.00 1.20 41.07 48.7 0.87 
C23 1.00 1.16 39.95 47.8 0.90 
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Sample 23 C did not clustered with its replicates, so this sample was not included 
for further analysis as it could be a potential outlier. This was also evident from 
the qRT-PCR data (Fig: 3.4.6.1). 
 
 
 
 
 
 
 
 
 
 
Fig: 3.4.4 Hierarchical clustering of the MIN6 B1(GSIS) and MIN6 B1(Non-
GSIS) cells. 23-A, 23-B and 23-C represents MIN6 B1(Non-GSIS) whereas, 
19-A, 19-B and 19-C represents MIN6 B1(GSIS) cells.  
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3.4.5  Gene lists generated after normalization  
As explained gene expression changes associated with the loss of GSIS were 
investigated using microarray technology. Gene lists were generated after 
normalizing the data obtained from the microarray study. dChip was used to 
compare gene expression profiles of MIN6 B1(GSIS) and MIN6 B1(Non-GSIS) 
samples to identify gene transcripts that were differentially-expressed. In this 
study, 111 genes were found to be differentially-regulated with 53 genes found to 
be up-regulated (Table: 3.4.5.1) and 58 genes to be down-regulated (Table: 
3.4.5.2) in high passage compared to low passage MIN6 B1 cells. Gene 
transcripts were considered differentially-expressed if the p-value was less than 
0.05, fold change of greater than or equal to 1.2, and difference of greater than 
100. Table 3.4.5.1 lists significantly up-regulated gene transcripts with the fold 
change ≥1.2, p-value < 0.05 and difference of >100. The Table 3.4.5.2 lists 
significantly down-regulated gene transcripts with the fold change ≥1.2, p-value 
< 0.05 and difference of >100.    
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Probe set Gene F C 
Differen
ce of 
means 
P 
value 
1415997_at thioredoxin interacting protein 5.25 167.59 0.003 
1422134_at FBJ osteosarcoma oncogene B 4.63 429.35 0.013 
1417409_at Jun oncogene 2.73 1101.34 0.045 
1448694_at Jun oncogene 2.67 485.15 0.024 
1417394_at Kruppel-like factor 4 (gut) 2.36 370.13 0.008 
1417395_at Kruppel-like factor 4 (gut) 2.25 200.1 0.004 
1448830_at dual specificity phosphatase 1 2.15 933.63 0.028 
1423100_at FBJ osteosarcoma oncogene 2.12 1754.64 0.036 
1418025_at 
basic helix-loop-helix domain containing, 
class B2 
2.04 168.67 0.014 
1448285_at regulator of G-protein signaling 4 2.02 257.74 0.015 
1417065_at early growth response 1 1.98 1513.88 0.034 
1419157_at SRY-box containing gene 4 1.89 132.54 0.044 
1449556_at histocompatibility 2, T region locus 23 1.82 122.18 0.021 
1416287_at regulator of G-protein signaling 4 1.75 401.72 0.007 
1455010_at RIKEN cDNA 1500012F01 gene 1.71 302.38 0.025 
1450376_at Max interacting protein 1 1.7 126.34 0.038 
1453851_a_
at 
growth arrest and DNA-damage-inducible 
45 gamma 
1.59 116.24 0.042 
1424880_at tribbles homolog 1 (Drosophila) 1.56 107.84 0.048 
1417612_at immediate early response 5 1.51 133.79 0.040 
1422825_at 
cocaine and amphetamine regulated 
transcript 
1.48 242.39 0.003 
1460645_at 
cysteine and histidine-rich domain 
(CHORD)-containing, zinc-binding 
protein 1 
1.45 148.71 0.033 
1416286_at regulator of G-protein signaling 4 1.43 599.47 0.048 
1417719_at sin3 associated polypeptide 1.42 136.84 0.039 
1418835_at 
pleckstrin homology-like domain, family 
A, member 1 
1.42 210.02 0.007 
1449482_at histone 3, H2ba 1.42 135.06 0.018 
1450084_s_
at influenza virus NS1A binding protein 
1.42 375.64 0.029 
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1416756_at 
DnaJ (Hsp40) homolog, subfamily B, 
member 1 
1.4 112.9 0.036 
1423825_at RIKEN cDNA 5031439A09 gene 1.38 112.54 0.040 
1419091_a_
at annexin A2 
1.37 119.33 0.036 
1415688_at 
ubiquitin-conjugating enzyme E2G 1 
(UBC7 homolog, C. elegans) 
1.36 197.23 0.035 
1433668_at proline-rich nuclear receptor coactivator 1 1.36 210.43 0.034 
1453481_at zinc finger, DHHC domain containing 2 1.36 147.12 0.040 
1418191_at ubiquitin specific peptidase 18 1.35 122.85 0.015 
1437234_x_
at 
heterogeneous nuclear ribonucleoprotein 
methyltransferase-like 1 (S. cerevisiae) 
1.35 117.92 0.036 
1424638_at 
Cyclin-dependent kinase inhibitor 1A 
(P21) 
1.34 322.81 0.027 
1453326_at RIKEN cDNA 3300001A09 gene 1.33 346.91 0.024 
1425927_a_
at activating transcription factor 5 
1.31 422.03 0.049 
1428850_x_
at RIKEN cDNA 2410026K10 gene 
1.29 107.59 0.027 
1449509_at small EDRK-rich factor 1 1.29 108.06 0.009 
1420088_at 
nuclear factor of kappa light chain gene 
enhancer in B-cells inhibitor, alpha 
1.28 148.62 0.037 
1426378_at eukaryotic translation initiation factor 4B 1.28 161.64 0.040 
1419595_a_
at gamma-glutamyl hydrolase 
1.27 125.79 0.013 
1427060_at mitogen activated protein kinase 3 1.27 162.24 0.021 
1434642_at 
dehydrogenase/reductase (SDR family) 
member 8 
1.27 186.79 0.035 
1416924_at brain protein I3 1.25 235.53 0.040 
1426547_at Group specific component 1.25 269.83 0.021 
1424233_at mesenchyme homeobox 2 1.23 128.32 0.048 
1448987_at 
acetyl-Coenzyme A dehydrogenase, long-
chain 
1.23 140.63 0.049 
1431665_a_
at 
translocase of inner mitochondrial 
membrane 8 homolog b (yeast) 
1.22 167.02 0.036 
1452655_at zinc finger, DHHC domain containing 2 1.22 132.21 0.023 
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1432264_x_
at 
cytochrome c oxidase subunit VIIa 
polypeptide 2-like 
1.21 255.99 0.038 
1436915_x_
at 
lysosomal-associated protein 
transmembrane 4B 
1.21 148.76 0.021 
1448493_at 
polyadenylate-binding protein-interacting 
protein 2 
1.21 186.71 0.042 
 
Table: 3.4.5.1 Gene transcripts significantly up-regulated in Min6 B1(Non-
GSIS) compared to MIN6 B1(GSIS). The list of gene transcripts was sorted 
by F C (fold change) (1.2-fold or more) in descending order. Identity of 
columns, from left to right: probe set, name of gene, averaged fold change, 
difference of means and p-value. 
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Probe set Gene 
Fold 
change 
Difference 
of means 
P-
value 
1450734_at leucine zipper transcription regulator 2 -2.65 -149.95 0.018 
1439618_at phosphodiesterase 10A -1.78 -104.29 0.042 
1418890_a_at RAB3D, member RAS oncogene family -1.62 -237.15 0.021 
1455643_s_at expressed sequence  -1.62 -133.81 0.040 
1433502_s_at expressed sequence  -1.6 -136.9 0.027 
1428154_s_at 
phosphatidic acid phosphatase type 2 
domain containing 1 
-1.58 -227.39 0.028 
1425952_a_at Glucagons -1.55 -998 0.016 
1443609_s_at 
synovial apoptosis inhibitor 1, 
synoviolin 
-1.54 -186.43 0.043 
1418891_a_at RAB3D, member RAS oncogene family -1.51 -272.47 0.014 
1452830_s_at 
carbamoyl-phosphate synthetase 2, 
aspartate transcarbamylase, and 
dihydroorotase 
-1.5 -205.35 0.016 
1428070_at 
synovial apoptosis inhibitor 1, 
synoviolin 
-1.48 -174.24 0.042 
1423914_at RIKEN cDNA C630004H02 gene -1.44 -163.36 0.031 
1418141_at doublecortin -1.43 -356.27 0.024 
1428111_at Solute carrier family 38, member 4 -1.43 -153.92 0.012 
1427294_a_at RIKEN cDNA 1810073N04 gene -1.41 -231.45 0.013 
1435247_at 
ubiquitin-activating enzyme E1-domain 
containing 1 
-1.41 -134.29 0.042 
1423730_at RIKEN cDNA C130052I12 gene -1.4 -308.1 0.023 
1456397_at cadherin 4 -1.4 -250.13 0.021 
1424024_at multiple coagulation factor deficiency 2 -1.39 -266.45 0.014 
1434698_at RIKEN cDNA 9130229H14 gene -1.37 -115.47 0.028 
1451254_at 
inhibitor of kappa light polypeptide 
enhancer in B-cells, kinase complex-
associated protein 
-1.37 -102.19 0.017 
1454810_s_at expressed sequence AI315068 -1.37 -106.84 0.044 
1428112_at 
arginine-rich, mutated in early stage 
tumours  
-1.36 -768.66 0.049 
1448704_s_at histocompatibility 47 -1.35 -394.94 0.027 
1427295_at RIKEN cDNA 1810073N04 gene -1.34 -146.01 0.023 
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1448411_at Wolfram syndrome 1 homolog (human) -1.34 -125.52 0.045 
1451091_at thioredoxin domain containing 5 -1.34 -134.3 0.018 
1418139_at doublecortin -1.33 -144.76 0.046 
1416949_s_at 
solute carrier family 39 (zinc 
transporter), member 7 
-1.32 -232.58 0.021 
1456175_a_at 
coatomer protein complex, subunit beta 
2 (beta prime) 
-1.32 -137.06 0.048 
1415670_at 
coatomer protein complex, subunit 
gamma 
-1.31 -268.62 0.048 
1456393_at RIKEN cDNA 2310002J21 gene -1.31 -430.03 0.043 
1440849_at Adult male medulla oblongata cDNA -1.3 -148.01 0.031 
1417763_at Signal sequence receptor, alpha -1.29 -336.47 0.030 
1418774_a_at 
ATPase, Cu++ transporting, alpha 
polypeptide 
-1.29 -143.63 0.038 
1451967_x_at karyopherin (importin) beta 1 -1.29 -153.85 0.016 
1417542_at 
ribosomal protein S6 kinase, 
polypeptide 2 
-1.28 -127.3 0.044 
1437620_x_at 
Aldehyde dehydrogenase 18 family, 
member A1 (Aldh18a1), transcript 
variant 2, mRNA 
-1.26 -155.74 0.026 
1438510_a_at histidyl-tRNA synthetase -1.26 -123 0.045 
1435050_at 
DNA segment, Chr 10, Brigham & 
Women's Genetics 1379 expressed 
-1.26 -160.6 0.045 
1416395_at guanylate kinase 1 -1.25 -129.64 0.044 
1455066_s_at RIKEN cDNA 9130229H14 gene -1.25 -292.77 0.022 
1417710_at RIKEN cDNA 0610012D09 gene -1.24 -195.99 0.046 
1426674_at 
eukaryotic translation initiation factor 3, 
subunit 9 (eta) 
-1.24 -105.26 0.027 
1427347_s_at 
TUBULIN BETA CHAIN (T BETA-
15) 
-1.24 -224.42 0.044 
1423670_a_at 
signal recognition particle receptor 
('docking protein') 
-1.23 -279.61 0.012 
1427464_s_at 
heat shock 70kD protein 5 (glucose-
regulated protein) 
-1.23 -588.19 0.012 
1450675_at 
stromal membrane-associated protein 1-
like 
-1.23 -123.64 0.049 
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1451255_at 
liver-specific bHLH-Zip transcription 
factor 
-1.23 -112.78 0.044 
1452230_at RIKEN cDNA 1200006L06 gene -1.23 -127.05 0.042 
1452767_at ribosome binding protein 1 -1.23 -180.53 0.027 
1419287_at HSPC171 protein -1.22 -106.87 0.034 
1423030_at valosin containing protein -1.22 -412.44 0.035 
1435277_x_at 
expressed in non-metastatic cells 1, 
protein 
-1.22 -222.04 0.039 
1438225_x_at 
translocating chain-associating 
membrane protein 1 
-1.22 -196.84 0.037 
1452102_at 
coatomer protein complex, subunit beta 
2 (beta prime) 
-1.22 -194.57 0.031 
1417287_at histocompatibility 13 -1.2 -273.34 0.012 
1424255_at 
Suppressor of Ty 5 homolog (S. 
cerevisiae) 
-1.2 -100.82 0.037 
Table: 3.4.5.2 Gene transcripts significantly down-regulated in MIN6 
B1(Non-GSIS) compared to MIN6 B1(GSIS). The list of gene transcripts 
was sorted by fold change (1.2-fold or more) in descending order. Identity of 
columns, from left to right: probe set, name of gene, averaged fold change, 
difference of means and p-value. 
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3.4.6 Gene Ontology 
3.4.6.1 GenMAPP (Gene Microarray Pathway Profiler) 
The 111 differentially-regulated genes from the microarray study on MIN6 B1 
cells were analysed using freely available software GenMAPP. The gene 
expression changes associated with a particular GO term was identified by 
MAPPFinder. MAPPFinder compares the genes that are differentially-regulated 
to the total number of input genes.   
Fig 3.4.6.1.1 shows the percentage of down-regulated genes associated with the 
following GO categories: protein targeting to ER, endoplasmic reticulum lumen, 
signal sequence binding, secretory pathway, protein transport, intracellular 
protein transport, cell adhesion, Miscellaneous and Unknown (Fig: 3.4.6.1.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 3.4.6.1.1 Representation of down-regulated categories of gene 
transcripts in MIN6 B1(Non-GSIS) compared to MIN6 B1(GSIS). 
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Fig 3.4.6.1.2 shows the percentage of up-regulated genes associated with the 
following GO categories: transcription factor activity, regulation of protein 
kinase activity, DNA damage, Response to stress, Oxidoreductase activity, 
Signal transduction, GTPase activity, Translation, Metabolic, Zinc ion binding, 
Ubiquitin cycle, Miscellaneous and Unknown (Fig: 3.4.6.1.2). Table 3.4.6.1.3 
shows the list of gene transcripts associated with different GO categories. 
 
 
 
 
 
 
 
 
 
Fig: 3.4.6.1.2 Representation of up-regulated categories of gene transcripts 
in MIN6 B1(Non-GSIS) compared to MIN6 B1(GSIS). 
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Gene name Affy –ID 
Gene 
Symbol 
Fold 
change 
Protein targeting to ER/protein targeting to membrane 
Translocating chain-associating membrane 
protein 1 
1438225_x_at Tram1 -1.22 
Signal recognition particle receptor 
('docking protein') 
1423670_a_at Srpr -1.23 
Signal sequence receptor, alpha 1417763_at Ssr1 -1.29 
Endoplasmic reticulum lumen 
Heat shock 70kD protein 5 (glucose-
regulated protein) 
1427464_s_at Hspa5 -1.23 
Signal recognition particle receptor 
('docking protein') 
1423670_a_at Srpr -1.23 
Thioredoxin domain containing 5 1451091_at Txndc5 -1.34 
Signal sequence receptor, alpha 1417763_at Ssr1 -1.29 
Karyopherin (importin) beta 1 1451967_x_at Kpnb1 -1.29 
Secretory pathway 
Coatomer protein complex, subunit beta 2 
(beta prime) 
1452102_at Copb2 -1.22 
Translocating chain-associating membrane 
protein 1 
1438225_x_at Tram1 -1.22 
Signal recognition particle receptor 
('docking protein') 
1423670_a_at Srpr -1.23 
Signal sequence receptor, alpha 1417763_at Ssr1 -1.29 
Multiple coagulation factor deficiency 2 1424024_at Mcfd2 -1.39 
Glucagon 1425952_a_at Gcg -1.55 
RAB3D, member RAS oncogene family 1418891_a_at Rab3d -1.62 
Protein transport 
Nuclear factor of kappa light chain gene 
enhancer in B-cells 
1420088_at Nfkbia 1.28 
Translocase of inner mitochondrial 
membrane 8 homolog b (yeast) 
1431665_a_at Timm8b 1.22 
Ribosome binding protein 1 1452767_at Rrbp1 -1.23 
Guanylate kinase 1 1416395_at Guk1 -1.25 
Histocompatibility 47 1448704_s_at H47 -1.35 
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Intracellular protein transport 
Coatomer protein complex, subunit beta 2 
(beta prime) 
1456175_a_at Copb2 -1.22 
Signal recognition particle receptor 
('docking protein') 
1423670_a_at Srpr -1.23 
Coatomer protein complex, subunit gamma 1415670_at Copg -1.31 
Response to unfolded protein 
DnaJ (Hsp40) homolog, subfamily B, 
member 1 
1416756_at Dnajb1 1.4 
Valosin containing protein 1423030_at Vcp -1.22 
Heat shock 70kD protein 5 (glucose-
regulated protein) 
1427464_s_at Hspa5 -1.23 
Synovial apoptosis inhibitor 1, synoviolin 1428070_at Syvn1 -1.54 
Cell adhesion 
Cadherin 4 1456397_at Cdh4 -1.4 
Transcription factor activity 
FBJ osteosarcoma oncogene 1422134_at Fos 4.63 
Jun oncogene 1417409_at Jun 2.73 
Kruppel-like factor 4 (gut) 1417394_at Klf4 2.36 
Basic helix-loop-helix domain containing, 
class B2 
1418025_at Bhlhb2 2.04 
Early growth response 1 1417065_at Egr1 1.98 
SRY-box containing gene 4 1419157_at Sox4 1.89 
Max interacting protein 1 1450376_at Mxi1 1.7 
Sin3 associated polypeptide 1417719_at Sap30 1.42 
Influenza virus NS1A binding protein 1450084_s_at Ivns1abp 1.42 
Activating transcription factor 5 1425927_a_at Atf5 1.31 
Mesenchyme homeobox 2 1424233_at Meox2 1.23 
Inhibitor of kappa light polypeptide 
enhancer in B-cells 
1451254_at Ikbkap -1.37 
Regulation of protein kinase activity 
Regulator of G-protein signaling 4 1448285_at Rgs4 2.02 
Growth arrest and DNA-damage-inducible 
45 gamma         
1453851_a_at Gadd45g 1.59 
Tribbles homolog 1 (Drosophila) 1424880_at Trib1 1.56 
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Cyclin-dependent kinase inhibitor 1A (P21) 1424638_at Cdkn1a 1.34 
DNA damage 
Growth arrest and DNA-damage-inducible 
45 gamma 
1453851_a_at Gadd45g 1.59 
Mitogen activated protein kinase 3 1427060_at Mapk3 1.27 
Valosin containing protein 1423030_at Vcp -1.22 
Response to stress 
Thioredoxin interacting protein 1415997_at Txnip 5.25 
Dual specificity phosphatase 1 1448830_at Dusp1 2.15 
Growth arrest and DNA-damage-inducible 
45 gamma     
1453851_a_at Gadd45g 1.59 
DnaJ (Hsp40) homolog, subfamily B, 
member 1 
1416756_at Dnajb1 1.4 
Annexin A2 1419091_a_at Anxa2 1.37 
Mitogen activated protein kinase 3 1427060_at Mapk3 1.27 
Oxidoreductase activity 
Cytochrome c oxidase subunit VIIa 
polypeptide 2-like 
1432264_x_at Cox7a2l 1.21 
Liver-specific bHLH-Zip transcription 
factor 
1451255_at Lsr -1.23 
Aldehyde dehydrogenase 18 family, 
member A1 (Aldh18a1)       
1437620_x_at Aldh18a1 -1.26 
Ribosomal protein S6 kinase, polypeptide 2 1417542_at Rps6ka2 -1.28 
Solute carrier family 39 (zinc transporter), 
member 7 
1416949_s_at Slc39a7 -1.32 
Signal transduction 
DNA segment, Chr 10, Brigham & 
Women's Genetics 1379 D10    
1435050_at 
Bwg1379
e 
-1.26 
Doublecortin 1418139_at Dcx -1.43 
Phosphodiesterase 10A 1439618_at Pde10a -1.78 
GTPase activity 
Stromal membrane-associated protein 1-like 1450675_at Smap1l -1.23 
Expressed in non-metastatic cells 1, protein 1435277_x_at Nme1 -1.5 
Translation 
Histidyl-tRNA synthetase 1438510_a_at Hars 1.28 
Eukaryotic translation initiation factor 3, 1426674_at Eif3b 1.21 
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subunit 9 (eta) 
Polyadenylate-binding protein-interacting 
protein 2 
1448493_at Paip2 -1.24 
Eukaryotic translation initiation factor 4B 1426378_at Eif4b -1.26 
Metabolic 
Gamma-glutamyl hydrolase 1419595_a_at Ggh 1.27 
ATPase, Cu++ transporting, alpha 
polypeptide 
1418774_a_at Atp7a 1.27 
Dehydrogenase/reductase (SDR family) 
member 8 
1434642_at 
Hsd17b1
1 
1.27 
Acetyl-Coenzyme A dehydrogenase, long-
chain 
1448987_at Acadl -1.41 
Zinc ion binding 
Cysteine and histidine-rich domain 
(CHORD)-containing 
1460645_at Chordc1 -1.29 
Ubiquitin cycle 
Ubiquitin specific peptidase 18 1418191_at Usp18 1.45 
Ubiquitin-activating enzyme E1-domain 
containing 1 
1435247_at Ube1dc1 -1.41 
Miscellaneous 
Cocaine and amphetamine regulated 
transcript 
1422825_at Cartpt 1.48 
Wolfram syndrome 1 homolog (human) 1448411_at Wfs1 1.42 
Zinc finger, DHHC domain containing 2 1453481_at Zdhhc11 1.36 
Leucine zipper transcription regulator 2 1450734_at Sec16b 1.36 
Heterogeneous nuclear ribonucleoprotein 
methyltransferase-like 1 
1437234_x_a
t 
Prmt2 1.35 
Carbamoyl-phosphate synthetase 2, 
aspartate transcarbamylase 
1452830_s_a
t 
Cad -1.22 
Histone 3, H2ba 1449482_at Hist3h2ba -1.28 
Histocompatibility 2, T region locus 23 1449556_at H2-23 -1.34 
Ubiquitin-conjugating enzyme E2G 1 
(UBC7 homolog) 
1415688_at Ube2g1 -2.65 
Unknown 
Immediate early response 5 1417612_at Ier5 1.51 
Pleckstrin homology-like domain, family A, 1418835_at Phlda1 1.42 
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member 1 
Proline-rich nuclear receptor coactivator 1 1433668_at Pnrc1 1.36 
Small EDRK-rich factor 1 1449509_at Serf1 1.29 
Brain protein I3 1416924_at Bri3 1.25 
Histocompatibility 13 1417287_at H13 -1.2 
HSPC171 protein 1419287_at Hspc171 -1.22 
Methyltransferase like 9 1417710_at Mettl9 -1.24 
Melanoma inhibitory activity 3 1434698_at Mia3 -1.25 
Adult male medulla oblongata cDNA                                       
1440849_at 
6330417G0
4Rik 
-1.3 
RIKEN cDNA 2310002J21 gene                                     
1456393_at 
2310002J2
1Rik 
-1.31 
RIKEN cDNA 1810073N04 gene                                    
1427295_at 
1810073N0
4Rik 
-1.34 
Arginine-rich, mutated in early stage 
tumours  
1428112_at Armet -1.36 
CLPTM1-like 1423730_at Clptm1l -1.4 
RIKEN cDNA C630004H02 gene          
1423914_at 
C630004H
02Rik 
-1.44 
Phosphatidic acid phosphatase type 2 
domain containing 1 
1428154_s_a
t 
Ppapdc1 -1.58 
 
Table: 3.4.6.1.3 111 gene transcripts up- or down-regulated MIN6 B1(Non-
GSIS) compared to MIN6 B1(GSIS) associated with overall GO categories. 
List of mRNAs that increased or decreased by 1.2-fold in MIN6 B1(Non-
GSIS) compared to MIN6 B1(GSIS). Identity of columns, from left to right: 
functional cluster assignment and name of gene, gene symbol and averaged 
fold change. 
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3.4.7 Pathway analysis 
 3.4.7.1 Pathway-Express 
To determine if differentially-expressed genes were associated with any well-
known pathways, David software was used. This software graphically displays 
the distribution of differentially-expressed genes (Fig: 3.4.7.1.1.2 and Fig: 
3.4.7.1.2.1).  
The differentially-expressed genes in MIN6 B1(GSIS) and MIN6 B1(Non-GSIS) 
were analysed using David software. The pathway associated with these 
differentially-regulated genes is listed in the Table:  3.4.7.1 and the software 
calculates and gives the impact factor to the entire pathway. The impact factor of 
the entire pathway includes a probabilistic term that takes into consideration the 
proportion of differentially-regulated genes on the pathway and relative 
importance of each differentially-regulated gene in the pathway. The impact 
factors of all pathways are used to rank the pathways (Table: 3.4.7.1). 
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Fig: 3.4.7.1 Pathway-Express (PE), using DAVID software performs a 
pathway level impact analysis and orders the affected pathways in the 
decreasing order of their expected importance for the given condition. 
 
Pathway Name Impact Factor 
MAPK signaling pathway 7.111 
mTOR signaling pathway 6.518 
B cell receptor signaling pathway 5.816 
Colorectal cancer 5.188 
Toll-like receptor signaling pathway 5.044 
T cell receptor signaling pathway 4.656 
Long-term potentiation 3.337 
Prion disease 2.969 
Gap junction 2.835 
GnRH signaling pathway 2.691 
Circadian rhythm 2.606 
Neurodegenerative disorders 1.95 
Type II diabetes mellitus 1.701 
Focal adhesion 1.572 
Adipocytokine signaling pathway 1.291 
Antigen processing and presentation 1.291 
VEGF signaling pathway 1.291 
Long-term depression 1.254 
Fc epsilon RI signaling pathway 1.23 
Adherens junction 1.23 
TGF-beta signaling pathway 1.163 
Apoptosis 1.153 
Natural killer cell mediated cytotoxicity 0.971 
Insulin signaling pathway 0.783 
Axon guidance 0.777 
Cell adhesion molecules (CAMs) 0.772 
Wnt signaling pathway 0.708 
Regulation of actin cytoskeleton 0.512 
Neuroactive ligand-receptor interaction 0.328 
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 3.4.7.1.1 MAPK signalling pathway 
Signal transduction cascades activated for mitogen-activated protein kinase 
(MAP kinase) pathways are stimulated by different stimuli such as growth 
factors, stress, cytokines and inflammation. These are stress-activated kinases 
and are also induced by hyperglycemia and high glucose, which increases ROS 
production and causes oxidative stress. Oxidative stress induces MAPK-
signalling pathway, which causes insulin resistance and beta cell dysfunction. 
Table 3.4.7.1.1.1 includes the differentially-regulated genes in MIN6 B1(GSIS) 
and MIN6 B1(Non-GSIS) associated with MAPK-signalling pathway.  
KEGG_PATHWAY:MMU04010:MAPK SIGNALING PATHWAY; 8 
Gene(s) 
AFFY_ID Gene Name F C 
1423100_at FBJ osteosarcoma oncogene B 4.63 
1417409_at, 1448694_at Jun oncogen 2.73 
1448830_at Dual specificity phosphatase 1 2.15 
1453851_a_at 
Growth arrest and DNA-damage-
inducible 45 gamma 
1.59 
1420088_at Nuclear factor of kappa light 1.28 
1427060_at 
Mitogen activated protein kinase 
3 
1.27 
1427464_s_at 
Heat shock 70kD protein 5 
(glucose-regulated protein) 
-1.23 
1417542_at Ribosomal protein S6 kinase -1.28 
Table: 3.4.7.1.1.1 Differentially-regulated genes between MIN6 B1(GSIS) 
and MIN6 B1(Non-GSIS) cells, associated with MAPK-signalling pathway 
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Fig 3.4.7.1.1.2 graphically represent gene transcript associated with the MAP kinase 
pathway. White and yellow coloured gene transcript are the differentially-regulated 
genes in MIN6 B1(GSIS) and MIN6 B1(Non-GSIS). 
 
 
 
 
 
 
 
 
 
 
Fig: 3.4.7.1.1.2 Differentially-regulated genes associated with MAPK signalling 
pathway. Yellow coloured genes with red arrow (    ) represent up-regulated gene 
transcripts and white coloured genes with blue arrow ( ) represent down-
regulated genes associated MIN6 B1 microarray study. 
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3.4.7.1.2 Insulin signalling pathway 
Signalling through the insulin pathway is critical for the regulation of intracellular and 
blood glucose levels and the avoidance of diabetes. Insulin signalling is mediated by a 
complex, highly integrated network that controls several processes (Fig: 3.4.7.1.2.1). 
Fig 3.4.7.1.2.1 represent various gene transcript associated with insulin signalling 
pathway. Gene transcript circled with white line are the gene transcript that were 
found to up-regulated in the microarray study in MIN6 B1(Non-GSIS) compared to 
MIN6 B1(GSIS). 
 
 
 
 
 
 
 
Fig: 3.4.7.1.2.1 Differentially-regulated genes associated with Insulin signalling 
pathway. Genes circled in white are the up-regulated genes associated with 
MIN6 B1 microarray study. 
Table 3.4.7.1.2.2 shows the up-regulated genes associated with insulin signalling 
pathway. High glucose induces the expression of c-fos and c-jun. c-jun and c-fos 
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represses human insulin promoter (Susini et al., 1998). Research has shown that 
MAP-kinase mediate transcription of immediate early genes like c-fos and c-jun (Yao 
et al., 1995). 
BIOCARTA:m_insulinPathway:Insulin Signaling Pathway: 3 Gene(s) 
AFFY_ID Gene Name F C 
1423100_at FBJ osteosarcoma oncogene 4.63 
1417409_at Jun oncogen 2.73 
1427060_at Mitogen activated protein kinase 3 1.27 
Table: 3.4.7.1.2.2 Differentially-regulated genes associated with insulin signalling 
pathway. Genes are arranged by fold change (FC) in descending order. 
3.4.8 qRT-PCR validation of the microarray data 
To validate the microarray results, twelve up-regulated genes, Fos, Egr1, Txnip, Sox4, 
Gadd45g, Mapk3, Jun, Anxa2, Dusp1, Ier5, Klf4 and Fosb, and four down-regulated 
genes, Gcg, Slc38a4, Txndc5 and Pcsk9 were selected for qRT-PCR analysis. qRT-
PCR was performed in triplicate for each gene transcript (See Section: 2.5.3), and the 
fold change was determined after normalization to the expression of a housekeeping 
gene, Beta-actin. Comparison of qRT-PCR data with microarray data demonstrated 
matching trends in expression changes for both methods. 
An internal housekeeping gene control was selected based on the expression levels, of 
which were not significantly different between MIN6 B1(GSIS) and MIN6 B1(Non-
GSIS) cells. qRT-PCR was performed on MIN6 B1(GSIS) and MIN6 B1(Non-GSIS) 
cell RNA to see if there were difference in the expression of Beta-actin and Gapdh. 
There was no significant difference in the expression of either Beta-actin or Gapdh, 
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therefore Beta-actin as a housekeeping gene was included to normalise any possible 
differences in RNA isolation and RNA degradation (Table: 3.4.8.1).   
 MIN6 B1(Non-GSIS) MIN6 B1(GSIS) 
Beta-actin 18.317 17.795 
Gapdh 18.078 18.66 
Table: 3.4.8.1 Shows the cycle threshold (ct) values of Beta-actin and Gapdh in 
MIN6 B1(GSIS) and MIN6 B1(Non-GSIS). 
To exclude any amplification product derived from genomic DNA or any other 
contaminent that could contaminate the RNA preparation, total RNA without reverse 
transcription and water on its own was amplified as a negative control (See Section: 
2.5.3.1). Fig 3.4.8.2 shows the detection of target gene transcript, control, -RT control 
and water control. 
 
 
 
 
 
 
Table: 3.4.8.2 Detection of target gene transcript, endogenous control, -RT 
control and water control. 
 
 
Endogenous 
Target 
-RT control 
Water control 
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qRT-PCR validation was performed on the same samples of RNA that were used for 
microarray study. P-value and fold change was calculated using 19A, B and C VS. 
23A and B. 23C sample was not included in the study as it did not cluster with its 
replicates in the microarray study. Standard deviation shown was calculated on 
triplicate technical repeat analysis of samples 23A and B (Table: 3.4.8.3). The fold 
change for both qRT-PCR and microarray study was calculated using 19A, 19B and 
19C vs. 23A and 23B only. Table 3.4.8.4 shows the fold change from microarray and 
qRT-PCR validation study. qRT-PCR study confirmed the trends observed in the 
microarray experiment for the gene transcripts studied (Table: 3.4.8.4). Fig 3.4.8.5 
compares the fold change from microarray and qRT-PCR studies (i.e. table 3.4.8.3 in 
graphical form).    
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MIN6 B1(GSIS) RQ 
value 
MIN6 B1(Non-
GSIS) RQ value  Gene 
19A 19B 19C 23A 23B 23C 
Average 
Repeat 
1+2 
F C 
P-
value 
S.D 
Up-regulated 
Anxa A2 1 1 1 1.83 1.67 1.41 1.75 1.75 0.001 0.113 
Dusp1 
1 1 1 3.51 3.73 0.66 3.62 3.60 
0.000
06 
0.154 
Egr1 1 1 1 4.14 5.14 0.48 4.64 4.64 0.002 0.709 
Fos 1 1 1 6.03 6.94 0.29 6.49 6.49 0.001 0.641 
FosB 1 1 1 55.01 62.98 0.39 58.99 58.9 0.000 5.636 
Gadd45g 1 1 1 1.47 1.70 0.81 1.59 1.59 0.006 0.159 
Ier-5 1 1 1 1.83 1.94 0.54 1.89 1.89 0.000 0.078 
Jun 1 1 1 2.54 3.32 0.35 2.93 2.93 0.007 0.554 
Klf4 1 1 1 2.49 2.44 0.43 2.47 2.47 0.000 0.037 
Mapk3 1 1 1 1.23 1.10 0.54 1.16 1.16 0.043 0.093 
Sox4 1 1 1 1.39 1.93 0.68 1.66 1.66 0.044 0.375 
Txnip 1 1 1 2.90 3.80 0.99 3.35 3.35 0.006 0.636 
Down-regulated 
Gcg 1 1 1 0.72 0.39 0.915 0.555 1.803 0.036 0.233 
Pcsk9 1 1 1 0.45 0.32 1.133 0.386 2.591 0.001 0.091 
Slc38a4 1 1 1 0.81 0.63 1.065 0.719 1.392 0.026 0.129 
Txndc5 1 1 1 0.85 0.68 0.791 0.764 1.309 0.037 0.124 
Table: 3.4.8.3 RQ (relative quantification) of transcript expression in MIN6 B1 
samples as determined by qRT-PCR. RQ of MIN6 B1(GSIS) was set to 1. 19A, 
19B and 19C are biological replicates of MIN6 B1(GSIS) cells whereas 23A, 23B 
and 23C are biological replicates of MIN6 B1(Non-GSIS) cells. p-value and fold 
change was calculated using 19A, B and C VS. 23A and B. 23C (shown in red 
font) sample was not included in the study as it did not cluster with its replicates 
in the microarray study. Standard deviation shown was calculated on triplicate 
technical repeats of samples 23A and B. 
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Gene Transcripts qRT-PCR Microarray 
Anxa A2 1.75 1.37 
Dusp1 3.62 2.15 
Egr1 4.64 1.98 
Fos 6.49 2.12 
FosB 59.00 4.63 
Gadd45g 1.59 1.59 
Ier-5 1.89 1.51 
Jun 2.93 2.73 
Klf4 2.47 2.36 
Mapk3 1.17 1.27 
Sox4 1.66 1.89 
 
Up-regulated 
Txnip 3.11 5.25 
Gcg -1.80 -1.55 
Pcsk9 -2.59 -1.5 
Slc38a4 -1.39 -1.43 
Down-regulated 
Txndc5 -1.31 -1.34 
Table: 3.4.8.4 Validation of microarray data by qRT-PCR. Comparison of fold 
change from qRT-PCR and microarray study, showing gene transcripts up- or 
down-regulated in MIN6 B1(Non-GSIS) compared to MIN6 B1(GSIS). 
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Fig: 3.4.8.5 Comparison of microarray expression data and qRT-PCR data for 
selected differentially expressed genes identified by microarray analysis of MIN6 
B1(Non-GSIS) and MIN6 B1(GSIS) cells. Range of expression from qRT-PCR 
analysis was relative to the corresponding microarray expression data. Results 
are included for Anxa2, Dusp1, Egr1, Fos, Fosb, Gadd45g, Ier5, Jun, Klf4, 
Mapk3, Sox4, Txnip, Gcg, Pcsk9 Slc38a4, and Txndc5. qRT-PCR was performed 
on biological triplicates of MIN6 B1(GSIS) and MIN6 B1(Non-GSIS) cells. p-
value and fold change for both qRT-PCR and microarray was calculated using 
19A, B and C VS. 23A and B. 23C sample was not included in the study as it did 
not cluster with its replicates in the microarray study. Standard deviation shown 
was calculated triplicate technical repeats on samples 23A and B. 
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3.4.9 Comparison of MIN6 and MIN6 B1 microarray data with protein 
 Changes in the proteome between glucose-responsive MIN6 (L) and glucose non-
responsive MIN6 (H) cells were studied using 2D-DIGE (2-D difference gel 
electrophoresis). A total of 3551 protein spots in the pH range of 4-7 were identified. 
A criteria of fold change ≥ 1.2 and p-value <0.01 was used to identify differentially-
regulated proteins. A total of 35 proteins were identified that passed the above 
criteria, 18 were down-regulated, whereas 17 were found to be up-regulated in MIN6 
(H) compared to MIN6 (L) cells.  
MIN6 and MIN6 B1 probe set identifiers (ID) were converted to Entrez ID, using 
freely available software DAVID (http://david.abcc.ncifcrf.gov/). The same was done 
with protein ID and was compared using access.  
Name p-value FC 
Ubiquitin thiolesterase 1.70E-10 2.98 
Phosphoglycerate mutase 1 2.00E-06 2.95 
3-phosphoglycerate dehydrogenase 0.00087 2.65 
Chromogranin A precursor (CgA) 3.00E-07 2.47 
protein 1 homolog gamma (HP1 gamma) 1.10E-07 2.41 
High mobility group box 1 (Amphoterin) 8.20E-10 2.18 
Annexin A4 0.00032 1.99 
Chromatin assembly factor 1 subunit C (CAF-1 
subunit) 
2.40E-08 1.85 
Ubiquinol-cytochrome-c-reductase complex core 
protein 1 
2.80E-07 1.6 
Stathmin 1 3.50E-05 1.57 
Tropomyosin alpha 3 chain 3.40E-06 1.53 
Transaldolase 1 0.0048 1.5 
S-adenosylhomocysteine hydrolase 2.60E-06 1.45 
deoxyuridine triphosphatase 4.00E-07 1.41 
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Prohibitin 7.30E-05 1.31 
protein phosphatase 1, catalytic subunit, beta 0.0019 1.25 
Chaperonin subunit 2 (beta) 0.0051 1.22 
bisphosphate 3'-nucleotidase 1 0.0047 -1.24 
proteasome(prosome, macropain) subunit, alpha type 1 0.00018 -1.29 
6-phosphogluconolactonase 0.00019 -1.31 
proteasome (prosome, macropain) 28 subunit 0.00015 -1.33 
Enolase 1, alpha non-neuron 2.10E-05 -1.53 
Malate dehydrogenase, cytoplasmic 5.50E-06 -1.61 
6-pyruvoyl-tetrahydropterin synthase/dimerization 
cofactor 
4.90E-07 -1.75 
Hypoxanthine guanine phosphoribosyl transferase 6.60E-05 -1.75 
Superoxide dismutase 1, soluble 2.50E-08 -1.97 
Stromal cell -derived growth factor 4.00E-10 -2.28 
Endoplasmic reticulum protein ERp29 precursor 8.90E-12 -2.34 
Prolyl 4-hydrolase, beta polypeptide;protein disulfide 
isomerase 
1.40E-07 -2.44 
Succinyl-CoA ligase [GDP-forming] beta chain 9.80E-05 -2.59 
Glucose Regulated Protein 94 1.60E-06 -2.73 
Peroxiredoxin 4 1.10E-13 -2.77 
galactose-4-epimerase, UDP 0.00018 -2.86 
heat shock 70kDa protein 5 (glucose-regulated protein) 9.30E-07 -2.91 
carbonyl reductase 3 3.40E-07 -3.56 
Table: 3.4.9 List of 35 differentially expressed proteins in MIN6 (H) cells versus 
MIN6 (L) cells.  Identity of columns, from left to right: protein name, p-value 
and FC (fold change).  
3.4.9.1 Common genes in MIN6 Microarray and MIN6 protein study 
MIN6 probe set ID from the microarray study and protein ID, from the protein study 
performed on MIN6 (H) passage 40 and MIN6 (L) passage 18, was converted to 
entrez ID and compared using access. There were 12 common gene transcripts in 
MIN6 microarray study and MIN6 protein study (Fig: 3.4.9.1.1). Table 3.4.9.1.2 
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shows the lists of common gene transcripts that were differentially regulated in MIN6 
microarray and MIN6 protein study. 
  
    
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 3.4.9.1.1 Venn diagram showing common genes in MIN6, MIN6 B1 
microarray study and MIN6 protein study. 
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Table: 3.4.9.1.2 List of genes and their fold change differentially regulated in 
microarray and protein study performed on MIN6 (H) passage 40 and MIN6 (L) 
passage 18. Identity of columns, from left to right: probe set, gene name, F C 
(fold change), Entrez ID and Input ID.  
3.4.9.2 Common genes in MIN6 and MIN6 B1 microarray study 
Previously microarray study was performed on long-term cultured MIN6 cells to 
identify genes associated with loss of GSIS. This microarray study was done on 
heterogeneous population of MIN6 cells and was about 22 passages apart.  Present 
study was designed on homogenous population of cells (MIN6 B1) that were very 
limited passage numbers apart (4 passage apart) and the experiment was performed 
using whole genome microarray. A set of 33 common differentially-regulated gene 
Probe set Gene name F C Entrez ID Input ID 
96244_at 
ubiquitin carboxy-terminal 
hydrolase L1 
1.79 22223 *Q9R0P9 
100584_at annexin A4 1.68 11746 *33416530 
93265_at tropomyosin 5 1.49 59069 *20178336 
95066_at transaldolase 1 1.47 21351 *33859640 
96892_at 
proteasome (prosome, macropain) 
subunit, alpha type 1 
1.45 26440 *33563282 
160272_at Chromobox homolog 3 1.44 12417 *P23198 
95654_at Cluster Incl AF109905: 1.31 114584 *15617203 
97909_at leukemia-associated gene 1.25 16765 *Q91XT3 
96318_at 
DNA segment, Chr 17, Wayne 
State University 104, expressed 
-1.27 28106 *17027227 
93495_at peroxiredoxin 4 -1.53 53381 *O08807 
160428_at 
Succinate-coenzyme A ligase, 
GDP-forming, Beta subunit 
-1.89 20917 *52788304 
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transcripts were found in MIN6 and MIN6 B1 microarray study (Fig: 3.4.9.2.1). Table 
3.4.9.2.2 shows the lists of common gene transcripts that were differentially-
expressed in the MIN6 and MIN6 B1 microarray study. There were 7 common up-
regulated and 18 down-regulated genes in MIN6 and MIN6 B1 cells. There were 8 
gene transcripts that were down-regulated in MIN6 but were up-regulated in MIN6 
B1 cells and 1 gene transcript that was down-regulated in MIN6 B1 and up-regulated 
in MIN6 cells. 
 
 
 
 
 
 
 
 
 
Fig: 3.4.9.2.1 Venn diagram showing common genes in MIN6, MIN6 B1 
microarray study and MIN6 protein study. 
MIN6 
B1 
Probe 
ID 
MIN6 B1 Gene 
Name 
Entrez 
ID 
MIN
6 B1 
F C 
MIN6 
Probe 
ID 
MIN6 Gene Name 
MIN6 
F C 
1415997
_AT 
thioredoxin 
interacting protein 
56338 5.25 
160547
_s_at 
NA 2.28 
1417065
_AT 
Early growth 
response 1 
13653 1.98 
98579_
at 
Early growth 
response 1 
-4.62 
1449556
_AT 
histocompatibility 
2, T region locus 
23 
15040 1.82 
98472_
at 
histocompatibility 
2, T region locus 
23 
-2.19 
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1460645
_AT 
cysteine and 
histidine-rich 
domain (CHORD)-
containing, zinc-
binding protein 1 
66917 1.45 
160330
_at 
NA 
1.44 
1417719
_AT 
sin3 associated 
polypeptide 
60406 1.42 
160068
_at 
NA 
2.14 
1418835
_AT 
pleckstrin 
homology-like 
domain, family A, 
member 1 
21664 1.42 
160829
_at 
NA 
3 
1423825
_AT 
RIKEN cDNA 
5031439A09 gene 
68151 1.38 
101001
_at 
RIKEN cDNA 
5031439A09 gene 
-2.89 
1415688
_AT 
ubiquitin-
conjugating 
enzyme E2G 1  
67128 1.36 
93312_
at 
RIKEN cDNA 
2700059C12 gene 1.49 
1424638
_AT 
cyclin-dependent 
kinase inhibitor 1A 
(P21) 
12575 1.34 
94881_
at 
cyclin-dependent 
kinase inhibitor 1A 
(P21) 
1.37 
1419595
_A_AT 
gamma-glutamyl 
hydrolase 
14590 1.27 
93575_
at 
gamma-glutamyl 
hydrolase 
-3.75 
1434642
_AT 
dehydrogenase/red
uctase (SDR 
family) member 8 
114664 1.27 
102370
_at 
Cluster Incl 
AA822174 -8.65 
1426547
_AT 
group specific 
component 
14473 1.25 
99197_
at 
group specific 
component 
-12.93 
1431665
_A_AT 
translocase of inner 
mitochondrial 
membrane 8 
homolog b (yeast) 
30057 1.22 
97477_
at 
translocase of inner 
mitochondrial 
membrane 8 
homolog b (yeast) 
1.39 
1432264
_X_AT 
cytochrome c 
oxidase subunit 
VIIa polypeptide 2-
like 
629383 1.21 
160383
_at 
NA 
-1.51 
1436915
_X_AT 
lysosomal-
associated protein 
114128 1.21 
100571
_at 
Cluster Incl 
AW123934 
-1.32 
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transmembrane 4B 
1417287
_AT 
histocompatibility 
13 
14950 -1.2 
96117_
r_at 
histocompatibility 
13 
-1.44 
1438225
_X_AT 
translocating chain-
associating 
membrane protein 
1 
72265 -1.22 
160936
_at 
NA 
-1.8 
1452102
_AT 
coatomer protein 
complex, subunit 
beta 2 (beta prime) 
50797 -1.22 
93340_
f_at 
coatomer protein 
complex, subunit 
beta 2 (beta prime) 
-1.73 
1423670
_A_AT 
signal recognition 
particle receptor  
67398 -1.23 
93757_
at 
RIKEN cDNA 
1300011P19 gene 
-1.31 
1451255
_AT 
liver-specific 
bHLH-Zip 
transcription factor 
54135 -1.23 
162274
_f_at 
NA 
1.68 
1452767
_AT 
RIKEN CDNA 
5730465C04 
GENE 
81910 -1.23 
92850_
at 
RIKEN cDNA 
5730465C04 gene -2.22 
1455066
_S_AT 
RIKEN CDNA 
9130229H14 
GENE 
236520 -1.25 
103295
_at 
Cluster Incl 
AI854482: r -1.69 
1417542
_AT 
ribosomal protein 
S6 kinase, 
polypeptide 2 
20112 -1.28 
98007_
at 
ribosomal protein 
S6 kinase -1.34 
1456175
_A_AT 
coatomer protein 
complex, subunit 
beta 2 
50797 -1.32 
93340_
f_at 
coatomer protein 
complex, subunit 
beta 2 
-1.73 
1448411
_AT 
Wolfram syndrome 
1 homolog (human) 
22393 -1.34 
103824
_at 
Wolfram syndrome 
1 homolog (human) 
-1.91 
1451091
_AT 
thioredoxin domain 
containing 5 
105245 -1.34 
98918_
at 
DNA segment, Chr 
13, 
-1.42 
1434698
_AT 
RIKEN CDNA 
9130229H14 
GENE 
236520 -1.37 
103295
_at 
Cluster Incl 
AI854482: -1.69 
1424024
_AT 
RIKEN CDNA 
1810021C21 
193813 -1.39 
97451_
at 
Cluster Incl 
AI837599: 
-1.4 
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GENE 
1427294
_A_AT 
RIKEN CDNA 
1810073N04 
GENE 
72055 -1.41 
160414
_at 
NA 
-1.43 
 
1435247
_AT 
ubiquitin-activating 
enzyme E1-domain 
containing 1 
 
66663 
 
-1.41 
 
102812
_i_at 
RIKEN cDNA 
5730525G14 gene 
 
-1.57 
1428111
_AT 
solute carrier 
family 38, member 
4 
69354 -1.43 
104286
_at 
RIKEN cDNA 
1700012A18 gene -1.61 
1452830
_S_AT 
carbamoyl-
phosphate 
synthetase 2, 
aspartate 
transcarbamylase, 
and dihydroorotase 
69719 -1.5 
96827_
at 
RIKEN cDNA 
2410008J01 gene 
-1.43 
1425952
_A_AT 
Glucagon 
14526 -1.55 
94633_
at 
glucagon 
-2.59 
1418890
_A_AT 
RAB3D, member 
RAS oncogene 
family 
19340 -1.62 
97415_
at 
RAB3D, member 
RAS oncogene 
family 
-3.14 
Table: 3.4.9.2.2 List of genes and their fold change differentially regulated in 
microarray and protein study. Identity of columns, from left to right: MIN6 B1 
Probe ID, MIN6 B1 Gene Name, Entrez ID, MIN6 B1 F C, MIN6 Probe ID, 
MIN6 Gene Name and MIN6 F C (F C= fold change; NA= no name were given to 
these Probe ID). 
3.4.9.3 Common genes in MIN6 protein and MIN6 B1 microarray study 
A comparison of MIN6 protein study and MIN6 B1 microarray study resulted in a 
single common gene. It was down-regulated in both protein and microarray study 
(Table: 3.4.9.3). 
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Table: 3.4.9.3 Gene transcript and its fold change differentially-regulated in 
microarray and protein study. Identity of columns, from left to right: Probe ID, 
Gene Name, Entrez ID, F C and Protein ID (F C=fold change). 
Probe ID Gene Name Entrez ID F C Protein ID 
1427464_S_AT 
HEAT SHOCK 70KD 
PROTEIN 5 (GLUCOSE-
REGULATED PROTEIN) 
14828 -1.23 *31981722 
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3.5 siRNA analysis of target genes for their effect on GSIS 
Microarray was done on MIN6 B1 cells whereas siRNA knock-down was carried out 
on MIN6 cells. The reason for switching from MIN6 B1 to MIN6 cells was that MIN6 
B1 did not survive after thawing back at the later (functional validation) part of the 
study. MIN6 B1 was also unavailable to borrow from other laboratory and/or to buy.     
Based on the results from microarray analysis and qRT-PCR validation of MIN6 
B1(GSIS) and MIN6 B1(Non-GSIS), siRNA targets were chosen. The levels of 
silencing vary between species, cells and tissues due to differences in the efficiency 
with which the siRNAs are taken up by target cells. To minimise this problem, 
conditions for siRNA transfection into MIN6 cell line were optimised in 24-well 
plates using Gapdh as positive control and scrambled siRNA as a negative control.  
For every siRNA transfection carried out, both non-transfected (NT) cells and a 
scrambled (Scr) siRNA transfected cells were used as controls. Scrambled siRNA can 
be any sequence that does not have homology to any genomic sequence. The 
scrambled non-targeting siRNA used in this study was commercially produced and 
promised limited sequence similarity to known genes and their products. It has also 
been functionally proven to have minimal effects on cell proliferation and viability. 
For each set of experiments investigating the effect of siRNA, the cells transfected 
with target-specific siRNA were compared to cells transfected with scrambled siRNA. 
This took account of any effects due to the transfection reagents and also any non-
specific effects caused by introduction of short RNA oligos.  
Transfections were carried out in 24-well plates (See Section: 2.5.4.1). In order to 
determine the success of transfection Gapdh siRNA was used for optimization in 24-
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well plates. Gapdh silencing was seen as a measure of the successful achievement of 
suitable transfection conditions. Western blots (See Section: 2.5.5) were used to 
determine if siRNA had an effect at a protein level. 
3.5.1 Transfection optimization using Gapdh siRNA 
Gapdh siRNA was transfected in MIN6 cell line for optimization in 24-well plates. 
Western blots (See Section: 2.5.5) were performed to determine if siRNA had an 
effect at a protein level (Fig: 3.5.1). α-tubulin was used as a loading control for the 
samples. Down-regulation of Gapdh protein was observed in Gapdh siRNA-
transfected cells whereas no down-regulation of protein was observed in non-
transfected cells and scrambled siRNA-transfected cells.   
 
 
 
 
 
 
Fig: 3.5.1 Western blot showing protein expression of Gapdh after Gapdh siRNA 
transfection in MIN6 cell line.  NT = Non-transfected, Scr = Scrambled, and 
Gapdh siRNA. 
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3.6 Glucagon (Gcg) 
Microarray and qRT-PCR analysis showed Gcg was down-regulated in the MIN6 
B1(Non-GSIS) cells compared to MIN6 B1(GSIS) cells. The microarray study 
showed a 1.55-fold, and qRT-PCR showed 1.8-fold, down-regulation of Gcg in MIN6 
B1(Non-GSIS) compared to MIN6 B1(GSIS) cells. Therefore it was planned to 
knock-down Gcg in glucose-responsive MIN6 cells to determine if Gcg likely played 
an active role in GSIS.  
3.6.1 Proliferation assay 
Cells grown in 96-well plates were assayed for changes in proliferation at 72hrs. using 
the acid phosphatase assay (See Section: 2.3.3). Proliferation assays were carried out 
on MIN6 low passage cells transfected with three Gcg-specific siRNA including 
Kinesin siRNA as a positive control. Cellular arrest in the presence of Kinesin siRNA 
was taken as confirmation of efficient transfection conditions. Significantly reduced 
growth (p-value = 0.02) of Kinesin siRNA-transfected cells compared to scrambled 
siRNA-transfected cells was observed. There was no significant effect in growth 
when transfected with Gcg siRNA compared to scrambled siRNA-transfected cells 
(Fig: 3.6.1.1).  
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Fig: 3.6.1.1 Growth rate of MIN6 low passage cells after siRNA transfection 
using Gcg (n=3), Scrambled, Gapdh and Kinesin. NT=non-transfected cells, Scr= 
scrambled transfected, Gcg-1, 2, 3= 3 different siRNA. 
There was no change in the morphology of the cells after siRNA transfection except 
for kinesin-transfected cells that showed a rounded morphology, indicating cell cycle 
arrest (Fig: 3.6.1.2). 
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 Effect of siRNA on cell morphology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
(F) Gapdh 
 
  
(A) Non-transfected (B) Scrambled 
(C) Gcg-1 (D) Gcg-2 
(G) Kinesin 
 
(E)Gcg-3 
 
Fig: 3.6.1.2 Photographs (A) Non-
transfected, (B) scrambled, (C) 
Gcg-1, (D) Gcg-2, (E) Gcg-3 (F) 
Gapdh and (G) kinesin siRNA 
transfected cells. Rounded 
morphology of cells indicates cell 
growth arrest. 
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3.6.2 qRT-PCR after siRNA transfection 
qRT-PCR was carried out on MIN6 low passage cells (passage 35) transfected with 3 
independent Gcg-specific siRNA. RNA was isolated (See Section: 2.5.1.2.3) from the 
non-transfected, scrambled siRNA-transfected, Gcg siRNA-transfected and Gapdh 
siRNA-transfected cells after 72hrs. of transfection. Fig: 3.6.2 shows a knock-down of 
Gcg mRNA in Gcg siRNA-transfected cells compared to scrambled-transfected cells. 
Gcg-1 and Gcg-2 siRNA transfection showed a knock-down of approx. 32% and 
27%, respectively, whereas no knock-down was seen with the Gcg-3 siRNA 
transfection compared to scrambled siRNA-transfected cells (Fig: 3.6.2). 
To exclude any amplification product derived from genomic DNA that could 
contaminate the RNA preparation –RT and water was used as negative control. For -
RT control total RNA from Gcg, Gapdh, scrambled siRNA-transfected and non-
transfected cells were amplified without reverse transcriptase enzyme. Water was also 
amplified as a control to exclude any contamination in it. 
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Fig: 3.6.2 MIN6 low passage cells were transfected with Gcg, Scr and Gapdh. 
After 72hrs. of siRNA transfection RNA was isolated and qRT-PCR was 
performed for Gcg mRNA level. Gcg-1 induced 32.7%, Gcg-2 induced 27.5% 
whereas Gcg-3 showed no knock-down in MIN6 low passage cells. NT=non-
transfected, Scr= Scrambled, Gcg-1, 2, 3= Gcg siRNA (n=3) and Gapdh= Gapdh 
siRNA transfected cells. Results represent mean ± S.D from three different 
experiments.  
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3.6.3 GSIS after Gcg siRNA 
These three Gcg-specific siRNA were transfected in MIN6 low passage cells to 
determine if silencing of Gcg affects GSIS. GSIS assay (See Section: 2.3.2.1) was 
performed after 72hrs. of siRNA transfection (See Section: 2.5.4.1.2). The three Gcg-
transfected MIN6 low passage cells along with Gapdh-transfected cells, scrambled-
transfected cells and non-transfected cells were incubated in 3.3 and 16.7mmol/L 
glucose for 1hr (See Section: 2.3.2.1). Insulin secretion was determined using ELISA 
(See Section: 2.3.2.4) and normalised to total protein. 
 There was significant loss of GSIS in Gcg-1 (p-value=0.00009), Gcg-2 (p-
value=0.015) and Gcg-3 (p-value= 0.032) siRNA transfected MIN6 low passage cells 
(Fig: 3.6.3) compared to cells transfected with the scrambled sequence. Gcg-1 showed 
1.0-fold, Gcg-2 showed 1.2-fold and Gcg-3 showed 1.4-fold GSIS, whereas non-
transfected and scrambled-transfected cells showed 2.2-fold and 2.3-fold GSIS, 
respectively (Fig: 3.6.3).  
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Fig: 3.6.3 siRNA-mediated knockdown of Gcg led to a significant loss of GSIS in 
MIN6 low passage cells (Gcg-1 (p-value= 0.00009), Gcg-2 (p-value= 0.015), Gcg-3 
(p-value=0.032)). GSIS was quantitated in non-transfected MIN6 low passage 
cells and MIN6 cells transfected with either scrambled siRNA, Gcg siRNA or the 
Gapdh siRNA. GSIS assay was performed 72hrs. after transfection. Insulin 
secretion was measured by ELISA and normalised to total cellular protein. The 
other numbers near the bars shows the GSIS fold change. NT= non-transfected, 
Scr= scrambled transfected, Gcg-1, 2, 3= Gcg siRNA (n=3), Gapdh= Gapdh 
siRNA transfected cells. Results represent mean ± S.D from three different 
experiments.  
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3.6.4 qRT-PCR after cDNA over-expression 
qRT-PCR was carried out on Gcg cDNA over-expressed MIN6 high passage cells 
(passage 47) along with empty plasmid-transfected and non-transfected cells. RNA 
was isolated (See Section: 2.5.1.2.3) and treated with DNase enzyme (See Section: 
2.5.1.3.1). cDNA was prepared from the treated RNA (See Section: 2.5.2.1). Fig: 
3.6.4 shows a 10.9-fold increase of Gcg mRNA in MIN6 high passage cells 72hrs. 
after Gcg cDNA over-expression compared to empty plasmid transfected cells. To 
exclude any amplification product derived from genomic DNA or any other 
contaminent that could contaminate the DNase-treated RNA preparation, DNase-
treated RNA without reverse transcriptase enzyme and water on its own was 
amplified as a negative control (See Section: 2.5.3.1). 
  
 
 
 
 
Fig: 3.6.4 MIN6 high passage cells were transfected with empty plasmid and Gcg 
plasmid. qRT-PCR for Gcg mRNA level was performed after 72hrs. of cDNA 
over-expression in MIN6 high passage cells. A 10.9-fold increased Gcg mRNA 
was observed in Gcg plasmid-transfected cells compared to empty plasmid-
transfected cells  The results represent mean ± S.D from three different 
experiments.  
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3.6.5 GSIS after Gcg cDNA over-expression 
Gcg cDNA over-expression was performed on MIN6 high passage cells (passage 47) 
as shown in section 3.6.4. GSIS assay (See Section: 2.3.2.1) was performed 72hrs. 
after transfection. There was an increase in GSIS in Gcg over-expressed cells (1.43-
fold) compared to empty plasmid transfected-cells (1.16) (Fig: 3.6.5).  
 
 
 
 
 
 
 
 
 
Fig: 3.6.5 Over-expression of Gcg increases GSIS in MIN6 high passage cells. 
GSIS was quantitated in non-transfected MIN6 high passage cells and MIN6 
cells transfected with either empty plasmid or the Gcg plasmid. GSIS was 
evaluated 72hrs. after plasmid transfection. Results represent mean ± S.D from 
three different experiments. 
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3.6.6 Immunofluorescence 
To investigate the presence of insulin secreting beta cells and glucagon secreting 
alpha cells in MIN6 cell line immunofluorescence was performed. In this study we 
were trying to determine the percentage of (i) insulin, (ii) glucagon and (iii) glucagon 
and insulin expressing cells in the MIN6 cell line. MIN6 low passage cells (passage 
35) were cultured over night on slides, fixed and immunofluorescence was performed 
(See Section: 2.5.8). Immunofluorescence labeling showed the presence of insulin in 
all most all the cells. However, we were unable to optimise the conditions for 
immunofluorescence labeling using glucagon antibody (Fig: 3.6.6).  
 
 
 
 
 
 
 
Fig: 3.6.6 Immunofluorescence using insulin and glucagon on MIN6 low passage 
cell line using fluorescence microscope. Magnifications 20X. Insulin - green; 
glucagon – red; nuclear stain – blue. 
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3.6.7 Summary of results for Gcg study on MIN6 cells 
Results from proliferation assays showed that the optimum conditions for transfection 
were used, as a reduction in growth of cells transfected with kinesin siRNA was 
observed in MIN6 low passage cells. This also showed that transfection of Gcg 
siRNA did not have a notable effect on proliferation. After transfection with three 
separate Gcg siRNAs, there was a decrease in Gcg mRNA (Gcg-1 and Gcg-2 
siRNAs) in Gcg siRNA-transfected cells as assessed by qRT-PCR evaluation 
compared to scrambled siRNA-transfected cells. This was accompanied by a 
significant decrease in GSIS in Gcg siRNA-transfected glucose responsive MIN6 low 
passage cells compared to scrambled siRNA-transfected cells. 
Gcg cDNA was then transfected into high passage MIN6 cells to see if GSIS was 
increased following Gcg over-expression. Gcg mRNA level was determined using 
qRT-PCR after DNase-treatment of the transfected cells. There was a 10.9-fold 
increase in Gcg expression in Gcg plasmid-transfected cells compared to empty 
plasmid-transfected cells. Gcg cDNA over-expression showed a marked increase in 
GSIS in MIN6 high passage cells compared to empty plasmid-transfected cells.  
Immunofluorescence labeling showed the presence of insulin in all most all the cells 
but we were unable to optimise the conditions for immunofluorescence labeling using 
glucagon antibody. 
 
 217 
3.7 Proprotein convertase subtilisin/kexin type 9 (Pcsk9)  
Pcsk9 was down-regulated in the MIN6 B1(Non-GSIS) cells compared to MIN6 
B1(GSIS) cells in the microarray study. The microarray study showed a 1.5-fold and 
qRT-PCR showed 2.59-fold down-regulation of Pcsk9 in MIN6 B1(Non-GSIS) 
compared to MIN6 B1(GSIS) cells. Therefore it was planned to knock-down Pcsk9 in 
glucose responsive MIN6 cells to determine the role of Pcsk9 in GSIS.  
3.7.1 Proliferation assay 
Proliferation assay was done in 96-well plate after 72hrs. of siRNA transfection using 
the acid phosphatase assay (See Section: 2.3.3). Proliferation assays were carried out 
on MIN6 low passage cells transfected with three independent Pcsk9 siRNA, 
including Kinesin siRNA as a positive control. Cellular arrest in the presence of 
Kinesin siRNA was taken as confirmation of efficient transfection conditions. 
Reduced growth of Kinesin siRNA transfected cells compared to scrambled 
transfected cells was observed. There was no significant effect in growth when 
transfected with Pcsk9 siRNA and Gapdh siRNA compared to scrambled-transfected 
cells (Fig: 3.7.1.1). 
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Fig: 3.7.1.1 Growth rate of MIN6 low passage cells after siRNA transfection 
using Pcsk9 (n=3), Scrambled, Gapdh and Kinesin. NT=non-transfected cells, 
Scr= scrambled transfected, Pcsk9-1, 2, 3= 3 different siRNA. 
There was no change in the morphology of the cells after siRNA transfection except 
for Kinesin transfected cells that showed a rounded morphology indicating cell 
growth arrest (Fig:3.7.1.2). 
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Effect of Pcsk9 and kinesin siRNA on cell morphology of MIN6 cells 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
(F) Gapdh 
(A) Non-transfected 
Fig: 3.7.1.2 Photographs (A) Non-
transfected, (B) scrambled, (C) 
Pcsk9-1, (D) Pcsk9-2, (E) Pcsk9-3, 
(F) Gapdh and (G) kinesin siRNA 
transfected cells. Rounded 
morphology of cells indicates cell 
arrest. 
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3.7.2 qRT-PCR 
qRT-PCR was performed on three independent Pcsk9 siRNA transfected MIN6 low 
passage cells (passage 35) along with scrambled and non-transfected cells. After 
72hrs. of siRNA transfection RNA was isolated (See Section: 2.5.1.2.3) and cDNA 
was prepared (See Section: 2.5.2.1). Fig: 3.7.2 shows the qRT-PCR results 72hrs. 
after transfection. qRT-PCR showed a knock-down of approx. 39% in Pcsk9-1, 4.3% 
in Pcsk9-2 and 46.6% in Pcsk9-3 siRNA-transfected cells compared to scrambled 
siRNA-transfected cells 
 
 
 
 
 
 
 
 
 
Fig: 3.7.2 MIN6 low passage cells were transfected with Pcsk9, Scr and Gapdh. 
After 72hrs. of siRNA transfection RNA was isolated and qRT-PCR was 
performed for Pcsk9  mRNA level. Pcsk9 -1 induced 39%, Pcsk9 -3 induced 
46.6% whereas Pcsk9 -2 showed just 4.3% knock-down in MIN6 low passage 
cells. NT=non-transfected, Scr= Scrambled, Pcsk9 -1, 2, 3= Pcsk9 siRNA (n=3) 
and Gapdh= Gapdh siRNA transfected cells. Results represent mean ± S.D from 
three different experiments. 
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3.7.3 GSIS after Pcsk9 siRNA transfection 
Three independent Pcsk9-specific siRNA was transfected in MIN6 low passage cells 
to determine if silencing of Pcsk9 affects GSIS. GSIS assay (See Section: 2.3.2.1) was 
performed after 72hrs. of siRNA transfection (See Section: 2.5.4.1.2). The three 
Pcsk9-specific siRNA transfected MIN6 low passage cells along with Gapdh-
transfected cells, scrambled-transfected cells and non-transfected cells were incubated 
in 3.3 and 16.7mmol/L glucose for 1hr (See Section: 2.3.2.1). Insulin secretion was 
determined using ELISA (See Section: 2.3.2.4) and normalised to total cellular 
protein.  
There was a significant loss of GSIS in Pcsk9-1 (p-value=0.007) and Pcsk9-3 (p-
value= 0.013) siRNA transfected MIN6 low passage cells whereas Pcsk9-2 
transfected cells did not show a significant loss of GSIS (Pcsk9-2 (p-value=0.058)) 
compared to scrambled siRNA-transfected cells. Pcsk9-1 showed 1.5-fold, Pcsk9-2 
showed 1.7-fold and Pcsk9-3 showed 1.2-fold GSIS whereas non-transfected and 
scrambled-transfected cells showed 2.2-fold and 2.0-fold GSIS respectively 
(Fig:3.7.3). Gapdh-transfected cells showed a GSIS of 1.6-fold and were not 
significantly (0.76) different compared to scrambled siRNA-transfected cells. 
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Fig: 3.7.3 siRNA-mediated knockdown of Pcsk9 decreases GSIS in MIN6 low 
passage cells. GSIS was quantitated in non-transfected MIN6 low passage cells 
and MIN6 cells transfected with either scrambled siRNA, Pcsk9 siRNA or the 
Gapdh siRNA. GSIS assay was performed 72hrs. after transfection. Insulin 
secretion was measured by ELISA and normalised to total cellular protein. The 
other numbers near the bars shows the GSIS fold change. NT= non-transfected, 
Scr= scrambled transfected, Pcsk9 -1, 2, 3= Pcsk9 siRNA (n=3), Gapdh= siRNA 
transfected cells. Results represent mean ± S.D from three different experiments.  
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3.7.4 Summary of results for Pcsk9 siRNA transfection in MIN6 low passage 
Results from proliferation assays showed that the optimum conditions for transfection 
were used, as a reduction in growth of cells transfected with kinesin siRNA was 
observed in MIN6 low passage cells. This also showed that transfection of Pcsk9 
siRNA did not have a notable effect on proliferation. After transfection with three 
separate Pcsk9 siRNAs, there was a decrease in Pcsk9 mRNA as estimated by qRT-
PCR. This was accompanied by a significant decrease in GSIS. 
There was no over-expression study performed on this gene transcript as there was no 
cDNA available to purchase and time did not allow cloning of this product.  
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3.8 Thioredoxin interacting protein (Txnip) 
Txnip was up-regulated in the MIN6 B1(Non-GSIS) cells compared to MIN6 
B1(GSIS) cells in the microarray study. The microarray study showed a 5.25-fold and 
qRT-PCR showed 3.11-fold up-regulation of Txnip in MIN6 B1(Non-GSIS) cells 
compared to MIN6 B1(GSIS). To investigate the relevance of Txnip in glucose-
stimulated insulin secretion, Txnip specific siRNA transfection was performed in high 
passage MIN6 cells.  
3.8.1 Proliferation assay 
Cells grown in 96-well plates were assayed for changes in proliferation at 72hrs. using 
the acid phosphatase assay (See Section: 2.3.3). Proliferation assays were carried out 
on MIN6 high passage cells transfected with Txnip siRNA including Kinesin siRNA 
as a positive control. Cellular growth arrest in the presence of Kinesin siRNA was 
taken as confirmation of efficient transfection conditions. Reduced growth of Kinesin 
siRNA-transfected cells compared to scrambled siRNA-transfected cells was 
observed. There was no significant effect in growth when transfected with Txnip 
specific siRNA compared to scrambled siRNA-transfected cells (Fig: 3.8.1.1).  
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Fig: 3.8.1.1 Growth rate of MIN6 high passage cells after siRNA transfection 
using Txnip (n=3), Scrambled and Kinesin. Scrambled, Gapdh and Kinesin. 
NT=non-transfected cells, Scr= scrambled transfected, Txnip -1, 2, 3= 3 different 
siRNA. 
There was no change in the morphology of the cells after siRNA transfection except 
for kinesin siRNA-transfected cells that showed a rounded morphology indicating cell 
growth arrest (Fig:3.8.1.2). 
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Effect of Txnip and kinesin siRNA on cell morphology of MIN6 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Non-transfected 
 
(B) Scrambled 
 
(C) Txnip-1 
 
(D) Txnip-2 
 
(E) Txnip-3 
 
(F) Gapdh 
Fig: 3.8.1.2 Photographs (A) Non-
transfected, (B) scrambled, (C) Txnip-
1, (D) Txnip-2, (E) Txnip-3, (F) Gapdh 
and (G) kinesin siRNA transfected 
cells. Rounded morphology of cells 
indicates cell growth arrest. 
 
(G) Kinesin 
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3.8.2 qRT-PCR after siRNA transfection 
qRT-PCR was carried out on MIN6 high passage cells (passage 47) transfected with 
three independent Txnip siRNA. RNA was isolated (See Section: 2.5.1.2.3) from the 
non-transfected, scrambled siRNA-transfected, Txnip siRNA-transfected and Gapdh 
siRNA-transfected cells after 72hrs. of transfection. Fig: 3.8.2 shows a knock-down of 
Txnip mRNA in Txnip specific siRNA-transfected cells compared to scrambled 
siRNA-transfected cells. qRT-PCR showed Txnip mRNA knock-down of approx. 
43.5% in Txnip-1, 42.4% in Txnip-2 and 25.3% in Txnip-3 siRNA-transfected cells 
compared to scrambled siRNA-transfected cells (Fig: 3.8.2).  
 
 
 
 
 
 
 
 
Fig: 3.8.2 MIN6 high passage cells were transfected with Txnip, Scr and Gapdh. 
After 72hrs. of siRNA transfection RNA was isolated and qRT-PCR was 
performed for Txnip  mRNA level. Txnip -1 induced 43.5%; Txnip -2 induced 
42.4% whereas Txnip -3 induced 25.3% knock-down in MIN6 high passage cells. 
NT=non-transfected, Scr= Scrambled, Txnip -1, 2, 3= Txnip siRNA (n=3) and 
Gapdh= Gapdh siRNA transfected cells. Results represent mean ± S.D from 
three different experiments.  
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3.8.3 GSIS after Txnip siRNA 
Three independent Txnip-specific siRNAs were transfected in MIN6 high passage 
cells (passage 47) to determine if silencing of Txnip affects GSIS. GSIS assay (See 
Section: 2.3.2.1) was performed after 72hrs. of siRNA transfection (See Section: 
2.5.4.1.2). The three Txnip-specific siRNA transfected MIN6 high passage cells along 
with Gapdh siRNA-transfected cells, scrambled-transfected cells and non-transfected 
cells were incubated in 3.3 and 16.7mmol/L glucose for 1hr (See Section: 2.3.2.1). 
Insulin secretion was determined using ELISA (See Section: 2.3.2.4) and normalised 
to total cellular protein.  
There was a significant increase in GSIS in Txnip -1 (p-value=0.03) and Txnip -2 (p-
value=0.019) siRNA transfected MIN6 high passage cells whereas there was no 
significant increase in GSIS with Txnip-3 (p-value=0.93) compared to scrambled 
siRNA transfected cells (Fig: 3.8.3). Txnip -1 showed 1.4-fold, Txnip -2 showed 1.6-
fold and Txnip-3 showed 0.9-fold GSIS whereas non-transfected and scrambled-
transfected cells showed 0.9-fold and 0.9-fold GSIS respectively (Fig: 3.8.3).  
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Fig: 3.8.3 siRNA-mediated knockdown of Txnip increases GSIS in MIN6 high 
passage cells. GSIS was quantitated in non-transfected MIN6 high passage cells 
and transfected with either scrambled siRNA, Txnip siRNA or the Gapdh siRNA. 
GSIS assay was performed 72hrs. after transfection. Insulin secretion was 
measured by ELISA and normalised to total cellular protein. NT= non-
transfected, Scr= scrambled transfected, Txnip -1, 2, 3= Txnip siRNA (n=3), 
Gapdh= Gapdh siRNA transfected cells. Results represent mean ± S.D from 
three different experiments. 
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3.8.4 qRT-PCR after cDNA over-expression 
qRT-PCR was carried out on Txnip cDNA over-expressed MIN6 low passage cells 
(passage 35). RNA was isolated (See Section: 2.5.1.2.3) from the cells 72hrs. after 
cDNA over-expression. RNA were then treated with DNase enzyme (See Section: 
2.5.1.3.1) and cDNA prepared from the treated RNA (See Section: 2.5.2.1). Fig: 3.8.4 
shows a 23.7-fold increase of Txnip mRNA in Txnip plasmid-transfected cells 
compared to empty plasmid-transfected cells. To exclude any amplification product 
derived from genomic DNA or any other contaminent that could contaminate the 
DNase-treated RNA preparation, DNase-treated RNA without reverse transcriptase 
enzyme and water on its own was amplified as a negative controls (See Section: 
2.5.3.1). 
 
 
 
 
 
Fig: 3.8.4 MIN6 low passage cells were transfected with empty plasmid and 
Txnip plasmid. qRT-PCR for Txnip  mRNA level was performed after 72hrs. of 
cDNA over-expression in MIN6 low passage cells. A 23.7-fold increased 
expression of Txnip  mRNA was observed in Txnip  plasmid-transfected cells 
compared to empty plasmid-transfected cells  The results represent mean ± S.D 
from three different experiments.  
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3.8.5 GSIS after Txnip cDNA over-expression 
 Txnip cDNA over-expression was performed on MIN6 low passage cells (passage 
35). GSIS assay (See Section: 2.3.2.1) was performed 72hrs. after transfection. Txnip 
cDNA transfected MIN6 low passage cells along with empty-transfected cells and 
non-transfected cells were incubated in 3.3 and 16.7mmol/L glucose for 1hr (See 
Section: 2.3.2.1). Insulin secretion was measured using ELISA (See Section: 2.3.2.4) 
and normalised to total cellular protein.  
There was a significant loss (p-value= 0.013) of GSIS in Txnip over-expressed cells 
compared to empty plasmid-transfected cells (Fig: 3.8.5). Txnip cDNA transfected 
cells showed 1.89-fold GSIS whereas non-transfected and empty-transfected cells 
showed 2.9-fold and 2.67-fold GSIS respectively.  
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Fig: 3.8.5 Over-expression of Txnip led to a significant (p-value= 0.013) loss of 
GSIS in MIN6 low passage cells compared to empty-transfected cells. GSIS was 
quantitated in non-transfected MIN6 low passage cells and MIN6 cells 
transfected with either empty plasmid or the Txnip Plasmid. GSIS was measured 
72hrs. after plasmid transfection. Txnip cDNA transfected cells showed 1.89-fold 
GSIS whereas non-transfected and empty-transfected cells showed 2.9-fold and 
2.67-fold GSIS respectively.  Results represent mean ± S.D from three different 
experiments. 
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3.8.6 Western Blot analysis  
Western blot analysis was performed using Txnip specific antibody to detect the 
expression of Txnip protein in MIN6 cells. However there was no band detected for 
Txnip protein using MIN6 cell lysate. Some cell lines including, MDA-MB-453, 
MDA-MB-231, BT-474, MCF 7 and MDA-MB-157 were used as positive controls. 
These cells showed high expression of Txnip mRNA in microarray study (publicly 
available datasets) and was used as positive control. Fig 3.8.6 shows detectable band 
for Txnip protein at 50 kDa using cell lysate from  MDA-MB-453, MDA-MB-231, 
BT-474, MCF 7 and MDA-MB-157, whereas no band was detected in MIN6 cell 
lysate. Gapdh was used as a control to show equal loading of cell lysate in all wells. 
Gapdh was detected at 40 kDA in cell lysate from all the cell lines (Fig: 3.8.6).  
 
 
 
 
 
Fig: 3.8.6 Western blot showing level of expression of Txnip protein in MDA-
MB-453, MDA-MB-231, BT-474, MCF 7 and MDA-MB-157 used as positive 
control and MIN6 cell lysate.  
 
M
D
A
-
M
B
-
45
3 
M
D
A
-
M
B
-
23
1 
B
T-
47
4 
M
CF
 
7 
M
D
A
-
M
B
-
15
7 
M
IN
6 
Txnip (50 kDa) 
 
Gapdh (40 kDa) 
 
 234 
3.8.7 Summary of results for Txnip siRNA transfection in MIN6 high passage 
Results from proliferation assays showed a reduction in growth of MIN6 high passage 
cells transfected with kinesin siRNA and that transfected with Txnip siRNA did not 
have a major effect on proliferation. After transfection with two out of three separate 
Txnip siRNAs there was a decrease in Txnip mRNA as estimated by qRT-PCR. This 
was accompanied by significant increase in GSIS in Txnip specific siRNA-transfected 
cells compared to scrambled siRNA-transfected cells.  
Txnip was then over-expressed in low passage MIN6 cells to see if GSIS was lost 
following over-expression. Txnip mRNA level was determined using qRT-PCR after 
DNase-treatment of the RNA from the transfected cells. There was a 23.7-fold 
increase in Txnip expression in Txnip plasmid-transfected cells compared to empty 
plasmid-transfected cells. Txnip cDNA over-expression showed a significant (p-
value= 0.013) loss of GSIS in MIN6 low passage cells compared to empty plasmid-
transfected cells.  
Western blot analysis was performed using Txnip specific antibody but no bands were 
detected for Txnip protein using MIN6 cell lysate, whereas there was a band detected 
using Gapdh antibody. 
 235 
3.9 Txnip shRNA transfection 
A significant increase in GSIS was observed after Txnip specific siRNA transfection 
in MIN6 high passage cells compared to scrambled transfected-cells. siRNA-induced 
silencing is short-lived so to study long-term effect of silencing a gene shRNA 
technique is used. Therefore Txnip shRNA was transfected in MIN6 high passage 
cells to establish a stable cell line that hopefully would not loose its GSIS phenotype 
with passaging. A set of five shRNA (Open biosystems, RMM4534-NM_001009935) 
were transfected in high passage MIN6 cells.  
3.9.1 qRT-PCR on heterogeneous population shRNA-transfected cells 
qRT-PCR was performed (See Section: 2.5.3.1) on heterogeneous cell population to 
check the expression level of Txnip mRNA. MIN6 high passage cells were transfected 
with Txnip shRNA and empty plasmid shRNA as control in a 24-well plate. After 
72hrs. of transfection cells were fed with puromycin containing media (selection 
media) for selection of transfected cells.  Cells were fed with this selection media 
every 2-3 days until the cells were confluent. Cells were then trypsinised and 
transfered to a T25cm2 flask and grown for RNA isolation. RNA was isolated (See 
Section: 2.5.1.2.3) from empty plasmid transfected cells as well as five independent 
Txnip shRNA transfected cells. qRT-PCR showed Txnip mRNA knock-down of 
approx. 21.8% in Txnip shRNA-3 and 25.4% in Txnip shRNA-4 transfected cells 
compared to empty shRNA-transfected cells. Whereas shRNA-1, shRNA-2 and 
shRNA-5 showed no knock-down of Txnip mRNA compared to empty shRNA-
transfected cells (Fig: 3.9.1).  
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Fig: 3.9.1 MIN6 high passage cells were transfected with Txnip shRNA and 
empty plasmid (Em) as control. RNA was isolated and qRT-PCR was performed 
for Txnip mRNA level. shRNA-1, shRNA-2 and shRNA-5 did not show any 
knock-down of Txnip mRNA whereas, shRNA-3 induced 21.8% and shRNA-4 
induced 25.4% knock-down of Txnip mRNA in MIN6 high passage cells.  
3.9.2 GSIS on heterogeneous population of shRNA-transfected cells 
GSIS assay (See Section: 2.3.2.1) was performed on heterogeneous population of 
Txnip shRNA-transfected and empty shRNA-transfected cells (See Section: 
2.5.4.1.2). Insulin secretion was determined using ELISA (See Section: 2.3.2.4) and 
normalised by protein. There was an increase in GSIS in Txnip shRNA-3 (2.16-fold) 
and shRNA-4 (1.28-fold) transfected cells compare to empty shRNA-transfected cells 
(1.16-fold) (Fig: 3.9.2).   
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Fig: 3.9.2 shRNA-mediated knock-down of Txnip increased GSIS in MIN6 high 
passage cells. GSIS was quantitated in empty shRNA-transfected cells and Txnip 
shRNA-3 and shRNA-4 transfected cells. Insulin secretion was measured by 
ELISA and normalised to total cellular protein. shRNA-3 and shRNA-4 
transfected cells showed Txnip mRNA knock-down by qRT-PCR. 
3.9.3 Cell morphology heterogeneous population of shRNA-transfected cells 
Morphological analysis was performed using phase contrast light microscopy. The 
morphological analysis indicated that Txnip shRNA-transfected cells grows as tight, 
rounded, localised clumps whereas, empty shRNA-transfected cells form a monolayer 
of “flat”, stretched cells (Fig: 3.9.3). 
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Fig: 3.9.3 MIN6 cells transfected with Txnip shRNA and empty shRNA plasmid 
and grown in T75cm2 vented flask. These cells were photographed using phase-
contrast microscope. (Magnification = 20X; scale bar = 200 µM) 
3.9.4 Establishing single cell colonies  
Heterogeneous population of Txnip shRNA-transfected cells and empty shRNA-
transfected cells were plated in 96-well plate for establishing single cell colonies (See 
Section: 2.5.4.3). When confluent enough these colonies were trypsinised and 
transferred to a 24-well plate and then to T25cm2 flask. Single cell colonies were 
developed from heterogeneous population of 2 different sets of Txnip shRNA-
transfected cells (shRNA-3 and shRNA-4) that showed maximum knock-down of 
Txnip mRNA.  
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3.9.4.1 qRT-PCR on clones 
Empty shRNA plasmid-transfected cells were harvested to check the Txnip mRNA 
level using qRT-PCR (See Section: 2.5.3.1).  Empty shRNA plasmid-transfected cells 
were used as controls in this study. In order to select the clones that showed high level 
of Txnip expression, RNA was isolated (See Section: 2.5.1.2.3) from each cell colony 
and was screened for Txnip mRNA level (Fig: 3.9.4.1.1).  
 
 
 
 
 
Fig: 3.9.4.1.1 Level of Txnip expression as determined by qRT-PCR in clones of 
empty shRNA-transfected cells. EM-C, EM-D, EM-E and EM-F represent 
different clones from heterogeneous population of empty shRNA-transfected 
cells. 
Txnip specific shRNA transfected colonies were used to study the effect of Txnip 
knock-down on GSIS. To verify the levels of Txnip mRNA in Txnip shRNA 
transfected cells, clones were harvested to check for low Txnip expressing colonies. 
RNA was isolated (See Section: 2.5.1.2.3) from each cell colony of Txnip shRNA-
transfected cells and was screened for Txnip mRNA knock-down (Fig: 3.9.4.1.2). The 
Txnip mRNA knock-down was calculated compared to empty shRNA plasmid-
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transfected clone (Em-D). Txnip shRNA-transfected clones sh-16, sh-1 and sh-9 
showed 74.7%, 81.4% and 78.5% Txnip mRNA knock-down respectively. The other 
clones showed the Txnip expression of 50% or less. For further study clones sh-1 and 
sh-9 was used as they showed a maximum knock-down of Txnip.  
  
 
 
 
 
 
 
Fig: 3.9.4.1.2 Level of Txnip expression as determined by qRT-PCR on clones of 
Txnip shRNA-transfected cells. Sh-4, sh-16, sh-20, sh-17, sh-18, sh-1, sh-3 and sh-
9 represent different clones from heterogeneous population of Txnip shRNA-
transfected cells. Clone sh-1 and sh-9 were chosen for further studies as they 
showed the maximum knock-down of Txnip mRNA.  
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3.9.4.2 ELISA on clones 
Txnip was up-regulated in the microarray study (5.25-fold) and qRT-PCR study (3.11-
fold) in MIN6 B1(Non-GSIS) cells compared to MIN6 B1(GSIS) cells. Clone sh-1 
(Txnip shRNA transfected clone#1) showed a significant increase in GSIS (p-
value=0.024) and a moderate but not significant (p-value=0.23) increase in sh-9 clone 
(Txnip shRNA-transfected clone#9) compared to empty shRNA-transfected cells.  
Txnip shRNA-transfected clones were incubated in 3.3 and 16.7mmol/L glucose for 
1hr (See Section: 2.3.2.1). Insulin secretion was determined using ELISA (See 
Section: 2.3.2.4) and normalised to total cellular protein. sh-1 showed 2.96-fold, sh-9 
showed 1.82-fold, sh-3 showed 1.08-fold and Em-F (empty shRNA-transfected cells) 
showed 1.58-fold GSIS (Fig: 3.9.4.2).  
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Fig: 3.9.4.2 shRNA-mediated knock-down of Txnip led to a significant increase in 
GSIS in sh-1 clone (Txnip shRNA-transfected cells clone#1 (p-value= 0.024)) and 
a mild increase in sh-9 clone but not significant (p-value=0.23) (Txnip shRNA-
transfected cells clone#9) compared to empty shRNA transfected cells. GSIS was 
quantitated in Em-F, sh-3, sh-1 and sh-9 clones. Insulin secretion was measured 
by ELISA and normalised to total cellular protein. Em-F (empty shRNA 
transfected clone), sh-3 (Txnip shRNA transfected clone with no Txnip mRNA 
knock-down) and sh-1 and sh-9 (clone showing Txnip mRNA knock-down). 
Results represent mean ± S.D from three different experiments.  
3.9.4.3 ROS levels in clones 
In order to assess whether Txnip knock-down exerted any effect in regulating ROS 
(reactive oxygen species) as an indicator of oxidative stress, the ROS level was 
detected by 2′,7′-dichlorodihydrofluorescein diacetate (DCFHDA) and expressed as 
percentage relative to empty shRNA-transfected cells (Em-F) (See Section: 2.5.9). 
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Txnip shRNA transfected clone sh-1 and sh-9 showed a reduced ROS level of 40.5% 
and 35.6% respectively compared to empty shRNA transfected clone Em-F. Whereas, 
Txnip shRNA-transfected clone sh-3 (which showed no Txnip mRNA knock-down) 
showed 3.4% more ROS compared to empty shRNA transfected clone Em-F (Fig: 
3.9.4.3).  
 
 
 
 
 
Fig: 3.9.4.3 Cells were assessed for ROS levels by DCFHDA fluorescence 
staining. Txnip shRNA transfected clone sh-1 and sh-9 showed a ROS % of 
40.5% and 35.6% respectively. sh-3 (with no Txnip mRNA knock-down) showed 
a 3.4% more ROS level compared to Em-F. Results represent mean ± S.D from 
three different experiments.  
3.9.4.4 Proliferation assay on clones 
Proliferation assay was performed on shRNA transfected cells using acid phosphatase 
assay (See Section: 2.3.3). Growth curves were plotted over 7 days following seeding 
at a density of 1 X 104 cells/well (96-well plate). An increased proliferation rate was 
observed in Txnip shRNA transfected sh-3 clone (Fig: 3.9.4.4).  
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Clone sh-3 (Txnip shRNA transfected clone#3) showed no Txnip mRNA knock-down 
compared to empty shRNA transfected cells.  Clone sh-3 showed 1.5-fold increased 
proliferation compared to Em-F whereas, clone sh-1 showed 1.3-fold reduced 
proliferation compared to Em-F (Fig: 3.9.4.4).   
 
 
 
 
 
 
Fig: 3.9.4.4 Graph showing comparison of proliferation assay performed on 
MIN6 Txnip shRNA-transfected and empty shRNA transfected cells. Empty 
shRNA transfected cells are shown as ( ), Txnip shRNA transfected cells 
clone#9 (sh-9) ( ), clone#1 (sh-1) ( ) and clone#3 (sh-3) ( ). Txnip 
shRNA transfected clone#3 did not show any knock-down of Txnip mRNA. 
Mean = ± S.D and n=3. 
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3.9.4.5 Gene transcripts affected by Txnip knock-down  
Txnip knock-down decreases Egr1 expression  
Egr1 was up-regulated in MIN6 B1(Non-GSIS) compared to MIN6 B1(GSIS) in the 
microarray (1.98-fold) and qRT-PCR (4.64-fold) study. The expression level of Egr1 
was determined by qRT-PCR in the single cell colonies of the Txnip shRNA 
transfected cells. Txnip knock-down clones showed a decreased expression of Egr1 in 
sh-1 (52.7%) and sh-9 clones (56.2%) compared to empty vector-transfected Em-F 
clone. There was 54.8% increased expression of Egr1 in sh-3 clones (with no Txnip 
knock-down) compared to empty vector-transfected Em-F clone (Fig: 3.9.4.5.1).  
 
 
 
 
 
 
Fig: 3.9.4.5.1 Egr1 expression as determined by qRT-PCR in sh-1, sh-9 and sh-3 
Txnip shRNA-transfected clone and Em-F empty shRNA transfected clone. sh-1 
clone showed 52.7% and sh-9 clone showed 56.2% knock-down of Egr1 
compared to Em-F. sh-3 (Txnip shRNA transfected clone with no Txnip mRNA 
knock-down) and sh-1 and sh-9 (clone showing Txnip mRNA knock-down). 
Results represent mean ± S.D. 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
Em-F sh-1 sh-9 sh-3
Eg
r1
 
e
x
pr
e
s
s
io
n
 
52.7% 
56.2% 
 246 
Txnip knock-down decreases Fos expression  
The microarray (2.12-fold) and qRT-PCR (6.49-fold) study showed an up-regulation 
of Fos gene transcript in MIN6 B1(Non-GSIS) compared to MIN6 B1(GSIS). Fos 
expression level was determined by qRT-PCR in the single cell colony of the Txnip 
shRNA transfected cells. Fos expression was decreased in Txnip knock-down sh-1 
clone (80.5%) and sh-9 clones (73.8%) compared to empty vector-transfected Em-F 
clone. Whereas, there was no knock-down of Fos in sh-3 clones (with no Txnip 
knock-down) compared to empty shRNA-transfected Em-F clone (Fig: 3.9.4.5.2).  
 
 
 
 
 
 
Fig: 3.9.4.5.2 Fos expression as determined by qRT-PCR in sh-1, sh-9 and sh-3 
Txnip shRNA-transfected clones and Em-F empty shRNA transfected clone. Sh-1 
clone showed 80.5% and sh-9 clone showed 73.8% knock-down of Fos compared 
to Em-F. sh-3 (Txnip shRNA transfected clone with no Txnip mRNA knock-
down) and sh-1 and sh-9 (clone showing Txnip mRNA knock-down). Results 
represent mean ± S.D. 
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Txnip knock-down decreases Gadd45g expression  
An up-regulation of Gadd45g gene transcript was observed in MIN6 B1(Non-GSIS) 
compared to MIN6 B1(GSIS) following microarray (1.59-fold) and qRT-PCR (1.59-
fold) study. The expression level of Gadd45g was determined by qRT-PCR in the 
single cell colony of the Txnip shRNA transfected cells. Txnip knock-down decreased 
the expression of Gadd45g in sh-1 (43.7%) and sh-9 clones (29.2%) compared to 
empty shRNA-transfected Em-F clone. Whereas, 16% knock-down of Gadd45g was 
observed in sh-3 clones (with no Txnip knock-down) compared to empty shRNA-
transfected Em-F clone (Fig: 3.9.4.5.3).  
 
 
 
 
 
 
Fig: 3.9.4.5.3 Gadd45g expression as determined by qRT-PCR in sh-1, sh-9 and 
sh-3 Txnip shRNA-transfected clones and Em-F empty shRNA transfected clone. 
Sh-1 clone showed 43.7% and sh-9 clone showed 29.2% knock-down of Gadd45g 
compared to Em-F. sh-3 (Txnip shRNA transfected clone with no Txnip mRNA 
knock-down) and sh-1 and sh-9 (clone showing Txnip mRNA knock-down). 
Results represent mean ± S.D. 
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Txnip knock-down decreases Jun expression  
Up-regulation of Jun gene transcript was observed in MIN6 B1(Non-GSIS) compared 
to MIN6 B1(GSIS) following microarray (2.73-fold) and qRT-PCR (2.93-fold) study. 
qRT-PCR was performed to check the expression level of Jun in the single cell colony 
of the Txnip shRNA transfected cells. Expression of Jun was decreased in Txnip 
knock-down sh-1 clones (44.5%) and sh-9 clones (16.5%) compared to empty 
shRNA-transfected Em-F clone.  There was 23% increased expression of Jun in sh-3 
clones (with no Txnip knock-down) compared to empty shRNA-transfected Em-F 
clone (Fig: 3.9.4.5.4).  
 
 
 
 
 
Fig: 3.9.4.5.4 Jun expression as determined by qRT-PCR in sh-1, sh-9 and sh-3 
Txnip shRNA-transfected clones and Em-F empty shRNA transfected clone. Sh-1 
clone showed 44.5% and sh-9 clone showed 16.5% knock-down of Jun compared 
to Em-F. sh-3 (Txnip shRNA transfected clone with no Txnip mRNA knock-
down) and sh-1 and sh-9 (clone showing Txnip mRNA knock-down). Results 
represent mean ± S.D. 
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Txnip knock-down increases Mapk3 expression  
Up-regulation of Mapk3 gene transcript was observed in MIN6 B1(Non-GSIS) 
compared to MIN6 B1(GSIS) following microarray (1.27-fold) and qRT-PCR (1.17-
fold) study. qRT-PCR was performed to check the expression level of Mapk3 in the 
single cell colony of the Txnip shRNA transfected cells. Txnip knock-down increased 
the expression of Mapk3 in sh-1 (14.8%) and sh-9 clones (66.9%) whereas, there is no 
effect on Mapk3 in sh-3 clones (with no Txnip knock-down) compared to empty 
shRNA-transfected Em-F clone (Fig: 3.9.4.5.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 3.9.4.5.5 Mapk3 expression as determined by qRT-PCR in sh-1, sh-9 and sh-
3 Txnip shRNA-transfected clone and Em-F empty shRNA transfected clone. Sh-
1 (14.8%) and sh-9 clone (66.9%) showed an increase in expression of Mapk3 
compared to Em-F. sh-3 (Txnip shRNA transfected clone with no Txnip mRNA 
knock-down) and sh-1 and sh-9 (clone showing Txnip mRNA knock-down). 
Results represent mean ± S.D. 
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3.10 Analysis of conditioned media for amplifiable Gene Transcripts 
Extracellular RNA has been detected in plasma and serum of patients presenting with 
various forms of cancer (Wieczorek et al., 1987; Kopreski et al., 1999; Hasselmann et 
al., 2001); DNA and mRNA from foetal origin have been discovered in the plasma of 
pregnant women (Bianchi et al., 1997; Poon et al., 2000; Tsui et al., 2006); and 
significantly higher levels of rhodopsin mRNA have been reported in peripheral 
blood from diabetic individuals compared to healthy controls (Hamaoui et al., 2004). 
While the possibility exists that there may be circulating RNA biomarkers indicative 
of beta cell mass and function in diabetes patients, no studies have yet investigated 
this.  
Insulin-producing cells were grown and conditioned media (CM) collected at different 
time points to analyze the suitable time-point for CM collection and analysis. Once a 
suitable time-point was established, we extracted and amplified mRNA from CM to 
determine if extracellular mRNAs are reproducibly detectable in CM from insulin-
producing cell lines. Secondly this study aimed to identify if the presence and 
amounts of CM are indicative of beta cell number and/or function.  
All transcript underwent 45 PCR cycles, while 30 cycles of PCR was found to be 
adequate for analysis of transcripts using RNA isolated from cell lines, amplified 
products often did not results from CM RNA at this stage. For this reason, 45 cycles 
was used for all subsequent experiments to analyse gene transcripts from both cells 
and CM.  
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3.10.1 Identifying suitable time-point for CM collection and analysis from 
insulin-producing cell lines  
Conditioned media (CM) samples were collected at 4 time-points (24, 48, 72 and 96 
hrs.) after seeding cells in T75cm2 flask, to identify a suitable time-point at which 
amplifiable mRNA could be routinely isolated for analysis. After samples were 
collected and they were stored at -80°C until required, RNA was extracted from the 
samples and reverse- transcribed. PCR was then carried out. In the case of relatively 
highly expressed gene transcripts such as Beta-actin, mRNA could be isolated and 
amplified at all time points evaluated. However, for gene transcripts where levels 
expressed by the cell populations were lower (e.g. Egr1) amplified product was 
undetected after 24hrs., but was present when analysed after 48hrs., or more, of 
culture. To ensure that all CM analysed was from healthy, proliferating cells, all 
subsequent analysis was performed using 48hrs. CM.  
3.10.2 Analysis of CM and cells MIN6 for amplifiable Gene Transcripts 
After identifying a suitable time point for CM collection and analysis, cells were 
seeded in T75cm2 flask at 2x106 cells with 8 mls culture medium. Conditioned media 
was removed after 48hrs. and filtered with 0.45 µm filter. Aliquots of 250 µl filtered 
CM were added to 750 µl of TriReagent. RNA was isolated, quantified and RT-PCR 
analysis was done. RT-PCR analysis of the CM taken from MIN6 (L) & (H) passage 
showed the presence of amplifiable mRNA. 
3.10.3 mRNA Detection in CM: Identifying Suitable PCR Cycle Number  
mRNA transcripts were detected in medium conditioned by all cell types included in 
this study i.e. MIN6 (L), (H), MIN6 B1 and Vero-PPI cell lines. 
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While 30 cycles of PCR was found to be adequate for analysis of transcripts using 
RNA isolated from cell lines, amplified products often did not results from CM RNA 
at this stage. In the case of CM the bands were undetectable or very low in intensity 
following 30 cycles of PCR (Fig: 3.10.3 (A): pancreatic and duodenal homeobox 
gene-1 (Pdx1)). Forty-five cycles of PCR, however, was found to be adequate to 
produce a detectable band from CM RNA (Fig: 3.10.3 (B)). There were no bands 
detected in negative controls including water instead of RNA as control and water 
instead of cDNA as a control. For this reason, 45 cycles was used for all subsequent 
experiments to analyse gene transcripts from both cells and CM. 
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Fig: 3.10.3 Pdx1 mRNA analysis of MIN6 B1 cells, grown at a range of 
densities, and their corresponding CM using (A) 30 PCR cycles and (B) 45 
PCR cycles. RT-VE = reaction with H2O instead of RNA as control; PCR-
VE = PCR reaction with H2O instead of cDNA as a control. M = molecular 
weight marker: ФX174 DNA HaeIII digest. Results are representative of n = 
3 biological repeats. 
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3.10.4 RNase- and DNase-treated RNA Samples 
To ensure that any products detected following RT-PCR analysis of isolates from 
cells and/or CM were of mRNA, not DNA, origin, aliquots of isolates were 
treated with DNase enzyme (to destroy any contaminating DNA), with RNase 
enzyme (to destroy RNA, as control) or were untreated (See Section: 2.5.1.3).  
3.10.4.1 Bioanalyzer on RNase- and DNase-treated RNA Samples 
The quality of the RNA after treating the RNA samples with RNase, DNase and 
untreated were analysed using Bioanalyzer (See Section: 2.5.1.5). For the RNA 
standard, the electropherograms obtained from the Agilent Bioanalyzer 2100 
gave clear and well-defined 28S and 18S RNA peaks, with high 28S/18S RNA 
ratio for the untreated cell RNA.  
1. Untreated samples showed a distinct peak of 28s and 18s RNA (Fig: 3.10.4.1 
(A)). 
2. RNase treated samples showed a complete degradation of cell and CM RNA. 
CM sample showed 2 peaks but were not at the right place and when the values 
of y axis were compared it was of very low value. The RNase-treated cell RNA 
showed a complete degradation of the RNA (Fig: 3.10.4.1 (B)).  
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Fig: 3.10.4.1 MIN6 B1 cell and CM RNA samples showing 18S and 28S 
ribosomal bands after (A) untreated, (B) RNase-treated and (C) DNase-
treated.  
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3. However DNase-treatment has also caused some degradation to the RNA 
samples as 28S and 18S RNA peaks are not so well-defined (Fig: 3.10.4.1 (C)).  
3.10.4.2 RT-PCR on RNase- and DNase-treated RNA Samples 
Reverse-transcriptase (RT) reactions were subsequently performed prior to PCR. 
In parallel, RT reactions were set up with and without reverse transcriptase 
enzyme (MMLV-RT) – an enzyme which is necessary for the formation of 
cDNA on an mRNA template.  
The absence of reverse transcriptase enzyme resulted in no amplified PCR 
products, regardless of whether the cell and CM isolates were untreated, treated 
with RNase or treated with DNase (Fig: 3.10.4.2.1 (A)). This was found to be the 
cases for all products investigated. The presence of MMLV-RT enzyme in the 
RT reaction did, however, result in amplified products from cell and CM isolates 
that were untreated with a digestive enzyme or that were treated with DNase 
enzyme. However, no bands were detected where samples had been treated with 
RNase enzyme (Fig: 3.10.4.2.1 (B). These results indicate that the amplified 
products detected in cell and CM isolates are of mRNA, not DNA, origin. 
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Fig: 3.10.4.2.1 Cell and CM RNA isolates treated with RNase or DNase prior 
to cDNA formation, using MMLV-RT enzyme, and amplification using 
Beta-actin primers. (+) MMLV-RT (B) represents reverse transcriptase 
(RT) reaction performed with necessary RT enzyme, MMLV-RT; (A) (–) 
MMLV = represent RT cycle performed in the absence of MMLV-RT 
enzyme, as control. RT-VE = reaction with H2O instead of RNA as control; 
PCR-VE = PCR reaction with H2O instead of cDNA as a control. M = 
molecular weight marker: ФX174 DNA Hae III digest. 
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Pdx1 
Contaminating genomic DNA can lead to false-positive signals, reduced 
specificity, or overestimation of specific RNA amounts in RT-PCR. RT-PCR 
primers for Pdx1 were designed to flank a region within a single exon. The 
primers were aligned against mRNA and DNA sequence from PubMed to check 
the fragment size of the products that would be amplified from mRNA and 
genomic DNA (Fig: 3.10.4.2.2). There were no size difference of the products to 
detect the presence of contaminating DNA (125 bp) or mRNA (125 bp) 
amplified product.  
So the reverse transcriptase reaction was carried with or without reverse 
transcriptase enzyme MMLV. The absence of reverse transcriptase enzyme 
resulted in no amplified PCR products, regardless of whether the cell and CM 
isolates were untreated, treated with RNase or treated with DNase (Fig: 
3.10.4.2.3 (A)). The presence of MMLV-RT enzyme in the RT reaction did, 
however, result in amplified products from cell and CM isolates that were 
untreated with a digestive enzyme or that were treated with DNase enzyme. 
However, no bands were detected where samples had been treated with RNase 
enzyme (Fig: 3.10.4.2.3 (B)). These results indicate that the amplified products 
detected in cell and CM isolates are of mRNA, not DNA, origin. 
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Fig: 3.10.4.2.2 Multalin results for Pdx1 mRNA (A) and DNA (B) sequence 
(black letters) with forward and reverse RT-PCR primers (blue letters)        
(         ) showing the coding sequence 114-968. 
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Fig: 3.10.4.2.3 Cell and CM RNA isolates treated with RNase or DNase prior 
to cDNA formation, using MMLV-RT enzyme, and amplification using Pdx1 
primers. (+) MMLV-RT represents reverse transcriptase (RT) reaction 
performed with necessary RT enzyme, MMLV-RT; (–) MMLV = represent 
RT cycle performed in the absence of MMLV-RT enzyme, as control. RT-
VE = reaction with H2O instead of RNA as control; PCR-VE = PCR 
reaction with H2O instead of cDNA as a control. M = molecular weight 
marker: ФX174 DNA Hae III digest. 
 
Untreated 
RNase 
treated 
DNase 
treated 
125 bp 
(-)MMLV-RT 
(+)MMLV-RT 
M
 
M
IN
6 
B
1 
M
IN
6 
B
1 
CM
 
M
IN
6 
B
1 
M
IN
6 
B
1 
CM
 
M
IN
6 
B
1 
M
IN
6 
B
1 
CM
 
R
T-
V
E 
PC
R
-
V
E 
 
 125 bp if genomic 
DNA amplified 
A 
B 
 261 
Insulin I (Ins1) 
 Ins1 (Fig: 3.10.4.2.4) has only one exon so the RT-PCR primers were designed 
through the coding region. The primers were aligned using multialin software 
against mRNA and DNA sequence from PubMed to check the fragment size of 
the products that would be amplified from mRNA and genomic DNA. Products 
that were amplified from mRNA (288 bp) were smaller than those amplified 
from genomic DNA (407 bp). The size difference of the products was used to 
detect the presence of RNA or contaminating DNA. 
Reverse transcriptase reaction was carried out with or without reverse 
transcriptase enzyme MMLV. No amplified PCR products were obtained in the 
absence of reverse transcriptase enzyme, regardless of whether the cell and CM 
isolates were untreated, treated with RNase or treated with DNase (Ins1 (Fig: 
3.10.4.2.5 (A)). Amplified products were obtained from cell and CM isolates that 
were untreated or that were treated with DNase enzyme. However, no bands 
were detected where samples had been treated with RNase enzyme (Ins1 (Fig: 
3.10.4.2.5 (B)). 
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Ins1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 3.10.4.2.4 Multalin results for Ins1 mRNA (A) and DNA (B) sequence 
(black letters) with forward and reverse RT-PCR primers (blue letters)        
(         ) showing the coding sequence 184-510. 
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Fig: 3.10.4.2.5 Cell and CM RNA isolates treated with RNase or DNase prior 
to cDNA formation, using MMLV-RT enzyme, and amplification using Ins1 
primers. (B)(+) MMLV-RT represents reverse transcriptase (RT) reaction 
performed with necessary RT enzyme, MMLV-RT; (A) (–) MMLV = 
represent RT cycle performed in the absence of MMLV-RT enzyme, as 
control. RT-VE = reaction with H2O instead of RNA as control; PCR-VE = 
PCR reaction with H2O instead of cDNA as a control. M = molecular weight 
marker: ФX174 DNA Hae III digest. 
Untreated 
RNase 
treated 
DNase 
treated 
288 bp 
(-)MMLV-RT 
(+)MMLV-RT 
M
 
M
IN
6 
B
1 
M
IN
6 
B
1 
CM
 
M
IN
6 
B
1 
M
IN
6 
B
1 
CM
 
M
IN
6 
B
1 
M
IN
6 
B
1 
CM
 
R
T-
V
E 
PC
R
-
V
E 
 
 407 bp if genomic 
DNA amplified 
A 
B 
 264 
Insulin II (Ins2) 
Ins2 has only one exon so the RT-PCR primers were designed through the 
coding region. The primers were aligned using multialin software against mRNA 
and DNA sequence from PubMed to check the fragment size of the products that 
would be amplified from mRNA and genomic DNA. Products that were 
amplified from mRNA (212 bp) were smaller than those amplified from genomic 
DNA (701 bp) (Fig: 3.10.4.2.6). The size difference of the products was used to 
detect the presence of RNA or contaminating DNA. 
Reverse transcriptase reaction was carried out with or without reverse 
transcriptase enzyme MMLV. No amplified PCR products were obtained in the 
absence of reverse transcriptase enzyme, regardless of whether the cell and CM 
isolates were untreated, treated with RNase or treated with DNase (Ins2 (Fig: 
3.10.4.2.7 (A)). Amplified products were obtained from cell and CM isolates that 
were untreated or that were treated with DNase enzyme. However, no bands 
were detected where samples had been treated with RNase enzyme (Ins2 (Fig: 
3.10.4.2.7 (B)). 
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Fig: 3.10.4.2.6 Multalin results for Ins2 mRNA (A) and DNA (B) sequence 
(black letters) with forward and reverse RT-PCR primers (blue letters)        
(         ) showing the exon region 75-407. 
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Fig: 3.10.4.2.7 Cell and CM RNA isolates treated with RNase or DNase prior 
to cDNA formation, using MMLV-RT enzyme, and amplification using Ins2 
primers. (B)(+) MMLV-RT represents reverse transcriptase (RT) reaction 
performed with necessary RT enzyme, MMLV-RT; (A) (–) MMLV = 
represent RT cycle performed in the absence of MMLV-RT enzyme, as 
control. RT-VE = reaction with H2O instead of RNA as control; PCR-VE = 
PCR reaction with H2O instead of cDNA as a control. M = molecular weight 
marker: ФX174 DNA Hae III digest. 
212 bp 
Untreated 
RNase 
treated 
DNase 
treated 
(-)MMLV-RT 
(+)MMLV-RT 
M
 
M
IN
6 
B
1 
M
IN
6 
B
1 
CM
 
M
IN
6 
B
1 
M
IN
6 
B
1 
CM
 
M
IN
6 
B
1 
M
IN
6 
B
1 
CM
 
R
T-
V
E 
PC
R
-
V
E 
 
 701 bp if genomic 
DNA amplified 
A 
B 
 267 
Neuropeptide Y (Npy) 
As Npy gene transcripts has only one exon so the RT-PCR primers were 
designed through the coding region. The primers were aligned using multialin 
software against mRNA and DNA sequence from PubMed to check the fragment 
size of the products that would be amplified from mRNA and genomic DNA. 
Products that were amplified from mRNA (249 bp) were smaller than those 
amplified from genomic DNA (5679 bp) (Fig: 3.10.4.2.8). The size difference of 
the products was used to detect the presence of RNA or contaminating DNA. 
Reverse transcriptase reaction was carried out with or without reverse 
transcriptase enzyme MMLV. No amplified PCR products were obtained in the 
absence of reverse transcriptase enzyme, regardless of whether the cell and CM 
isolates were untreated, treated with RNase or treated with DNase enzyme (Npy 
(Fig: 3.10.4.2.9 (A)). Amplified products were obtained from cell and CM 
isolates that were untreated or that were treated with DNase enzyme. However, 
no bands were detected where samples had been treated with RNase enzyme 
(Npy (Fig: 3.10.4.2.9 (B)). 
 268 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 3.10.4.2.8 Multalin results for Neuropeptide Y mRNA (A) and DNA (B) 
sequence (black letters) with forward and reverse RT-PCR primers (blue 
letters) (         ) showing the exon region 74-367. 
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Fig: 3.10.4.2.9 Cell and CM RNA isolates treated with RNase or DNase prior 
to cDNA formation, using MMLV-RT enzyme, and amplification using Npy 
primers. (B)(+) MMLV-RT represents reverse transcriptase (RT) reaction 
performed with necessary RT enzyme, MMLV-RT; (A) (–) MMLV = 
represent RT cycle performed in the absence of MMLV-RT enzyme, as 
control. RT-VE = reaction with H2O instead of RNA as control; PCR-VE = 
PCR reaction with H2O instead of cDNA as a control. M = molecular weight 
marker: ФX174 DNA Hae III digest. 
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Reverse-transcriptase (RT) reactions were subsequently performed prior to PCR 
with and without reverse transcriptase enzyme (MMLV-RT) – an enzyme which 
is necessary for the formation of cDNA on an mRNA template.  
The absence of reverse transcriptase enzyme resulted in no amplified PCR 
products, regardless of whether the cell and CM isolates were untreated, treated 
with RNase or treated with DNase (Pld1 (Fig: 3.10.4.2.10  (A)), Chgb (Fig: 
3.10.4.2.11 (A)), Egr1 (Fig: 3.10.4.2.12 (A))). This was found to be the cases for 
all products investigated. The presence of MMLV-RT enzyme in the RT reaction 
did, however, result in amplified products from cell and CM isolates that were 
untreated with a digestive enzyme or that were treated with DNase enzyme. 
However, no bands were detected where samples had been treated with RNase 
enzyme (Pld1 (Fig: 3.10.4.2.10 (B)), Chgb (Fig: 3.10.4.2.11 (B)), Egr1 (Fig: 
3.10.4.2.12 (B)). These results indicate that the amplified products detected in 
cell and CM isolates are of mRNA, not DNA, origin. 
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Fig: 3.10.4.2.10 Cell and CM RNA isolates treated with RNase or DNase 
prior to cDNA formation, using MMLV-RT enzyme, and amplification 
using Pld1 primers. (B)(+) MMLV-RT represents reverse transcriptase (RT) 
reaction performed with necessary RT enzyme, MMLV-RT; (A) (–) MMLV 
= represent RT cycle performed in the absence of MMLV-RT enzyme, as 
control. RT-VE = reaction with H2O instead of RNA as control; PCR-VE = 
PCR reaction with H2O instead of cDNA as a control. M = molecular weight 
marker: ФX174 DNA Hae III digest. 
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Fig: 3.10.4.2.11 Cell and CM RNA isolates treated with RNase or DNase 
prior to cDNA formation, using MMLV-RT enzyme, and amplification 
using Chgb primers. (B)(+) MMLV-RT represents reverse transcriptase 
(RT) reaction performed with necessary RT enzyme, MMLV-RT; (A) (–) 
MMLV = represent RT cycle performed in the absence of MMLV-RT 
enzyme, as control. RT-VE = reaction with H2O instead of RNA as control; 
PCR-VE = PCR reaction with H2O instead of cDNA as a control. M = 
molecular weight marker: ФX174 DNA Hae III digest. 
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Egr1 
 
 
 
 
 
 
 
 
Fig: 3.10.4.2.12 Cell and CM RNA isolates treated with RNase or DNase 
prior to cDNA formation, using MMLV-RT enzyme, and amplification 
using Egr1 primers. (B) (+) MMLV-RT represents reverse transcriptase 
(RT) reaction performed with necessary RT enzyme, MMLV-RT; (A) (–) 
MMLV = represent RT cycle performed in the absence of MMLV-RT 
enzyme, as control. RT-VE = reaction with H2O instead of RNA as control; 
PCR-VE = PCR reaction with H2O instead of cDNA as a control. M = 
molecular weight marker: ФX174 DNA Hae III digest. 
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3.10.5 Glucose-Responsiveness and corresponding mRNA Levels in CM 
CM collected from glucose-responsive MIN6 (L) and glucose non-responsive 
MIN6 (H) cells were collected and filtered as described in Section 2.4.3.2. RNA 
was isolated (See Section: 2.5.1.2.1) and cDNA was prepared as in section 
2.5.2.1. CM collected from glucose-responsive MIN6 (L) and glucose non-
responsive MIN6 (H) cells was analyzed for the presence of a range of 
transcripts, including phospholipase D1 (Pld1), Egr1, Chgb and InsI. Pld1, Egr1 
and Chgb were reproducibly detected in the triplicate biological repeat analysis 
of MIN6 (L) CM samples, but were undetected in MIN6 (H) CM. Beta-actin 
(Fig: 3.10.5.1), Ins1 (Fig: 3.9.5.2) Ins2 (Fig: 3.10.5.3) and Pdx1 (Fig: 3.10.5.4)  
however, were detected, at similar levels, in MIN6 (L) and (H) CM. 
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Beta-Actin (actb) 
Beta-actin was detected in all triplicate samples of CM from MIN6 (L) and (H). 
Densitometry analysis of the PCR product from medium conditioned by MIN6 
(L) and (H) cells showed no significant difference (p-value = 0.686) (Fig: 
3.10.5.1). RNA from MIN6 (L) cells was taken as control.  
           
 
  
 
 
Fig: 3.10.5.1 Beta-actin amplification of cDNA prepared from MIN6 (L) & 
(H) CM RNA. (-)MMLV-RT = RT-PCR reaction carried out without 
reverse transcriptase enzyme; RT-VE = reaction with H2O instead of RNA 
as control; PCR-VE = PCR reaction with H2O instead of cDNA as a control; 
M = molecular weight marker: ФX174 DNA Hae III digest. 1, 2 & 3 
represent biological repeat experiments. Densitometry analysis indicates 
that the levels of RNA detectable in CM from MIN6 (L) and (H) did not 
differ significantly (T-test: P = 0.686). 
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Insulin I (Ins1) 
CM obtained from MIN6 (L) and (H) passage cells after 48 hrs. was amplified at 
45 PCR cycles for Ins1. RNA from MIN6 (L) cells were taken as positive 
control. Densitometry analysis showed no significant difference in the PCR band 
between MIN6 (L) and (H) CM (p-value = 0.543) (Fig: 3.10.5.2).  
 
 
 
 
 
 
Fig: 3.10.5.2 Ins1 analysis in CM from MIN6 (L) and (H). RT-VE = reaction 
with H2O instead of RNA as control; PCR-VE = PCR reaction with H2O 
instead of cDNA as a control; (-) MMLV-RT = RT-PCR reaction carried out 
without reverse transcriptase enzyme. M = molecular weight marker: 
ФX174 DNA Hae III digest. 1, 2 & 3 represent biological repeat 
experiments. Densitometry analysis indicates that the levels of detected in 
CM from MIN6 (L) and (H) did not differ significantly (T-test: P = 0.543). 
M
 
M
IN
6 
(H
) C
M
1 
M
IN
6 
(H
) C
M
2 
M
IN
6 
(H
) C
M
3 
M
IN
6 
(L
) C
M
1 
M
IN
6 
(L
) C
M
2 
M
IN
6 
(L
) C
M
3 
M
IN
6 
(L
) +
Co
n
tr
o
l 
(-)
M
M
LV
-
R
T 
R
T-
V
E 
PC
R
-
V
E 
229 bp 
 277 
Insulin II (Ins2) 
Ins2 gene transcript was detected in all triplicate samples of medium conditioned 
by MIN6 (L) and (H) passage cells. MIN6 (L) cell RNA was taken as positive 
control. There was no significant change in expression between MIN6 (L) and 
(H) CM as analysed by densitometer (p-value = 0.092) (Fig: 3.10.5.3). 
 
 
 
 
 
Fig: 3.10.5.3 Ins2 analysis in CM from MIN6 (L) and (H). RT-VE = reaction 
with H2O instead of RNA as control; PCR-VE = PCR reaction with H2O 
instead of cDNA as a control; (-) MMLV-RT = RT-PCR reaction carried out 
without reverse transcriptase enzyme. M = molecular weight marker: 
ФX174 DNA Hae III digest. 1, 2 & 3 represent biological repeat 
experiments. Densitometry analysis indicates that the levels of detected in 
CM from MIN6 (L) and (H) did not differ significantly (T-test: P = 0.092). 
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Pancreatic and duodenal homeobox gene 1 (Pdx1) 
Pdx1 was amplified using CM RNA from all MIN6 (L) and (H) passage cells. 
Densitometry analysis showed no significant difference in expression of Pdx1 in 
CM RNA from MIN6 (L) and (H) passage cells (Fig: 3.10.5.4). 
 
 
 
 
 
Fig: 3.10.5.4 Pancreatic and duodenal homeobox gene 1 (Pdx1) analysis in 
CM from MIN6 (L) and (H). (-) MMLV-RT = RT-PCR reaction carried out 
without reverse transcriptase enzyme. M = molecular weight marker: 
ФX174 DNA Hae III digest. 1, 2 & 3 represent biological repeat 
experiments.  
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Neuropeptide Y (Npy) 
RNA from CM collected from glucose responsive MIN6 (L) and glucose non-
responsive MIN6 (H) were analysed for Npy. Npy (Fig: 3.10.5.5) were amplified 
using RNA from media conditioned by MIN6 (L) cells but were undetected in 
media conditioned by MIN6 (H) cells.  
 
 
 
 
 
 
Fig: 3.10.5.5 Neuropeptide Y analysis in CM from MIN6 (L) and (H). RT-VE 
= reaction with H2O instead of RNA as control; PCR-VE = PCR reaction 
with H2O instead of cDNA as a control; (-) MMLV-RT = RT-PCR reaction 
carried out without reverse transcriptase enzyme. M = molecular weight 
marker: ФX174 DNA Hae III digest. 1, 2 & 3 represent biological repeat 
experiments.  
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Chromogranin B (Chgb) 
Fig 3.10.5.6 shows that Chgb was amplified using MIN6 (L) CM RNA whereas 
no amplification was detected using CM RNA from MIN6 (H). RNA from MIN6 
(L) was taken as positive control. 
 
 
 
 
 
 
Fig: 3.10.5.6 Chromogranin B (Chgb) analysis in CM from MIN6 (L) and 
(H). RT-VE = reaction with H2O instead of RNA as control; PCR-VE = PCR 
reaction with H2O instead of cDNA as a control; (-) MMLV-RT = RT-PCR 
reaction carried out without reverse transcriptase enzyme. M = molecular 
weight marker: ФX174 DNA Hae III digest. 1, 2 & 3 represent biological 
repeat experiments.  
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Prohormone convertase 2 (PC2) 
RNA from CM collected from glucose responsive MIN6 (L) and glucose non-
responsive MIN6 (H) were analysed for PC2. PC2 (Fig: 3.10.5.7) were amplified 
using RNA from media conditioned by MIN6 (L) cells but were undetected in 
media conditioned by MIN6 (H) cells.  
 
 
 
 
 
 
Fig: 3.10.5.7 Prohormone convertase 2 (PC2) analysis in CM from MIN6 (L) 
and (H). RT-VE = reaction with H2O instead of RNA as control; PCR-VE = 
PCR reaction with H2O instead of cDNA as a control; (-) MMLV-RT = RT-
PCR reaction carried out without reverse transcriptase enzyme. M = 
molecular weight marker: ФX174 DNA Hae III digest. 1, 2 & 3 represent 
biological repeat experiments.  
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Phospholipase D1 (Pld1) 
Pld1 was amplified using RNA from media conditioned by MIN6 (L) cells but 
was undetected in media conditioned by MIN6 (H) cells (Fig: 3.10.5.8). RNA 
from MIN6 (L) was used as control. 
 
 
 
 
 
Fig: 3.10.5.8 Phospholipase D1 (Pld1) analysis in CM from MIN6 (L) and 
(H). RT-VE = reaction with H2O instead of RNA as control; PCR-VE = PCR 
reaction with H2O instead of cDNA as a control; (-) MMLV-RT = RT-PCR 
reaction carried out without reverse transcriptase enzyme. M = molecular 
weight marker: ФX174 DNA Hae III digest. 1, 2 & 3 represent biological 
repeat experiments.  
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Early growth response 1 (Egr1) 
Fig 3.10.5.9 shows that Egr1 was amplified using MIN6 (L) CM RNA whereas 
no amplification was detected using CM RNA from MIN6 (H). RNA from MIN6 
(L) was taken as positive control. 
 
 
 
 
 
 
Fig: 3.10.5.9 Early growth response 1 (Egr1) analysis in CM from MIN6 (L) 
and (H). RT-VE = reaction with H2O instead of RNA as control; PCR-VE = 
PCR reaction with H2O instead of cDNA as a control; (-) MMLV-RT = RT-
PCR reaction carried out without reverse transcriptase enzyme. M = 
molecular weight marker: ФX174 DNA Hae III digest. 1, 2 & 3 represent 
biological repeat experiments.  
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Glutamate decarboxylase 1 (Gad1) 
Conditioned media RNA isolated from MIN6 (L), glucose responsive and MIN6 
(H), glucose non-responsive were amplified for Gad1. Gad1 was amplified using 
MIN6 (H) CM RNA (Fig: 3.10.5.10), whereas it was undetected in MIN6 (L) 
CM RNA. This result shows that the expression of this gene was up-regulated in 
MIN6 (H) cells compared to MIN6 (L) cells. 
 
 
 
 
 
Fig: 3.10.5.10 Glutamate decarboxylase 1 analysis in CM from MIN6 (L) and 
(H). RT-VE = reaction with H2O instead of RNA as control; PCR-VE = PCR 
reaction with H2O instead of cDNA as a control; (-) MMLV-RT = RT-PCR 
reaction carried out without reverse transcriptase enzyme. M = molecular 
weight marker: ФX174 DNA Hae III digest. 1, 2 & 3 represent biological 
repeat experiments.  
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3.10.6 Analysis of mRNA from cells and conditioned media at different cell 
density 
3.10.6.1 Analysis of mRNA from cells and conditioned media of MIN6 B1 
cell line 
To investigate if the abundance of specific mRNAs detectable in CM reflected 
the cell numbers conditioning the medium, MIN6 B1 cells were seeded at a range 
of densities. Insulin-producing MIN6 B1 were seeded at different densities i.e. 1x 
106 cells, 5x106 cells and 1x107 cells per T25cm2 flask along with a total of 4 mls 
of culture media. Cells were allowed to grow for 48 hrs. Conditioned media was 
taken off and sterile filtered using 0.45 µm to make sure that there are no cells 
(See Section: 2.4.3.1).  
Beta-actin (Fig: 3.10.6.1) was amplified using all cell and CM RNA from MIN6 
B1 cells. The presence and amounts of a number of transcripts including Pdx1 
(Fig: 3.10.6.5), early growth response gene 1 (Egr1) (Fig: 3.10.6.3), 
chromagranin B (Chgb) (Fig: 3.9.6.2), insulin I (Ins1) (Fig: 3.10.6.7), 
Glucokinase (Gck) (Fig: 3.10.6.4), and paired box transcription factor 4 (Pax4) 
(Fig: 3.10.2.1) were investigated. As shown, all 5 transcripts analysed were 
detected in MIN6 B1 cell RNA isolates and all – with the exception of Pax4 – 
were detected in the corresponding CM samples.  
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Fig: 3.10.6.1   Beta-Actin mRNA analysis of MIN6 B1 cells, grown at a range 
of densities, and their corresponding CM. RT-VE = reaction with H2O 
instead of RNA as control; PCR-VE = PCR reaction with H2O instead of 
cDNA as control. (A) Densitometry analysis of amplified gene products 
shown above image of gel. M = molecular weight marker: ФX174 DNA Hae 
III digest. Results are representative of n = 3 biological repeats. 
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Chromogranin B (Chgb) 
Chgb was amplified in all cell RNA from different cell densities and their 
corresponding CM. The intensity of the Chgb band produced following 45 cycles 
of PCR was directly associated with the numbers of cells conditioning the 
medium i.e. increased number of cells resulted in increased levels of these 
transcripts detectable in a fixed volume of CM (Fig: 3.10.6.2).  
 
 
 
 
 
 
 
 
 
 
 288 
 
 
 
 
 
 
 
 
 
 
Fig: 3.10.6.2   Chromogranin B mRNA analysis of MIN6 B1 cells, grown at a 
range of densities, and their corresponding CM. RT-VE = reaction with H2O 
instead of RNA as control; PCR-VE = PCR reaction with H2O instead of 
cDNA as control. (A) Densitometry analysis of amplified gene products 
shown above image of gel. M = molecular weight marker: ФX174 DNA Hae 
III digest. Results are representative of n = 3 biological repeats. 
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Early growth response 1 (Egr1) 
Egr1 was amplified in RNA from range of different cell densities and their 
corresponding CM. Increased number of cells resulted in increased levels of 
Egr1 transcript detectable in a fixed volume of CM. Fig: 3.10.6.3 shows that the 
intensity of Egr1 band produced following 45 cycles of PCR was directly 
associated with the numbers of cells conditioning the medium. 
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Fig: 3.10.6.3   Early growth response 1 mRNA analysis of MIN6 B1 cells, 
grown at a range of densities, and their corresponding CM. RT-VE = 
reaction with H2O instead of RNA as control; PCR-VE = PCR reaction with 
H2O instead of cDNA as control. (A) Densitometry analysis of amplified 
gene products shown above image of gel. M = molecular weight marker: 
ФX174 DNA Hae III digest. Results are representative of n = 3 biological 
repeats. 
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Glucokinase (Gck) 
Amplification of cell RNA from different cell densities using 45 cycles of PCR 
showed increased levels of transcript corresponding with increased number of 
cells analysed.  
   
 
 
 
 
 
 
 
 
Fig: 3.10.6.4   Glucokinase mRNA analysis of MIN6 B1 cells, grown at a 
range of densities, and their corresponding CM. RT-VE = reaction with H2O 
instead of RNA as control; PCR-VE = PCR reaction with H2O instead of 
cDNA as control. (A) Densitometry analysis of amplified gene products 
shown above image of gel. M = molecular weight marker: ФX174 DNA Hae 
III digest. Results are representative of n = 3 biological repeats. 
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Similar result was seen with the media conditioned by these cells. Fig: 3.10.6.4 
shows that the intensity of Egr1 band produced following 45 cycles of PCR was 
directly associated with the numbers of cells conditioning the medium. 
Pancreatic and duodenal homeobox gene 1(Pdx1) 
 
 
 
 
 
 
 
 
 
Fig: 3.10.6.5   Pancreatic and duodenal homeobox gene 1 mRNA analysis of 
MIN6 B1 cells, grown at a range of densities, and their corresponding CM. 
RT-VE = reaction with H2O instead of RNA as control; PCR-VE = PCR 
reaction with H2O instead of cDNA as control. (A) Densitometry analysis of 
amplified gene products shown above image of gel. M = molecular weight 
marker: ФX174 DNA Hae III digest. Results are representative of n = 3 
biological repeats. 
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CM and cell RNA from MIN6 B1 cells seeded at range of different densities 
were amplified for Glutamate decarboxylase1, Insulin II and Phospholipase D1. 
Gad1 (Fig: 3.10.6.6) was amplified using cell RNA from 106 cells and 5x106 
cells however there was no further increase in band size/intensity upon analysis 
of 1x107 cells RNA. This may be due to the high levels of Gad1 present in the 
cells, which are reaching plateau phase for PCR analysis at the higher cell 
densities. Gad1 was amplified only in CM RNA isolated from 1x107 cells.  
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Fig: 3.10.6.6 Glutamate decarboxylase 1 mRNA analysis of MIN6 B1 cells, 
grown at a range of densities, and their corresponding CM. RT-VE = 
reaction with H2O instead of RNA as control; PCR-VE = PCR reaction with 
H2O instead of cDNA as control. (A) Densitometry analysis of amplified 
gene products shown above image of gel. M = molecular weight marker: 
ФX174 DNA Hae III digest. Results are representative of n = 3 biological 
repeats. 
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Insulin II (Ins2) 
Ins2 (Fig: 3.10.6.7) was amplified using cell RNA from 106 cells and 5x106 cells 
however there was no further increase in band size/intensity upon analysis of 
1x107 cells RNA which seemed to reach plateau phase of PCR analysis. 
 
 
 
 
 
 
 
 
 
Fig: 3.10.6.7   Insulin II mRNA analysis of MIN6 B1 cells, grown at a range 
of densities, and their corresponding CM. RT-VE = reaction with H2O 
instead of RNA as control; PCR-VE = PCR reaction with H2O instead of 
cDNA as control. (A) Densitometry analysis of amplified gene products 
shown above image of gel. M = molecular weight marker: ФX174 DNA Hae 
III digest. Results are representative of n = 3 biological repeats. 
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Phospholipase D1 (Pld1) 
Pld1 (Fig: 3.10.6.8) was amplified in RNA isolated from 106 cells, 5x106 cells 
and 1x107 cells following 45 cycles of PCR, however very low level of this 
transcript was detectable in a fixed volume of CM.  
 
 
 
 
 
 
 
 
 
Fig: 3.10.6.8   Phospholipase D1 mRNA analysis of MIN6 B1 cells, grown at 
a range of densities, and their corresponding CM. RT-VE = reaction with 
H2O instead of RNA as control; PCR-VE = PCR reaction with H2O instead 
of cDNA as control. (A) Densitometry analysis of amplified gene products 
shown above image of gel. M = molecular weight marker: ФX174 DNA Hae 
III digest. Results are representative of n = 3 biological repeats. 
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Insulin I (Ins1) 
In the case of Ins1 (Fig: 3.10.6.9 ) increased amounts of amplified product 
resulted for RNA isolated from medium conditioned by 5X106 cells compared to 
medium conditioned by 1X106 cells.  
 
 
 
 
 
 
  
 
Fig: 3.10.6.9   Insulin I mRNA analysis of MIN6 B1 cells, grown at a range 
of densities, and their corresponding CM. RT-VE = reaction with H2O 
instead of RNA as control; PCR-VE = PCR reaction with H2O instead of 
cDNA as control. (A) Densitometry analysis of amplified gene products 
shown above image of gel. M = molecular weight marker: ФX174 DNA Hae 
III digest. Results are representative of n = 3 biological repeats. 
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However, a further increase in band size/intensity was not found upon analysis of 
medium conditioned by 1X107 cells. This is likely to be due to the high levels of 
Ins1 present in CM, which are reaching plateau phase for PCR analysis at the 
higher cell densities. 
3.10.7 Selective release of gene transcript 
Pax4 (Fig: 3.10.7) was expressed by MIN6 B1 cells and on amplification of cell 
RNA using  45 cycles of PCR increased levels of transcript were found to 
correspond with increased number of cells analysed. However, using RT-PCR 
methods, this gene transcript was not detected in medium conditioned by these 
cells. 
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Fig: 3.10.7   Paired box gene 4 mRNA analysis of MIN6 B1 cells, grown at a 
range of densities, and their corresponding CM. RT-VE = reaction with H2O 
instead of RNA as control; PCR-VE = PCR reaction with H2O instead of 
cDNA as control. (A) Densitometry analysis of amplified gene products 
shown above image of gel. M = molecular weight marker: ФX174 DNA Hae 
III digest. Results are representative of n = 3 biological repeats. 
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3.10.8 Analysis of mRNA from cells and conditioned media from Vero-PPI 
cell line  
After investigating specific mRNAs detectable in CM reflected the cell numbers 
conditioning the medium in MIN6 B1 cells, Vero-PPI cells were investigated. 
Insulin-producing Vero-PPI cells were seeded at a range of densities i.e. 1x 106 
cells, 5x106 cells and 1x107 cells per T25cm2 flask along with a total of 4 mls of 
culture media. Cells were allowed to grow for 48hrs. Conditioned media was 
taken off and sterile filtered using 0.45 µm to make sure that there are no cells 
(See Section: 2.4.3.1). The presence and amounts of preproinsulin was 
investigated.  
Analysis of human preproinsulin mRNA (Fig: 3.10.8), transcribed by Vero-PPI 
cells, showed increasing levels of preproinsulin mRNA in 1x 106 cells and 5x106 
cells; however, the amounts of preproinsulin detected in 1x107 cells seemed to 
reach plateau phase and PCR was no longer exponential beyond analysis of  
RNA from 5X106 cells. Similarly the amounts of preproinsulin detected in CM 
seemed to reach plateau phase and PCR was no longer exponential beyond 
analysis of CM from 5X106 cells. 
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Preproinsulin 
 
 
 
 
 
  
 
 
 
Fig: 3.10.8 Human preproinsulin mRNA analysis of Vero-PPI cells, grown at a 
range of densities, and their corresponding CM. RT-VE = reaction with H2O 
instead of RNA as control; PCR-VE = PCR reaction with H2O instead of cDNA 
as a control. M = molecular weight marker: ФX174 DNA Hae III digest. Results 
are representative of n = 3 biological repeats. 
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3.11 Analysis of serum for amplifiable Gene Transcripts 
In the study of media conditioned by insulin-producing cell lines we were able to 
reproducibly amplify extracellular mRNAs. Building on these findings we advanced 
our study to serum from people with diabetes and those without this condition as 
control. 
3.11.1 Patient information 
The study involved patients with newly diagnosed Type 2 diabetes (4.36 +/- 2.33 
months mean duration) (6 male and 5 female) with a mean age of 56 ± 9 (male 53 ± 8 
years, female 59 ± 11 years; mean ± S.D.). This study also included control group 
with a mean age of 52 ± 8 (male 49 ± 9 years, female 56 ± 5; mean ± S.D.). All the 
controls had normal oral glucose tolerance test. The oral glucose tolerance for non-
diabetic controls used were cut-off values less than 5.6 fasting glucose and less than 
7.8 two hours postprandial blood glucose.  Table 3.11.1 shows the details of controls 
and Type 2 diabetes subjects. 
Haemoglobin A1C (HbA1C) level were significantly higher in Type 2 diabetes 
subject compared to controls (p-value=0.00036). Fasting glucose was significantly 
higher in Type 2 diabetes subject compared to controls (p-value=0.005) with no 
significant change in insulin secretion or fasting insulin levels. Controls showed a 
significantly higher cholesterol (p-value=0.001) and LDL-cholesterol level (p-
value=0.006) compared to Type 2 diabetes subjects whereas, there was no significant 
difference in HDL-cholesterol.  
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Table: 3.11.1 General characteristics of the study population 
 Controls 
Type 2 
Diabetes 
subject 
p-value 
Age (years) 52 ± 8 56 ± 9.8 0.387 
BMI (kg/m2) 29.31 ± 4.8 31.9 ± 4 0.187 
Waist/hip ratio 0.93±0.05 0.98±0.09 0.27 
Fasting glucose (mmol/L) 5.15 ± 0.4 7.62 ± 2.6 0.005 
Insulin (pmmol/L) 50.24 ± 32.6 52.36 ± 28.4 0.872 
Cholesterol (mmol/L) 5.9 ± 1.0 4.24 ± 1.0 0.001 
2hPP Glc 5.17 ± 0.9 NA NA 
HOMA IR 1.08 ± 0.7 1.24 ± 0.6 0.591 
HOMA %S 112.8 ± 45.8 94.05 ± 59.1 0.415 
HOMA %B 97.9 ± 55.0 67.15 ± 43.6  0.162 
Diastolic BP (mmHg) 82 ± 8.1 83.45 ± 7.0 0.658 
Systolic BP (mmHg) 138.45 ± 17.4 139.45 ± 17.4 0.894 
HDL-cholesterol  (mmol/L) 1.46 ± 0.5 1.14 ± 0.3 0.100 
LDL-cholesterol  (mmol/L) 3.78 ± 0.8 2.5  ± 1.0 0.006 
HbA1C 5.4 ± 0.3 7.43 ± 1.53 0.000 
Triglyceride  (mmol/L) 1.96 ± 1.6 1.28 ± 0.4 0.186 
BMI, body mass index; HOMA IR, homeostasis model assessment-insulin resistance; 
HbA1C, haemoglobin A1C; 2hPP Glc, 2 hours postprandial blood glucose 
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3.11.2 Txnip expression in Type 2 diabetes and controls 
There was 1.8-fold increase in Txnip expression but was not significant (p-
value=0.12) in Type 2 diabetes subjects compared to controls. To exclude any 
amplification product derived from genomic DNA that could contaminate the RNA 
preparation, total RNA from Type 2 diabetes subjects and controls were amplified 
without reverse transcriptase enzyme as a negative control. Water on its own was 
amplified as a negative control to rule out presence of any contaminating RNA or 
DNA in it. 
 
 
 
 
 
 
Fig: 3.11.2.1 Txnip expression as determined by qRT-PCR in controls and Type 
2 diabetes subjects. Type 2 diabetes subject showed 1.8-fold increase in Txnip 
expression compared to controls. Beta-actin was taken as endogenous control. 
Results represent mean ± S.D from 11 Type 2 diabetes and controls. –RT was 
used as control to prove that amplification was RNA specific and not from 
contaminating-DNA 
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The Txnip was amplified at 31.6 cycle threshold (ct) in Type 2 diabetes subject and 
30.2 ct in controls (Fig: 3.11.2.2).    
 
 
 
 
 
 
 
Fig: 3.11.2.2 Average cycle threshold (ct) at which Txnip mRNA was amplified in 
controls and Type 2 diabetes subjects. The graph shows the mean ct values of 11 
controls and Type 2 diabetes subjects. Results represent mean ± S.D. 
Txnip expression and insulin levels (fasting) (correlation= -0.46) as well as insulin 
secretion in Type 2 diabetes subjects was negatively correlated (correlation= -0.50). 
Comparison of Txnip expression and insulin levels (fasting) in 11 Type 2 diabetes 
(Fig: 3.11.2.3) and controls (Fig: 3.11.2.4). 
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Fig: 3.11.2.3 Txnip expression and insulin levels (fasting) in different controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 3.11.2.4 Txnip expression and insulin levels (fasting) in different Type 2  
diabetes subjects. 
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3.11.3 Egr1 expression in Type 2 diabetes subjects and controls  
Egr1 expression was significantly (p-value=0.017) down-regulated in Type 2 diabetes 
subjects compared to controls. Egr1 expression was down-regulated 2.21-fold in Type 
2 diabetes subject (Fig: 3.11.3.1). In order to exclude any amplification product 
derived from genomic DNA that could contaminate the RNA preparation, total RNA 
from Type 2 diabetes subjects and controls were amplified without reverse 
transcriptase enzyme as a negative control. Water on its own was amplified as a 
negative control to rule out presence of any contaminating RNA or DNA in it. 
 
 
 
 
  
 
Fig: 3.11.3.1 Egr1 expression as determined by qRT-PCR in Type 2 diabetes and 
controls. Type 2 diabetes subjects showed -2.21-fold down-regulation of Egr1 
expression compared to controls. Beta-actin was taken as endogenous control. 
Results represent mean ± S.D form 11 Type 2 diabetes and controls.   
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The Egr1 was amplified at 37.5 ct in Type 2 diabetes subject and 35.5 ct in controls 
(Fig: 3.11.3.2). 
 
 
 
  
 
 
Fig: 3.11.3.2 Average cycle threshold (ct) at which Egr1 mRNA was amplified in 
Type 2 diabetes and controls. The graph shows the mean ct values of 11 Type 2 
diabetes and controls. Results represent mean ± S.D. 
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Egr1 expression and insulin fasting (correlation= 0.53) was positively correlated in 
Type 2 diabetes subject and was negatively correlated (correlation= -0.12) in controls. 
 
 
 
 
 
 
Fig: 3.11.3.3 Egr1 expression and insulin fasting in different controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 3.11.3.4 Egr1 expression and insulin fasting in different Type 2 diabetes 
subjects. 
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3.11.4 Beta-actin expression in Type 2 diabetes subjects and controls 
Beta-actin was amplified at 34.4 ct in Type 2 diabetes subjects and at 33.9 in controls 
with no significant difference (p-value=0.5). To exclude any amplification product 
derived from genomic DNA that could contaminate the RNA preparation, total RNA 
from Type 2 diabetes subjects and controls were amplified without reverse 
transcriptase enzyme as a negative control. Water on its own was amplified as a 
negative control to rule out presence of any contaminating RNA or DNA in it. 
 
 
 
 
 
 
Fig: 3.11.4 Average cycle threshold (ct) at which Beta-actin mRNA was amplified 
in Type 2 diabetes subjects and controls. The graph shows the mean ct values of 
11 Type 2 diabetes subjects and controls. Results represent mean ± S.D. 
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3.11.5 Validating qRT-PCR assay on demand  
cDNA from different cancerous cell lines (Table: 3.11.5.1) were used to make a pool 
as positive control for validating qRT-PCR assay on demand in Table: 2.5.3.1.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table: 3.11.5.1 cell lines and their origin used to make cDNA pool as positive 
control for validating qRT-PCR assay on demand. 
Cell line Origin 
HCC1954 Breast cancer 
HCC1419 Breast cancer 
HCC1937 Breast cancer 
BT20 Breast cancer 
SK-Mel28 Melanoma 
MCF7 Breast cancer 
MDA-MB-231 Breast cancer 
Mel5 Melanoma 
MDA-MB-435S Breast cancer 
MALME-3M Melanoma 
HT144 Melanoma 
M14 Melanoma 
MDA-MB-468 Breast cancer 
LOX Melanoma 
SKBR3 Breast cancer 
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Chgb, Npy, Pdx1, Pld1 and INS were amplified using cDNA pool from different 
cancerous cell lines (Table: 3.11.5.1) showing that the assays were working but was 
just not amplified in the serum samples. Pax4 was not amplified in the cDNA pool. 
Fig 3.11.5.2 shows the ct values of different gene transcripts amplified in the cDNA 
pool.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 3.11.5.2 ct values at which the different assay on demand was amplified in 
cDNA pool from cancer cell line.  
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Section 4.0 DISCUSSION 
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4.1 Introductions  
There is currently 246 million people worldwide suffering from diabetes making 
it fourth or fifth leading cause of death in most developed countries. Diabetes is 
now one of the most common non-communicable diseases globally and there is 
substantial evidence that it is epidemic in many developing and newly 
industrialized nations (http://www.eatlas.idf.org/).  
Complications from diabetes, such as coronary artery and peripheral vascular 
disease, stroke, diabetic neuropathy, amputations, renal failure and blindness are 
resulting in increasing disability, reduced life expectancy and enormous health 
costs for virtually every society. Diabetes is certain to be one of the most 
challenging health problems in the 21st century. Careful control is needed to 
regulate glucose homeostasis and reduce the risk of long-term complications. 
This could be achieved with combinations of diet, exercise and weight loss (Type 
2 diabetes) (Hainer et al., 2008), various oral diabetic drugs (Type 2 diabetes 
only) and insulin use (Type 1 and for Type 2 not responding to oral medications, 
mostly those with extended duration diabetes). In Type 1 diabetes only realistic 
method of achieving normoglycaemia is by replacing the patients' destroyed beta 
cells by beta cell/islet replacement (White et al., 2001). Annual Report published 
by CITR (2008) summarizes information on 325 islet transplant recipients and 
649 islet infusion procedures. According to CITR, at 3 years post-first infusion, 
about 23% are insulin independent, 29% are insulin dependent with detectable C-
peptide, 26% have no detectable C-peptide (lost function) and 22% have missing 
data (required but not yet reported) (Collaborative islet transplant registry 
coordinating center, 2008). 
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Type 2 diabetes is characterized by progressive deterioration in the function of 
the pancreatic beta cells. In this present study we found that the MIN6 B1 cells 
lose their function of insulin secretion in long-term culture. Gene transcripts 
including Txnip, Pcsk9 and Gcg manipulation using siRNA, shRNA and cDNA 
transfection the GSIS function was improved in non glucose-responsive cells. 
This work could be clinically relevant in maintaining beta cell function in 
patients suffering from Type 2 diabetes. 
In this project we also investigated circulating extracellular mRNA in CM and 
serum specimens. Study on extracellular mRNA in CM was directed towards 
identifying biomarkers indicative of cell number and function, which could be 
clinically relevant to identifying loss of beta cells in patients suffering from Type 
1 diabetes. Studies on serum specimens were performed to identify differentially-
regulated gene transcripts that could be indicative of loss of beta cell function in 
Type 2 diabetes. However, studies on large numbers of Type 2 diabetes and 
controls would be required to establish the relevance, of these mRNAs as 
biomarkers. 
4.2 MIN6 cell line- model for studying GSIS 
Insulin is secreted from the beta cells in response to glucose. Studies on MIN6 
cell line have shown a loss of glucose-stimulated insulin secretion (GSIS) 
phenotype in continuous culture (O'Driscoll et al., 2004 and 2006). One way to 
identify the genes associated with impaired GSIS would be to compare the genes 
expressed in the beta cell of normal subjects with those of Type 2 diabetes 
patients who have impaired secretion. However, this is not practical, as 
pancreatic islets from human subjects are difficult to obtain. Alternatively, islets 
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from model animals such as the Goto-Kakizaki (GK) rat can be used for this 
purpose (Ihara et al., 1996). Another approach is to compare gene expression 
between two different beta cell lines (or variants of the same cell line) that 
exhibit different insulin secretory profiles, i.e. between a cell line showing 
normal insulin response to glucose and one showing impaired response (Minami 
et al., 2000). 
One of the most commonly studied beta cell lines is MIN6 (See Section: 1.10.1). 
This insulinoma cell line MIN6, was derived from a transgenic mouse expressing 
the large T-antigen of SV40 in pancreatic beta cells (Miyazaki et al., 1990). 
Glucose-stimulated insulin secretion, glucose transport, glucose phosphorylation 
and glucose utilization have been characterized in MIN6 cell line. Glucose 
utilization quantitatively and qualitatively reflected glucose phosphorylation in 
MIN6 cells, a characteristic very similar to those of isolated islets, indicating that 
this cell line is an appropriate model for studying the mechanism of GSIS in 
pancreatic beta cells (Ishihara et al., 1993). 
The MIN6 cell line maintains a substantial component of beta cell function at 
early passages i.e. the cells respond synchronously and physiologically to 
changes in glucose concentration (Webb et al., 2000). Previous MIN6 studies, by 
ourselves and others, have indicated that the GSIS phenotype is relatively 
unstable in long-term culture. This loss in functional GSIS correlated with 
changes in morphology and increased proliferation, suggesting that the loss of 
GSIS may be due to de-differentiation of the high passage MIN6 cells (Kayo et 
al., 1996; O’ Driscoll et al., 2004; O’ Driscoll et al., 2006) 
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It is very important to identify means of preserving beta cell function i.e. GSIS, 
while in culture for possible future applications involving the use of cultured 
replacement tissue for diabetes. The MIN6 system, i.e. glucose responsive low 
passage cells versus glucose non-responsive high passage cells, has the potential 
to facilitate discovery of crucial pathways in beta cell development and function.  
4.2.1 Loss of GSIS in MIN6/MIN6 B1 cells following prolonged sub-culture 
Differing levels of GSIS, ranging from 1.2 to 30-fold, have been reported for 
MIN6 cells. Following the initial establishment of MIN6 as a cell line, exposure 
to 25mmol/L glucose (compared to 0.7mmol/L) resulted in an approximately 30-
fold GSIS, with similar results reported to be achieved after 30 passages 
(Miyazaki et al., 1990). Results from studies of MIN6 cells at passage 16 
indicated a 2-fold GSIS that was reduced to approximately 1.2-fold by passage 
35 when stimulated with 5mmol/L compared to 25mmol/L glucose (Kayo et al., 
1996). Other reported glucose-stimulated insulin secretion results for these cells 
include a 7.3-fold GSIS (Ishihara et al., 1993) and an approximately 4.8-fold 
GSIS from MIN6 cells analyzed between passages 12 to 15 when stimulated with 
5mmol/L compared to 25mmol/L glucose (Kinoshita et al., 2001).  
Studies carried out previously in our laboratory on MIN6 cells demonstrated that 
low passage MIN6 (p 18) cells responded to changes in glucose concentrations, 
producing an approximately four- to five-fold GSIS in response to 26.7mmol/L, 
compared to 3.3mmol/L glucose. After continuous culture of MIN6 cells to 
passage 40 to 49, this GSIS was no longer present (O'Driscoll et al., 2004; 
O'Driscoll et al., 2006).  
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As described in section 1.10.2 MIN6 B1 subline was derived from the mouse 
pancreatic beta cell line MIN6. In this study we report that MIN6 B1, like MIN6 
heterogeneous population, show a gradual loss of GSIS in continuous passage. 
To analyze insulin secretion from MIN6 B1(GSIS) (low passage glucose 
responsive MIN6 B1 cells) and MIN6 B1(Non-GSIS) (high passage non-glucose 
responsive MIN6 B1 cells) cells, response to glucose at different concentration 
(3.3mmol/L and 16.7mmol/L) were tested. Our present study on MIN6 B1 cells 
showed a 2.9-fold insulin secretion at passage 17, and was lost to 1.35-fold at 
passage 23 when stimulated with 3.3mmol/L was compared with 16.7mmol/L 
glucose. 
4.3 Phenotypic changes in MIN6 / MIN6 B1 cells following prolonged sub-
culture 
Low passage glucose-responsive MIN6 and MIN6 B1 cells grow in multilayered 
clumps (Fig: 3.1.2) facilitating cell-to-cell interactions and formation of gap-
junctions. The integrated secretory response of intact islets of Langerhans is 
greater than that of dispersed islet cells (Hauge-Evans et al., 1999). This 
reaggregation improves secretory responsiveness, suggesting that intra-islet 
interactions are essential for normal secretory responses (Hauge-Evans et al., 
1999). High passage glucose non-responsive MIN6 and MIN6 B1 cells grow in a 
monolayer pattern. Previous studies have reported disruptions in GSIS when 
MIN6 cells are unable to interact and form gap junctions (Hauge-Evans et al., 
1999).  
The earlier study in our laboratory indicated that continuous sub-culturing of 
MIN6 cells resulted in an increase in proliferation rate exhibiting approximately 
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two-fold increased proliferation in MIN6 (H) than that of MIN6 (L) (O'Driscoll 
et al., 2006). Growth curves plotted over 7 days following seeding for this study 
showed rate of proliferation in MIN6 (H) cells was approximately 2.4-fold 
greater than that of MIN6 (L). The MIN6 (H) population demonstrated greater 
proliferation potential than MIN6 (L) (Fig: 3.2.2). Zimmer et al. (1999) stated in 
their study that growth arrest of the proliferating beta cell line stimulated the 
expression of genes associated with beta cell function and resulted in a 
phenotype that more closely resembled to that of the mature terminally 
differentiated beta cell. A study on MIN6 passage 17 and passage 41, Sawada et 
al. (2001) found that on the eighth day, the growth rate of passage 41 was nearly 
twice that of passage 17. 
Like MIN6 cells, MIN6 B1(GSIS) (low passage) cells grow in clumps whereas 
MIN6 B1(Non-GSIS) (high passage) cells spread out to grow as monolayer (Fig: 
3.1.1). Increase in the proliferation rate was observed as the MIN6 B1(Non-
GSIS) cells when compared to MIN6 B1(GSIS) cells. The rate of proliferation in 
MIN6 B1(Non-GSIS) was approximately 2-fold greater than that of MIN6 
B1(GSIS) (Fig: 3.2.1). MIN6 B1 proliferation result is in collaboration with the 
MIN6 proliferation study that described an increased rate of proliferation in high 
passage cells (O'Driscoll et al., 2006). 
4.4 Microarray profiling of MIN6 B1(GSIS) and MIN6 B1(Non-GSIS) cells 
Whole genome microarray experiment was performed on triplicates of glucose 
responsive MIN6 B1(GSIS) and non-glucose responsive MIN6 B1(Non-GSIS) 
cells (See Section: 2.6). In this study GeneChip® Mouse Genome 430 2.0 Array 
was used that represented 45,101 transcripts. Continuous culture of MIN6 B1 
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cells caused changes in gene expression resulting in both up-regulation and 
down-regulation of gene transcripts associated with transcription factor, protein 
kinase activity, response to stress, secretory pathway and intracellular protein 
transport (Table: 3.4.5.1 and Table: 3.4.5.2) in MIN6 B1(Non-GSIS) compared 
to MIN6 B1(GSIS) cells. Whereas in the MIN6 study, 1000 genes were 
significantly differentially-expressed that was involved in regulated insulin 
secretion, proliferation, adhesion and development (O’Driscoll et al., 2006). 
4.4.1 Effect of continuous passaging on expression of gene transcripts and 
GSIS 
4.4.1.1 Endoplasmic reticulum related genes 
The largest cluster of genes that were differentially-regulated was related to 
Endoplasmic Reticulum (ER), an important cellular organelle for proper 
functioning of pancreatic beta cells by correct folding of proinsulin into mature 
insulin and, subsequent insulin secretion.  
It has been reported that Copb2 and Mcfd2 are associated with protein transport 
and their down-regulation fails to transport protein from ER to Golgi apparatus 
(Barlowe 2003; Nyfeler et al., 2006). Copb2 and Mcfd2, were found to be down-
regulated in association with loss of GSIS in MIN6 B1(Non-GSIS) cells. Cargo 
receptor protein Mcfd2 helps in quality control of protein folding in the ER 
involving in homeostasis of the intermediate compartment and Golgi complex 
(Renna et al., 2006).   
Hspa5, Heat shock 70kD protein 5 (glucose-regulated protein) (Dnajb1) and 
WFS1 are localised in ER and were found to be down-regulated in MIN6 
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B1(Non-GSIS) cells. Hspa5 reportedly helps in protein folding activity, reducing 
the load of new protein synthesis and degradation of misfolded proteins in ER 
(Oyadomari et al., 2002; Wang et al., 2008). Wolfram syndrome 1 homolog 
(human) (WFS1) is found to be associated with ER stress signalling component 
and helps in maintaining ER homeostasis in beta cell (Fonseca et al., 2005). 
Although WFS1 is found to be present in rat pancreatic beta cells and acts as a 
regulator of ER calcium channel activity, it is not yet definitively established if it 
plays a role in secretion and membrane trafficking (Ueda et al., 2005). Recently, 
single nucleotide polymorphisms (SNPs) in WFS1 have been associated with 
Type 2 diabetes (Florez et al., 2008). Florez et al., (2008) concluded WFS1 
polymorphisms to be modest contributors to diabetes risk and suggested that they 
may do so by conferring impairment in insulin secretion. WFS1 was down-
regulated in MIN6 B1(Non-GSIS) compared to MIN6 B1(GSIS) and therefore 
may be responsible for its loss of its function of insulin secretion. 
4.4.1.2 Oxidative stress related genes 
The strongest effect of continuous passaging was seen on the expression of 
thioredoxin interacting protein (Txnip) with the microarray data showing five-
fold increase in its expression in high passage cells. The beta cell is particularly 
vulnerable to oxidative stress, probably due to its low anti-oxidative enzyme 
activity, which makes it difficult to inactivate reactive oxygen species (Grankvist 
et al., 1981; Lenzen et al., 1996; Tiedge et al., 1997). 
Activation of stress-sensitive pathways like the MAPK leads to insulin 
resistance, beta cell dysfunction and eventual development of late complications 
of diabetes (Evans et al., 2002). The activation of MAPK signal processing 
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pathways are controlled via multiple mechanisms, including change in 
expression of effector members by upstream kinase components of the pathway 
(Sung et al., 2007). Gadd45g is an ubiquitously expressed mammalian gene and 
is induced by genotoxic stresses (Vairapandi et al., 2002). DNA damage leads to 
the over-expression of Gadd45g gene which in turn induces the activation of 
MAPK pathways (Takekawa et al., 1998). Tribbles are identified as regulators of 
signal processing system and their involvement in diabetes. Trib1 increases the 
expression of Cdkn1a and leads to the MAPK phosphorylation /activation 
(Devgan et al., 2006; Kiss-Toth et al., 2004; Hegedus et al., 2006; Eder et al., 
2008). Cdkn1a and Gadd45g are nuclear proteins and have been implicated in 
induction of growth arrest, apoptosis, excision repair and DNA stability (Dotto, 
2000). Devgan et al. (2006) therefore speculated that the direct interaction 
between Cdkn1a and Gadd45 may have a direct bearing on modulation of 
MAPK and its related proteins. Trib1, a modulator of MAPK, has been 
associated with proliferation of vascular smooth muscle (Sung et al., 2007; 
Hermanto et al., 2000; Xu et al., 1999). Interestingly, Hermanto et al. (2000) 
reported reduced proliferation in breast cancer cells following blocking of 
MAPK pathway. The up-regulation of genes associated with MAPK pathway 
which we observed in MIN6 B1(Non-GSIS) cells may potentially contribute to 
their increased proliferation rate.  
There is evidence that regulator of G-protein signaling 4 (Rgs4) suppresses G-
protein signalling (Berman et al., 1996), which is critically important for 
regulation of Ca2+ channels (Béguin et al., 2001). Furthermore, Rgs4 inhibits 
Ca2+ signalling in rat pancreatic acinar cells, thereby affecting the exocytotic 
release of digestive enzymes (Xu et al., 1999). Here we report Rgs4 to be up-
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regulated in MIN6 B1(Non-GSIS) cells, which may inhibit the Ca2+ signalling 
necessary for insulin exocytosis.  
Dusp1, identified as a stress-responsive immediate-early gene expressed 
following oxidative stress in a diabetic rat model (Wu et al., 2006), was found to 
be up-regulated in MIN6 B1(Non-GSIS) cells. Over-expression of this gene has 
previously been shown to induce insulin expression through its 
dephosphorylation reaction of the JNK/c-jun pathway (Zhang et al., 2003). 
Dusp1 is also up-regulated during MAPK activation and plays a negative 
feedback role by directly inactivating multiple MAP kinases in insulin-producing 
cells (McMorran et al., 2003; Wu et al., 2006). Txnip is reported to be a pro-
apoptotic beta cell gene that is found to be elevated in insulin resistance (Minn et 
al., 2005). It is known as endogenous inhibitor of thioredoxin, inhibiting 
thioredoxin antioxidative function by binding to its redox-active cysteine 
residues resulting in a shift of the cellular redox balance that promotes increased 
intracellular oxidative stress (Schulze et al., 2004). Oxidative stress associated 
with over-expression of Txnip (5.25-fold higher in MIN6 B1(Non-GSIS)) may 
contribute to the impaired insulin secretion observed in these cells. 
4.4.1.3 Transcription factors  
Transcriptional factors are modulated by up-stream signalling activity and 
influence gene regulation (Vukkadapu et al., 2005). Klf4 is a zinc-finger 
transcription factor and in vitro studies have suggested that it plays an important 
role in cell proliferation and/or differentiation (Katz et al., 2002). Gary et al., 
(2002) in their over-expression study of Klf4 reported that it reduces the 
expression of GLUT4 in 3T3-L1 cells. The over-expression of Klf4 observed here 
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in beta cells, in association with loss of glucose-responsiveness, may similarly 
affect GLUT2 (another member of the GLUT transporters; well established as an 
important component of beta cell glucose sensing). ROS-induced over-
expression of redox-sensitive Klf4 gene may cause proliferation and over-
expression of Cdkn1a (Nickenig et al., 2002). The role of Atf5 in islet function or 
maintenance is not known and is associated with neuroendocrine as well as 
pancreatic endocrine development and function (Vukkadapu et al., 2005).  High 
expression of Atf4, Atf5, and Hspa5 during insulitis in BDC2.5/N mice suggests 
ER stress (Vukkadapu et al., 2005). Insulitis is an inflammation of the islets of 
Langerhans caused by lymphocyte infiltration. This lymphocyte infiltration 
results in destruction of the insulin producing beta cells of the islets and clinical 
diabetes (Rossini et al., 1977).  
AP-1 has been reported to be a redox-sensitive transcription factor constituted 
from Jun, FOS and ATF family protein (Kunsch et al., 1999). Here c-jun, c-fos 
and fosB were all found to be expressed at higher levels in MIN6 B1(Non-GSIS) 
cells. qRT-PCR results were in agreement to microarray study with a dramatic 
59-fold up-regulation of fosB gene (See Section: 3.4.8). It has been reported that 
c-jun and c-fos represses the basal activities of the insulin promoter in hamster 
beta (HIT) cells (Inagaki et al., 1992). c-jun is also found to be associated with 
increased proliferation (Shaulian et al., 2002) and was up-regulated in rapidly 
proliferating MIN6 B1(Non-GSIS) cells. 
4.4.1.4 Secretory pathway 
Mcfd2 forms a cargo receptor complex in the early secretory pathway on 
interaction with different proteins (Renna et al., 2006). The secretory granules of 
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pancreatic beta cell contain four Rab3 isoforms with similar roles in the 
regulation of insulin secretion (Iezzi et al., 1999). In fact, Riedel et al. (2002) 
reported presences of Rab3D in several secretory cells including pancreatic cells 
and are not involved in exocytosis but plays role in granule maturation. The loss 
of Rab3d expression found in MIN6 B1(Non-GSIS) is in keeping with this role. 
Secretory and membrane proteins are transported across, or integrated into, the 
membrane of the ER by a multi-protein assembly, termed the translocon. Tram, 
Srpr and Sec61p complex are essential component of the translocon component 
(Webb et al., 2000). Interestingly, our microarray study showed a down-
regulation (by 1.2-fold) of Tram1 and Srpr in MIN6 B1(Non-GSIS) compared to 
MIN6 B1(GSIS) cells. In a study of early-passage (passages 17-19) MIN6 cells 
exposed to high (25mM) or low (5.5mM) glucose, Webb et al. (2000) reported 
that the secretory pathway genes including Trapα, SRP receptor and tram protein 
are up-regulated in glucose-responsive MIN6 cells. In their study, an increased 
rate of proinsulin biosynthesis at the ER in glucose-responsive MIN6 cells was 
observed, suggesting a role of secretory pathway genes in glucose-responsive 
beta cell function (Webb et al., 2000). Again, in agreement with this, our study 
on MIN6 B1 cells showed down-regulation of Ssr1, Tram1 and Srpr genes in non 
glucose-responsive cells.  
Furthermore, our previous study on heterogeneous MIN6 cells (passages 18-40) 
reported reduced expression of genes associated with vesicle formation, 
transportation and secretion in MIN6 (H) cells (passage 40) (O’Driscoll et al., 
2006). O’Driscoll et al. (2006) reported gene transcripts associated with secretion 
including nucleobindin, PC2, secretogranin V, synaptotagmin 1 etc to be 
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significantly lower in MIN6 (H) compared with MIN6 (L) cells. Egr1 has been 
specifically associated with insulin secretion (Josefsen et al., 1999). O’Driscoll et 
al. (2006) reported down-regulation of Egr1 by 5.5-fold in high passage MIN6 
cells, whereas our present microarray study showed a 1.98-fold and qRT-PCR 
showed 4.64-fold up-regulation of Egr1 in MIN6 B1(Non-GSIS) compared to 
MIN6 B1(GSIS) cells. Here we report a different set of gene transcripts 
associated with secretion, including Ssr1, Tram1 and Srpr, to be significantly 
down-regulated in MIN6 B1(Non-GSIS) compared to MIN6 B1(GSIS) cells.   
4.5 Glucagon (Gcg) 
The pancreatic islets are comprised of different type of cells, predominant beta 
cells (approximately 70%) with alpha cells constituting approximately 20% of 
the islets (Baetens et al., 1979). Type 2 diabetes is associated with a defect in 
beta cell function and mass, insulin secretion and resistance, as well as 
abnormalities in glucagon secretion (Diao et al., 2005). The key regulatory 
hormones for glucose homeostasis are insulin and glucagon. Glucagon acts as 
counter-regulatory hormone of insulin by raising plasma glucose levels in 
response to insulin-induced hypoglycaemia (Jiang et al., 2003). Glucagon 
contributes to the maintenance of the glucose-induced insulin secretion 
phenotype of beta cells, a key feature commonly impaired in Type 2 diabetes 
(Huypens et al., 2000). It also helps in differentiation of precursor cells into 
insulin-secreting beta cells in the embryonic pancreas (Kumagai et al., 2002).  
Glucagon is a 29 amino acid peptide hormone secreted by alpha cells (Bromer et 
al., 1957). RIN, HIT, beta TC, MIN6 and INS-1 cells are the most commonly 
used and studied insulin-secreting cell lines. These cell lines represent a good 
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model of beta cells but are also known to secrete glucagon and somatostatin 
(Poitout et al., 1996; Hohmeier et al., 2004). There has been evidence of loss of 
GSIS along with down-regulation of glucagon mRNA expression with increased 
passage in MIN6 cells (O'Driscoll et al., 2004). Here we report the down-
regulation of glucagon mRNA expression in MIN6 B1(Non-GSIS) compared to 
MIN6 B1(GSIS) in a microarray study which was validated by qRT-PCR. 
Impaired glucagon secretion is observed in Type 1 Diabetes mellitus (T1DM) 
(Fanelli et al., 2006). The physiological decrease in endogenous insulin secretion 
from the beta cell in response to hypoglycaemia is a mechanism believed to be 
necessary in order for glucagon to be released by the alpha cell. The intra-islet 
insulin hypothesis suggests that a decrease in beta cell insulin secretion leads to a 
decreased intra-islet alpha cell inhibition by insulin and is a signal for increased 
glucagon secretion in response to hypoglycemia. This mechanism is altered in 
diabetes because of the loss of beta cell mass and function, which is thought to 
blunt the response of glucagon to hypoglycaemia (Fanelli et al., 2003). Various 
in vitro studies have suggested a role of intra-islet insulin or beta cell product in 
the glucagon response (Taborsky et al., 1998; Banarer et al., 2002). A tight co-
regulation has been observed between loss of the glucagon response and loss of 
the endogenous insulin secretion (Banarer et al., 2002). The distorted biphasic 
insulin secretion in diabetes is known to cause altered docking and fusion of 
insulin granules (Ohara-Imaizumi et al., 2004). During the process of exocytosis 
the secretory organelles containing pre-formed material fuse with the plasma 
membrane releasing their contents through a resulting connection between the 
lumen of the organelle and the extracellular space called the fusion pore (Scepek 
et al., 1998). Diabetes could also distort this fusion pore opening dynamics of 
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both alpha and beta cells, thereby perturbing paracrine and autocrine control 
(Gaisano et al., 2008).  
Glucagon has the ability to induce GSIS from the beta cell (Moens et al., 2002). 
Glucagon secretion, in conjunction with changes in glucose levels, stimulates 
insulin secretion and separation of beta cells from alpha cells shows lower 
secretory activity of purified beta cell as compared with isolated islets 
(Pipeleerset et al., 1985). Endogenous glucagon secretion was found to amplify 
glucose-induced insulin release from isolated islet cell preparations (Pipeleers et 
al., 1985; Moens et al., 2002). Insulin release from perifused purified beta cells is 
greatly enhanced in the presence of added glucagon or co-culture with alpha cells 
(Pipeleers et al., 1982). These earlier reported results shows that glucagon helps 
in insulin secretion and the knock-down of glucagon by Gcg-specific siRNA, as 
performed in this study reported here (See Section: 3.6.3), could have contributed 
to the significant loss of GSIS in MIN6 low passage cells.  
Cell composition and distribution in the pancreatic islet varies in different part of 
the pancreas. Dorsal islets contained 10 times more glucagon than ventral islets, 
whereas insulin and total protein contents are similar (Baetens et al., 1979). The 
basal rates of insulin secretion and proinsulin biosynthesis were similar in dorsal 
and ventral islets but, under conditions of glucose stimulation, both insulin 
secretion and proinsulin biosynthesis were significantly greater in the alpha cell 
rich dorsal islets. Similarly, glucose utilization rates and ATP levels were greater 
in dorsal islets. These observations reported by Trimble et al., (1982) indicated 
that a greater alpha cell number and glucagon content is associated with higher 
rates of GSIS and biosynthesis. Purified flow-sorted rat beta cells separated from 
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glucagon-producing alpha cells show poor insulin secretory response to glucose 
(Huypens et al., 2000). Here, down-regulation of glucagon by 1.5-fold in MIN6 
B1(GSIS) was associated with a significant loss of GSIS compared to scrambled 
transfected cells (See Section: 3.6.3), suggesting that in this cell model paracrine 
glucagon plays a role in glucose-responsiveness of MIN6 B1(GSIS).  
A number of in vitro studies using purified islet cells have supported the idea that 
the glucose stimulation of insulin release is strongly influenced by the 
intracellular cAMP level which, in turn, is found to potentiate Ca2+-dependent 
exocytosis (Renström et al., 1997). cAMP is regulated by various hormones and 
neurotransmitters (Moens et al., 2002). Endogenously released glucagon 
apparently determines the cAMP production in beta cells and thus participates in 
the nutrient-induced secretory process (Pipeleers et al., 1985). cAMP induces 
glycogenolysis increasing the intracellular ATP level for translocation, docking 
and fusion of secretory granules (He et al., 1998). Dalle et al., (1999 and 2004) 
in their study of beta cell models, they reported that glucagon increases cAMP 
level thereby activating protein kinase A (PKA) which, in turn, phosphorylates 
the L-type voltage-dependent calcium channel (VDCC). This leads to an 
increased glucose-induced calcium entry causing membrane depolarization and 
thus potentiating insulin secretion (Dalle et al., 1999; Dalle et al., 2004). 
Glucagon also acts in a paracrine fashion as a modulator of glucose induced 
calcium oscillations in mouse pancreatic islets. GSIS is also mediated by an 
increase in the intracellular free Ca2+ concentration (Baltrusch et al., 2007). In 
our experiments (See Section: 3.6.5) glucagon over-expression in MIN6 high 
passage cells resulted in a marked increase in the GSIS. 
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In this study we report that glucagon plays an important role in regulating GSIS 
in MIN6 cells. Using Gcg-specific siRNA, here we report a significant loss of 
GSIS in MIN6 low passage cells (passage 35). cDNA over-expression of Gcg in 
MIN6 high passage cells (passage 47) resulted an increase in GSIS. Therefore we 
can conclude that glucagon is a regulator of GSIS in MIN6 cells and any 
abnormality in its secretion would result in an impaired insulin secretion. 
4.6 Proprotein convertase subtilisin/kexin type 9 (Pcsk9) 
In the study reported in the thesis, Pcsk9 was down-regulated by a 1.5-fold in the 
microarray study and 2.59-fold in qRT-PCR study in MIN6 B1(Non-GSIS) cells 
compared to MIN6 B1(GSIS) cells. Pcsk9 knock-down, using three independent 
siRNAs, resulted in a significant loss of GSIS (Pcsk9-1 (p-value=0.007) and 
Pcsk9-3 (p-value=0.013)) in MIN6 B1(GSIS) cells compared to scrambled 
siRNA transfected cells (See Section: 3.7.3). Pcsk9 is found to be responsive to 
insulin but not glucose (Costet et al., 2006). In an in vitro study in primary 
cultures of hepatocytes and in vivo study during hyperinsulinemic-euglycemic 
clamps Pcsk9 was found to be up-regulated by insulin via sterol regulatory 
element-binding protein-1c (SREBP-1c). Insulin increases the expression of 
Pcsk9 mRNA suggesting that Pcsk9 might play a role in insulin-related 
pathologies including Type 2 diabetes and the metabolic syndrome (Costet et al., 
2006). Niesen et al., (2008) reported that streptozotocin-induced diabetic rats 
showed a significant reduction in Pcsk9 protein expression.  
Pcsk9 is thought to be involved in liver regeneration and neuronal differentiation 
(Ouguerram et al., 2004). Type 2 diabetes is associated with hepatic fat 
accumulation (hepatic steatosis) and dyslipidemia, a major risk factor for the 
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development of diabetes-associated coronary heart disease (Seppälä-Lindroos et 
al., 2002). The causative factor of diabetic dyslipidemia are elevated plasma 
triglyceride (TG) levels, low concentrations of high density lipoprotein (HDL) 
cholesterol and the presence of small, low density lipoprotein (LDL) particles 
(Taskinen, 2003). The major cause of diabetic dyslipidemia is an increased 
production of TG-rich very low density lipoprotein (VLDL) (Ginsberg et al., 
2005). As VLDL is an attribute of insulin resistance and Type 2 diabetes in 
humans, Costet et al. (2006) proposed the possibility that Pcsk9 function might 
be altered in the metabolic syndrome and/or diabetes. Adenoviral mediated 
Pcsk9 over-expression in fasting mice resulted in massive hypertriglyceridemia, 
associated with a striking increase in VLDL hepatic output (Naoumova et al., 
2005).  
Oxidized LDL reduces GSIS in the clonal hamster beta cell line, HIT-T15 
(Abderrahmani et al., 2007), as well as reduces both insulin content and 
preproinsulin mRNA expression in isolated islets (Hao et al., 2007). It also 
increases beta cell apoptosis (Brunham et al., 2008). The level of cell-surface 
LDL receptor (LDLR) is indirectly proportional to the level of Pcsk9 in the liver 
and small intestine (Rashid et al., 2005). In an in vivo study of Pcsk9 knockout 
mice, Rashid et al. (2005) reported an increase in LDLR protein causing 
increased clearance of circulating lipoproteins and decreased plasma cholesterol 
levels. Increased levels of circulating LDL cholesterol have been observed in 
mice over-expressing Pcsk9 following recombinant adenoviral infections 
(Benjannet et al., 2006). In the Pcsk9-specific siRNA study, here we propose that 
Pcsk9 is associated with the loss of GSIS in MIN6 low passage cells. 
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4.7 Thioredoxin interacting protein (Txnip) 
Thioredoxin-interacting protein (Txnip) was first isolated from a 1,25-
dihydroxyvitamin D3-treated HL-60 human promyelocytic cell line and therefore 
is also known as vitamin D3-up-regulated gene 1 (VDUP1) (Chen et al., 1994). 
Txnip was found to be up-regulated in an oligonucleotide microarray study 
assessing glucose effects on isolated human pancreatic islets (Shalev et al., 2002) 
as well as in islets of insulin-resistant and diabetic mice (Minn et al., 2005). 
Txnip has been identified as a potential diabetogenic signal in human skeletal 
muscle (Muoio, 2007). Diabetes leads to glucose toxicity affecting different 
organ systems including pancreatic islets leading to beta cell apoptosis. Txnip is 
induced by glucose and up-regulated in diabetes in the cardiovascular system 
(Schulze et al., 2004) as well as in pancreatic beta cells. This suggests its 
involvement in glucose toxicity, beta cell loss and diabetes complications (Minn 
et al., 2005; Chen et al., 2008). In our microarray study, we identified Txnip to 
be up-regulated in non-glucose responsive MIN6 B1(Non-GSIS) compared to 
MIN6 B1(GSIS). The exact role of Txnip in glucose homeostasis is not known, 
but the up-regulation of Txnip in high passage cells may have contributed to 
glucose toxicity, stress and loss of GSIS function. 
Txnip has been studied in various cancer forms and is associated with increased 
tumour cell growth and metastatic potential in human breast cancer, colon 
cancer, and malignant pheochromocytomas (Goldberg et al., 2003; Butler et al., 
2003; Ohta et al., 2005). Txnip is also associated with cell cycle arrest at the 
G0/G1 phase and has been shown to inhibit proliferation in a variety of cell types 
including human aortic smooth muscle cells (Schulze et al., 2002; Han et al., 
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2003). Over-expression of Txnip renders cells more susceptible to oxidative 
stress and it induces apoptosis (Wang et al., 2002; Minn et al., 2005). 
 Chen et al. (2008) reported that the beta cell-specific knockout of Txnip in 
bTKO mice enhanced beta cell mass and protected against diabetes. They also 
proposed that down-regulation of Txnip induces Akt/Bcl-xL signaling which in 
turn inhibits mitochondrial beta cell death, suggesting that these mechanisms 
may mediate the beta cell protective effects of Txnip deficiency (Chen et al., 
2008). Our study of Txnip-specific siRNA in MIN6 high passage cells resulted in 
a significant increase in GSIS in high passage cells (See Section: 3.8.3). These 
results suggest that lowering beta cell Txnip mRNA expression levels could serve 
as a novel strategy for the treatment of Type 2 diabetes by promoting 
endogenous beta cell survival (Chen et al., 2008). 
Txnip expression has been found to govern glucose uptake in insulin-responsive 
cells. In an over-expression study of Txnip using lentiviral transduction in 
adipocyte differentiated 3T3-L1, Parikh et al. (2007) reported a diminished basal 
and insulin-stimulated glucose uptake, whereas Txnip siRNA enhanced both 
basal and insulin-stimulated glucose uptake (Parikh et al., 2007). In our Txnip 
siRNA study on MIN6 high passage cells we found a significant increase in 
GSIS (Txnip -1 (p-value=0.03) and Txnip -2 (p-value=0.019)), whereas over-
expression of Txnip significantly reduced (p-value= 0.013) the GSIS in MIN6 
low passage cells (See Section: 3.8.3). A significant increase (p-value=0.024) in 
GSIS was also observed in Txnip shRNA transfected MIN6 clones (See Section: 
3.9.4.2). 
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Elevated glucose concentration in beta cells may trigger the mechanism of beta 
cell toxicity by generating free radicals in beta cells during oxidative metabolism 
of glucose via production of proinflammatory cytokines such as interleukin-1 and 
by the induction of ER stress in beta cells (Corbett, 2008). Chen et al. (2008) 
have also proposed that the loss of beta cell mass in response to elevated 
concentrations of glucose is the result of enhanced expression of a single protein, 
Txnip which has been found to negatively regulate thioredoxin. Over-expression 
of thioredoxin in streptozotocin-induced diabetic mice protected pancreatic beta 
cells from autoimmune destruction by reducing apoptosis (Hotta et al., 1998). 
Txnip may be causing pro-apoptotic effects on beta cells by inhibiting 
thioredoxin and inducing oxidative stress (Junn et al., 2000), leading to beta cell 
glucotoxicity and apoptosis (Robertson et al., 2003; Kajimoto et al., 2004). 
Vascular Txnip expression is also found to be elevated in streptozotocin-induced 
diabetic rats where it induces vascular oxidative stress (Schulze et al., 2004). 
Reactive oxygen species (ROS) have been suggested to have a role in insulin 
resistance. It has been proposed that cells may interpret elevated ROS levels as a 
signal to limit the input to the electron transport chain by decreasing glucose 
uptake causing insulin resistance (Houstis et al., 2006). Varying Txnip mRNA 
level has been associated with differences in ROS levels and thioredoxin activity. 
Low Txnip mRNA level in MCF10A/MCF-7/T47D cells has been associated 
with significantly lower fold increase of ROS levels compared with the high 
Txnip mRNA level in MDA-MB-435s/MDA-MB-231 cells (Turturro et al., 
2007). Our study of ROS level in Txnip shRNA-transfected clones have shown 
reduced ROS level by 40.5% and 35.6% in sh-1 and sh-9 clones respectively 
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compared to empty shRNA-transfected clone (See Section: 3.9.4.3), suggesting 
that Txnip is associated with increasing levels of ROS.  
Txnip has shown to possess tumour-suppressive activity in breast, gastrointestinal 
and lung cancers, suppressing cell proliferation via cell cycle arrest at the G1 
phase (Filby et al., 2006; Yu et al., 2007). Over-expression of Txnip was found 
to inhibit the proliferation of stomach cancer and promyelocytic leukemia cells 
(Han et al., 2003). Suppressed tumour growth and metastasis was also reported 
in a Txnip over-expression study of tumour transplant in nude mice model 
(Goldberg et al., 2003). However, in their study of pretumorous livers from 
Txnip-deficient mice, Sheth et al. (2006) found that there was no increase in 
cellular proliferation suggesting that loss of Txnip itself is not sufficient to induce 
proliferation. In the studies reported in this thesis, the proliferation rate of Txnip 
shRNA-transfected clone#1 (sh-1) were reduced by 1.3-fold compared to empty 
shRNA-transfected cells and reduced by 2-fold compared to sh-3 clone (i.e. a 
clone with no Txnip knock-down) (See Section: 3.9.4.4). Beta cell-specific Txnip 
deletion in HcB-19 mice has been found to enhance beta cell mass and protect 
against diabetes (Chen et al., 2008). In a study of INS-1 beta cells and primary 
mouse islet, Chen et al. (2008) suggested that inhibition of Txnip could be a 
novel approach to reduce glucotoxic beta cell loss (Chen et al., 2008).  
Pancreatic islets express Egr1 mRNA and its reduced expression may inhibit 
beta cell proliferation (Garnett et al., 2005). Garnett et al. (2005) in their Egr1 
siRNA study on INS-1 cells found that it had no effect on GSIS but did inhibit 
proliferation. Our study showed a 52.7% and 56.2% knock-down by qRT-PCR of 
Egr1 gene transcript in Txnip shRNA-transfected clones sh-1 and sh-9 
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respectively. Studies performed on tissue culture models such as rodent and 
avian fibroblasts suggested that c-Jun and the Fos proteins positively regulate 
cell proliferation (Shaulian et al., 2002). In the study reported in this thesis (See 
Section: 3.9.4.5), qRT-PCR on Txnip shRNA-transfected clones showed a 80.5% 
and 73.8% knock-down of Fos gene transcript in sh-1 and sh-9 clones 
respectively. qRT-PCR showed a knock-down of 44.5% and 16.5% of Jun gene 
transcript transcript in sh-1 and sh-9 clones respectively. Reduced expression of 
Egr1, Fos and Jun suggests that Txnip knock-down alone may not be responsible 
for reduced proliferation in Txnip knock-down clones but they might act in 
harmony possibly with other intracellular molecules to reduce proliferation. 
Our findings in this study suggest that Txnip is associated with insulin secretion 
in MIN6 cells. Txnip-specific siRNA and cDNA transfection study showed that 
Txnip expression was inversely related to insulin secretion in MIN6 cells. Txnip 
shRNA transfected clones showed a reduced ROS levels suggesting reduced 
oxidative stress and increased insulin secretion compared to empty shRNA 
transfected clone. Increased ROS levels also suggest increased oxidative stress in 
MIN6 high passage cells that may lead to an increased expression of Txnip and 
insulin resistance. 
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4.8 Extracellular nucleic acid  
Presence of extracellular nucleic acids was first reported by Mandel and Métais 
(Mandel et al., 1948).  Circulating mRNAs have more recently been detected in 
plasma and serum from people with cancer, as well as people with no history of 
cancer (El-Hefnawy et al., 2004). These RNAs are apparently not only able to 
escape from cells, but are also protected from degradation by the serum 
ribonucleases (Ng et al., 2002; Tsui et al., 2002). Wiecozorek et al. (1985 and 
1987) reported that tumour cells secrete RNA-proteolipid complexes into the 
serum of the cancer patients, which may protect the RNA from the plasma 
ribonucleases. Normal cells in culture have been found to release RNA-DNA 
nucleoprotein complexes (Stroun et al., 1978) and it has been shown in our 
laboratory that mRNAs can be detected in culture medium conditioned by a 
broad range of cultured cancer cell types (O’Driscoll et al., 2005). However, 
although there is increasing evidence to suggest the existence of extracellular 
mRNAs that may be clinically-relevant as biomarkers, extracellular mRNAs 
associated with pancreatic beta cells have not previously been investigated. Here 
we analysed a range of gene transcripts in media conditioned by insulin-
producing cell lines, investigating if their presence is in any way indicative of 
beta cell mass/density and/or function, and assessing the reproducibility of the 
procedures employed.  
4.8.1 Identifying a suitable time point for CM collection and analysis 
As described in section 2.4.1 and 2.4.2 conditioned media (CM) samples were 
collected at 4 time-points after cell seeding to identify a suitable time-point at 
which amplifiable mRNA could be routinely isolated for analysis. In the case of 
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Beta-actin, mRNA could be isolated and amplified at all time points evaluated. 
The increasing intensity of the PCR bands in the samples over the 24hrs. 
intervals may be due to the increasing amounts of Beta-actin transcripts secreted 
into the CM, assuming that the transcripts are stable in CM for that length of 
time. As the cells were in a healthy, proliferating state at the 48hrs. time-point 
with no dead cells floating in the media, this time-point was chosen for all further 
studies using the RNA extraction protocol as described in section: 2.5.1.2.1. 
4.8.2 Identifying Suitable PCR Cycle Number 
Studying medium conditioned by a range of insulin-producing cell types, 
including glucose-responsive and non-responsive murine beta cells, MIN6 (L) 
and (H), respectively, the glucose-responsive clonal population of MIN6 (MIN6 
B1), and monkey fibroblast cells engineered to produce human insulin (Vero-
PPI), here we have shown, for the first time, that a range of mRNAs are 
detectable extracellularly to insulin-producing cells. The amplified products 
detected range in size from 125-288 bp and the results obtained were highly 
reproducible between triplicate biological repeat experiments.  
Although 30 cycles of PCR were sufficient for amplification of RNA from 
cultured cells, 45 cycles was generally found to be necessary for CM studies. 
However, use of nested or semi-nested primers and large number of PCR cycles, 
as reported for some of the serum studies (Wieczorek et al., 1987; Chen et al., 
2000), were found not to be necessary in our analyses. 
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4.8.3 RT-PCR on RNase- and DNase-treated RNA Samples  
It had been suggested (Kumar et al., 2006) that expression microarray and qRT-
PCR analysis of saliva specimens might be detecting genomic DNA, rather than 
mRNA. This assumption was based on the analysis of “no-RT” (i.e. no reverse 
transcriptase enzyme included in cDNA reaction: RT (-)) and “+RT” (RT (+)) 
conditions yielding similar amounts of PCR product; microarrays signals, 
unaffected by RNase-treatment; and the absence of RT-PCR products following 
DNase-treatment. In order to investigate if the extracellular nucleic acids 
detected in CM were either wholly or partly DNA in origin and not from mRNA 
as controls, we included analysis following DNase treatment, RNase treatment, 
and in the absence of RT enzyme. The presence of amplified products following 
DNase treatment of samples, and the complete lack of product following RNase 
treatment and in the absence of RT enzyme, and the fact that the amplified 
products detected are of the sizes expected for cDNA, but not genomic DNA, 
supports the assumption that the nucleic acids that we detected throughout the 
course of these studies are of RNA, not DNA, origin.   
4.8.4 Cell Density and corresponding mRNA Levels 
In order to investigate if levels of specific mRNAs in CM correlate with numbers 
of cells conditioning the medium, MIN6 B1 and Vero-PPI cells were grown at a 
range of densities in fixed volumes of medium and RT-PCR was performed on 
both cells and their CM. Our results from the amplification of a number of beta 
cell gene transcripts (including Pdx1, Egr1 and Chgb) indicated that levels of 
expression reflected the numbers of MIN6 B1 cells conditioning the medium. 
Although previous beta cell studies have not been performed to which these 
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findings can be compared, it is interesting to note that a correlation has been 
reported between increased amount of circulating tumour-specific mRNA and 
tumour stage (Stroun et al., 1978; Morozkin et al., 2004). Increased extracellular 
DNA is also detected in the plasma of the patients after trauma correlating with 
the severity of injury and it is also found to be predictive of late post-traumatic 
complications, such as organ failure (Wong et al., 2004). From our analysis of 
MIN6 B1 and Vero-PPI CM, we can speculate that by quantification of the level 
of circulating mRNA, assessment of surviving beta cell as in Type 1 diabetes 
patient could be possible. 
4.8.5 Glucose-Responsiveness and corresponding mRNA Levels 
To establish if the presence of extracellular mRNAs may reflect beta cell 
function i.e. specifically the ability of beta cells to secrete insulin in a glucose-
regulated manner,  analysis of mRNA in medium conditioned by glucose-
responsive MIN6 (L) and glucose non-responsive MIN6 (H) was performed. 
Choice of transcripts to study were based on our previously reported analysis of 
MIN6 (L) and (H) where we identified a number of mRNAs to be differentially 
expressed between these cells (O’Driscoll et al., 2006). Using both microarray 
and quantitative RT-PCR, we found Egr1, Pld1, and Chgb to be significantly 
down-regulated in MIN6 (H) cells compared to MIN6 (L). In agreement with our 
previous analysis of cells, in studies of CM reported here, we detected these 3 
gene transcripts in biological repeat analysis of MIN6 (L); however, these 
mRNAs were not detectable in MIN6 (H) CM. Our microarray analysis indicated 
no significant difference in expression levels Ins I, Ins II or Beta-actin mRNAs 
between MIN6 (L) and (H) cells. Similarly, all 3 of these transcripts were 
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detected in MIN6 (L) and (H) CM, but the amounts present in CM from these 
cell populations did not differ significantly. 
4.8.6 Possible selective release of gene transcript into CM 
Furthermore, results from this study suggest that the secretion of mRNA by 
pancreatic beta cells may be somewhat selective, and not just be a general 
“dumping” mechanism. This is supported by the fact that although Pdx1, Egr1, 
Chgb, Pax4 and Beta-actin are expressed by MIN6 B1 and Pdx1, Egr1, Chgb, 
and Beta-actin are detectable in corresponding CM, Pax4 is not. It should, 
however, be considered that alternative explanations to selective secretion of the 
gene transcripts may be insensitivity of RT-PCR as a methods of detection very 
low levels of mRNA or, alternatively, differing stabilities of mRNAs secreted 
into the extracellular environment. 
4.10 Serum study 
Serum and plasma has been the subject of extensive research for years. 
Circulating RNA in plasma and serum has emerged as an upcoming field for 
non-invasive diagnostic applications (Ng et al., 2002). Quantitative real-time RT-
PCR (qRT-PCR) is a very sensitive assay which makes serum/plasma RNA 
detection assays more informative and sensitive (Tsui et al., 2002). Currently all 
the routinely used serum markers are proteins and the conventional methods used 
for measuring them are labor-intensive (Chen et al., 2008). Some of the 
examples of the serum protein include adipocyte fatty acid-binding protein. 
Serum Adipocyte fatty acid-binding protein has been associated with glucose 
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dysregulation and predicting the development of Type 2 diabetes in Chinese 
population (Tso et al., 2007).  
In order to investigate if the amplified signal was of RNA origin and not from 
contaminated DNA, as controls, we included analysis following DNase 
treatment, RNase treatment and in the absence of RT enzyme. In the case of 
serum RNA treated with RNase enzyme there was no amplification observed. 
Amplified products were observed in few samples following DNase treatment of 
serum RNA. The reason for this could be that the DNase treatment could have 
lead to the degradation of RNA resulting in amplification at later cycle that is 
beyond the detection limit of the qRT-PCR machine. Therefore in the case of 
serum RNA study only –RT (reverse transcription carried out in the absence of 
reverse transcriptase enzyme) was taken as control.  
All the gene transcripts chosen for the serum RNA study were selected from 
previously reported microarray analysis of MIN6 (L) and (H) cells and were 
validated using qRT-PCR (Table: 2.5.3.1.3). These gene transcripts were also 
amplified in our study of medium conditioned by insulin secreting cell lines (See 
Section: 3.10).    
Glucose and hyperglycemia induces Txnip expression in breast-cancer derived 
cells, MDA-MB-231 (Turturro et al., 2007), along with the islets of different 
mouse models of diabetes and insulin resistance. This suggests that Txnip 
contributes to the pathogenesis and secondary complications of diabetes (Minn et 
al., 2005). The 1q21-1q23 chromosomal area has been involved in Type 2 
diabetes in several human populations (van Greevenbroek et al., 2007). Several 
lines of evidence and functional data on the roles of Txnip and thioredoxin, 
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combined with its chromosomal localization on 1q21-23 leads to the hypothesis 
that variations in the Txnip gene may affect susceptibility to Type 2 diabetes or to 
hyper-triglyceridaemia in Type 2 diabetes (van Greevenbroek et al., 2007). 
Txnip mRNA expression was found to be suppressed by insulin in healthy 
subjects, but this relationship was lost in diabetes subjects (Muoio, 2007). 
Muscle expression of Txnip was also found to be higher in patients with diabetes 
or pre-diabetes, as compared to those with normal glucose tolerance (Muoio, 
2007). 
In the present study, we have detected increased amount of Txnip in Type 2 
diabetes serum compared to controls. Since Txnip has been associated with 
oxidative stress and inhibits the function of thioredoxin, our result suggests that 
the diabetic condition enhance the expression of Txnip. In the cell line model 
reported in this thesis we have also found that increased expression of Txnip, in 
microarray and qRT-PCR study, is associated with loss of function of insulin 
secretion in MIN6 B1(Non-GSIS) cells. 
Stronger induction of Egr1 mRNA was found in glucose-responsive cell lines 
including, MIN6, βTC3 and INS-1 cells, compared to weakly glucose-responsive 
RINm5F cells (Josefsen et al., 1999). Egr1 was undetected in beta cell lines 
including, HIT-T15 cells, that do not secrete insulin in response to glucose 
(Josefsen et al., 1999). Egr1 mRNA is also expressed in pancreatic beta cells and 
primary rat islets (Garnett et al., 2005). Eto et al. (2006) proposed that Egr1 
contributes to the function of pancreatic beta cells by regulation of Pdx1 
expression and activation of insulin gene transcript and glucose responsiveness. 
In our present study we observed that Egr1 mRNA expression was significantly 
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(p-value=0.017) down-regulated in Type 2 diabetes subjects compared to 
controls.  
Serum is supposed to contain large amounts of RNA that is derived from various 
tissues and organs. The serum RNA expression profile could be used as a novel 
serum-based biomarker and potentially is more sensitive and specific tests for 
early diagnosis of diabetes and other related diseases. Studies on large number of 
Type 2 diabetes and controls are required to determine the diagnostic and 
prognostic value of this measurement. 
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5.1 Studies on MIN6 / MIN6 B1 
• MIN6 B1 at p19 showed a glucose concentration-dependent increase in 
insulin secretion producing a 2.15-fold increased insulin secretion when 
glucose stimulation was increased from 3.3 mmol/L to 16.7 mmol/L for 1 
hr and so these cells were subsequently termed MIN6 B1(GSIS). By 
contrast, the same increase in glucose concentration when added to MIN6 
B1 at p23 cells resulted in 1.35-fold increase in insulin secretion only i.e. 
MIN6 B1(Non-GSIS) cells. 
• Gradual loss of GSIS was observed in continuously cultured MIN6 B1 
cell. 
• The loss in functional GSIS after continuous culture correlated with 
phenotypic changes, including an increased proliferation and change in 
cell morphology. MIN6 B1 cells grow in clumps at low passages (MIN6 
B1(GSIS), passage 19) whereas, at  high passages (MIN6 B1(Non-GSIS), 
passage 23), it formed a monolayer of “flat”, stretched, cells 
5.2 Whole genome microarray studies on MIN6 B1 cell 
• Of the 45,101 transcripts represented on the Mouse Whole Genome 430 
2.0 Array, 111 genes were differentially regulated with 53 genes found to 
be up-regulated and 58 genes down-regulated in MIN6 B1(Non-GSIS) 
compared to MIN6 B1(GSIS) cells. 
• To validate the microarray results, twelve up-regulated genes and four 
down-regulated genes were selected for qRT-PCR analysis based on fold 
change >1.2 and p-value <0.05. qRT-PCR validation was performed on 
the following differentially-regulated genes Anxa A2, Dusp1, Egr1, Fos, 
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FosB, Gadd45g, Ier-5, Jun, Klf4, Mapk3, Sox4, Txnip, Gcg, Pcsk9, 
Slc38a4 and Txndc5. Comparison of qRT-PCR data with microarray data 
demonstrated matching trends in expression change for both methods. 
• Up-regulated gene transcripts including Gadd45g, Cdkn1a, Rgs4 and 
Trib1 are known, from the literature, to be associated with regulation of 
protein kinase activity. 
• Txnip, Dusp1, Dnajb1, Anxa2, Gadd45g and Mapk3 are known, from the 
literature, to be associated with response to stress were up-regulated in 
MIN6 B1(Non-GSIS) compared to MIN6 B1(GSIS). 
• mRNAs, including Ssr1, Tram1, and Srpr are known from the literature 
to be associated with protein targeting to endoplasmic reticulum and were 
down-regulated in MIN6 B1(Non-GSIS). 
• Down-regulated gene transcripts including Copb2, Mcfd2 and Rab3d are 
known from the literature to be associated with secretory pathway. 
5.3 Gcg siRNA and Over-expression on MIN6 cells 
• Gcg was down-regulated in the MIN6 B1 high passage cells compared to 
low passage cells in the microarray study and validated by qRT-PCR. 
• Gcg-1 and Gcg-2 siRNA transfection showed a knock-down of approx. 
32% and 27% respectively in qRT-PCR study, compared to scrambled-
siRNA transfected control cells. 
• There was no change in cell proliferation or cell morphology following 
Gcg siRNA transfection. 
• Significant loss of GSIS (Gcg-1 (p-value=0.00009), Gcg-2 (p-
value=0.015) and Gcg-3 (p-value= 0.032)) was observed in low passage 
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MIN6 cells following Gcg (Gcg-1, Gcg-2 and Gcg-3) siRNA 
transfection. 
• 10.9-fold increase of Gcg mRNA in MIN6 high passage cells was 
observed by qRT-PCR after 72hrs. of Gcg cDNA over-expression 
compared to empty plasmid transfected cells. 
• Increase in GSIS in Gcg over-expressing cells (1.43-fold) was observed 
compared to empty plasmid transfected cells (1.16) (p-value= 0.14). 
• Gcg expression was directly related to insulin secretion in MIN6 B1 cells. 
Therefore we can conclude that by regulating glucagon secretion in Type 
2 diabetes we can increase the insulin secretion. 
5.4 Pcsk9 siRNA on MIN6 low passage cells 
• Pcsk9 was down-regulated in the MIN6 B1 high passage cells compared 
to low passage cells in the microarray study and validated by qRT-PCR. 
• qRT-PCR showed a knock-down of approx 39% in Pcsk9-1, 4.3% in 
Pcsk9-2, and 46% in Pcsk9-3 siRNA transfected cells. 
• There was no change in cell proliferation or cell morphology followed by 
Pcsk9 siRNA transfection. 
• Significant loss of GSIS (Pcsk9-1 (p-value=0.007) and Pcsk9-3 (p-value= 
0.013)) was observed in low passage MIN6 cells following Pcsk9 (Pcsk9 
-1 and Pcsk9 -3) siRNA transfection. 
• Reduced expression of Pcsk9 was associated with reduced insulin 
secretion in MIN6(L) cells.  In this study for the first time we have 
reported association of Pcsk9 with beta cell and loss of GSIS. 
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5.5 Study of Txnip 
• Txnip was up-regulated in the MIN6 B1 high passage cells compared to 
low passage cells in the microarray study and validated by qRT-PCR. 
• qRT-PCR showed Txnip mRNA knock-down of approx. 43% in Txnip-1, 
42% in Txnip-2 and 25% in Txnip-3 siRNA transfected cells. 
• There was no change in cell proliferation or cell morphology followed by 
Txnip siRNA transfection. 
• Significant increase in GSIS was observed in high passage MIN6 cells 
following Txnip (Txnip-1 (p-value=0.03) and Txnip-2 (p-value=0.019)) 
siRNA transfection. 
• 23.7-fold increase of Txnip mRNA in MIN6 low passage cells was 
observed by qRT-PCR after 72hrs. of Txnip cDNA over-expression, 
compared to empty plasmid transfected cells. 
• There was a significant loss (p-value= 0.013) of GSIS in MIN6 low 
passage cells following Txnip cDNA over-expression. 
• qRT-PCR was performed on clones to select the clones with lowest 
expression of Txnip  
• Txnip shRNA transfected clone#1 (sh-1) showed a significant increase in 
GSIS (p-value=0.024) with (2.96-fold) and a moderate increase in 
clone#9 (sh-9) (p-value=0.23) (1.82-fold) compared to empty shRNA-
transfected cells (Em-F).  
• Txnip shRNA transfected clones sh-1 and sh-9 showed reduced ROS 
levels of 40.5% and 35.6%, respectively, compared to empty shRNA 
transfected clone Em-F. 
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• Clone sh-3 showed 1.5-fold increased proliferation compared to Em-F, 
whereas clone sh-1 showed 1.3-fold reduced proliferation compared to 
Em-F.   
• Reduced expression of Egr1 was observed in Sh-1 clone (52.7%) and sh-
9 clone (56.2%), compared to Em-F. 
• Sh-1 clone showed 80.5% and sh-9 clone showed 73.8% knock-down of 
Fos, compared to Em-F. 
• Sh-1 clone showed 43.7% and sh-9 clone showed 29.2% knock-down of 
Gadd45g, compared to Em-F. 
• Sh-1 clone showed 44.5% and sh-9 clone showed 16.5% knock-down of 
Jun, compared to Em-F. 
• Increased expression of Mapk3 in Sh-1 (14.8%) and sh-9 clones (66.9%) 
was observed, compared to Em-F. 
• Reduced expression of Egr1, Fos and Jun in Txnip shRNA transfected 
clones may contribute to its reduced proliferation.  
• Expression of Txnip is inversely related to insulin secretion in MIN6 
cells. So we can conclude that by beta cell specific deletion of Txnip 
mRNA GSIS function of beta cells could be preserved. 
5.6 Study on medium conditioned by insulin-producing cells 
• A range of healthy, proliferating, insulin-producing cell lines in culture 
apparently pass many gene transcripts out into their media, which can be 
reproducibly detected extracellularly. 
• Forty-five cycles of PCR was found to be adequate to produce a 
detectable band from CM (conditioned media) RNA. 
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• Gene transcripts including Beta-actin, Ins1, Ins2 and Pdx1 were detected 
at similar levels in MIN6 low passage (L) and high passage (H) CM. 
• Gene transcripts including Npy, Chgb, Pld1, Egr1 and PC2 were 
amplified using RNA from medium conditioned by MIN6 (L) cells but 
were undetected in medium conditioned by MIN6 (H) cells. 
• Gad1 was amplified using MIN6 (H) CM RNA, whereas it was 
undetected in MIN6 (L) CM RNA. 
• In case of Chgb, Egr1, Gck and Pdx1, the intensity of the band produced 
following 45 cycles of PCR was directly associated with the numbers of 
cells conditioning the medium i.e. increased number of cells resulted in 
increased levels of these transcripts detectable in a fixed volume of CM. 
• Ins1, Ins2 and Pld1 was amplified using cell RNA from 106 cells and 
5x106 cells, however, there was no further increase in band size/intensity 
upon analysis of 1x107 cells RNA which seemed to reach plateau phase 
of PCR analysis. 
• Human preproinsulin transcribed by Vero-PPI cells showed increased 
levels of mRNA in medium conditioned by increasing number of cells; 
however, amounts of preproinsulin detected in CM seemed to reach 
plateau phase and PCR was no longer exponential beyond analysis of CM 
from 5X106 cells. 
• mRNAs is detected in the extracellular environment and these mRNAs 
may have potential as extracellular biomarkers for assessing beta cell 
mass and function. 
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5.7 Study on serum 
• A 1.8-fold increase in Txnip mRNA expression was observed in Type 2 
diabetes compared to controls. 
• A negative correlation was observed between Txnip mRNA expression 
and insulin fasting (correlation= -0.46) as well as insulin secretion 
(correlation= -0.50) in Type 2 diabetes subjects. 
• Egr1 mRNA expression was significantly (p-value=0.017) down-
regulated in Type 2 diabetes subjects compared to controls. 
• Egr1 mRNA expression and insulin fasting (correlation= 0.53) was 
positively correlated in Type 2 diabetes subjects and was negatively 
correlated (correlation= -0.12) in controls. 
• Amplification of Beta-actin was not significantly different in Type 2 
diabetes compared to controls. 
• Egr1 mRNA expression was significantly (p-value=0.017) down-
regulated whereas, Txnip mRNA expression was up-regulated in Type 2 
diabetes compared to controls. Studies on large number of serum 
specimens from Type 2 diabetes and controls are required to determine 
the diagnostic and prognostic value of this measurement. 
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Section 6 Future Work
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Future work 
• siRNA, shRNA and cDNA transfection for other gene transcripts (Egr1, 
Fos, FosB and Jun) that were up-regulated in MIN6 B1 microarray study. 
Transfection study of these gene transcripts would possibly help to 
understand their role in GSIS.   
• Txnip shRNA-transfected clones showed an increase in GSIS. Microarray 
study on Txnip shRNA-transfected clone and empty shRNA-transfected 
clone would help to identify differentially-regulated gene transcripts in 
Txnip knock-down clone that would possibly be associated with GSIS. 
• Knock-down of Txnip mRNA in MIN6 high passage cells resulted in 
significantly increase in GSIS. It could be possible that Txnip could be 
interacting with some other gene to restore insulin secretion in MIN6 
cells. LC-mass spectrometry could be performed to identify other proteins 
that interact with Txnip to increase GSIS. 
• Txnip knock-down mouse models to better understand the role of this 
protein in insulin secretion. Plasmid vector containing the Txnip gene 
could be electroporated into ES cell. Chimeric mice could be generated 
by injecting of clones into blastocysts. These could then be implanted into 
pseudopregnant female recipients to produce chimeras. Txnip knock-
down mouse model would also enable the analysis of other genes 
regulated by Txnip protein. 
• Microarray on serum from Type 2 diabetes and controls to find any 
potential biomarker. 
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• Detection of amplifiable mRNA extracellular to isolated pancreatic islets 
cells.  
• Detection of amplifiable gene transcript in isolated pancreatic islets 
seeded at range of densities and corresponding mRNA levels in their CM. 
• Identify gene transcripts extracellular to isolated islet cells showing the 
functional status of the isolated islet cells. Glucose responsive and 
glucose non-responsive islets could be identified by determining the 
glucose-stimulated insulin secretion (GSIS) in freshly isolated islet cells 
and then growing them in culture for few days when GSIS is lost.   
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